(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number
WO 03/035065 A1

(51) International Patent Classification[7]: **A61K 31/4184**, C07D 403/04, 403/14, 413/04, 413/14, 405/14, 409/14, 491/04, 401/14, 487/04, 471/04, A61P 35/00 // (C07D 491/04, 319:00, 235:00)

(21) International Application Number: PCT/GB02/04763

(22) International Filing Date: 24 October 2002 (24.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

01/13868	26 October 2001 (26.10.2001)	FR
0206893.0	22 March 2002 (22.03.2002)	GB
0206895.5	22 March 2002 (22.03.2002)	GB
60/395,151	11 July 2002 (11.07.2002)	US
60/395,060	11 July 2002 (11.07.2002)	US

(71) Applicant *(for all designated States except US)*: **AVENTIS PHARMACEUTICALS INC** [US/US]; 300 Somerset Corporate Boulevard, Bridgewater, NJ 08807 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **EDWARDS, Michael, Louis** [US/US]; 31 Rolling Hill Drive, Morristown, NJ 07960 (US). **COX, Paul, Joseph** [US/US]; 238 Skyline Drive, Millington, NJ 07964 (US). **AMENDOLA, Shelley** [GB/US]; 271 Thistle Lane, Bedminster, NJ 07921 (US). **DEPRETS, Stephanie, Daniele** [FR/FR]; 203, rue de Vaugirard, F-75015 Paris (FR). **GILLESPY, Timothy, Alan** [US/US]; 42 Foxhill Lane, Hillsboro, NJ 08844 (US). **EDLIN, Christopher, David** [GB/GB]; 19 Garden Row, Hitchin, Herts SG5 1QD (GB). **MORLEY, Andrew, David** [GB/GB]; 9 Home Farm Avenue, Macclesfield, Cheshire SK10 3QW (GB). **GARDNER, Charles, J.** [US/US]; 644 S. Fifth Avenue, Royersford, NJ 10469 (US). **PEDGRIFT, Brian** [US/US]; 55 Post House Road, Morristown, NJ 07960 (US). **BOUCHARD, Hervé** [FR/FR]; 7 alle de la Prevote, F-94320 Thiais (FR). **BABIN, Didier** [FR/FR]; 22, rue de la Grenovillette, F-78180 Montigny (FR). **GAUZY, Laurence** [FR/FR]; 6, rue Louis Thuillier, F-75005 Paris (FR). **LE BRUN, Alain** [FR/FR]; 17, allée Georges Brassens, F-91270 Vigneux (FR). **MAJID, Tahir, Nedeem** [GB/US]; 77 Park Avenue # 1511, Hoboken, NJ 07030 (US). **READER, John, C.** [GB/GB]; 5 Coles Lane, Linton, Cambridge, CB1 6JS (GB). **PAYNE, Lloyd, J.** [GB/GB]; 73 Frank Bridges Close, Soham, Ely, Cambridge CB7 5EZ (GB). **KHAN, Nawaz, M.** [GB/GB]; The Rushden, 5 Hall Drive, Hardwick, Cambridge CB3 7QN (GB). **CHERRY, Michael** [GB/GB]; 20 Lowther Street, Newmarket, Suffolk CB8 0JS (GB).

(74) Agent: **JONES, Stephen, Anthony**; Adamson Jones, Broadway Business Centre, 32a Stoney Street, Nottingham NG1 1LL (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR. GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,

[Continued on next page]

(54) Title: BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS



(Ix)

(57) Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

WO 03/035065 A1

TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS

This invention is directed to benzimidazoles of formula (Ix), their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of the protein kinases. Such protein kinases belong especially to the following group: EGFR, Fak, FLK-1, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, flt-1, IGF-1R, KDR, PDGFR, tie2, VEGFR, ITK and SYK.

Protein kinases are a family of enzymes that participate in the signalling events which control the activation, growth and differentiation of cells in response to extracellular mediators and to changes in the environment. In general, these kinases fall into several groups; those which preferentially catalyse the phosphorylation of hydroxy groups of serine and/or threonine residues and those which preferentially catalyse the phosphorylation of hydroxy groups of tyrosine residues [S.K.Hanks and T.Hunter, FASEB. J., 1995, 9, pages 576-596]. Such phosphorylations may greatly modify the function of the proteins; thus, protein kinases play an important role in regulating a wide variety of cell processes including, especially, metabolism, cell proliferation, cell differentiation or cell survival.

Among the various cellular functions in which the activity of a kinase protein is involved, certain processes represent attractive targets for treating certain diseases. As an example, mention may be made especially of angiogenesis and the control of the cell cycle, in which kinase proteins can play an essential role. These processes are essential for the growth of solid tumours and also for other diseases.

Angiogenesis or the formation of new blood vessels by sprouting from the preexisting vasculature is of central importance for embryonic development and organogenesis. Should the need arise, the vascular system has the potential to generate a network of new vessels so as to maintain the correct functioning of the tissues and organs. Angiogenesis is a complex multistage process which includes activation, migration, proliferation and survival of endothelial cells. In adults, angiogenesis is fairly limited, appearing mainly only in the processes of repair after an injury or of vascularization of the endometrium. (Merenmies et al., Cell Growth & Differentiation, 8, 3-10, 1997). However, uncontrolled angiogenesis is found in certain pathologies such as retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration or cancer (solid tumours) (Folkman, Nature Med., 1, 27-31, 1995). The kinase proteins whose involvement it has been possible to demonstrate in the angiogenesis process include three members of the family of growth factor receptor tyrosine kinases: VEGF-R2 (vascular endothelial growth factor receptor 2, also known as KDR, kinase insert domain receptor, or FLK-1), FGF-R (fibroblast growth factor receptor) and TEK (also known as Tie-2).

In conjunction with other systems, the Vascular Endothelial Growth Factor receptors (VEGFRs) transmit signals involved in the migration, proliferation and survival of endothelial cells. The family VEGFR includes VEGFR-1 (Flt-1), VEGFR-2 (KDR) and VEGFR3 (Flt4). The receptor VEGF-R2, which is expressed only in the endothelial cells, binds to the angiogenic growth factor VEGF, and thus serves as a transduction signal mediator via the activation of its intracellular kinase domain. Thus, the direct inhibition of the kinase activity of VEGF-R2 makes it possible to reduce the phenomenon of angiogenesis in the presence of exogenous VEGF (Strawn et al., Cancer Research, 56, 3540-3545, 1996), this process being demonstrated especially with the aid of VEGF-R2 mutants (Millauer et al., Cancer Research, 56, 1615-1620, 1996). The VEGF-R2 receptor appears to have no other function in adults than that associated with the angiogenic activity of VEGF. Thus, a selective inhibitor of the kinase activity of VEGF-R2 should show only little toxicity.

In addition to this central role in the dynamic angiogenic process, recent results suggest that the expression of VEGF contributes towards the survival of tumoral cells after chemotherapy and radiotherapy, underlining the potential synergism of KDR inhibitors with other agents (Lee C.G., Heijn M. et al., (2000), Cancer Research, 60 (19), 5565-70). The KDR inhibitors thus especially constitute anti-angiogenic agents and such agents might be used as a first line treatment against the emergence or regrowth of malignant tumours. The inhibition or regulation of VEGFR-2 (KDR) thus provides a powerful new mechanism of action for the treatment of a large number of solid tumours.

Extensive studies in the field of tumor angiogenesis in the past two decades have identified a number of therapeutic targets including kinases, proteases and integrins resulting in the discovery of many new anti-angiogenic agents, including KDR inhibitors some of which are currently under clinical evaluation (Jekunen, et al Cancer Treatment Rev. 1997 , 23, pages 263-286.).

The present patent application thus relates particularly to novel inhibitors of the VEGFR-2 (KDR) receptor that may be used especially for anti-angiogenic treatment in oncology.

The protein kinases which preferentially catalyse the phosphorylation of hydroxy groups of serine and/or threonine residues include for example, protein kinase C isoforms [A.C.Newton, J. Biol. Chem., 1995, 270, pages 28495-28498] and a group of cyclin-dependent kinases such as cdk2 [J.Pines, Trends in Biochemical Sciences, 1995, 18, pages 195-197]. The protein kinases which preferentially catalyse the phosphorylation of hydroxy groups of serine and/or threonine residues include membrane-spanning growth factor receptors such as the epidermal growth factor receptor [S.Iwashita and M.Kobayashi,

Cellular Signalling, 1992, 4, pages 123-132], and cytosolic non-receptor kinases such as p56lck, p59fYn, ZAP-70 and csk kinases [C.Chan et. al., Ann. Rev. Immunol., 1994, 12, pages 555-592].

Inappropriately high protein kinase activity has been implicated in many diseases resulting from abnormal cellular function. This might arise either directly or indirectly, for example by failure of the proper control mechanisms for the kinase, related for example to mutation, over-expression or inappropriate activation of the enzyme; or by over- or underproduction of cytokines or growth factors also participating in the transduction of signals upstream or downstream of the kinase. In all of these instances, selective inhibition of the action of the kinase might be expected to have a beneficial effect.

SYK (Spleen Tyrosine Kinase) is a 72-kDa cytoplasmic protein tyrosine kinase that is expressed in a variety of hematopoietic cells and is an essential element in several cascades that couple antigen receptors to cellular responses. Thus, SYK plays a pivotal role in signalling of the high affinity IgE receptor, FcεR1, in mast cells and in receptor antigen signalling in T and B lymphocytes. The signal transduction pathways present in mast, T and B cells have common features. The ligand binding domain of the receptor lacks intrinsic tyrosine kinase activity. However, they interact with transducing subunits that contain immunoreceptor tyrosine based activation motifs (ITAMs) [M.Reth, Nature, 1989, 338, pages 383-384]. These motifs are present in both the β and γ subunits of the FcεR1, in the ξ-subunit of the T cell receptor (TCR) and in the IgGα and IgG β subunits of the B cell receptor (BCR). [N.S.van Oers and A.Weiss, Seminars in Immunology, 1995, 7, pages 227-236] Upon binding of antigen and multimerization, the ITAM residues are phosphorylated by protein tyrosine kinases of the Src family. SYK belongs to a unique class of tyrosine kinases that have two tandem Src homology 2 (SH2) domains and a C terminal catalytic domain. These SH2 domains bind with high affinity to ITAMs and this SH2 -mediated association of SYK with an activated receptor stimulates SYK kinase activity and localises SYK to the plasma membrane.

In SYK deficient mice, mast cell degranulation is inhibited, suggesting that this is an important target for the development of mast cell stabilising agents [P.S.Costello, Oncogene, 1996, 13, pages 2595-2605]. Similar studies have demonstrated a critical role for SYK in BCR and TCR signalling [A.M.Cheng, Nature, 1995, 378, pages 303-306, (1995) and D.H.Chu et al., Immunological Reviews, 1998, 165, pages 167-180]. SYK also appears to be involved in eosinophil survival in response to IL-5 and GM-CSF [S.Yousefi et al., J. Exp. Med., 1996, 183, pages 1407-1414]. Despite the key role of SYK in mast cell, BCR and T cell signalling, little is known about the mechanism by which SYK transmits downstream effectors. Two adaptor proteins, BLNK (B cell Linker protein, SLP-65) and SLP-76 have been shown to be substrates of SYK in B cells and mast cells respectively and have been postulated to interface SYK with downstream effectors [M.Ishiai et al., Immunity, 1999, 10, pages 117-

125 and L.R.Hendricks-Taylor et al., J.Biol. Chem, 1997, 272, pages 1363-1367]. In addition SYK appears to play an important role in the CD40 signalling pathway, which plays an important role in B cell proliferation [M.Faris et al., J.Exp. Med., 1994, 179, pages 1923-1931].

SYK is further involved in the activation of platelets stimulated via the low-affinity IgG receptor (Fc gamma-RIIA) or stimulated by collagen [F.Yanaga et al., Biochem. J., 1995, 311, (Pt. 2) pages 471-478].

ITK, is a T cell specific tyrosine kinase of the Tec family that is required for normal Th2 function. Asthma is a disease characterised by increased Th2 cytokine production including IL-4. An inhibitor of ITK should therefore have an impact on disease progression in asthma through inhibition of Th2 cytokine production.

We have now found a novel group of benzimidazoles, which have valuable pharmaceutical properties, in particular, the ability to inhibit protein kinases, more particularly, the ability to inhibit the protein kinase SYK, the protein kinase KDR, the protein kinase tie2 or the protein kinase ITK.

Thus, in one aspect, the present invention is directed to pharmaceutical compositions comprising compounds of general formula (Ix):-



(Ix)

wherein, for the purposes of (Ix):-

X represents C-R^2 and W, Y and Z, which may be identical or different, represent CH or CR^3; or

W represents CH, X represents N, Y represents CH or CR^3, and Z represents CH or CR^3; or

W represents N, X represents CH or CR^2, Y represents CH and CR^3, and Z represents CH or CR^3; or

W represents N, X represents CH or CR^2, Y represents N, and Z is CH or CR^3; or

W represents N, X represents CH or CR^2, Y represents CH or CR^3, and Z represents N; or

W represents N, X represents N, Y represents CH or CR^3, and Z represents CH or CR^3;

A_5 represents H or alkyl;

R^1 represents aryl or heteroaryl, each optionally substituted by one or more groups selected from carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R^4, $-C(=O)R^4$, $-C(=O)NY^1Y^2$, $-C(=O)OR^4$, $-N(R^6)C(=O)R^4$, $-N(R^6)C(=O)NY^1Y^2$, $-N(R^6)C(=O)OR^4$, $-N(R^6)SO_2R^4$, $-N(R^6)SO_2NY^1Y^2$, $-NY^1Y^2$, $-OR^4$, $-OCF_2H$, $-OCF_3$, $-OC(=O)R^4$, $-OC(=O)NY^1Y^2$, $-OS(O)_nR^4$, $-S(O)_nR^4$, $-S(O)_nNY^1Y^2$ and $-S(O)_nOR^4$;

R^2 and R^3 are such that:

R^2 and R^3, which may be identical or different, represent H, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R^4, $-C(=O)R^4$, $-C(=O)NY^1Y^2$, $-C(=O)OR^4$, $-NY^1Y^2$, $-N(R^6)C(=O)R^4$, $-N(R^6)C(=O)NY^1Y^2$, $-N(R^6)C(=O)OR^4$, $-N(R^6)SO_2R^4$, $-N(R^6)SO_2NY^1Y^2$, $-OR^4$, $-OCF_2H$, $-OCF_3$, $-OC(=O)R^4$, $-OC(=O)NY^1Y^2$, $-S(O)_nR^4$, $-S(O)_nNY^1Y^2$ or $-S(O)_nOR^4$; or

R^2 represents H, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R^4, $-C(=O)R^4$, $-C(=O)NY^1Y^2$, $-C(=O)OR^4$, $-NY^1Y^2$, $-N(R^6)C(=O)R^4$, $-N(R^6)C(=O)NY^1Y^2$, $-N(R^6)C(=O)OR^4$, $-N(R^6)SO_2R^4$, $-N(R^6)SO_2NY^1Y^2$, $-OR^4$, $-OCF_2H$, $-OCF_3$, $-OC(=O)R^4$, $-OC(=O)NY^1Y^2$, $-S(O)_nR^4$, $-S(O)_nNY^1Y^2$ or $-S(O)_nOR^4$ and R^3 represents alkyl, haloalkyl, halogen and OR^6; or

R^2 and R^3 groups on adjacent carbon atoms may form a 5- to 6-membered carbon-based ring containing one or more heteroatoms, which may be identical or different, chosen from O, N and S, and which may be optionally substituted by alkyl [examples include those where R^2 and R^3 form a group selected from $-O-CH_2-O-$, $-O-CH_2-CH_2-O-$; $-CH_2-O-CH_2-$, $-CH_2-N(R^{14})-CH_2-$, $-CH_2-CH_2-CH_2-$, $-CH_2-C(CH_3)_2-CH_2-$, $-CH_2-O-CH_2-CH_2-$, $-CH_2-N(R^{14})-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-CH_2-$, $-CH_2-C(CH_3)_2-CH_2-CH_2-$, $-CH=CH-CH=CH-$, $-N=CH-CH=CH-$, $-CH=N-CH=CH-$, $-CH=CH-N=CH-$ or $-CH=CH-CH=N$, in which R^{14} is H or alkyl)];

R^4 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, each optionally substituted with one or more substituents selected from alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, halo, hydroxy, hydroxyalkyl, $-C(=O)NY^3Y^4$, $-C(=O)OR^6$, $-N(R^6)C(=O)NY^1Y^2$, $-NY^1Y^2$, $-OR^5$ or alkyl substituted by $-NY^3Y^4$;

R^5 is alkyl, alkenyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

R^6 is chosen from the values of R^5;

n is zero or an integer 1 or 2;

Y^1 and Y^2 are independently hydrogen, alkenyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, heterocycloalkylalkyl or alkyl optionally substituted by one or more groups selected from cyano, aryl,

heteroaryl, hydroxy, $-C(=O)OR^6$, $-C(=O)NY^3Y^4$, $-NY^3Y^4$ or $-OR^5$, or the group $-NY^1Y^2$ may form a cyclic amine;

Y^3 and Y^4 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group $-NY^3Y^4$ may form a cyclic amine;

all the alkyl (or alk, which represents alkyl), alkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl radicals present in the above radicals furthermore being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, acylamino (NH-COalk), $-C(=O)OR^6$, $-C(=O)R^6$, hydroxyalkyl, carboxyalkyl, $S(O)_n$-alk, $S(O)_n-NH_2$, $S(O)_n$-NH(alk), $S(O)_n-N(alk)_2$, CF_3, OCF_3, NO_2, arylalkoxy, aryl, heteroaryl, aryloxy, aryloxyalkyl, $-C(=O)-NY^3Y^4$ and NY^3Y^4 radicals, the latter radicals containing alkyl, aryl and heteroaryl being themselves optionally substituted with one or more radicals chosen from halogen atoms and alkyl radicals, free, salified or esterified carboxyl radicals and acylamino radicals $NH-C(O)R^5$;

and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and their prodrugs, and their acid bioisosteres; together with one or more pharmaceutically acceptable carriers or excipients.

In another aspect, the invention concerns the compounds of formula (Ix) as defined above wherein R^1 is a pyrazolyl moiety  in which R^7 is hydrogen or alkyl, and R^8 and R^9 are independently selected from hydrogen, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R^4, $-C(=O)R^4$, $-C(=O)NY^1Y^2$, $-C(=O)OR^4$, $-N(R^6)C(=O)R^4$, $-N(R^6)C(=O)NY^1Y^2$, $-N(R^6)C(=O)OR^4$, $-N(R^6)SO_2R^4$, $-N(R^6)SO_2NY^1Y^2$, $-NY^1Y^2$, $-OR^4$, $-OC(=O)R^4$, $-OC(=O)NY^1Y^2$, $-S(O)_nR^4$ and $-S(O)_2NY^1Y^2$; or R^8 and R^9 together with the carbon atoms to which they are attached form (i) a 5 to 8 membered carbocyclic ring optionally substituted by one or more carbocyclic ring substituents; (ii) a phenyl ring optionally substituted by one or more aryl group substituents; (iii) a 5 or 6 membered heteroaromatic ring in which one or more of the ring members is/are nitrogen, oxygen or sulfur (examples of such groups include furyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl groups) and which is optionally substituted by one or more groups selected from haloalkyl, hydroxy, halo, cyano, nitro, R^4, $-C(=O)NY^1Y^2$, $-N(R^6)C(=O)R^4$, $-N(R^6)C(=O)NY^1Y^2$, $-N(R^6)SO_2R^4$,

$-NY^1Y^2$ and $-OR^5$; or (iv) a 5 or 6 membered heterocyclic ring optionally substituted by alkyl or oxo, and containing a heteroatom-containing group selected from O, S, SO_2, or NY^5 (where Y^5 is hydrogen, R^4, $-C(=O)R^4$, $-C(=O)NY^1Y^2$, $-C(=O)OR^4$ or $-SO_2R^4$); but excluding the compounds: 2-(2H-pyrazol-3-yl)-1H-benzoimidazole; 2-(5-methyl-2H-pyrazol-3-yl)-1H-benzoimidazole; 5-methyl-6-[2-(2H-pyrazol-3-yl)-3H-benzoimidazol-5-yl]-4,5-dihydro-2H-pyridazin-3-one; 5-methyl-6-[2-(2H-pyrazol-3-yl)-1H-benzoimidazol-4-yl]-4,5-dihydro-2H-pyridazin-3-one; 3,5-bis(benzimidazol-2-yl)-1H-pyrazole; 5,6-dimethyl-2-(5-methyl-1H-pyrazol-3-yl)-1H-benzoimidazole; 6-methyl-2-(5-methyl-1H-pyrazol-3-yl)-1H-benzoimidazole; 5,6-dichloro-2-(5-methyl-1H-pyrazole-3-yl)-1H-benzoimidazole; 5-nitro-2-(5-methyl-1H-pyrazole-3-yl)-1H-benzoimidazole; 2-(5-methyl-1H-pyrazole-3-yl)-1H-benzoimidazole-5-carboxylic acid; 2-(5-phenyl-1H-pyrazole-3-yl)-1H-benzoimidazole; 5,6-dimethyl-2-(5-phenyl-1H-pyrazole-3-yl)-1H-benzoimidazole; 5-methyl-2-(5-phenyl-1H-pyrazole-3-yl)-1H-benzoimidazole; 6-chloro-2-(5-methyl-1H-pyrazole-3-yl)-1H-benzoimidazole; 5-chloro-2-(5-phenyl-1H-pyrazole-3-yl)-1H-benzoimidazole; 5,6-dichloro-2-(5-phenyl-1H-pyrazole-3-yl)-1H-benzoimidazole; N-[2-(5-isoquinolin-4-yl-1H-indazol-3-yl)-3H-benzoimidazol-5-yl]-methanesulfonamide; 3-(1H-benzoimidazol-2-yl)-5-(1H-indazol-4-yl)-1H-indazole, 3-[3-(1H-benzoimidazol-2-yl)-1H-indazol-5-yl]-2-methoxyphenol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-5-yl]isoquinoline; 4-{3-[6-(4-methyl-piperazin-1-yl)-1H-benzoimidazol-2-yl]-1H-indazol-5-yl}-isoquinoline; 4-[3-(4-chloro-1H-benzoimidazol-2-yl)-1H-indazol-5-yl]-isoquinoline; 4-[2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-phenol; 3-[5-(4-methoxy-phenyl)-1H-benzoimidazol-2-yl]-1H-indazole; 3-[5-(4-methoxy-phenyl)-1H-benzoimidazol-2-yl]-1H-indazole; 3-[5-(3-methoxy-phenyl)-1H-benzoimidazol-2-yl]-1H-indazole; 3-(1H-benzoimidazol-2-yl)-5-phenyl-1H-indazole; 2-(4-bromo-1-methyl-1H-pyrazol-3-yl)-1H-benzoimidazole; 2-(5-*tert*-butyl-1H-pyrazol-3-yl)-1H-benzoimidazole; 3-(1H-benzoimidazol-2-yl)-6-(3-methoxy-phenyl)-1H-indazole; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid; 5-{[3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carbonyl]-amino}-2-hydroxy-benzoic acid methyl ester; 5-{[3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carbonyl]-amino}-furan-2-carboxylic acid methyl ester; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (3-hydroxy-4-methoxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (5-hydroxy-1H-pyrazol-3-yl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (1H-pyrazol-3-yl)-amide; [3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-[4-(2-hydroxy-ethyl)-piperidin-1-yl]-methanone; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (9H-purin-6-yl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid dimethylamide; [3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-morpholin-4-yl-methanone; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid pyrazin-2-ylamide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid cyclohexylamide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (1H-indazol-5-yl)-amide; [3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-pyrrolidin-1-yl-methanone; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic

acid (1H-indazol-5-yl)-amide; [3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-[4-(furan-2-carbonyl)-piperazin-1-yl]-methanone; [3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-(4-methyl-piperazin-1-yl)-methanone; 1-{4-[3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carbonyl]-piperazin-1-yl}-ethanone; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (6-methoxy-pyridin-3-yl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (3-hydroxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid pyridin-4-ylamide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (2-morpholin-4-yl-ethyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (2-hydroxy-ethyl)-methyl-amide; 3-{[3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carbonyl]-amino}-butyric acid ethyl ester; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (3-hydroxy-propyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid phenylamide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid pyridin-3-ylamide; 3-(6-methoxy-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-6-pyridin-4-yl-1H-indazole; 3-(5-chloro-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(5-fluoro-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(6-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(6-*tert*-butyl-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(6,7-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(5,6-dichloro-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(5,6-difluoro-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (3-fluoro-4-hydroxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-2,3-dimethyl-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-2-methyl-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid cyclopropylamide; 2-[6-(4-hydroxy-2-methoxy-phenyl)-1H-indazol-3-yl]-3H-benzoimidazole-5-sulfonic acid amide; 4-[3-(6-dimethylamino-1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-3-methoxy-phenol; 2-[6-(4-hydroxy-2-methoxy-phenyl)-1H-indazol-3-yl]-3H-benzoimidazole-5-carboxylic acid methylamide; 3-methoxy-4-{3-[6-(4-methyl-piperazin-1-yl)-1H-benzoimidazol-2-yl]-1H-indazol-6-yl}-phenol; 2-[6-(4-hydroxy-2-methoxy-phenyl)-1H-indazol-3-yl]-3H-benzoimidazole-5-carboxylic acid (2-morpholin-4-yl-ethyl)-amide; 4-[3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl]-3-methoxy-phenol; 3-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-2-methoxy-phenol; 3-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-phenol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-3,5-dimethyl-phenol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-3-phenoxy-phenol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-benzene-1,3-diol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-3-methoxy-phenol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-2-methoxy-phenol;

N-{3-[3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carbonyl]-phenyl}-benzamide; 6-[2-(1,5-dimethyl-1H-pyrazol-3-yl)-3H-benzoimidazol-5-yl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one; 5-methyl-6-[2-(1-methyl-1H-pyrazol-3-yl)-3H-benzoimidazol-5-yl]-4,5-dihydro-2H-pyridazin-3-one; 8-(1,5-dimethyl-1H-pyrazol-3-yl)-7H-purine; 2-(1,5-dimethyl-1H-pyrazol-3-yl)-1H-imidazo[4,5-b]pyridine and 2-(5-methyl-1H-pyrazol-3-yl)-1H-imidazo[4,5-b]pyridine.

In the present specification, the term "compounds of the invention", and equivalent expressions, are meant to embrace compounds of general formula (Ix) as hereinbefore described, which expression includes the prodrugs, the pharmaceutically acceptable salts, and the solvates, e.g. hydrates, where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits. For the sake of clarity, particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative and it is not intended to exclude other instances when the context so permits.

As used above for compounds of formula (Ix), and throughout the description of the invention hereinafter, the following terms unless otherwise indicated, shall be understood to have the following meanings:-

"Patient" includes both human and other mammals.

"Acid bioisostere" means a group which has chemical and physical similarities producing broadly similar biological properties to a carboxy group (see Lipinski, Annual Reports in Medicinal Chemistry, 1986,21,p283 "Bioisosterism In Drug Design"; Yun, Hwahak Sekye, 1993, 33, pages 576-579 "Application Of Bioisosterism To New Drug Design"; Zhao, Huaxue Tongbao, 1995, pages 34-38 "Bioisosteric Replacement And Development Of Lead Compounds In Drug Design"; Graham, Theochem, 1995, 343, pages 105-109 "Theoretical Studies Applied To Drug Design:ab initio Electronic Distributions In Bioisosteres"). Examples of suitable acid bioisosteres include: -C(=O)-NHOH, -C(=O)-CH_2OH, -C(=O)-CH_2SH, -C(=O)-NH-CN, sulfo, phosphono, alkylsulfonylcarbamoyl, tetrazolyl, arylsulfonylcarbamoyl, heteroarylsulfonylcarbamoyl, N-methoxycarbamoyl, 3-hydroxy-3-cyclobutene-1,2-dione, 3,5-dioxo-1,2,4-oxadiazolidinyl or heterocyclic phenols such as 3-hydroxyisoxazolyl and 3-hydoxy-1-methylpyrazolyl.

"Acyl" denotes a radical R-C(=O)- in which R represents a radical chosen from a hydrogen atom, linear or branched alkyl radicals containing not more than 6 carbon atoms; optionally substituted amino; aryl, heteroaryl, cycloalkyl or heterocycloalkyl radicals, for example phenyl or pyrrolidinyl

radicals: the term “acyl” thus especially denotes, for example, formyl radicals and acetyl, propionyl, butanoyl, pentanoyl, hexanoyl, benzoyl and pyrrolidinylcarbonyl radicals.

“Acylamino” denotes $-C(=O)-NH_2$, -C(O)-NH(alk) and –C(O)-N(alk)(alk) radicals: in these radicals, NH(alk) and N(alk)(alk) have the meanings given hereinafter defined.

"Alkenyl" means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain and containing one or more double bonds. Preferred alkenyl groups have 2 to about 12 carbon atoms in the chain; and more preferably 2 to about 6 carbon atoms (e.g. 2 to 4 carbon atoms) in the chain. "Branched," as used herein and throughout the text, means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear chain; here a linear alkenyl chain. "Lower alkenyl" means about 2 to about 4 carbon atoms in the chain, which may be straight or branched. Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexylbutenyl, decenyl, and 3,7-dimethyl-octa-2,6-dienyl.

"Alkoxy" means an alkyl-O- group in which the alkyl group is as described herein. Exemplary alkoxy groups include difluoromethoxy, methoxy, trifluoromethoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, pentoxy, hexoxy and heptoxy, and also the linear or branched positional isomers thereof.

"Alkoxycarbonyl" means an alkyl-O-CO- group in which the alkyl group is as described herein. Exemplary alkoxycarbonyl groups include methoxy- and ethoxycarbonyl.

"Alkyl" means, unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched chain having about 1 to about 15 carbon atoms in the chain, optionally substituted by one or more halogen atoms. Particular alkyl groups have from 1 to about 6 carbon atoms. "Lower alkyl" as a group or part of a lower alkoxy, lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl group means unless otherwise specified, an aliphatic hydrocarbon group which may be a straight or branched chain having 1 to about 4 carbon atoms in the chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl, 3-pentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl and dodecyl, and also the linear or branched positional isomers thereof. Exemplary alkyl groups substituted by one or more halogen atoms include trifluoromethyl, difluoromethyl, trifluoroethyl and difluoroethyl.

"Alkylene" means an aliphatic bivalent radical derived from a straight or branched alkyl group, in which the alkyl group is as described herein. Exemplary alkylene radicals include methylene, ethylene and trimethylene.

"Alkylenedioxy" means an -O-alkylene-O- group in which alkylene is as defined above. Exemplary alkylenedioxy groups include methylenedioxy and ethylenedioxy.

"Alkylsulfinyl" means an alkyl-SO- group in which the alkyl group is as previously described. Preferred alkylsulfinyl groups are those in which the alkyl group is C_{1-4}alkyl.

"Alkylsulfonyl" means an alkyl-SO_2- group in which the alkyl group is as previously described. Preferred alkylsulfonyl groups are those in which the alkyl group is C_{1-4}alkyl.

"Alkylsulfonylcarbamoyl" means an alkyl-SO_2-NH-C(=O)- group in which the alkyl group is as previously described. Preferred alkylsulfonylcarbamoyl groups are those in which the alkyl group is C_{1-4}alkyl.

"Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Exemplary alkylthio groups include methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, isopentylthio, hexylthio, isohexylthio and heptylthio, and also the linear or branched positional isomers thereof. Preferred alkylthio groups have not more than 4 carbon atoms.

"Alkynyl" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which group may be a straight or branched chain having about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have 2 to about 12 carbon atoms in the chain; and more preferably 2 to about 6 carbon atoms (e.g. 2 to 4 carbon atoms) in the chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, i-butynyl, 3-methylbut-2-ynyl, and n-pentynyl.

"Aroyl" means an aryl-CO- group in which the aryl group is as described herein. Exemplary aroyl groups include benzoyl and 1- and 2-naphthoyl.

"Aroylamino" is an aroyl-NH- group wherein aroyl is as previously defined.

"Aryl" as a group or part of a group denotes: (i) an optionally substituted monocyclic or multicyclic aromatic carbocyclic moiety of about 6 to about 14 carbon atoms, such as phenyl or naphthyl; or (ii) an optionally substituted partially saturated multicyclic aromatic carbocyclic moiety in which a monocyclic aromatic carbocyclic moiety and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure, such as a tetrahydronaphthyl, indenyl or indanyl ring. Except where otherwise defined, aryl groups may be substituted with one or more aryl group substituents, which may be the same or different, where "aryl group substituent" includes, for example, acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy (or an acid bioisostere), cyano, cycloalkyl, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, heterocycloalkyl, hydroxy, nitro, trifluoromethyl, $-C(=O)NY^1Y^2$, $-NY^1-C(=O)alkyl$, $-NY^1SO_2alkyl$, $-NY^1Y^2$, $-SO_2NY^1Y^2$ or alkyl, alkenyl or alkynyl each optionally substituted with aryl, cycloalkyl, heteroaryl, hydroxy, $-C(=O)OR^6$, $-C(=O)NY^1Y^2$, $-NY^1Y^2$ or $-OR^5$.

"Arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contain a C_{1-4}alkyl moiety. Exemplary arylalkyl groups include benzyl, 2-phenethyl and naphthlenemethyl.

"Arylalkyloxy" means an arylalkyl-O- group in which the arylalkyl group is as previously described. Exemplary arylalkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy.

"Arylalkyloxycarbonyl" means an arylalkyl-O-CO- group in which the arylalkyl group is as previously described. An exemplary arylalkyloxycarbonyl group is benzyloxycarbonyl.

"Arylalkylthio" means an arylalkyl-S- group in which the arylalkyl group is as previously described. An exemplary arylalkylthio group is benzylthio.

"Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Exemplary aryloxy groups include phenoxy and naphthoxy, each optionally substituted.

"Aryloxycarbonyl" means an aryl-O-C(=O)- group in which the aryl group is as previously described. Exemplary aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.

"Arylsulfinyl" means an aryl-SO- group in which the aryl group is as previously described.

"Arylsulfonyl" means an aryl-SO_2- group in which the aryl group is as previously described.

"Arylsulfonylcarbamoyl" means an aryl-SO_2-NH-C(=O)- group in which the aryl group is as previously described.

"Arylthio" means an aryl-S- group in which the aryl group is as previously described. Exemplary arylthio groups include phenylthio and naphthylthio.

"Carbocyclic" means a saturated ring system comprising carbon atoms.

"Carbocyclic group substituent" includes, for example, acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy (or an acid bioisostere), cyano, cycloalkyl, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, heterocycloalkyl, hydroxy, nitro, trifluoromethyl, -C(=O)NY^1Y^2, -NY^1-C(=O)alkyl, -NY^1SO_2alkyl, -NY^1Y^2, -$SO_2NY^1Y^2$ or alkyl, alkenyl or alkynyl each optionally substituted with aryl, cycloalkyl, heteroaryl, hydroxy, -C(=O)OR^6, -C(=O)NY^1Y^2, -NY^1Y^2 or –OR^5.

"Cyclic amine" means a 3 to 8 membered monocyclic cycloalkyl ring system wherein one of the ring carbon atoms is replaced by nitrogen and which (i) may also contain a further heteroatom-containing group selected from O, S, SO_2, or NY^6 (where Y^6 is hydrogen, alkyl, aryl, arylalkyl, -C(=O)R^5, -C(=O)OR^5, -C(=O)NY^1Y^2 or -SO_2R^5); and (ii) may be fused to additional aryl (e.g. phenyl), heteroaryl (e.g. pyridyl), heterocycloalkyl or cycloalkyl rings to form a bicyclic or tricyclic ring system. Exemplary cyclic amines include pyrrolidine, piperidine, morpholine, piperazine, indoline, pyrindoline, tetrahydroquinoline and the like groups.

"Cycloalkenyl" means a non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having about 3 to about 10 carbon atoms. Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl and cycloheptenyl.

"Cycloalkyl" means a saturated monocyclic or bicyclic ring system of about 3 to about 10 carbon atoms, optionally substituted by oxo. Exemplary monocyclic cycloalkyl rings include C_{3-8}cycloalkyl rings such as cyclopropyl, cyclopentyl, cyclohexyl and cycloheptyl.

"Cycloalkylalkyl" means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described. Exemplary monocyclic cycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.

"Halo" or "halogen" means fluoro, chloro, bromo, or iodo. Preferred are fluoro, bromo and chloro.

"Haloalkyl" means an alkyl group having about 1 to about 6 carbon atoms in the chain and substituted by one or more halo atoms. Exemplary haloalkyl groups include trifluoromethyl.

"Heteroaroyl" means a heteroaryl-C(=O)- group in which the heteroaryl group is as described herein. Exemplary heteroaryl groups include pyridylcarbonyl.

"Heteroaroylamino" means a heteroaroyl-NH- group in which the heteroaryl moiety is as previously described.

"Heteroaryl" as a group or part of a group denotes: (i) an optionally substituted aromatic monocyclic or multicyclic organic moiety of about 5 to about 10 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulfur (examples of such groups include benzoimidazolyl, benzothiazolyl, furyl, imidazolyl, indazolyl, indolyl, indolizinyl, isoxazolyl, isoquinolinyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl groups, optionally substituted by one or more aryl group substituents as defined above except where otherwise defined); (ii) an optionally substituted partially saturated multicyclic heterocarbocyclic moiety in which a monocyclic heteroaromatic moiety and a cycloalkyl, cycloalkenyl or heterocycloalkyl group are fused together to form a cyclic structure (examples of such groups include tetrahydro-indazole, tetrahydro-pyrazolopyridine, 5-oxo-1,4,5,6,7,8,9,9a-octahydro-1,2,4,5a-tetraza-cyclopenta[a]naphthyl, optionally substituted by one or more "aryl group substituents" as defined above, except where otherwise defined). Optional substituents include one or more "aryl group substituents" as defined above, except where otherwise defined. When R^1 is heteroaryl this may particularly represent pyrazolyl, triazolyl, isoxazolyl, isothiazolyl, thiazolyl, oxazolyl, imidazolyl, pyrrolyl, furanyl, thiophenyl, phenyl, pyridinyl, oxodihydropyridinyl, pyrimidinyl, indolyl, indazolyl, thienopyrazolyl, tetrahydroindazolyl, tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl, oxodihydropyridazinyl, tetrahydropyrrolopyrazolyl, oxotetrahydropyrrolopyrazolyl, tetrahydropyranopyrazolyl, tetahydropyridinopyrazolyl, or oxodihydropyridinopyrazolyl.

"Heteroarylalkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a C_{1-4}alkyl moiety. Exemplary heteroarylalkyl groups include pyridylmethyl.

"Heteroarylalkyloxy" means an heteroarylalkyl-O- group in which the heteroarylalkyl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridylmethoxy.

"Heteroaryloxy" means an heteroaryl-O- group in which the heteroaryl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridyloxy.

"Heteroarylsulfonylcarbamoyl" means a heteroaryl-SO_2-NH-C(=O)- group in which the heteroaryl group is as previously described.

"Heterocycloalkyl" means: (i) a cycloalkyl group of about 3 to 10 ring members which contains one or more heteroatoms or heteroatom-containing groups selected from O, S and NY^6 and may be optionally substituted by oxo (examples of such groups include hexahydropyran, pyrrolidinyl, piperidinyl, tetrahydropyranyl and octahydro-pyrido[1,2-c]pyrimidin-1-one); (ii) a partially saturated multicyclic heterocarbocyclic moiety in which an aryl (or heteroaryl) ring, each optionally substituted by one or more "aryl group substituents," and a heterocycloalkyl group are fused together to form a cyclic structure (examples of such groups include chromanyl, dihydrobenzofuranyl, indolinyl and pyrindolinyl groups).

"Heterocycloalkylalkyl" means a heterocycloalkyl-alkyl- group in which the heterocycloalkyl and alkyl moieties are as previously described.

"Hydroxyalkyl" means an alkyl group substituted by one or hydroxy groups.

"NH(alk)" and "N(alk)(alk)" denote an amino radical substituted, respectively, with one or two alkyl radicals, such alkyl radicals being linear or branched and chosen from alkyl radicals as defined above, preferably containing not more than 4 carbon atoms.

"Prodrug" means a compound which is convertible *in vivo* by metabolic means (e.g. by hydrolysis) to a compound of formula (Ix), including N-oxides thereof. For example an ester of a compound of formula (Ix) containing a hydroxy group may be convertible by hydrolysis *in vivo* to the parent molecule. Alternatively, an ester of a compound of formula (Ix) containing a carboxy group may be convertible by hydrolysis *in vivo* to the parent molecule.

Suitable esters of compounds of formula (Ix) containing a hydroxy group are, for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-β-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonatcs, cyclohexylsulfamates and quinates.

Suitable esters of compounds of formula (Ix) containing a carboxy group are, for example, those described by F.J.Leinweber, Drug Metab. Res., 1987, 18, page 379.

An especially useful class of esters of compounds of formula (Ix) containing a hydroxy group, may be formed from acid moieties selected from those described by Bundgaard et. al., J. Med. Chem., 1989, 32 , pages 2503-2507, and include substituted (aminomethyl)-benzoates, for example dialkylamino-methylbenzoates in which the two alkyl groups may be joined together and/or interrupted by an oxygen atom or by an optionally substituted nitrogen atom, e.g. an alkylated nitrogen atom, more especially (morpholino-methyl)benzoates, e.g. 3- or 4-(morpholinomethyl)-benzoates, and (4-alkylpiperazin-1-yl)benzoates, e.g. 3- or 4-(4-alkylpiperazin-1-yl)benzoates.

Where the compound of the invention of formula (Ix) contains a carboxy group, or a sufficiently acidic bioisostere, base addition salts may be formed and are simply a more convenient form for use; in practice, use of the salt form inherently amounts to use of the free acid form. The bases which can be used to prepare the base addition salts include preferably those which produce, when combined with the free acid, pharmaceutically acceptable salts, that is, salts whose cations are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the cations. Pharmaceutically acceptable salts, including those derived from alkali and alkaline earth metal salts, within the scope of the invention include those derived from the following bases: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, tetramethylammonium hydroxide, and the like.

Some of the compounds of the present invention of formula (Ix) are basic, and such compounds are useful in the form of the free base or in the form of a pharmaceutically acceptable acid addition salt thereof.

Acid addition salts are a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free base form. The acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the anions. Although pharmaceutically acceptable salts of said basic compounds are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures. Pharmaceutically acceptable salts within the scope of the invention include those derived from mineral acids and organic acids, and include hydrohalides, e.g. hydrochlorides and hydrobromides, sulfates, phosphates, nitrates, sulfamates, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methane-sulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates.

As well as being useful in themselves as active compounds, salts of compounds of the invention of compounds of formula (Ix) are useful for the purposes of purification of the compounds, for example by exploitation of the solubility differences between the salts and the parent compounds, side products and/or starting materials by techniques well known to those skilled in the art.

It will be appreciated that compounds of the present invention of formula (Ix) may contain asymmetric centres. These asymmetric centres may independently be in either the R or S configuration. It will be apparent to those skilled in the art that certain compounds of the invention may also exhibit geometrical isomerism. It is to be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds of formula (Ix) hereinabove. Such isomers can be separated from their mixtures, by the application or adaptation of known methods, for example chromatographic techniques and recrystallisation techniques, or they are separately prepared from the appropriate isomers of their intermediates. Additionally, tautomers of the compounds of formula (Ix) are possible, and the present invention is intended to include all tautomeric forms of the compounds.

One subject of the present invention is thus the compounds of formula (I):



(I)

in which:

X represents C-R^2 and W, Y and Z, which may be identical or different, represent CH or CR^3;

R^1 represents aryl or heteroaryl chosen from pyrazolyl, triazolyl, imidazolyl, indolyl, indazolyl, thieno-pyrazolyl, tetrahydroindazolyl, tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl, oxodihydropyridazinyl, tetrahydropyrrolopyrazolyl, oxotetrahydropyrrolopyrazolyl, tetrahydropyranopyrazolyl, tetrahydropyridinopyrazolyl, and oxodihydropyridinopyrazolyl radicals, all these radicals being optionally substituted with one or more radicals X^1, X^2 or X^3 chosen from H, halogen, haloalkyl, OH, R^4, NO_2, CN, $S(O)_nR^4$, OR^4, NY^1Y^2, COR^4, $-C(=O)NY^1Y^2$, $-C(=O)OR^4$, -C(=O)OH, $-N(R^6)C(=O)R^4$, $-N(R^6)SO_2R^4$, $-N(R^6)C(=O)NY^1Y^2$, $-N(R^6)C(=O)OR^4$, -S(O)nOR^4, $-S(O)_nNY^1Y^2$, $-OC(=O)NY^1Y^2$, $-OS(O)_nR^4$, $-OC(=O)R^4$ and optionally substituted thienyl,

R^2 and R^3 are such that:

either R^2 and R^3, which may be identical or different, represent H, R^4, halogen, haloalkyl, OH, NO_2, CN, OR^4, COR^4, $S(O)_nR^4$, $-C(=O)NY^1Y^2$, $-C(=O)OR^4$, -C(=O)OH, $-NY^1Y^2$, $-N(R^6)C(=O)R^4$, $-N(R^6)SO_2R^4$, $-N(R^6)C(=O)NY^1Y^2$, $-N(R^6)C(=O)OR^4$, $-S(O)_nOR^4$, $-S(O)_nNY^1Y^2$, $-OC(=O)NY^1Y^2$ and $-OC(=O)R^4$

or R^2 represents H, R^4, halogen, haloalkyl, OH, NO_2, CN, OR^4, COR^4, $S(O)_nR^4$, $-C(=O)NY^1Y^2$, $-C(=O)OR^4$, -C(=O)OH, $-NY^1Y^2$, $-N(R^6)C(=O)R^4$, $-N(R^6)SO_2R^4$, $-N(R^6)C(=O)NY^1Y^2$, $-N(R^6)C(=O)OR^4$, $-S(O)_nOR^4$, $-S(O)_nNY^1Y^2$, $-OC(=O)NY^1Y^2$ and $-OC(=O)R^4$ and R^3 represents alkyl, haloalkyl, halogen and OR^6

or R^2 and R^3 together form a 5- to 6-membered carbon-based ring containing one or more hetero atoms, which may be identical or different, chosen from O, N and S,

R^4 represents alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, heteroarylalkyl and arylalkyl, all these radicals being optionally substituted with one or more radicals chosen from aryl (optionally substituted), halogen, alkyl, hydroxyalkyl, OH, OR^5, $C(=O)NY^3Y^4$, NY^3Y^4, alk-NY^3Y^4 and $C(=O)OR^6$,

R^5 represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl.

Y^1 and Y^2 are such that: either Y^1 and Y^2, which may be identical or different, represent H and optionally substituted alkyl, alkenyl, cycloalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl,
or Y^1 and Y^2 form, together with the nitrogen atom to which they are attached, a cyclic amino radical,

Y^3 and Y^4 are such that: either Y^3 and Y^4, which may be identical or different, represent hydrogen, alkcnyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl or Y^3 and Y^4 form, together with the nitrogen atom to which they are attached, an optionally substituted cyclic amino radical,

A_5 represents H or alkyl,

R^6 is chosen from the values of R^5,
all the alkyl (or alk, which represents alkyl), alkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl radicals present in the above radicals furthermore being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, acylamino (NH-COalk), -C(=O)OR^6, acyl -C(=O)R^6, hydroxyalkyl, carboxyalkyl, $S(O)_n$-alk, $S(O)_n$-NH_2, $S(O)_n$-NH(alk), $S(O)_n$-$N(alk)_2$, CF_3, OCF_3, NO_2, arylalkoxy, aryl, heteroaryl, aryloxy, aryloxyalkyl, -C(=O)-NY^3Y^4 and NY^3Y^4 radicals,

the latter radicals containing alkyl, aryl and heteroaryl being themselves optionally substituted with one or more radicals chosen from halogen atoms and alkyl radicals, free, salified or esterified carboxyl radicals and acylamino radicals NH-C(O)R^5,

the phenyl radicals furthermore being optionally substituted with a dioxole radical,

n represents an integer from 0 to 2,

it being understood that when R^1 represents an indazolyl radical to give the compounds of formula (F) below:



(F)

with X representing H, R^2 or R^3 as defined above, then W necessarily represents H or unsubstituted alkyl,

the said compounds of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral bases.

One subject of the present invention is thus the compoundss of formula (I) as defined above corresponding to the formula (Ia):



(Ia)

in which:

Xa represents C-R^2a and Wa, Ya and Za, which may be identical or different, represent CH or CR^3a; R_1a represents aryl or heteroaryl chosen from pyrazolyl, triazolyl and indazolyl radicals, all these radicals being optionally substituted with one or more radicals X^1a, X^2a or X^3a chosen from H, halogen, OH, R^4a, OR^4a, NY^1aY^2a, $S(O)_nR^4a$, -C(=O)NY^1aY^2a, -C(=O)OR^4a, -N(R^6a)C(=O)R^4a, -N(R^6a)SO_2R^4a, -N(R^6a)C(=O)NY^1aY^2a, -N(R^6a)C(=O)OR^4a, -OC(=O)NY^1aY^2a, -OC(=O)R^4a, -OS$(O)_nR^4$a and thienyl optionally substituted with an alkyl radical,

R^2a and R^3a are such that:

either R^2a and R^3a, which may be identical or different, represent H, R^4a, halogen, OH, OR^4a, C(=O)NY^1aY^2a, -C(=O)OR^4a and -C(=O)OH, and R^3a represents alkyl, halogen and OR^6a,

or R^2a represents H, R^4a, halogen, OH, OR^4a, C(=O)NY^1aY^2a, -C(=O)OR^4a and -C(=O)OH, and R^3a represents alkyl, halogen and OR^6a,

or R^2a and R^3a together form an -O-CH_2-O- or -O-CH_2-CH_2-O- ring,

R^4a represents alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, heteroarylalkyl and arylalkyl, all these radicals being optionally substituted with one or more radicals chosen from aryl (optionally substituted), halogen, alkyl, hydroxyalkyl, OH, OR^5a, C(=O)NY^3aY^4a, NY^3aY^4a, alk-NY^3aY^4a and C(=O)OR^6a,

R^5a represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl, all these radicals being optionally substituted,

Y^1a and Y^2a are such that: either Y^1a and Y^2a, which may be identical or different, represent H, alkyl, alkoxyalkyl, aryloxyalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkyl, aryl and heteroaryl, all these radicals being optionally substituted, or Y^1a and Y^2a form, together with the nitrogen atom to which they are attached, an optionally substituted cyclic amino radical,

Y^3a and Y^4a are such that: either Y^3a and Y^4a, which may be identical or different, represent hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl,

or Y^3a and Y^4a form, together with the nitrogen atom to which they are attached, a cyclic amino radical,

A_5 represents H or alkyl,

all the alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl radicals present in the above radicals furthermore being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, acylamino (NH-C(O)R^6a), -C(=O)OR^6a, acyl -C(=O)R^6a, hydroxyalkyl, carboxyalkyl, $S(O)_n$-alk, $S(O)_n$-NH_2, $S(O)_n$-NH(alk), $S(O)_n$-$N(alk)_2$, CF_3, OCF_3, NO_2, arylalkoxy, aryl, heteroaryl, aryloxy, aryloxyalkyl, -C(=O)-NY^3aY^4a and NY^3aY^4a radicals,

the latter radicals containing alkyl, aryl and heteroaryl themselves being optionally substituted with one or more radicals chosen from halogen atoms and alkyl radicals, alkoxy radicals, free, salified or esterified carboxyl radicals and acylamino radicals NH-C(O)R^6a,

the phenyl radicals furthermore being optionally substituted with a dioxole radical,

R^6a is chosen from the values of R^5a,

n represents an integer from 0 to 2,

the said compounds of formula (Ia) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral bases.

One subject of the present invention is thus the compounds of formula (I):



(I)

in which:

X represents C-R^2 and W, Y and Z, which may be identical or different, represent CH or CR^3;

R^1 represents aryl or heteroaryl chosen from pyrazolyl, triazolyl, imidazolyl, indolyl, indazolyl, thieno-pyrazolyl, tetrahydroindazolyl, tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl, oxodihydropyridazinyl, tetrahydropyrrolopyrazolyl, oxotetrahydropyrrolopyrazolyl, tetrahydropyrano-pyrazolyl, tetrahydropyridinopyrazolyl, and oxodihydro-pyridinopyrazolyl radicals, all these radicals optionally being substituted with one or more radicals X^1, X^2 or X^3 chosen from H, halogen, haloalkyl, OH, R^4, NO_2, CN, $S(O)_nR^4$, OR^4, NY^1Y^2, COR^4, -C(=O)NY^1Y^2, -C(=O)OR^4, -C(=O)OH, -N(R^6)C(=O)R^4, -N(R^6)SO_2R^4, -N(R^6)C(=O)NY^1Y^2, -N(R^6)C(=O)OR^4, -$S(O)_nOR^4$, -$S(O)_nNY^1Y^2$, -OC(=O)NY^1Y^2, -$OS(O)_nR^4$, -OC(=O)R^4 and optionally substituted thienyl,

R^2 and R^3 are such that:

either R^2 and R^3, which may be identical or different, represent H, R^4, halogen, haloalkyl, OH, NO^2, CN, OR^4, COR^4, $S(O)_nR^4$, -C(=O)NY^1Y^2, -C(=O)OR^4, -C(=O)OH, -NY^1Y^2, -N(R^6)C(=O)R^4, -N(R6)SO2R4, -N(R6)C(=O)NY1Y2, -N(R6)C(=O)OR4, -S(O)nOR4, -S(O)nNY1Y2, -OC(=O)NY^1Y^2 and -OC(=O)R^4

or R^2 represents H, R^4, halogen, haloalkyl, OH, NO_2, CN, OR^4, COR^4, $S(O)_nR^4$, -C(=O)NY^1Y^2, -C(=O)OR^4, -C(=O)OH, -NY^1Y^2, -N(R^6)C(=O)R^4, -N(R^6)SO_2R^4, -N(R_6)C(=O)NY^1Y^2, -N(R^6)C(=O)OR^4, -$S(O)_nOR^4$, -$S(O)_nNY^1Y^2$, -OC(=O)NY^1Y^2 and -OC(=O)R^4

and R^3 represents alkyl, haloalkyl, halogen and OR^6

or R^2 and R^3 together form a 5- to 6-membered carbon-based ring containing one or more hetero atoms, which may be identical or different, chosen from O, N and S,

R^4 represents alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, hetero-arylalkyl and arylalkyl, all these radicals being optionally substituted with one or more radicals chosen from aryl, OH, OR^5, C(=O)NY^3Y4, NY^3Y^4 and C(=O)OR^6,

R^5 represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl.

R^6 represents H and C1-C4 alkyl,

n represents an integer from 0 to 2

Y^1 and Y^2 are such that: either Y^1 and Y^2, which may be identical or different, represent H, alkyl, alkenyl, cycloalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, all these radicals being optionally substituted with one or more radicals chosen from hydroxyl, -C(=O)-NY^3Y^4, -C(=O)OR^6 and NY^3Y^4, or Y^1 and Y^2 form, together with the nitrogen atom to which they are attached, a cyclic amino radical,

Y^3 and Y^4 are such that: either Y^3 and Y^4, which may be identical or different, represent hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl or Y^3 and Y^4 form, together with the nitrogen atom to which they are attached, a cyclic amino radical,

A_5 represents H or alkyl,

it being understood that when R^1 represents an indazolyl radical
to give the compounds of formula (F) below:



(F)

with X representing H, R^2 or R^3 as defined above, then W necessarily represents H or unsubstituted alkyl,

the said compounds of formula (F) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral bases.

It is obvious that, according to the ring represented by R^1 and its number of members, R^1 can comprise one, two or three substituents represented by X^1, X^2 and X^3.

One subject of the present invention is thus the compounds of formula (I) as defined above corresponding to the formula (Ia):



(Ia)

in which:

Xa represents C-R^2a and Wa, Ya and Za, which may be identical or different, represent CH or CR^3a;

R^1a represents aryl or heteroaryl chosen from pyrazolyl, triazolyl or indazolyl radicals, all these radicals being optionally substituted with one or more radicals X^1a, X^2a or X^3a chosen from H, halogen, OH, R^4a, OR^4a, NY^1aY^2a, $S(O)_nR^4$a, -C(=O)NY^1aY^2a, -C(=O)OR^4a, -N(R^6a)C(=O)R^4a, -N(R^6a)SO_2R^4a, -N(R^6a)C(=O)NY^1aY^2a, -N(R^6a)C(=O)OR^4a, -OC(=O)NY^1aY^2a and -OC(=O)R^4a, -OS$(O)_nR^4$a and thienyl optionally substituted with an alkyl radical,

R^2a and R^3a are such that:

either R^2a and R^3a, which may be identical or different, represent H, R^4a, halogen, OH, OR^4a, C(=O)NY^1aY^2a, -C(=O)OR^4a, -C(=O)OH, and R^3a represents alkyl, halogen and OR^6a,

or R^2a represents H, R^4a, halogen, OH, OR^4a, C(=O)NY1aY^2a, -C(=O)OR^4a, -C(=O)OH, and R^3a represents alkyl, halogen and OR^6,

or R^2a and R^3a together form an –O-CH_2-O or -O-CH_2-CH_2-O- ring,

R^4a represents alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, heteroarylalkyl or arylalkyl, all these radicals being optionally substituted with one or more radicals chosen from aryl, OH, OR^5a, C(=O)NY^3aY^4a, NY^3aY^4a and C(=O)OR^6a,

R5a represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl,

R^6a represents H and C1-C4 alkyl,

n represents an integer from 0 to 2,

Y^1a and Y^2a are such that: either Y^1a and Y^2a, which may be identical or different, represent H, alkyl, cycloalkyl, aryl and heteroaryl, all these radicals being optionally substituted with one or more radicals chosen from hydroxyl, -C(=O)-NY^3Y^4, -C(=O)OR^6 and NY^3Y^4, or Y^1a and Y^2a form, together with the nitrogen atom to which they are attached, a cyclic amino radical,

Y^3a and Y^4a are such that: either Y^3a and Y^4a, which may be identical or different, represent hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl, or Y^3a and Y^4a form, together with the nitrogen atom to which they are attached, a cyclic amino radical,

A_5 represents H or alkyl,

the said compounds of formula (Ia) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral bases.

One subject of the present invention is thus the compounds of formula (I) as defined above corresponding to the formula (IA):



(IA)

in which A represents a saturated heterocyclic radical which is either a 5- or 6-membered monocyclic radical or a bicyclic radical that is not more than 10-membered, these members being such that at least two of them represent a nitrogen atom and the others, which may be identical or different, represent a carbon member or a hetero atom member chosen from O, N

and S, this heterocycle A being optionally substituted with one or more radicals XA^1, XA^2 or XA^3 chosen from the values indicated hereinabove for the radicals X^1, X^2 or X^3,

A_1, A_2, A_3 and A_4, which may be identical or different, are chosen from a hydrogen atom, halogen atoms and hydroxyl, alkyl, alkenyl, alkoxy, nitro, cyano, aryl, heteroaryl and aryloxy radicals, a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA^6A^7 such that either A^6 and A^7, which may be identical or different, are chosen from a hydrogen atom and optionally substituted alkyl, alkoxyalkyl, phenoxyalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl radicals, or A^6 and A^7 form, together with the nitrogen atom to which they are attached, an optionally substituted 5- or 6-membered cyclic radical,

it being understood that two consecutive radicals among A_1, A_2, A_3 and A_4 can form, with the benzimidazole radical to which they are attached, a 5- to 6-membered carbon-based ring containing one or more hetero atoms, which may be identical or different, chosen from O, N and S,

A_5 represents a hydrogen atom or an alkyl radical,

R^6b represents hydrogen, alkyl, alkenyl, cycloalkyl, phenyl, phenylalkyl and cycloalkylalkyl,

all the alkyl, alkenyl, aryl, heteroaryl, aryloxy, cycloalkyl and heterocycloalkyl radicals present in the above radicals being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, acylamino (NH-COR^6), -C(=O)OR^{6}b, acyl -C(=O)R^{6}b, hydroxyalkyl, carboxyalkyl, phenoxyalkyl, $S(O)_n$-alk, $S(O)_n$-NH_2, $S(O)_n$-NH(alk), $S(O)_n$-N(alk)$_2$, CF_3, OCF_3, NO_2, CN, phenyl, itself optionally substituted with one or more halogen atoms, thienyl, phenoxy, phenylalkoxy, -C(=O)-NH_2, -C(=O)-NH(alk) and C(=O)-N(alk)$_2$ radicals,

all the above alkyl, alkenyl, alkoxy and alkylthio radicals being linear or branched and containing not more than 4 carbon atoms,

all the phenyl radicals of the above radicals furthermore being optionally substituted with a dioxole radical,

n represents an integer from 0 to 2,

the said compounds of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IA).

A subject of the present invention is thus the compounds of formula (I) as defined above, corresponding to the formula (IAa):



(IAa)

in which Aa represents a pyrazolyl, triazolyl or indazolyl radical, this heterocycle Aa being optionally substituted with one or more radicals XA^1, XA^2 or XA^3 chosen from the values indicated hereinabove for the radicals X^1, X^2 or X^3,

A_1a, A_2a, A_3a and A_4a, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkoxy, nitro, cyano, phenyl and phenoxy radicals, and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA^6aA^7a such that either A^6a and A^7a, which may be identical or different, are chosen from a hydrogen atom and alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, thienylalkyl and pyridylalkyl radicals, or A6a and A7a form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, morpholino or piperazinyl radical optionally substituted on the second nitrogen atom with an alkyl or phenyl radical, which are themselves optionally substituted,

it being understood that two consecutive radicals from among A_1a, A_2a, A_3a and A_4a may form, with the benzimidazole radical to which they are attached, an optionally substituted 5- to 6-membered carbon-based ring containing one or two oxygen atoms,

A_5a represents a hydrogen atom or an alkyl radical,

the phenyl and phenoxy radicals above being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, free, salified or esterified carboxyl, and dioxole radicals,

all the alkyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 6 carbon atoms,

the said compounds of formula (IAa) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAa).

The substituents X^1, X^2 and X^3 as defined above are in particular such that one represents a hydrogen atom and the other two, which may be identical or different, are chosen from halogen atoms and OH, R^4a, OR^4a, CF_3, OCF_3, NO_2, CN, NY^1aY^2a, acylamino (NH-COR^6b), $S(O)_n$-alk, $S(O)_n$-NH_2, $S(O)_n$-NH(alk), $S(O)_n$-N$(alk)_2$, -C(=O)-NH_2, -C(=O)-NH(alk), C(=O)-N$(alk)_2$, -C(=O)OR^4a, -N(R^6b)C(=O)R^4a, -N(R^6b)SO_2R^4a, -N(R^6b)C(=O)NY^1aY^2a, -N(R^6b)C(=O)OR^4a, -OC(=O)NY^1aY^2a and thienyl radicals, the thienyl radical being optionally substituted with an alkyl radical,

R^4a, Y^1a, Y^2a and R^6b having the values defined above and alk representing a linear or branched alkyl radical including not more than 6 carbon atoms and optionally substituted as indicated above.

All the alkylthio radicals are such that the sulfur atom is optionally oxidized to sulfone or sulfoxide with one or two oxygen atoms.

Tables I, II and III described below give examples of compounds illustrating the present invention, with in particular substituents chosen from the values of X^1, X^2 and X^3 as defined above.

TABLE I





with X represents hydrogen, halogen or alkoxy as defined above.

TABLE II




















in which NR'R represents NY^1Y^2 as defined above.

TABLE III





in which X represents hydrogen, alkynyl or $NHCOCH_2Ph$ which is optionally substituted.

The subject of the present invention is thus the compounds of formula (I) as defined above in which the substituents of the said compounds of formula (I) have the any of the values indicated as defined hereinabove and in which the aryl radicals represent the phenyl and naphthyl radicals; the heteroaryl radicals represent the furyl, thienyl, benzothienyl, thianthrenyl, pyridyl, pyrazolyl, benzimidazolyl, benzofuran, isobenzofuran and dihydrobenzofuran radicals; the cycloalkyl radicals represent a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl radical; the heterocycloalkyl radicals represent the hexahydropyran, piperidyl or morpholino radicals; the heterocycloalkylalkyl radicals represent the hexahydropyranylalkyl, piperidylalkyl and morpholinoalkyl radicals; the arylalkyl radicals represent the phenylalkyl, ethylenedioxyphenylalkyl and naphthylalkyl radicals; the heteroarylalkyl radicals represent the thienylalkyl, pyridylalkyl, furylalkyl, pyrazolylalkyl, benzothienylalkyl, dihydrobenzofuranylalkyl and benzimidazolylalkyl radicals; the aryloxy radicals represent the phenoxy and naphthyloxy radicals; the arylalkoxy radicals represent the phenylalkoxy and naphthylalkoxy

radicals; and the aryloxyalkyl radicals represent the phenoxyalkyl radical; all these radicals being optionally substituted as indicated hereinabove.

One subject of the present invention is, more particularly, the compounds of formula (I) as defined above corresponding to the formula (IA):



(IA)

in which A represents a saturated heterocyclic radical which is either a 5- or 6-membered monocyclic radical or a bicyclic radical that is not more than 10-membered, these members being such that at least two of them represent a nitrogen atom and the others, which may be identical or different, represent a carbon member or a hetero atom member chosen from O, N and S, this heterocycle A optionally being substituted with one or more radicals XA^1, XA^2 or XA^3 chosen from halogen atoms, alkyl, alkoxy or alkylthio radicals or thienyl radicals optionally substituted with an alkyl radical,

A_1, A_2, A_3 and A_4, which may be identical or different, are chosen from a hydrogen atom, halogen atoms and hydroxyl, alkyl, alkoxy, nitro, cyano, phenyl and phenoxy radicals, a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA^6A^7 such that either A^6 and A^7, which may be identical or different, are chosen from a hydrogen atom and alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl and heteroarylalkyl radicals, or A^6 and A^7 form, together with the nitrogen atom to which they are attached, a 5- or 6-membered cyclic radical,
it being understood that two consecutive radicals among A_1, A_2, A_3 and A_4 can form, with the benzimidazole radical to which they are attached, a 5- to 6-membered carbon-based ring containing one or more hetero atoms, which may be identical or different, chosen from O, N and S,
A_5 represents a hydrogen atom or an alkyl radical,
all the phenyl, phenoxy, cycloalkyl and heteroarylalkyl radicals above being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, free, salified or esterified carboxyl, and dioxole radicals,
all the alkyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 6 carbon atoms,

the said compounds of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IA).

A subject of the present invention is also, more particularly, the compounds of formula (I) as defined above, corresponding to the formula (IAb):



(IAb)

in which Ab represents a pyrazolyl or indazolyl radical optionally substituted with one or two radicals chosen from halogen atoms and OH, alkyl, alkynyl, $-OR^6b$ (including alkoxy), $-COR^6b$, $-O-COR^6b$, $-OS(O)_nR^6b$, $-O(CH_2)_n-CO-R^6b$, phenyl, phenylalkyl, CF_3, OCF_3, NO_2, CN, NY^1bY^2b, $-NH-C(=O)NY^1bY^2b$, acylamino ($NH-CO-R^6b$), $S(O)_n$-alk, $S(O)_n-NY^1bY^2b$, $-C(=O)-NY^1bY^2b$, $-C(=O)OR^6b$, $-NH-C(=O)R^6b$, $-NH-S(O)_nR^6b$, $-NH-C(=O)OR^6b$, $-N(R^6b)C(=O)NY^1bY^2b$, $-OC(=O)NY^1bY^2b$ and thienyl radicals, all these radicals being optionally substituted,

with NY^1bY^2b such that either Y^1b and Y^2b, which may be identical or different, are chosen from hydrogen and optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, phenyl, naphthyl, phenoxy, phenylalkyl, phenylalkylthio and naphthylalkyl or Y^1b and Y^2b form, together with the nitrogen atom to which they are attached, a piperidyl, hexahydrofuran, morpholinyl or morpholinylalkyl radical,

A_1b, A_2b, A_3b and A_4b, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkenyl, $-OR^6b$ (including alkoxy), $-CO-R^6b$, $-O-COR^6b$, $-OS(O)_nR^6b$, $-O(CH_2)_n-CO-R^6b$, nitro, cyano, furyl, thienyl, benzothienyl, naphthyl, thianthrenyl, phenyl and phenoxy radicals and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA^6bA^7b such that either A^6b and A^7b, which may be identical or different, are chosen from hydrogen and alkyl, alkoxyalkyl, phenoxyalkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, naphthylalkyl, thienylalkyl, piperidylalkyl, pyridylalkyl, benzothienylalkyl, pyrazolylalkyl, dihydrobenzofuranylalkyl, hexahydropyranylalkyl, ethylenedioxyphenylalkyl and benzimidazolylalkyl radicals, all these radicals being optionally substituted, or A^6b and A^7b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or

piperazinyl radical, the piperazinyl radical being optionally substituted on the second nitrogen atom with an alkyl radical itself optionally substituted,

it being understood that two consecutive radicals among A_1b, A_2b, A_3b and A_4b can form, with the benzimidazole radical to which they are attached, an optionally substituted 4,5-ethylenedioxybenzimid-azole radical or an optionally substituted 4,5-methylenedioxybenzimidazole radical,

A_5b represents a hydrogen atom,

all the above radicals containing alkyl, alkenyl, phenyl, phenoxy, furyl, thienyl, piperidyl, pyridyl, pyrazolyl and benzimidazolyl being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, acylamino (NH-COR^{6}b), -C(=O)OR^{6}b, acyl -C(=O)R^{6}b, hydroxyalkyl, carboxyalkyl, phenoxyalkyl, $S(O)_n$-alk, $S(O)_n$-NH_2, $S(O)_n$-NH(alk), $S(O)_n$-$N(alk)_2$, CF_3, OCF_3, NO_2, CN, phenyl, itself optionally substituted with one or more halogen atoms, thienyl, phenoxy, phenylalkoxy, -C(=O)-NH_2, -C(=O)-NH(alk) and C(=O)-$N(alk)_2$ radicals,

with n representing an integer from 0 to 2,

and R^{6}b representing hydrogen, alkyl, alkenyl, cycloalkyl, phenyl, pyridyl, thienyl, naphthyl, isoxazole, adamentyl, quinoline, quinolone, dihydroquinolone, -NH-phenyl, phenylalkyl and cycloalkylalkyl, all these radicals being optionally substituted with a morpholino, piperidyl or phenyl radical itself optionally substituted with one or more radicals chosen from halogen atoms and the cyano, CF_3, OCF_3, alkyl, phenyl-S(O)n-alk-phenyl, alkoxy, NH_2, NHalk, $N(alk)_2$, SO_2NH_2, SO_2Nalk or $SO_2N(alk)_2$ radical,

all the alkyl, alkenyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 10 carbon atoms,

all the phenyl radicals of the above radicals furthermore being optionally substituted with a dioxole radical,

the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).

One subject of the present invention is thus in particular the compounds of formula (I) as defined above corresponding to the formula (IAb) in which Ab represents a pyrazolyl or indazolyl radical

optionally substituted with one or two radicals chosen from halogen atoms and OH, alkyl, alkynyl, alkoxy, phenyl, phenylalkyl, CF_3, OCF_3, NO_2, CN, NY^1bY^2b, -NH-C(=O)NY^1bY^2b, acylamino (NH-CO-R^6b), $S(O)_n$-alk, $S(O)_n$-NY^1bY^2b, -C(=O)-NY^1bY^2b, -C(=O)OR^6b, -NH-C(=O)R^6b, -NH-$S(O)_nR^6b$, -NH-C(=O)OR^6b, -N(R^6b)C(=O)NY^1bY^2b, -OC(=O)NY^1bY^2b and thienyl radicals which are optionally substituted,

with NY^1bY^2b such that either Y^1b and Y^2b, which may be identical or different, are chosen from hydrogen and optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, phenyl, naphthyl, phenoxy, phenylalkyl, phenylalkylthio and naphthylalkyl or Y^1b and Y^2b form, together with the nitrogen atom to which they are attached, a piperidyl, hexahydrofuran, morpholinyl or morpholinylalkyl radical,

A_1b, A_2b, A_3b and A_4b, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkenyl, alkoxy, nitro, cyano, furyl, thienyl, benzothienyl, naphthyl, thianthrenyl, phenyl and phenoxy radicals and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA^6bA^7b such that either A^6b and A^7b, which may be identical or different, are chosen from hydrogen and alkyl, alkoxyalkyl, phenoxyalkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, naphthylalkyl, thienylalkyl, piperidylalkyl, pyridylalkyl, benzothienylalkyl, pyrazolylalkyl, dihydrobenzofuranylalkyl, hexahydropyranylalkyl, ethylenedioxyphenylalkyl and benzimidazolylalkyl radicals, all these radicals being optionally substituted, or A^6b and A^7b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical, the piperazinyl radical being optionally substituted on the second nitrogen atom with an alkyl radical itself optionally substituted,

it being understood that two consecutive radicals among A_1b, A_2b, A_3b and A_4b can form, with the benzimidazole radical to which they are attached, an optionally substituted 4,5-ethylenedioxybenzimidazole radical or an optionally substituted 4,5-methylenedioxybenzimidazole radical,

A_5b represents a hydrogen atom,

all the above radicals containing alkyl, alkenyl, phenyl, phenoxy, furyl, thienyl, piperidyl, pyridyl, pyrazolyl and benzimidazolyl being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, acylamino (NH-COR^{6}b), -C(=O)OR^6b, acyl -C(=O)R^6b, hydroxyalkyl, carboxyalkyl, phenoxyalkyl, $S(O)_n$-alk, $S(O)_n$-NH_2, $S(O)_n$-NH(alk), $S(O)_n$-$N(alk)_2$, CF_3, OCF_3, NO_2,

CN, phenyl, itself optionally substituted with one or more halogen atoms, thienyl, phenoxy, phenylalkoxy, -C(=O)-NH_2, -C(=O)-NH(alk) and C(=O)-$N(alk)_2$ radicals,
with n representing an integer from 0 to 2,
and R^6b representing hydrogen, alkyl, alkenyl, cycloalkyl, phenyl, phenylalkyl and cycloalkylalkyl,

all the alkyl, alkenyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 10 carbon atoms,

all the phenyl radicals of the above radicals furthermore being optionally substituted with a dioxole radical,

the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).

A subject of the present invention is thus in particular the compounds of formula (I) as defined above corresponding to the formula (IAb) in which Ab represents a pyrazolyl radical substituted with one or two radicals such that one is chosen from hydrogen, halogen atoms and alkyl, alkynyl, -COR^6b, phenyl, phenylalkyl, CF_3, NO_2, CN, NY^1bY^2b, -NH-C(=O)NY^1bY^2b, NH-CO-R^6b, $S(O)_n$-alk, $S(O)_n$-NY^1bY^2b, -C(=O)-NY^1bY^2b, -C(=O)OR^6b, -NH-C(=O)R^6b, -NH-$S(O)_nR^6$b, -NH-C(=O)OR^6b, -N(R^6b)C(=O)NY^1bY^2b and thienyl radicals, all these radicals being optionally substituted,

and the other is chosen from OH, -OR^6b, -O-COR^6b, -$OS(O)_nR^6$b, -$O(CH_2)_n$-CO-R^6b and -OC(=O)NY^1bY^2b radicals, all these radicals being optionally substituted,

with NY^1bY^2b such that Y^1b and Y^2b, which may be identical or different, are chosen from hydrogen and optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, phenyl, naphthyl, phenoxy, phenylalkyl, phenylalkylthio and naphthylalkyl or Y^1b and Y^2b form, together with the nitrogen atom to which they are attached, a piperidyl, hexahydrofuran, morpholinyl or morpholinylalkyl radical,

A_1b, A_2b, A_3b and A_4b, which may be identical or different, are such that two of them represent hydrogen and the other two, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkenyl, -OR^6b (including alkoxy), -CO-R^6b, -O-COR^6b, -$OS(O)_nR^6$b, -$O(CH_2)_n$-CO-R^6b, nitro, cyano, furyl, thienyl, benzothienyl, naphthyl, thianthrenyl, phenyl and phenoxy radicals and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA^6bA^7b such that either A^6b and A^7b, which may be identical or different, are chosen from hydrogen and alkyl, alkoxyalkyl,

phenoxyalkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, naphthylalkyl, thienylalkyl, piperidylalkyl, pyridylalkyl, benzothienylalkyl, pyrazolylalkyl, dihydrobenzofuranylalkyl, hexahydropyranylalkyl, ethylenedioxyphenylalkyl and benz-imidazolylalkyl radicals, all these radicals being optionally substituted, or A^6b and A^7b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical, the piperazinyl radical being optionally substituted on the second nitrogen atom with an alkyl radical itself optionally substituted,

A_5b represents a hydrogen atom,

all the above radicals containing alkyl, alkenyl, phenyl, phenoxy, furyl, thienyl, piperidyl, pyridyl, pyrazolyl and benzimidazolyl being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, acylamino (NH-COR^{6}b), -C(=O)OR^{6}b, acyl -C(=O)R^{6}b, hydroxyalkyl, carboxyalkyl, phenoxyalkyl, $S(O)_n$-alk, $S(O)_n$-NH_2, $S(O)_n$-NH(alk), $S(O)_n$-$N(alk)_2$, CF_3, OCF_3, NO_2, CN, phenyl, itself optionally substituted with one or more halogen atoms, thienyl, phenoxy, phenylalkoxy, -C(=O)-NH_2, -C(=O)-NH(alk) and C(=O)-$N(alk)_2$ radicals,

with n representing an integer from 0 to 2,

and R^{6}b representing hydrogen, alkyl, alkenyl, cycloalkyl, phenyl, pyridyl, thienyl, naphthyl, isoxazole, adamentyl, quinoline, quinolone, dihydroquinolone, -NH-phenyl, phenylalkyl and cycloalkylalkyl, all these radicals being optionally substituted with a morpholino, piperidyl or phenyl radical itself optionally substituted with one or more radicals chosen from halogen atoms and the cyano, CF_3, OCF_3, alkyl, phenyl-S(O)n-alk-phenyl, alkoxy, NH_2, NHalk, $N(alk)_2$, SO_2NH_2, SO_2Nalk or $SO_2N(alk)_2$ radical,

all the alkyl, alkenyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 10 carbon atoms,

all the phenyl radicals of the above radicals furthermore being optionally substituted with a dioxole radical,

the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).

A subject of the present invention is thus in particular the compounds of formula (I) as defined above corresponding to the formula (IAb) in which Ab represents a pyrazolyl or indazolyl radical optionally

substituted with one or more radicals chosen from halogen atoms and alkyl, alkoxy and thienyl radicals,

A_1b, A_2b, A_3b and A_4b, which may be identical or different, are chosen from a hydrogen atom; halogen atoms; radicals of the following types: hydroxyl, alkyl, alkenyl optionally substituted with phenyl itself optionally substituted with one or more halogen atoms, alkoxy, nitro, cyano, furyl, thienyl optionally substituted with acyl COalk, benzothienyl, naphthyl, thianthrenyl, phenyl and phenoxy which are optionally substituted; and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA^6bA^7b such that either A^6b and A^7b, which may be identical or different, are chosen from hydrogen and radicals of the following types : alkyl, alkoxyalkyl containing not more than 6 carbon atoms, phenoxyalkyl optionally substituted with acylamino NH-C(O)alk, phenyl, optionally substituted phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl optionally substituted with one or more alkyl radicals, naphthylalkyl, thienylalkyl optionally substituted with alkyl or thienyl, piperidylalkyl optionally substituted with a carboxyl radical which is free, salified or esterified with an alkyl radical, pyridylalkyl optionally substituted with one or more radicals chosen from halogen and CF3, benzothienylalkyl, pyrazolylalkyl optionally substituted with one or more alkyl radicals, dihydrobenzofuranylalkyl, hexahydropyranylalkyl, ethylenedioxyphenylalkyl, and benzimidazolylalkyl optionally substituted with one or more alkyl radicals,

or A^6b and A^7b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical, the piperazinyl radical being optionally substituted on the second nitrogen atom with an alkyl radical,
it being understood that two consecutive radicals among A_1b, A_2b, A_3b and A_4b can form, with the benzimidazole radical to which they are attached, an optionally substituted 4,5-ethylenedioxybenzimidazole radical or an optionally substituted 4,5-methylenedioxybenzimidazole radical,
A_5a represents a hydrogen atom,

the phenyl, phenoxy and phenylalkyl radicals above being optionally substituted with one or more radicals chosen from halogen atoms, hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino and NH-COalk radicals, a carboxyl radical which is free, salified or esterified with an alkyl radical, and hydroxyalkyl, carboxyalkyl, phenoxyalkyl, alkylthio, SO_2alk, SO_2NH_2, SO_2-NH(alk), SO_2-N(alk)$_2$, CF_3, OCF_3, NO_2, CN, phenyl, itself optionally substituted with one or more halogen atoms, thienyl, phenoxy, phenylalkoxy, -C(=O)-NH_2, -C(=O)-NH(alk), C(=O)-N(alk)$_2$ and C(O)CH_3 radicals,

all the alkyl or alk, alkenyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 4 carbon atoms,

all the phenyl radicals of the above radicals furthermore being optionally substituted with a dioxole radical,

the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).

A subject of the present invention is thus in particular the compounds of formula (I) as defined above corresponding to the formula (IAb) in which Ab, A_1b, A_2b, A_3b, A_4b and A_5b have any of the meanings indicated hereinabove,

> and when one of A_1b, A_2b, A_3b and A_4b represents a carboxyl radical amidated with a radical NA^6bA^7b, then either one of A^6b and A^7b represents a hydrogen atom or an alkyl radical and the other of A^6b and A^7b is chosen from the values defined for A^6b and A^7b, or A^6b and A^7b form, together with the nitrogen atom to which they are attached, a 5- or 6-membered cyclic radical,
>
> the other substituents of the said compounds of formula (I) having the any of the values indicated hereinabove,

the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).

A subject of the present invention is thus in particular the compounds of formula (I) as defined above in which X, W, Y and Z are such that two or three of them represent CH and the others are chosen from the values of CR^2 or CR^3 and, if appropriate, i.e., when two of them represent CH and CR^2 and CR^3 are adjacent to each other, can form a dioxole radical,

R^2, R^3 and the other substituents of the said compounds of formula (I) having any of the values as defined hereinabove,

the said compounds of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (I).

The present invention thus relates in particular to the compounds of formula (IA) as defined above in which A_1, A_2, A_3 and A_4 are such that two or three of them represent a hydrogen atom and the others are chosen from the values of A_1, A_2, A_3 and A_4 and, if appropriate, i.e., when two of them represent a hydrogen atom and the other two are on adjacent carbons, can form a dioxole radical,

the other substituents of the compounds of formula (IA) having any of the values as defined hereinabove,

the said compounds of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IA).

A subject of the present invention is also, more particularly, the compounds of formula (I) as defined above, corresponding to the formula (IAa):



(IAa)

in which Aa represents a pyrazolyl, triazolyl or indazolyl radical, this heterocycle Aa being optionally substituted with one or more radicals XA^1, XA^2 or XA^3 chosen from halogen atoms, alkyl, alkoxy or alkylthio radicals and thienyl radicals optionally substituted with an alkyl radical,
A_1a, A_2a, A_3a and A_4a, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkoxy, nitro, cyano, phenyl and phenoxy radicals, and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA^6aA^7a such that either A^6a and A^7a, which may be identical or different, are chosen from a hydrogen atom and alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, thienylalkyl and pyridylalkyl radicals, or A^6a and A^7a form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, pyrazolidinyl,

pyrazolinyl, piperidyl, morpholino or piperazinyl radical optionally substituted on the second nitrogen atom with an alkyl or phenyl radical, which are themselves optionally substituted,
it being understood that two consecutive radicals from among A_1a, A_2a, A_3a and A_4a may form, with the benzimidazole radical to which they are attached, an optionally substituted 5- to 6-membered carbon-based ring containing one or two oxygen atoms,
A5a represents a hydrogen atom or an alkyl radical,
the phenyl and phenoxy radicals above being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, free, salified or esterified carboxyl, and dioxole radicals,
all the alkyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 6 carbon atoms,
the said compounds of formula (IAa) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAa).

One subject of the present invention is, more particularly, the compounds of formula (I) as defined above in which R represents a pyrazolyl or indazolyl radical, the other substituents having the values indicated above or below.

Among the preferred compounds that are particularly noted are the compounds of formula (I) in which Aa represents a pyrazolyl or indazolyl radical optionally substituted as indicated above and below, A_1a, A_2a, A_3a and A_4a are chosen from the following values:

- A_1a represents hydrogen or carboxyl or forms a ring with

the adjacent member A_2a

- A_4a represents hydrogen or carboxyl or forms a ring with the adjacent member A_3a
- A_2a represents a carboxyl radical that is free, salified, esterified with an optionally substituted alkyl radical or an amidated carboxyl as indicated above or below,
- A_2a and A_3a represent two optionally substituted alkyl radicals,

A_5 represents hydrogen.

One subject of the present invention is, even more particularly, the compounds of formula (I) as defined above, corresponding to the formula (IAb):



(IAb)

in which Ab represents a pyrazolyl or indazolyl radical optionally substituted with one or more radicals chosen from halogen atoms and alkyl, alkoxy and thienyl radicals,

A_1b, A_2b, A_3b and A_4b, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl and alkoxy, nitro, cyano, phenyl and phenoxy radicals, and a carboxyl radical that is free, salified, esterified with an alkyl radical or amidated with a radical NA^6bA^7b such that either A^6b and A^7b, which may be identical or different, are chosen from alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl and furylalkyl radicals, or A^6b and A^7b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical optionally substituted on the second nitrogen atom with an alkyl radical,

it being understood that two consecutive radicals from among A_1b, A_2b, A_3b and A_4b may form, with the benzimidazole radical to which they are attached, an optionally substituted 4,5-ethylenedioxybenzimidazole radical or 4,5-methylenedioxybenzimidazole radical,

A_5b represents a hydrogen atom,

the phenyl and phenoxy radicals above being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino and free, salified or esterified carboxyl radicals,

all the alkyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 4 carbon atoms,

the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereoisomeric isomer from, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).

With reference to formula (Ix) above, the following are particular and preferred groupings:

R^1 may particularly represent optionally substituted heteroaryl. Exemplary optionally substituted heteroaryls include dihydrofuropyrazolyl, imidazolyl, indazolyl, indolyl, isoxazolyl, oxodihydropyridazinyl, oxodihydropyridinopyrazolyl, oxodihydropyridinyl, oxotetrahydropyrrolopyrazolyl, pyrazolyl, thiazolyl, thienopyrazolyl, tetrahydrocyclopentapyrazolyl,

tetrahydroindazolyl, tetrahydropyranopyrazolyl, tetahydropyridinopyrazolyl, tetrahydropyrrolopyrazolyl or triazolyl. Optional substituents include one or more groups selected from carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R^4, $-C(=O)R^4$, $-C(=O)NY^1Y^2$, $-C(=O)OR^4$, $-N(R^6)C(=O)R^4$, $-N(R^6)C(=O)NY^1Y^2$, $-N(R^6)C(=O)OR^4$, $-N(R^6)SO_2R^4$, $-N(R^6)SO_2NY^1Y^2$, $-NY^1Y^2$, $-OR^4$, $-OCF_2H$, $-OCF_3$, $-OC(=O)R^4$, $-OC(=O)NY^1Y^2$, $-S(O)_nR^4$ and $-S(O)_2NY^1Y^2$. R^1 more preferably represents a heteroaryl moiety  in which R^7, R^8 and R^9 are as hereinbefore defined. It will be appreciated that compounds of formula (Ix) in which R^1 represents a heteroaryl moiety  and R^7 is hydrogen can exist in the tautomeric forms

 ,  ,

 and  .

W may particularly represent CH when X is CR^2, Y is CH or CR^3 and Z are CH or CR^3.

W may also particularly represent CH when X is N, Y is CH or CR^3 and Z is CH or CR^3.

W may also particularly represent N when X is CH or CR^2, Y is CH or CR^3 and Z is CH or CR^3.

W may also particularly represent N when X is CH or CR^2, Y is CH or CR^3 and Z is N.

It is to be understood that this invention covers all appropriate combinations of the particular and preferred groupings referred to herein.

A particular group of compounds of the invention are compounds of formula (Ixa):-



(Ixa)

in which W, X, Y, Z and R^7 are as hereinbefore defined for compounds of formula (Ix), and R^8 and R^9 are independently selected from hydrogen, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R^4, $-C(=O)R^4$, $-C(=O)NY^1Y^2$, $-C(=O)OR^4$, $-N(R^6)C(=O)R^4$, $-N(R^6)C(=O)NY^1Y^2$, $-N(R^6)C(=O)OR^4$, $-N(R^6)SO_2R^4$, $-NY^1Y^2$, $-OR^4$, $-OC(=O)R^4$, $-OC(=O)NY^1Y^2$, $-S(O)_nR^4$ and $-S(O)_2NY^1Y^2$; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixa) in which W represents CH, X represents CH, Y represents CH and Z represents CH or C-CH_3 are preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CH, Z represents CH and Y represents:

(i) C-C_{1-4}alkyl [e.g. C-CH_3, C-CH_2CH_3, C-$CH_2CH_2CH_3$ or C-$CH(CH_3)_2$];

(ii) C-aryl [e.g.



];

(iii) C-CN;

(iv) C-NO_2;

(v) C-halo [e.g. C-Br, C-Cl or C-F];

(vi) C-haloalkyl [e.g. C-CF_3];

(vii) C-heteroaryl [e.g.  or ];

(viii) C-OR^4 [e.g. C—OCH_3, C—OCH_2CH_3, C—$OCHF_2$, C—OCF_3,  ,

 or ];

(ix) C-C(=O)R^4 [e.g. ];

(x) C-C=O)NY^1Y^2 [e.g. C—C(=O)—NH—CH_3, C—C(=O)—N$(CH_3)_2$,

C—C(=O)—NH—CH_2CH_3, C—C(=O)—NH—CH$(CH_3)_2$,

C—C(=O)—NH—C$(CH_3)_2$-CH_2OH, C—C(=O)—NH—CH_2CH_2CN,

C—C(=O)—NH—$CH_2CH_2OCH_3$,  ,

 ,  ,

 ,  ,

 ,  ,

 ,  ,

, ,

 or ];

(xi) C-C(=O)OR^4 [e.g. C-C(=O)OH or C-C(=O)OCH_3];

(xii) C-NHC(=O)R^4 [e.g. C-NHC(=O)CH_3, C-NHC(=O)CH(CH_3)$_2$,

 or ]; or

(xiii) C-CH(OH)aryl [e.g. ];

(xiv) C-S(O)$_2$NY^{1}Y^2 [e.g. ];

(xv) C-S(O)$_n$R^4 [e.g. C-SO_2CH_3];

are also preferred.

Compounds of formula (Ixa) in which W represents CH, X represents C-CH_3, C-CH_2CH_3, C-CH(CH_3)$_2$, C-OCH_3, C-OCH_2CH_3, C-Br or C-Cl, Y represents C-CH_3, C-CH_2CH_3, C-OCH_3, C-Br, C-Cl, C-F,  or  and Z represents CH are also preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CH, Y represents C-CH_3 and Z represents C-CH_3 are also preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group -CH_2-O-CH_2-, and Z represents CH are also preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group $-CH_2-CH_2-CH_2-$, and Z represents CH are also preferred.

Compounds of formula (Ixa) in which R^7 represents hydrogen are preferred.

Compounds of formula (Ixa) in which R^8 represents:

(i) hydrogen;

(ii) C_{1-4}alkyl [e.g. CH_3, CH_2CH_3, $CH(CH_3)_2$ or $CH(CH_3)CH_2CH_3$];

(iii) $-SR^4$ [e.g. $-S-CH_3$, $-S-CH_2CH_3$ or  ,

];

(iv) $-NY^1Y^2$ [e.g. ]; or

(v) $-OR^5$ [e.g. $-OCH_2CH_3$]

are preferred.

Compounds of formula (Ixa) in which R^9 represents:

(i) hydrogen;

(ii) C_{1-7}alkyl [e.g. $-CH_3$, $-CH_2CH_2CH_3$, $-CH(CH_3)_2$ or $-CH_2-CH_2-CH(CH_3)_2$];

(iii) aryl [e.g. phenyl];

(iv) $-C(=O)NY^1Y^2$ [e.g. $-C(=O)-NH-CH_2CH_3$, $-C(=O)-NH-CH_2CH_2CH_3$, $-C(=O)-NH-CH_2CH(CH_3)_2$, $-C(=O)-NH-CH(CH_3)_2$, $-C(=O)-NH-C(CH_3)_3$, $-C(=O)-NH-C(CH_3)_2CH_2OH$, $-C(=O)-NH-CH_2CH_2OCH_3$, $-C(=O)-N(CH_3)_2$, $-C(=O)-N(CH_2CH_3)_2$,

 ,  or ];

(v) $-N(R^6)C(=O)R^4$, particularly $-NHC(=O)R^4$, in which (a) R^4 is alkyl optionally substituted by aryl, cycloalkyl, heteroaryl, heterocycloalkyl, NY^1Y^2 or $-OR^5$ [e.g.

$—NH—C(=O)—CH_3$, $—NH—C(=O)—(CH_2)_2CH_3$, $—NH—C(=O)—CH(CH_3)_2$,

$—NH—C(=O)—C(CH_3)_3$, $—NH—C(=O)—CH_2CH(CH_3)_2$,

$—NH—C(=O)—CH(CH_3)CH_2CH_3$, $—NH—C(=O)—CH_2C(CH_3)_3$,

, ,

, $—NH—C(=O)—CH_2—N(CH_3)_2$,

,  or

$—NH—C(=O)—CH_2OCH_3$], (b) R^4 is aryl [e.g.

,  or

], (c) R^4 is cycloalkyl [e.g. 

or ], (d) R^4 is heteroaryl [e.g. ,

,  or

] or (e) heterocycloalkyl [e.g.

];

(vi) $-N(R^6)C(=O)NY^1Y^2$, particularly $-NHC(=O)NY^1Y^2$ [e.g. —NH—C(=O)—NHCH$_3$, —NH—C(=O)—NHCH$_2$CH$_3$, —NH—C(=O)—NHCH(CH$_3$)$_2$, —NH—C(=O)—NHCH$_2$CH(CH$_3$)$_2$, —NH—C(=O)—NHC(CH$_3$)$_3$, —NH—C(=O)—N(CH$_3$)$_2$, —NH—C(=O)—N(CH$_2$CH$_3$)$_2$,

, ,

, ,

,  or

];

(vii) $-NY^1Y^2$ [e.g. $-NH_2$]; or

(viii) alkyl substituted by $-N(R^6)C(=O)NY^1Y^2$ [e.g. -CH$_2$-NH-C(=O)-CH(CH$_3$)$_2$ or

];

are preferred.

A preferred group of compounds of the invention are compounds of formula (Ixa) in which:- W represents CH; X represents CH; Y represents CH; Z represents CH or C-CH$_3$; R^7 represents hydrogen; R^8 represents (i) hydrogen, (ii) C_{1-4}alkyl [e.g. CH$_3$, CH$_2$CH$_3$, CH(CH$_3$)$_2$ or CH(CH$_3$)CH$_2$CH$_3$], (iii) $-SR^4$ [e.g. —S—CH$_3$, —S—CH$_2$CH$_3$ or ,

, , ,

 or ], (iv) $-NY^1Y^2$ [e.g. ] or (v) $-OR^5$ [e.g. -OCH$_2$CH$_3$]; R^9 represents (i) hydrogen; (ii) C_{1-7}alkyl [e.g. -CH$_3$, -CH$_2$CH$_2$CH$_3$, -CH(CH$_3$)$_2$ or -CH$_2$-CH$_2$-CH(CH$_3$)$_2$]; (iii) aryl [e.g. phenyl]; (iv) $-C(=O)NY^1Y^2$ [e.g.

$—C(=O)—NH—CH_2CH_3$, $—C(=O)—NH—CH_2CH_2CH_3$, $—C(=O)—NH—CH_2CH(CH_3)_2$, $—C(=O)—NH—CH(CH_3)_2$, $—C(=O)—NH—C(CH_3)_3$, $—C(=O)—NH—C(CH_3)_2CH_2OH$, $—C(=O)—NH—CH_2CH_2OCH_3$, $—C(=O)—N(CH_3)_2$, $—C(=O)—N(CH_2CH_3)_2$,

,  or ];

(v) -N(R^6)C(=O)R^4, particularly -NHC(=O)R^4, in which (a) R^4 is alkyl optionally substituted by aryl, cycloalkyl, heteroaryl, heterocycloalkyl, NY^1Y^2 or -OR^5 [e.g. $—NH—C(=O)—CH_3$, $—NH—C(=O)—(CH_2)_2CH_3$, $—NH—C(=O)—CH(CH_3)_2$, $—NH—C(=O)—C(CH_3)_3$, $—NH—C(=O)—CH_2CH(CH_3)_2$, $—NH—C(=O)—CH(CH_3)CH_2CH_3$,

$—NH—C(=O)—CH_2C(CH_3)_3$, , ,

, $—NH—C(=O)—CH_2—N(CH_3)_2$,

,  or

$—NH—C(=O)—CH_2OCH_3$], (b) R^4 is aryl [e.g.

,  or ],

(c) R^4 is cycloalkyl [e.g.  or ], (d) R^4 is heteroaryl

[e.g. , ,  or

] or (e) heterocycloalkyl [e.g. ];

(vi) -N(R^6)C(=O)NY^1Y^2, particularly -NHC(=O)NY^1Y^2 [e.g. —NH—C(=O)—$NHCH_3$, —NH—C(=O)—$NHCH_2CH_3$, —NH—C(=O)—$NHCH(CH_3)_2$, —NH—C(=O)—$NHCH_2CH(CH_3)_2$, —NH—C(=O)—$NHC(CH_3)_3$, —NH—C(=O)—$N(CH_3)_2$, —NH—C(=O)—$N(CH_2CH_3)_2$, , , , , ,  or ], (vii) -NY^1Y^2 [e.g. -NH_2] or (viii) alkyl substituted by -N(R^6)C(=O)NY^1Y^2 [e.g. -CH_2-NH-C(=O)-$CH(CH_3)_2$ or ]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixa) in which:- W represents CH; X represents CH; Z represents CH; Y represents (i) C-C_{1-4}alkyl [e.g. C-CH_3, C-CH_2CH_3, C-$CH_2CH_2CH_3$ or C-$CH(CH_3)_2$], (ii) C-aryl [e.g. , , , , , , ,  or ], (iii) C-CN, (iv) C-NO_2, (v) C-halo [e.g. C-Br, C-Cl or C-F], (vi) C-haloalkyl [e.g. C-CF_3], (vii) C-heteroaryl [e.g.  or

], (viii) C-OR^4 [e.g. C—OCH$_3$, C—OCH$_2$CH$_3$, C—OCHF$_2$, C—OCF$_3$,

 ,  or ], (ix) C-C(=O)R^4 [e.g.

], (x) C-C=O)NY^{1}Y^2 [e.g. C—C(=O)—NH—CH$_3$, C—C(=O)—N(CH$_3$)$_2$,

C—C(=O)—NH—CH$_2$CH$_3$, C—C(=O)—NH—CH(CH$_3$)$_2$, C—C(=O)—NH—C(CH$_3$)$_2$-CH$_2$OH,

C—C(=O)—NH—CH$_2$CH$_2$CN, C—C(=O)—NH—CH$_2$CH$_2$OCH$_3$,

 ,  ,

 ,  ,

 ,  ,

 ,  ,

 ,  ,

 , 

or ], (xi) C-C(=O)OR^4 [e.g. C-C(=O)OH or C-C(=O)OCH$_3$], (xii)

C-NHC(=O)R^4 [e.g. C-NHC(=O)CH$_3$ or C-NHC(=O)CH(CH$_3$)$_2$,  or

C-NH-C(=O)—C(=O)—CH_2—], (xiii) C-CH(OH)aryl [e.g. C-CH(OH)—], (xiv) C-$S(O)_2NY^1Y^2$ [e.g. C-SO_2—NH—CH_2—] or (xv) C-$S(O)_nR^4$ [e.g. C-SO_2CH_3]; R^7 represents hydrogen; R^8 represents (i) hydrogen, (ii) C_{1-4}alkyl [e.g. CH_3, CH_2CH_3, $CH(CH_3)_2$ or $CH(CH_3)CH_2CH_3$], (iii) -SR^4 [e.g. —S—CH_3, —S—CH_2CH_3 or —S—CH_2—, —S—CH_2—, —S—CH_2——OCH_3, —S—CH_2—CH_2—, —S—CH_2— or —S—CH_2—], (iv) -NY^1Y^2 [e.g. ] or (v) -OR^5 [e.g. -OCH_2CH_3]; R^9 represents (i) hydrogen; (ii) C_{1-7}alkyl [e.g. -CH_3, -$CH_2CH_2CH_3$, -$CH(CH_3)_2$ or -CH_2-CH_2-$CH(CH_3)_2$]; (iii) aryl [e.g. phenyl]; (iv) -C(=O)NY^1Y^2 [e.g.
—C(=O)—NH—CH_2CH_3, —C(=O)—NH—$CH_2CH_2CH_3$, —C(=O)—NH—$CH_2CH(CH_3)_2$, —C(=O)—NH—$CH(CH_3)_2$, —C(=O)—NH—$C(CH_3)_3$, —C(=O)—NH—$C(CH_3)_2CH_2OH$, —C(=O)—NH—$CH_2CH_2OCH_3$, —C(=O)—$N(CH_3)_2$, —C(=O)—$N(CH_2CH_3)_2$, —C(=O)—NH—, —C(=O)—NH—CH_2— or —C(=O)—NH—];

(v) -$N(R^6)C(=O)R^4$, particularly -NHC(=O)R^4, in which (a) R^4 is alkyl optionally substituted by aryl, cycloalkyl, heteroaryl, heterocycloalkyl, NY^1Y^2 or -OR^5 [e.g. —NH—C(=O)—CH_3, —NH—C(=O)—$(CH_2)_2CH_3$, —NH—C(=O)—$CH(CH_3)_2$, —NH—C(=O)—$C(CH_3)_3$, —NH—C(=O)—$CH_2CH(CH_3)_2$, —NH—C(=O)—$CH(CH_3)CH_2CH_3$, —NH—C(=O)—$CH_2C(CH_3)_3$, —NH—C(=O)—CH_2—, —NH—C(=O)—CH_2—, —NH—C(=O)—CH_2—, —NH—C(=O)—CH_2—$N(CH_3)_2$,

,  or

$—NH—C(=O)—CH_2OCH_3$], (b) R^4 is aryl [e.g.

,  or ],

(c) R^4 is cycloalkyl [e.g.  or ], (d) R^4 is heteroaryl[e.g. , ,  or ] or (e) heterocycloalkyl [e.g. ];

(vi) $-N(R^6)C(=O)NY^1Y^2$, particularly $-NHC(=O)NY^1Y^2$ [e.g. $—NH—C(=O)—NHCH_3$, $—NH—C(=O)—NHCH_2CH_3$, $—NH—C(=O)—NHCH(CH_3)_2$, $—NH—C(=O)—NHCH_2CH(CH_3)_2$, $—NH—C(=O)—NHC(CH_3)_3$, $—NH—C(=O)—N(CH_3)_2$, $—NH—C(=O)—N(CH_2CH_3)_2$, , , , , ,  or ],

(vii) $-NY^1Y^2$ [e.g. $-NH_2$] or (viii) alkyl substituted by $-N(R^6)C(=O)NY^1Y^2$ [e.g. $-CH_2-NH-C(=O)-CH(CH_3)_2$ or ] ; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixa) in which:- W represents CH; X represents C-CH_3, C-CH_2CH_3, C-$CH(CH_3)_2$, C-OCH_3, C-OCH_2CH_3, C-Br or C-Cl; Y represents C-CH_3, C-CH_2CH_3, C-OCH_3, C-Br, C-Cl, C-F,  or  ; Z represents CH; R^7 represents hydrogen; R^8 represents (i) hydrogen, (ii) C_{1-4}alkyl [e.g. CH_3, CH_2CH_3, $CH(CH_3)_2$ or $CH(CH_3)CH_2CH_3$], (iii) -SR^4 [e.g. $-S-CH_3$, $-S-CH_2CH_3$ or  ,  ,  ,  ,  or ], (iv) -NY^1Y^2 [e.g. ] or (v) -OR^5 [e.g. -OCH_2CH_3]; R^9 represents (i) hydrogen; (ii) C_{1-7}alkyl [e.g. -CH_3, -$CH_2CH_2CH_3$, -$CH(CH_3)_2$ or -CH_2-CH_2-$CH(CH_3)_2$]; (iii) aryl [e.g. phenyl]; (iv) -$C(=O)NY^1Y^2$ [e.g. $-C(=O)-NH-CH_2CH_3$, $-C(=O)-NH-CH_2CH_2CH_3$, $-C(=O)-NH-CH_2CH(CH_3)_2$, $-C(=O)-NH-CH(CH_3)_2$, $-C(=O)-NH-C(CH_3)_3$, $-C(=O)-NH-C(CH_3)_2CH_2OH$, $-C(=O)-NH-CH_2CH_2OCH_3$, $-C(=O)-N(CH_3)_2$, $-C(=O)-N(CH_2CH_3)_2$,  ,  or ]; (v) -$N(R^6)C(=O)R^4$, particularly -$NHC(=O)R^4$, in which (a) R^4 is alkyl optionally substituted by aryl, cycloalkyl, heteroaryl, heterocycloalkyl, NY^1Y^2 or -OR^5 [e.g. $-NH-C(=O)-CH_3$, $-NH-C(=O)-(CH_2)_2CH_3$, $-NH-C(=O)-CH(CH_3)_2$, $-NH-C(=O)-C(CH_3)_3$, $-NH-C(=O)-CH_2CH(CH_3)_2$, $-NH-C(=O)-CH(CH_3)CH_2CH_3$, $-NH-C(=O)-CH_2C(CH_3)_3$,

 ,  ,  ,

$—NH—C(=O)—CH_2—N(CH_3)_2$, ,

 or $—NH—C(=O)—CH_2OCH_3$], (b) R^4 is aryl [e.g.

,  or ],

(c) R^4 is cycloalkyl [e.g.  or ], (d) R^4 is

heteroaryl[e.g. , , 

or ] or (e) heterocycloalkyl [e.g. ];

(vi) $-N(R^6)C(=O)NY^1Y^2$, particularly $-NHC(=O)NY^1Y^2$ [e.g. $—NH—C(=O)—NHCH_3$,

$—NH—C(=O)—NHCH_2CH_3$, $—NH—C(=O)—NHCH(CH_3)_2$,

$—NH—C(=O)—NHCH_2CH(CH_3)_2$, $—NH—C(=O)—NHC(CH_3)_3$, $—NH—C(=O)—N(CH_3)_2$,

$—NH—C(=O)—N(CH_2CH_3)_2$, , ,

, ,

,  or ],

(vii) $-NY^1Y^2$ [e.g. $-NH_2$] or (viii) alkyl substituted by $-N(R^6)C(=O)NY^1Y^2$ [e.g. $-CH_2-NH-C(=O)-CH(CH_3)_2$ or ]; and their corresponding N-oxides, and their

prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixa) in which:-W represents CH; X represents CH; Y represents C-CH_3; Z represents C-CH_3; R^7 represents hydrogen; R^8 represents (i) hydrogen, (ii) C_{1-4}alkyl [e.g. CH_3, CH_2CH_3, $CH(CH_3)_2$ or $CH(CH_3)CH_2CH_3$], (iii) -SR^4 [e.g. $-S-CH_3$, $-S-CH_2CH_3$ or , ,

, ,  or

], (iv) -NY^1Y^2 [e.g. ] or (v) -OR^5 [e.g. -OCH_2CH_3]; R^9 represents (i) hydrogen; (ii) C_{1-7}alkyl [e.g. -CH_3, -$CH_2CH_2CH_3$, -$CH(CH_3)_2$ or -CH_2-CH_2-$CH(CH_3)_2$]; (iii) aryl [e.g. phenyl]; (iv) -$C(=O)NY^1Y^2$ [e.g.

$-C(=O)-NH-CH_2CH_3$, $-C(=O)-NH-CH_2CH_2CH_3$, $-C(=O)-NH-CH_2CH(CH_3)_2$,

$-C(=O)-NH-CH(CH_3)_2$, $-C(=O)-NH-C(CH_3)_3$, $-C(=O)-NH-C(CH_3)_2CH_2OH$,

$-C(=O)-NH-CH_2CH_2OCH_3$, $-C(=O)-N(CH_3)_2$, $-C(=O)-N(CH_2CH_3)_2$,

,  or ];

(v) -$N(R^6)C(=O)R^4$, particularly -$NHC(=O)R^4$, in which (a) R^4 is alkyl optionally substituted by aryl, cycloalkyl, heteroaryl, heterocycloalkyl, NY^1Y^2 or -OR^5 [e.g. $-NH-C(=O)-CH_3$,

$-NH-C(=O)-(CH_2)_2CH_3$, $-NH-C(=O)-CH(CH_3)_2$, $-NH-C(=O)-C(CH_3)_3$,

$-NH-C(=O)-CH_2CH(CH_3)_2$, $-NH-C(=O)-CH(CH_3)CH_2CH_3$,

$-NH-C(=O)-CH_2C(CH_3)_3$, , ,

, $-NH-C(=O)-CH_2-N(CH_3)_2$,

 or

—NH—C(=O)—CH_2OCH_3], (b) R^4 is aryl [e.g.



(c) R^4 is cycloalkyl [e.g.  or ], (d) R^4 is heteroaryl[e.g.



or ] or (e) heterocycloalkyl [e.g. ];

(vi) -N(R^6)C(=O)NY^1Y^2, particularly -NHC(=O)NY^1Y^2 [e.g. —NH—C(=O)—$NHCH_3$, —NH—C(=O)—$NHCH_2CH_3$, —NH—C(=O)—$NHCH(CH_3)_2$, —NH—C(=O)—$NHCH_2CH(CH_3)_2$, —NH—C(=O)—$NHC(CH_3)_3$, —NH—C(=O)—$N(CH_3)_2$, —NH—C(=O)—$N(CH_2CH_3)_2$, , ,





(vii) -NY^1Y^2 [e.g. -NH_2] or (viii) alkyl substituted by -N(R^6)C(=O)NY^1Y^2 [e.g. -CH_2-NH-C(=O)-$CH(CH_3)_2$ or ] ; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixa) in which:-W represents CH; X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group $-CH_2$-O-CH_2-; Z represents CH; R^7 represents hydrogen; R^8 represents (i) hydrogen, (ii) C_{1-4}alkyl [e.g. CH_3, CH_2CH_3, $CH(CH_3)_2$ or $CH(CH_3)CH_2CH_3$], (iii) $-SR^4$ [e.g. $-S-CH_3$, $-S-CH_2CH_3$

or 

], (iv) $-NY^1Y^2$ [e.g.

] or (v) $-OR^5$ [e.g. $-OCH_2CH_3$]; R^9 represents (i) hydrogen; (ii) C_{1-7}alkyl [e.g. $-CH_3$, $-CH_2CH_2CH_3$, $-CH(CH_3)_2$ or $-CH_2-CH_2-CH(CH_3)_2$]; (iii) aryl [e.g. phenyl]; (iv) $-C(=O)NY^1Y^2$ [e.g. $-C(=O)-NH-CH_2CH_3$, $-C(=O)-NH-CH_2CH_2CH_3$, $-C(=O)-NH-CH_2CH(CH_3)_2$, $-C(=O)-NH-CH(CH_3)_2$, $-C(=O)-NH-C(CH_3)_3$, $-C(=O)-NH-C(CH_3)_2CH_2OH$, $-C(=O)-NH-CH_2CH_2OCH_3$, $-C(=O)-N(CH_3)_2$, $-C(=O)-N(CH_2CH_3)_2$,

];

(v) $-N(R^6)C(=O)R^4$, particularly $-NHC(=O)R^4$, in which (a) R^4 is alkyl optionally substituted by aryl, cycloalkyl, heteroaryl, heterocycloalkyl, NY^1Y^2 or $-OR^5$ [e.g. $-NH-C(=O)-CH_3$, $-NH-C(=O)-(CH_2)_2CH_3$, $-NH-C(=O)-CH(CH_3)_2$, $-NH-C(=O)-C(CH_3)_3$, $-NH-C(=O)-CH_2CH(CH_3)_2$, $-NH-C(=O)-CH(CH_3)CH_2CH_3$,



 , $-NH-C(=O)-CH_2-N(CH_3)_2$,

 or

$—NH—C(=O)—CH_2OCH_3$], (b) R^4 is aryl [e.g.

 ,  or ],

(c) R^4 is cycloalkyl [e.g.  or ], (d) R^4 is heteroaryl[e.g.  ,  , 

or ] or (e) heterocycloalkyl [e.g. ];

(vi) $-N(R^6)C(=O)NY^1Y^2$, particularly $-NHC(=O)NY^1Y^2$ [e.g. $—NH—C(=O)—NHCH_3$, $—NH—C(=O)—NHCH_2CH_3$, $—NH—C(=O)—NHCH(CH_3)_2$, $—NH—C(=O)—NHCH_2CH(CH_3)_2$, $—NH—C(=O)—NHC(CH_3)_3$, $—NH—C(=O)—N(CH_3)_2$, $—NH—C(=O)—N(CH_2CH_3)_2$,  ,  ,

 ,  ,

 ,  or ],

(vii) $-NY^1Y^2$ [e.g. $-NH_2$] or (viii) alkyl substituted by $-N(R^6)C(=O)NY^1Y^2$ [e.g. $-CH_2-NH-C(=O)-CH(CH_3)_2$ or ] ; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixa) in which:-W represents CH; X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group $-CH_2-CH_2-CH_2-$; Z represents CH; R^7 represents hydrogen; R^8 represents (i) hydrogen, (ii) C_{1-4}alkyl [e.g. CH_3, CH_2CH_3, $CH(CH_3)_2$ or $CH(CH_3)CH_2CH_3$], (iii) $-SR^4$ [e.g. $-S-CH_3$, $-S-CH_2CH_3$ or , , , ,  or ], (iv) $-NY^1Y^2$ [e.g. ] or (v) $-OR^5$ [e.g. $-OCH_2CH_3$]; R^9 represents (i) hydrogen; (ii) C_{1-7}alkyl [e.g. $-CH_3$, $-CH_2CH_2CH_3$, $-CH(CH_3)_2$ or $-CH_2-CH_2-CH(CH_3)_2$]; (iii) aryl [e.g. phenyl]; (iv) $-C(=O)NY^1Y^2$ [e.g. $-C(=O)-NH-CH_2CH_3$, $-C(=O)-NH-CH_2CH_2CH_3$, $-C(=O)-NH-CH_2CH(CH_3)_2$, $-C(=O)-NH-CH(CH_3)_2$, $-C(=O)-NH-C(CH_3)_3$, $-C(=O)-NH-C(CH_3)_2CH_2OH$, $-C(=O)-NH-CH_2CH_2OCH_3$, $-C(=O)-N(CH_3)_2$, $-C(=O)-N(CH_2CH_3)_2$, ,  or ];

(v) $-N(R^6)C(=O)R^4$, particularly $-NHC(=O)R^4$, in which (a) R^4 is alkyl optionally substituted by aryl, cycloalkyl, heteroaryl, heterocycloalkyl, NY^1Y^2 or $-OR^5$ [e.g. $-NH-C(=O)-CH_3$, $-NH-C(=O)-(CH_2)_2CH_3$, $-NH-C(=O)-CH(CH_3)_2$, $-NH-C(=O)-C(CH_3)_3$, $-NH-C(=O)-CH_2CH(CH_3)_2$, $-NH-C(=O)-CH(CH_3)CH_2CH_3$, $-NH-C(=O)-CH_2C(CH_3)_3$, , , , $-NH-C(=O)-CH_2-N(CH_3)_2$, ,  or $-NH-C(=O)-CH_2OCH_3$], (b) R^4 is aryl [e.g.

 ,  or ],

(c) R^4 is cycloalkyl [e.g.  or ], (d) R^4 is heteroaryl[e.g.  ,  ,  or ] or (e) heterocycloalkyl [e.g. ];

(vi) -$N(R^6)C(=O)NY^1Y^2$, particularly -$NHC(=O)NY^1Y^2$ [e.g. $—NH—C(=O)—NHCH_3$, $—NH—C(=O)—NHCH_2CH_3$, $—NH—C(=O)—NHCH(CH_3)_2$, $—NH—C(=O)—NHCH_2CH(CH_3)_2$, $—NH—C(=O)—NHC(CH_3)_3$, $—NH—C(=O)—N(CH_3)_2$, $—NH—C(=O)—N(CH_2CH_3)_2$,  ,  ,  ,  ,  ,  or ],

(vii) -NY^1Y^2 [e.g. -NH_2] or (viii) alkyl substituted by -$N(R^6)C(=O)NY^1Y^2$ [e.g. -CH_2-NH-C(=O)-$CH(CH_3)_2$ or ] ; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixa) in which R^8 is hydrogen or -CH_3 and R^9 is -CH_2-CH_2-$CH(CH_3)_2$,

$—C(=O)—NH—CH_2CH_3$, $—C(=O)—NH—CH_2CH_2CH_3$, $—C(=O)—NH—CH(CH_3)_2$,

$—C(=O)—NH—C(CH_3)_3$, $—C(=O)—NH—C(CH_3)_2CH_2OH$,  ,

$—C(=O)—NH—CH_2CH_2OCH_3$, $—C(=O)—N(CH_3)_2$, $—C(=O)—N(CH_2CH_3)_2$,

, $—NH—C(=O)—CH_3$, $—NH—C(=O)—(CH_2)_2CH_3$,

$—NH—C(=O)—CH(CH_3)_2$, $—NH—C(=O)—C(CH_3)_3$, $—NH—C(=O)—CH_2CH(CH_3)_2$,

$—NH—C(=O)—CH(CH_3)CH_2CH_3$, $—NH—C(=O)—CH_2C(CH_3)_3$,

 ,  , ,

$—NH—C(=O)—CH_2—N(CH_3)_2$,  ,

, $—NH—C(=O)—CH_2OCH_3$,  ,

 , ,  ,

 , ,  ,

,  , $—NH—C(=O)—NHCH_3$,

$—NH—C(=O)—NHCH_2CH_3$, $—NH—C(=O)—NHCH(CH_3)_2$, $—NH—C(=O)—NHC(CH_3)_3$,

$—NH—C(=O)—N(CH_3)_2$, $—NH—C(=O)—N(CH_2CH_3)_2$,  ,

 ,  ,

 ,  ,

 ,  , $-CH_2-NH-C(=O)-CH(CH_3)_2$ or

 are particularly preferred.

Compounds of formula (Ixa) in which R^9 represents hydrogen and R^8 represents $-CH(CH_3)_2$, $-S-CH_3$, $-S-CH_2CH_3$ or  are also particularly preferred.

Compounds of formula (Ixa) in which W is CH, X is CH, Y is CH, $C-CH_2CH_3$, $C-CH_2CH_2CH_3$,

 ,  ,  ,  , C-CN, C-Br, $C-CF_3$,

 ,  , $C-OCH_3$, $C-OCH_2CH_3$, $C-OCHF_2$, $C-OCF_3$,

 , $C-C(=O)-NH-CH_3$, $C-C(=O)-NH-CH_2CH_3$,

$C-C(=O)-NH-CH(CH_3)_2$, $C-C(=O)-NH-C(CH_3)_2-CH_2OH$, $C-C(=O)-NH-CH_2CH_2CN$,

$C-C(=O)-NH-CH_2CH_2OCH_3$,  ,

 ,  ,

 ,  ,

, ,

, ,

, ,

, , C-C(=O)OCH_3, C-C(=O)OH,

, C-SO_2CH_3 or  and Z is CH are particularly preferred.

Compounds of formula (Ixa) in which W is CH, X is C-CH_3 or C-CH_2CH_3, Y is C-CH_3, C-CH_2CH_3, C-$CH(CH_3)_2$, C-Br, C-Cl, C-F,  or , and Z is CH are also particularly preferred.

Compounds of formula (Ixa) in which W is CH, X is C-OCH_3, Y is CH, C-CH_3, C-CH_2CH_3, C-Cl or C-OCH_3 and Z is CH are also particularly preferred.

Compounds of formula (Ixa) in which W is CH, X is C-OCH_2CH_3, Y is C-F and Z is CH are also particularly preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CR^2 and Y represents CR^3 where R^2 and R^3 atoms form the group -CH_2-CH_2-CH_2-, and Z represents CH are also particularly preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group -CH_2-O-CH_2-, and Z represents CH are also particularly preferred.

Compounds of formula (Ixa) in which R^8 is hydrogen or $-CH_3$ and R^9 is $-C(=O)-NH-CH_2CH_3$, $-C(=O)-NH-CH_2CH_2CH_3$, $-C(=O)-NH-CH(CH_3)_2$, $-C(=O)-NH-CH_2CH(CH_3)_2$, $-C(=O)-NH-C(CH_3)_3$, $-C(=O)-NH-C(CH_3)_2CH_2OH$, $-C(=O)-N(CH_2CH_3)_2$,



$-C(=O)-NH-CH_2CH_2OCH_3$, , $-NH-C(=O)-(CH_2)_2CH_3$,

$-NH-C(=O)-CH(CH_3)_2$, $-NH-C(=O)-C(CH_3)_3$, $-NH-C(=O)-CH_2CH(CH_3)_2$,

$-NH-C(=O)-CH(CH_3)CH_2CH_3$, $-NH-C(=O)-CH_2C(CH_3)_3$, ,

, , $-NH-C(=O)-CH_2OCH_3$,





, $-NH-C(=O)-NHCH_3$, $-NH-C(=O)-NHCH_2CH_3$,

$-NH-C(=O)-NHCH(CH_3)_2$, $-NH-C(=O)-NHC(CH_3)_3$, $-NH-C(=O)-N(CH_3)_2$,

$-NH-C(=O)-N(CH_2CH_3)_2$, , ,



  or  are especially preferred.

Compounds of formula (Ixa) in which W is CH, X is CH, Y is C-OCH_3, C-OCH_2CH_3, C-$OCHF_2$, C-CF_3, C—C(=O)—NH—CH_2—  or C—C(=O)—NH—CH_2—  and Z is CH are especially preferred.

Compounds of formula (Ixa) in which W is CH, X is C-CH_3 or C-CH_2CH_3, Y is C-CH_3 or C-CH_2CH_3, C-Cl or C-F and Z is CH are also especially preferred.

Compounds of formula (Ixa) in which W is CH, X is C-OCH_3, Y is C-CH_3, C-CH_2CH_3, C-Cl, C-F or C-OCH_3 and Z is CH are also especially preferred.

Compounds of formula (Ixa) in which W is CH, X is C-OCH_2CH_3, Y is C-Cl or C-F and Z is CH are also especially preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group -CH_2-CH_2-CH_2-, and Z represents CH are also especially preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group -CH_2-O-CH_2-, and Z represents CH are also especially preferred.

Another particular group of compounds of the invention are compounds of formula (Ix) wherein R^1 is a heteroaryl moiety 

in which R^8 and R^9 together with the carbon atoms to which they are attached form an optionally substituted phenyl ring, i.e. compounds of formula (Ixb):-



(Ixb)

in which W, X, Y, Z and R^7 are as hereinbefore defined for compounds of formula (Ix); R^{10} is carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R^4, $-C(=O)R^4$, $-C(=O)NY^1Y^2$, $-C(=O)OR^4$, $-N(R^6)C(=O)R^4$, $-N(R^6)C(=O)NY^1Y^2$, $-N(R^6)C(=O)OR^4$, $-N(R^6)SO_2R^4$, $-N(R^6)SO_2NY^1Y^2$, $-NY^1Y^2$, $-OR^4$, $-OCF_2H$, $-OCF_3$, $-OC(=O)R^4$, $-OC(=O)NY^1Y^2$, $-S(O)_nR^4$ or $-S(O)_2NY^1Y^2$; and p is zero, or an integer 1; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixb) in which W represents CH, X represents CH, Y represents CH and Z represents CH or $C-CH_3$ are preferred.

Compounds of formula (Ixb) in which W represents CH, X represents CH, Z represents CH and Y represents:

(i) $C-C_{1-4}alkyl$ [e.g. $C-CH_3$, $C-CH_2CH_3$, $C-CH_2CH_2CH_3$ or $C-CH(CH_3)_2$];

(ii) C-aryl [e.g. 



];

(iii) C-CN;

(iv) $C-NO_2$;

(v) C-halo [e.g. C-Br, C-Cl or C-F];

(vi) C-haloalkyl [e.g. $C-CF_3$];

(vii) C-heteroaryl [e.g. ];

(viii) C-OR^4 [e.g. C—OCH$_3$, C—OCH$_2$CH$_3$, C—OCHF$_2$, C—OCF$_3$,  ,

 or ];

(ix) C-C(=O)R^4 [e.g. ];

(x) C-C=O)NY^{1}Y^2 [e.g. C—C(=O)—NH—CH$_3$, C—C(=O)—N(CH$_3$)$_2$,

C—C(=O)—NH—CH$_2$CH$_3$,

C—C(=O)—NH—CH(CH$_3$)$_2$, C—C(=O)—NH—C(CH$_3$)$_2$-CH$_2$OH,

C—C(=O)—NH—CH$_2$CH$_2$CN, C—C(=O)—NH—CH$_2$CH$_2$OCH$_3$,



];

(xi) C-C(=O)OR^4 [e.g. C-C(=O)OH or C-C(=O)OCH_3];

(xii) C-NHC(=O)R^4 [e.g. C-NHC(=O)CH_3, C-NHC(=O)$CH(CH_3)_2$,

C-NH-C(=O) or C-NH—C(=O)—CH_2];

(xiii) C-CH(OH)aryl [e.g. C-CH(OH)];

(xiv) C-$S(O)_2NY^1Y^2$ [e.g. C-SO_2—NH—CH_2]; or

(xv) C-$S(O)_nR^4$ [e.g. C-SO_2CH_3];

are also preferred.

Compounds of formula (Ixb) in which W represents CH, X represents C-CH_3, C-CH_2CH_3, C-$CH(CH_3)_2$, C-OCH_3, C-OCH_2CH_3, C-Br or C-Cl, Y represents C-CH_3, C-CH_2CH_3, C-OCH_3, C-Br, C-Cl, C-F, C or C—C(=O)—NH—CH_2 . and Z represents CH are also preferred.

Compounds of formula (Ixb) in which W represents CH, X represents CH, Y represents C-CH_3 and Z represents C-CH_3 are also preferred.

Compounds of formula (Ixb) in which W represents CH, X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group -CH_2-O-CH_2-, and Z represents CH are also preferred.

Compounds of formula (Ixb) in which W represents CH, X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group -CH_2-CH_2-CH_2-, and Z represents CH are also preferred.

Compounds of formula (Ixb) in which R^7 represents hydrogen are preferred.

Compounds of formula (Ixb) in which p is zero or one are preferred.

Compounds of formula (Ixb) in which R^{10} represents:

(i) cyano

(ii) halo [e.g. chloro, fluoro];

(iii) C_{1-4}alkyl [e.g. methyl,

(iv) $-OR^4$ [e.g. $-OCH_3$, $-OCH_2CH_3$]; or

(v) $-C(=O)NY^1Y^2$ [e.g. $-C(=O)-NH_2$, $-C(=O)-NHCH(CH_3)_2$, $-C(=O)-N(CH_3)_2$

are preferred.

A preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W represents CH; X represents CH; Y represents CH; Z represents CH or C-CH_3; R^7 represents hydrogen; R^{10} represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) C_{1-4}alkyl [e.g. methyl], (iv) $-OR^4$ [e.g. $-OCH_3$ or $-OCH_2CH_3$] or (v) $-C(=O)NY^1Y^2$ [e.g. $-C(=O)-NH_2$, $-C(=O)-NHCH(CH_3)_2$ or $-C(=O)-N(CH_3)_2$]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W represents CH; X represents CH; Z represents CH; Y represents (i) C-C_{1-4}alkyl [e.g. C-CH_3, C-CH_2CH_3, C-$CH_2CH_2CH_3$ or C-$CH(CH_3)_2$], (ii) C-aryl [e.g.  ,  ,

 ,  ,  ,  ,

 ,  or ], (iii) C-CN, (iv) C-NO_2, (v) C-halo [e.g. C-Br, C-Cl or C-F], (vi) C-haloalkyl [e.g. C-CF_3], (vii) C-heteroaryl [e.g.  or ], (viii) C-OR^4 [e.g. $C—OCH_3$, $C—OCH_2CH_3$, $C—OCHF_2$, $C—OCF_3$,

,  or ], (ix) C-C(=O)R^4 [e.g.

], (x) C-C=O)NY^1Y^2 [e.g. C—C(=O)—NH—CH_3, C—C(=O)—N$(CH_3)_2$,

C—C(=O)—NH—CH_2CH_3, C—C(=O)—NH—CH$(CH_3)_2$, C—C(=O)—NH—C$(CH_3)_2$-CH_2OH,

C—C(=O)—NH—CH_2CH_2CN, C—C(=O)—NH—$CH_2CH_2OCH_3$,

, ,

, ,

, ,

, ,

, ,

, 

or ], (xi) -C(=O)OR^4 [e.g. C-C(=O)OH or C-C(=O)OCH_3], (xii)

C-NHC(=O)R^4 [e.g. C-NHC(=O)CH_3 or C-NHC(=O)CH$(CH_3)_2$,  or

], (xiii) C-CH(OH)aryl [e.g. ], (xiv)

$C\text{-}S(O)_2NY^1Y^2$ [e.g. ] or (xv) $C\text{-}S(O)_nR^4$ [e.g. $C\text{-}SO_2CH_3$]; R^7 represents hydrogen; p is zero or one; R^{10} represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) $C_{1\text{-}4}$alkyl [e.g. methyl], (iv) $-OR^4$ [e.g. $-OCH_3$ or $-OCH_2CH_3$] or (v) $-C(=O)NY^1Y^2$ [e.g. $-C(=O)\text{-}NH_2$, $-C(=O)\text{-}NHCH(CH_3)_2$ or $-C(=O)\text{-}N(CH_3)_2$]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W represents CH; X represents $C\text{-}CH_3$, $C\text{-}CH_2CH_3$, $C\text{-}CH(CH_3)_2$, $C\text{-}OCH_3$, $C\text{-}OCH_2CH_3$, C-Br or C-Cl; Y represents $C\text{-}CH_3$, $C\text{-}CH_2CH_3$, $C\text{-}OCH_3$, C-Br, C-Cl, C-F,  or

 ; Z represents CH; R^7 represents hydrogen; p is zero or one; R^{10} represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) $C_{1\text{-}4}$alkyl [e.g. methyl], (iv) $-OR^4$ [e.g. $-OCH_3$ or $-OCH_2CH_3$] or (v) $-C(=O)NY^1Y^2$ [e.g. $-C(=O)\text{-}NH_2$, $-C(=O)\text{-}NHCH(CH_3)_2$ or $-C(=O)\text{-}N(CH_3)_2$]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W represents CH; X represents CH; Y represents $C\text{-}CH_3$; Z represents $C\text{-}CH_3$; R^7 represents hydrogen; p is zero or one; R^{10} represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) C1-4alkyl [e.g. methyl], (iv) $-OR^4$ [e.g. $-OCH_3$ or $-OCH_2CH_3$] or (v) $-C(=O)NY^1Y^2$ [e.g. $-C(=O)\text{-}NH_2$, $-C(=O)\text{-}NHCH(CH_3)_2$ or $-C(=O)\text{-}N(CH_3)_2$]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W represents CH; X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group

$-CH_2-O-CH_2-$; Z represents CH; R^7 represents hydrogen; p is zero or one; R^{10} represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) C1-4alkyl [e.g. methyl], (iv) $-OR^4$ [e.g. $-OCH_3$ or $-OCH_2CH_3$] or (v) $-C(=O)NY^1Y^2$ [e.g. $-C(=O)-NH_2$, $-C(=O)-NHCH(CH_3)_2$ or $-C(=O)-N(CH_3)_2$]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W represents CH; X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group $-CH_2-CH_2-CH_2-$; Z represents CH; R^7 represents hydrogen; p is zero or one; R^{10} represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) C1-4alkyl [e.g. methyl], (iv) $-OR^4$ [e.g. $-OCH_3$ or $-OCH_2CH_3$] or (v) $-C(=O)NY^1Y^2$ [e.g. $-C(=O)-NH_2$, $-C(=O)-NHCH(CH_3)_2$ or $-C(=O)-N(CH_3)_2$]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixb) in which R^7 represents hydrogen and p is zero are particularly preferred.

Compounds of formula (Ixb) in which R^7 represents hydrogen; p is one and R^{10} represents cyano, chloro, fluoro, methyl, $-OCH_3$, $-OCH_2CH_3$, $-C(=O)-NH_2$, $-C(=O)-NHCH(CH_3)_2$ or $-C(=O)-N(CH_3)_2$ are also particularly preferred.

Compounds of formula (Ixb) in which W is CH, X is CH, Y is CH, $C-CH_2CH_3$, $C-CH_2CH_2CH_3$,

 ,  ,  ,  , C-CN, C-Br, $C-CF_3$,

 ,  , $C-OCH_3$, $C-OCH_2CH_3$, $C-OCHF_2$, $C-OCF_3$,

 , $C-C(=O)-NH-CH_3$, $C-C(=O)-NH-CH_2CH_3$,

$C-C(=O)-NH-CH(CH_3)_2$, $C-C(=O)-NH-C(CH_3)_2-CH_2OH$, $C-C(=O)-NH-CH_2CH_2CN$,

C—C(=O)—NH—$CH_2CH_2OCH_3$,  ,

 ,  ,

 ,  ,

 ,  ,

 ,  ,

 ,  ,

 ,  , C-C(=O)OCH_3 , C-C(=O)OH,

 , C-SO_2CH_3 or  and Z is CH are particularly preferred.

Compounds of formula (Ixb) in which W is CH, X is C-CH_3 or C-CH_2CH_3, Y is C-CH_3, C-CH_2CH_3, C-$CH(CH_3)_2$, C-Br , C-Cl, C-F,  ,  , and Z is CH are also particularly preferred.

Compounds of formula (Ixb) in which W is CH, X is C-OCH_3, Y is CH, C-CH_3, C-CH_2CH_3, C-Cl or C-OCH_3 and Z is CH are also particularly preferred.

Compounds of formula (Ixb) in which W is CH, X is C-OCH_2CH_3, Y is C-F and Z is CH are also particularly prcferred.

Compounds of formula (Ixb) in which W represents CH, X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group -CH_2-CH_2-CH_2-, and Z represents CH are also particularly preferred.

Compounds of formula (Ixb) in which W represents CH, X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group -CH_2-O-CH_2-, and Z represents CH are also particularly preferred.

Compounds of formula (Ixb) in which R^7 represents hydrogen and p is zero are especially preferred.

Compounds of formula (Ixb) in which R^7 represents hydrogen; p is one and R^{10} represents -OCH_3, -OCH_2CH_3 or -C(=O)-NHCH(CH_3)$_2$ attached to position 5 of the indazolyl ring are also especially preferred.

Compounds of formula (Ixb) in which W is CH, X is C-CH_3 or C-CH_2CH_3, Y is C-CH_3 or C-CH_2CH_3 and Z is CH are also especially preferred.

Another particular group of compounds of the invention are compounds of formula (Ix) wherein R^1 is a pyrazolyl moiety  in which R^8 and R^9 together with the carbon atoms to which they are attached form an optionally substituted C_{5-8}cycloalkyl ring, i.e. compounds of formula (Ixc):-



(Ixc)

in which W, X, Y, Z, X and p are as hereinbefore defined for compounds of formula (Ix),  is a C_{5-8}cycloalkyl ring and R^{12} is acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy (or an acid bioisostere), cyano, cycloalkyl, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, heterocycloalkyl, hydroxy, nitro, trifluoromethyl, $-C(=O)NY^1Y^2$, $-NY^1-C(=O)$alkyl, $-NY^1SO_2$alkyl, $-NY^1Y^2$, $-SO_2NY^1Y^2$ or alkyl, alkenyl or alkynyl each optionally substituted with aryl, cycloalkyl, heteroaryl, hydroxy, $-C(=O)OR^6$, $-C(=O)NY^1Y^2$, $-NY^1Y^2$ or $-OR^5$; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixc) in which W represents CH, X represents CH, Y represents CH and Z represents CH or $C-CH_3$ are preferred.

Compounds of formula (Ixc) in which W represents CH, X represents CH, Z represents CH and Y represents:

(i) $C-C_{1-4}$alkyl [e.g. $C-CH_3$, $C-CH_2CH_3$, $C-CH_2CH_2CH_3$ or $C-CH(CH_3)_2$];

(ii) C-aryl [e.g.  ,  ,  ,

 ,  ,  ,

 ,  or ];

(iii) C-CN;

(iv) $C-NO_2$;

(v) C-halo [e.g. C-Br, C-Cl or C-F];

(vi) C-haloalkyl [e.g. $C-CF_3$];

(vii) C-heteroaryl [e.g.  or ];

(viii) C-OR^4 [e.g. C—OCH$_3$, C—OCH$_2$CH$_3$, C—OCHF$_2$, C—OCF$_3$, ,

 or ];

(ix) C-C(=O)R^4 [e.g. ];

(x) C-C=O)NY^{1}Y^2 [e.g. C—C(=O)—NH—CH$_3$, C—C(=O)—N(CH$_3$)$_2$,

C—C(=O)—NH—CH$_2$CH$_3$,

C—C(=O)—NH—CH(CH$_3$)$_2$, C—C(=O)—NH—C(CH$_3$)$_2$-CH$_2$OH,

C—C(=O)—NH—CH$_2$CH$_2$CN, C—C(=O)—NH—CH$_2$CH$_2$OCH$_3$,

, ,

, ,

, ,

, ,

, ,

 ,  or

];

(xi) C-C(=O)OR^4 [e.g. C-C(=O)OH or C-C(=O)OCH$_3$];

(xii) C-NHC(=O)R^4 [e.g. C-NHC(=O)CH$_3$, C-NHC(=O)CH(CH$_3$)$_2$,

 or ]; or

(xiii) C-CH(OH)aryl [e.g. ];

(xiv) C-S(O)$_2$NY^{1}Y^2 [e.g. ];

(xv) C-S(O)$_n$R^4 [e.g. C-SO$_2$CH$_3$];

are also preferred.

Compounds of formula (lxc) in which W represents CH, X represents C-CH$_3$, C-CH$_2$CH$_3$, C-CH(CH$_3$)$_2$, C-OCH$_3$, C-OCH$_2$CH$_3$, C-Br or C-Cl, Y represents C-CH$_3$, C-CH$_2$CH$_3$, C-OCH$_3$, C-Br, C-Cl, C-F,  or  and Z represents CH are also preferred.

Compounds of formula (Ixc) in which W represents CH, X represents CH, Y represents C-CH$_3$ and Z represents C-CH$_3$ are also preferred.

Compounds of formula (Ixc) in which W represents CH, X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group -CH$_2$-O-CH$_2$-, and Z represents CH are also preferred.

Compounds of formula (Ixc) in which W represents CH, X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group $-CH_2-CH_2-CH_2-$, and Z represents CH are also preferred.

Compounds of formula (Ixc) in which R^7 represents hydrogen are preferred.

Compounds of formula (Ixc) in which A represents a cyclopentyl, cyclohexyl and cycloheptyl, especially cyclohexyl, ring are preferred.

Compounds of formula (Ixc) in which q is zero are preferred.

A preferred group of compounds of the invention are compounds of formula (Ixc) in which:- W represents CH; X represents CH; Y represents CH; Z represents CH or $C-CH_3$; R^7 represents hydrogen; A represents a cyclopentyl, cyclohexyl or cycloheptyl ring; q is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixc) in which:- W represents CH; X represents CH; Z represents CH; Y represents (i) $C-C_{1-4}$alkyl [e.g. $C-CH_3$, $C-CH_2CH_3$, $C-CH_2CH_2CH_3$ or $C-CH(CH_3)_2$], (ii) C-aryl [e.g. , ,

, , , ,

,  or ], (iii) C-CN, (iv) $C-NO_2$, (v) C-halo

[e.g. C-Br, C-Cl or C-F], (vi) C-haloalkyl [e.g. C-CF_3], (vii) C-heteroaryl [e.g.  or

], (viii) C-OR^4 [e.g. C—OCH_3, C—OCH_2CH_3, C—$OCHF_2$, C—OCF_3,

,  or ], (ix) C-C(=O)R^4 [e.g.

], (x) C-C=O)NY^1Y^2 [e.g. C—C(=O)—NH—CH_3, C—C(=O)—N$(CH_3)_2$,

C—C(=O)—NH—CH_2CH_3, C—C(=O)—NH—$CH(CH_3)_2$, C—C(=O)—NH—$C(CH_3)_2$-CH_2OH,

C—C(=O)—NH—CH_2CH_2CN, C—C(=O)—NH—$CH_2CH_2OCH_3$,

, ,

, ,

, ,

, ,

, ,

, 

or ], (xi) -C(=O)OR^4 [e.g. C-C(=O)OH or C-C(=O)OCH_3], (xii)

C-NHC(=O)R^4 [e.g. C-NHC(=O)CH_3 or C-NHC(=O)CH$(CH_3)_2$, C-NH-C(=O)  or C-NH–C(=O)–CH_2 ], (xiii) C-CH(OH)aryl [e.g. C-CH(OH) ], (xiv) C-S(O)$_2$NY^1Y^2 [e.g. C-SO_2–NH–CH_2 ] or (xv) C-S(O)$_n$$R^4$ [e.g. C-SO_2CH_3]; R^7 represents hydrogen; A represents a cyclopentyl, cyclohexyl or cycloheptyl ring; q is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixc) in which:- W represents CH; X represents C-CH_3, C-CH_2CH_3, C-CH$(CH_3)_2$, C-OCH_3, C-OCH_2CH_3, C-Br or C-Cl; Y represents C-CH_3, C-CH_2CH_3, C-OCH_3, C-Br, C-Cl, C-F, C  or C–C(=O)–NH–CH_2  ; Z represents CH; R^7 represents hydrogen; A represents a cyclopentyl, cyclohexyl or cycloheptyl ring; q is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixc) in which:-W represents CH; X represents CH; Y represents C-CH_3; Z represents C-CH_3; R^7 represents hydrogen; A represents a cyclopentyl, cyclohexyl or cycloheptyl ring; q is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W represents CH; X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group $-CH_2-O-CH_2-$; Z represents CH; R^7 represents hydrogen; A represents a cyclopentyl, cyclohexyl or cycloheptyl ring; q is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W represents CH; X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group $-CH_2-CH_2-CH_2-$; Z represents CH; R^7 represents hydrogen; A represents a cyclopentyl, cyclohexyl or cycloheptyl ring; q is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixc) in which R^7 represents hydrogen and p is zero are particularly preferred.

Compounds of formula (Ixc) in which W is CH, X is $C-CH_3$, Y is $C-CH_3$ and Z is CH are also particularly preferred.

Compounds of formula (Ixc) in which A is a cyclopentyl ring are particularly preferred.

Another particular group of compounds of the invention are compounds of formula (Ix) wherein R^1 is a pyrazolyl moiety



in which R^8 and R^9 together with the carbon atoms to which they are attached form an optionally substituted heterocycloalkyl ring, i.e. compounds of formula (Ixd):-



(Ixd)

in which W, X, Y, Z and X are as hereinbefore defined for compounds of formula (Ix), X^1 is O, S, SO_2, or NY^5 (where Y^5 is hydrogen, R^4, $-C(=O)R^4$, $-C(=O)NY^1Y^2$, $-C(=O)OR^4$ or $-SO_2R^4$), r is zero or an integer one or two and R^{13} is alkyl or two R^{13} groups attached to the same carbon atom form an oxo group; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixd) in which W represents CH, X represents CH, Y represents CH and Z represents CH or C-CH_3 are preferred.

Compounds of formula (Ixd) in which W represents CH, X represents CH, Z represents CH and Y represents:

(i) C-C_{1-4}alkyl [e.g. C-CH_3, C-CH_2CH_3, C-$CH_2CH_2CH_3$ or C-$CH(CH_3)_2$];

(ii) C-aryl [e.g.



(iii) C-CN;

(iv) C-NO_2;

(v) C-halo [e.g. C-Br, C-Cl or C-F];

(vi) C-haloalkyl [e.g. C-CF_3];

(vii) C-heteroaryl [e.g.  or ];

(viii) C-OR[4] [e.g. C—OCH_3, C—OCH_2CH_3, C—$OCHF_2$, C—OCF_3,  ,

 or ];

(ix) C-C(=O)R[4] [e.g. ];

(x) C-C=O)NY[1]Y[2] [e.g. C—C(=O)—NH—CH_3, C—C(=O)—N$(CH_3)_2$,

C—C(=O)—NH—CH_2CH_3, C—C(=O)—NH—$CH(CH_3)_2$,

C—C(=O)—NH—$C(CH_3)_2$-CH_2OH, C—C(=O)—NH—CH_2CH_2CN,

C—C(=O)—NH—$CH_2CH_2OCH_3$,  ,

 ,  ,

 ,  ,

 ,  ,

 ,  ,

 ,

 or

];

(xi) C-C(=O)OR^4 [e.g. C-C(=O)OH or C-C(=O)OCH$_3$];

(xii) C-NHC(=O)R^4 [e.g. C-NHC(=O)CH$_3$, C-NHC(=O)CH(CH$_3$)$_2$,

 or ];

(xiii) C-CH(OH)aryl [e.g. ];

(xiv) C-S(O)$_2$NY^{1}Y^2 [e.g. ]; or

(xv) C-S(O)$_n$R^4 [e.g. C-SO$_2$CH$_3$];

are also preferred.

Compounds of formula (Ixd) in which W represents CH, X represents C-CH$_3$, C-CH$_2$CH$_3$, C-CH(CH$_3$)$_2$, C-OCH$_3$, C-OCH$_2$CH$_3$, C-Br or C-Cl, Y represents C-CH$_3$, C-CH$_2$CH$_3$, C-OCH$_3$, C-Br, C-Cl, C-F,  or  and Z represents CH are also preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CH, Y represents C-CH$_3$ and Z represents C-CH$_3$ are also preferred.

Compounds of formula (Ixd) in which W represents CH, X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group -CH$_2$-O-CH$_2$-, and Z represents CH are also preferred.

Compounds of formula (Ixd) in which W represents CH, X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group $-CH_2-CH_2-CH_2-$, and Z represents CH are also preferred.

Compounds of formula (Ixd) in which R^7 represents hydrogen are preferred.

Compounds of formula (Ixd) in which X^1 is:

(i) O;

(ii) $N-C(=O)R^4$ [e.g. $N-C(=O)CH_3$, $N-C(=O)CH_2CH(CH_3)_2$, $N-C(=O)CH(CH_3)_2$, or $N-C(=O)C(CH_3)_3$ or N—(C=O)— ];

(iii) $N-C(=O)NY^1Y^2$ [e.g. $N-C(=O)N(CH_3)_2$, $N-C(=O)NCH(CH_3)_2$, $N-C(=O)N(CH_2CH_3)_2$ N—(C=O)-N  , N—(C=O)-N  or N—(C=O)-N  O];

(iv) $N-C(=O)OR^4$ [e.g. $N-C(=O)OCH_3$ or $N-C(=O)OCH_2CH_3$]; or

(v) $N-SO_2R^4$ [e.g. $N-SO_2CH_3$ or $N-SO_2CH(CH_3)_2$];

are preferred.

Compounds of formula (Ixd) in which r is zero are preferred.

A preferred group of compounds of the invention are compounds of formula (Ixd) in which:- W represents CH; X represents CH; Y represents CH; Z represents CH or $C-CH_3$; R^7 represents hydrogen; X^1 is (i) O; (ii) $N-C(=O)R^4$ [e.g. $N-C(=O)CH_3$, $N-C(=O)CH_2CH(CH_3)_2$, $N-C(=O)CH(CH_3)_2$, or $N-C(=O)C(CH_3)_3$ or N—(C=O)— ]; (iii) $N-C(=O)NY^1Y^2$ [e.g. $N-C(=O)N(CH_3)_2$, $N-C(=O)NCH(CH_3)_2$, $N-C(=O)N(CH_2CH_3)_2$ N—(C=O)-N  , N—(C=O)-N  or N—(C=O)-N  O]; (iv) $N-C(=O)OR^4$ [e.g. $N-C(=O)OCH_3$ or $N-C(=O)OCH_2CH_3$]; or (v) $N-SO_2R^4$ [e.g. $N-SO_2CH_3$ or $N-SO_2CH(CH_3)_2$] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically

acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixd) in which:- W represents CH; X represents CH; Z represents CH; Y represents (i) C-C_{1-4}alkyl [e.g. C-CH_3, C-CH_2CH_3, C-$CH_2CH_2CH_3$ or C-$CH(CH_3)_2$], (ii) C-aryl [e.g.  ,  ,

 ,  ,  ,  ,

 ,  or ], (iii) C-CN, (iv) C-NO_2, (v) C-halo [e.g. C-Br, C-Cl or C-F], (vi) C-haloalkyl [e.g. C-CF_3], (vii) C-heteroaryl [e.g.  or

], (viii) C-OR^4 [e.g. C—OCH_3, C—OCH_2CH_3, C—$OCHF_2$, C—OCF_3,

 ,  or ], (ix) C-C(=O)R^4 [e.g.

], (x) C-C=O)NY^1Y^2 [e.g. C—C(=O)—NH—CH_3, C—C(=O)—N$(CH_3)_2$,

C—C(=O)—NH—CH_2CH_3, C—C(=O)—NH—$CH(CH_3)_2$, C—C(=O)—NH—$C(CH_3)_2$-CH_2OH,

C—C(=O)—NH—CH_2CH_2CN, C—C(=O)—NH—$CH_2CH_2OCH_3$,

 ,  ,



or ], (xi) -C(=O)OR^4 [e.g. C-C(=O)OH or C-C(=O)OCH$_3$], (xii) C-NHC(=O)R^4 [e.g. C-NHC(=O)CH$_3$ or C-NHC(=O)CH(CH$_3$)$_2$,  or ], (xiii) C-CH(OH)aryl [e.g. ], (xiv) C-S(O)$_2$NY^{1}Y^2 [e.g. ] or (xv) C-S(O)$_n$R^4 [e.g. C-SO$_2$CH$_3$]; R^7 represents hydrogen; X^1 is (i) O; (ii) N-C(=O)R^4 [e.g. N-C(=O)CH$_3$, N-C(=O)CH$_2$CH(CH$_3$)$_2$, N-C(=O)CH(CH$_3$)$_2$, or N-C(=O)C(CH$_3$)$_3$ or ]; (iii) N-C(=O)NY^{1}Y^2 [e.g. N-C(=O)N(CH$_3$)$_2$, N-C(=O)NCH(CH$_3$)$_2$, N-C(=O)N(CH$_2$CH$_3$)$_2$  ,  or ]; (iv) N-C(=O)OR^4 [e.g. N-C(=O)OCH$_3$ or N-C(=O)OCH$_2$CH$_3$]; or (v) N-SO$_2$R^4 [e.g. N-SO$_2$CH$_3$ or N-SO$_2$CH(CH$_3$)$_2$] and r is zero; and their

corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixd) in which:- W represents CH; X represents C-CH_3, C-CH_2CH_3, C-$CH(CH_3)_2$, C-OCH_3, C-OCH_2CH_3, C-Br or C-Cl; Y represents C-CH_3, C-CH_2CH_3, C-OCH_3, C-Br, C-Cl, C-F, C—  or C—C(=O)—NH—CH_2—  ; Z represents CH; R^7 represents hydrogen; X^1 is (i) O; (ii) N-C(=O)R^4 [e.g. N-C(=O)CH_3, N-C(=O)$CH_2CH(CH_3)_2$, N-C(=O)$CH(CH_3)_2$, or N-C(=O)$C(CH_3)_3$ or N—(C=O)— ]; (iii) N-C(=O)NY^1Y^2 [e.g. N-C(=O)N$(CH_3)_2$, N-C(=O)N$CH(CH_3)_2$, N-C(=O)N$(CH_2CH_3)_2$ N—(C=O)-  , N—(C=O)-  or N—(C=O)- ]; (iv) N-C(=O)OR^4 [e.g. N-C(=O)OCH_3 or N-C(=O)OCH_2CH_3]; or (v) N-SO_2R^4 [e.g. N-SO_2CH_3 or N-$SO_2CH(CH_3)_2$] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixd) in which:-W represents CH; X represents CH; Y represents C-CH_3; Z represents C-CH_3; R^7 represents hydrogen; X^1 is (i) O; (ii) N-C(=O)R^4 [e.g. N-C(=O)CH_3, N-C(=O)$CH_2CH(CH_3)_2$, N-C(=O)$CH(CH_3)_2$, or N-C(=O)$C(CH_3)_3$ or N—(C=O)— ]; (iii) N-C(=O)NY^1Y^2 [e.g. N-C(=O)N$(CH_3)_2$, N-C(=O)N$CH(CH_3)_2$, N-C(=O)N$(CH_2CH_3)_2$ N—(C=O)-  , N—(C=O)-  or N—(C=O)- ]; (iv) N-C(=O)OR^4 [e.g. N-C(=O)OCH_3 or N-C(=O)OCH_2CH_3]; or (v) N-SO_2R^4 [e.g. N-SO_2CH_3 or N-$SO_2CH(CH_3)_2$] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g.

hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixd) in which:-W represents CH; X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group $-CH_2-O-CH_2-$; Z represents CH; R^7 represents hydrogen; X^1 is (i) O; (ii) $N-C(=O)R^4$ [e.g. $N-C(=O)CH_3$, $N-C(=O)CH_2CH(CH_3)_2$, $N-C(=O)CH(CH_3)_2$, or $N-C(=O)C(CH_3)_3$ or

N—(C=O)— ]; (iii) $N-C(=O)NY^1Y^2$ [e.g. $N-C(=O)N(CH_3)_2$, $N-C(=O)NCH(CH_3)_2$,

$N-C(=O)N(CH_2CH_3)_2$ N—(C=O)-  , N—(C=O)-  or N—(C=O)- ];

(iv) $N-C(=O)OR^4$ [e.g. $N-C(=O)OCH_3$ or $N-C(=O)OCH_2CH_3$]; or (v) $N-SO_2R^4$ [e.g. $N-SO_2CH_3$ or $N-SO_2CH(CH_3)_2$] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixd) in which:-W represents CH; X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group $-CH_2-CH_2-CH_2-$; Z represents CH; R^7 represents hydrogen; X^1 is (i) O; (ii) $N-C(=O)R^4$ [e.g. $N-C(=O)CH_3$, $N-C(=O)CH_2CH(CH_3)_2$, $N-C(=O)CH(CH_3)_2$, or $N-C(=O)C(CH_3)_3$ or

N—(C=O)— ]; (iii) $N-C(=O)NY^1Y^2$ [e.g. $N-C(=O)N(CH_3)_2$, $N-C(=O)NCH(CH_3)_2$,

$N-C(=O)N(CH_2CH_3)_2$, N—(C=O)-  , N—(C=O)-  or N—(C=O)- ];

(iv) $N-C(=O)OR^4$ [e.g. $N-C(=O)OCH_3$ or $N-C(=O)OCH_2CH_3$]; or (v) $N-SO_2R^4$ [e.g. $N-SO_2CH_3$ or $N-SO_2CH(CH_3)_2$] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixd) in which X^1 is $N-C(=O)CH(CH_3)_2$, $N-C(=O)CH_2CH(CH_3)_2$,

$N-C(=O)C(CH_3)_3$; N—(C=O)—  , $N-C(=O)N(CH_3)_2$, $N-C(=O)NCH(CH_3)_2$,

$N\text{-}C(=O)N(CH_2CH_3)_2$, 

$N\text{-}C(=O)OCH_3$ or $N\text{-}C(=O)OCH_2CH_3$ and r is zero are particularly preferred.

Compounds of formula (Ixd) in which W is CH, X is CH, Y is CH, $C\text{-}CH_2CH_3$, $C\text{-}CH_2CH_2CH_3$,

 , C-CN, C-Br, $C\text{-}CF_3$,

 , $C—OCH_3$, $C—OCH_2CH_3$, $C—OCHF_2$, $C—OCF_3$,

 , $C—C(=O)—NH—CH_3$, $C—C(=O)—NH—CH_2CH_3$,

$C—C(=O)—NH—CH(CH_3)_2$, $C—C(=O)—NH—C(CH_3)_2\text{-}CH_2OH$, $C—C(=O)—NH—CH_2CH_2CN$,

$C—C(=O)—NH—CH_2CH_2OCH_3$, 











 ,  , $C\text{-}C(=O)OCH_3$, $C\text{-}C(=O)OH$,

 , $C\text{-}SO_2CH_3$ or  and Z is CH are particularly preferred.

Compounds of formula (Ixd) in which W is CH, X is $C\text{-}CH_3$ or $C\text{-}CH_2CH_3$, Y is $C\text{-}CH_3$, $C\text{-}CH_2CH_3$, $C\text{-}CH(CH_3)_2$, C-Br , C-Cl, C-F,  ,  , and Z is CH are also particularly preferred.

Compounds of formula (Ixa) in which W is CH, X is $C\text{-}OCH_3$, Y is CH, $C\text{-}CH_3$, $C\text{-}CH_2CH_3$, C-Cl or $C\text{-}OCH_3$ and Z is CH are also particularly preferred.

Compounds of formula (Ixd) in which W is CH, X is $C\text{-}OCH_2CH_3$, Y is C-F and Z is CH are also particularly preferred.

Compounds of formula (Ixd) in which W represents CH, X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group $-CH_2\text{-}CH_2\text{-}CH_2\text{-}$, and Z represents CH are also particularly preferred.

Compounds of formula (Ixd) in which W represents CH, X represents CR^2 and Y represents CR^3 where R^2 and R^3 form the group $-CH_2\text{-}O\text{-}CH_2\text{-}$, and Z represents CH are also particularly preferred.

Compounds of formula (Ixd) in which X^1 is  , $N\text{-}C(=O)N(CH_3)_2$, $N\text{-}C(=O)NCH(CH_3)_2$, $N\text{-}C(=O)N(CH_2CH_3)_2$,  or  and r is zero are especially preferred.

Compounds of formula (Ixd) in which W represents CH, X represents C-CH_3, Y represents C-CH_3 or C-Cl and Z represents CH are especially preferred.

Particular compounds of the invention of formula (Ix) are selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (A1 to A110) shown in Table 1 to the carbon atom (*C) in the heteroaryl moiety of one of the fragments (B1 to B168) shown in Table 2.

Particular compounds of the invention of formula (Ixa) are selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (A1 to A110) shown in Table 1 to the carbon atom (*C) in the pyrazole ring of one of the fragments (B1 to B48, B74 to B107, B124 to B127, 130 to 142 or 144 to 150) shown in Table 2.

Particular compounds of the invention of formula (Ixb) are also selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (A1 to A110) shown in Table 1 to the carbon atom (*C) in the five membered ring of one of the fragments (B63 to B73, B108 to B114, B128 or B151) shown in Table 2.

Particular compounds of the invention of formula (Ixc) are selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (A1 to A110) shown in Table 1 to the carbon atom (*C) in the five membered ring of one of the fragments (B56, B59 or B129) shown in Table 2.

Particular compounds of the invention of formula (Ixd) are selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (A1 to A110) shown in Table 1 to the carbon atom (*C) in the five membered ring of one of the fragments (B115 to B123 or B157) shown in Table 2.

TABLE 1

A1		A2	
A3		A4	
A5		A6	
A7		A8	
A9		A10	
A11		A12	
A13		A14	
A15		A16	
A17		A18	
A19		A20	
A21		A22	

A23		A24	
A25		A26	
A27		A28	
A29		A30	
A31		A32	
A33		A34	
A35		A36	
A37		A38	
A39		A40	
A41		A42	
A43		A44	

A45		A46	
A47		A48	
A49		A50	
A51		A52	
A53		A54	
A55		A56	
A57		A58	
A59		A60	
A61		A62	
A63		A64	

A65		A66	
A67		A68	
A69		A70	
A71		A72	
A73		A74	
A77		A78	
A79		A80	
A81		A82	
A83		A84	

A85		A86	
A87		A88	
A89		A90	
A91		A92	
A93		A94	
A95		A96	
A97		A98	
A99		A100	
A101		A102	
A103		A104	

A105		A106	
A107		A108	
A109		A110	

TABLE 2

B1		B2	
B3		B4	
B5		B6	
B7		B8	
B9		B10	
B11		B12	

B13		B14	
B15		B16	
B17		B18	
B19		B20	
B21		B22	
B23		B24	
B25		B26	
B27		B28	

B29		B30	
B31		B32	
B33		B34	
B35		B36	
B37		B38	
B39		B40	
B41		B42	

B43		B44	
B45		B46	
B47		B48	
B49		B50	
B51		B52	
B53		B54	
B55		B56	
B57		B58	
B59		B60	

B61		B62	
B63		B64	
B65		B66	
B67		B68	
B69		B70	
B71		B72	
B73		B74	
B75		B76	

B77		B78	
B79		B80	
B81		B82	
B83		B84	
B85		B86	
B87		B88	
B89		B90	

B91		B92	
B93		B94	
B95		B96	
B97		B98	
B99		B100	
B101		B102	
B103		B104	

B105		B106	
B107		B108	
B109		B110	
B111		B112	
B113		B114	
B115		B116	
B117		B118	
B119		B120	

B121		B122	
B123		B124	
B125		B126	
B127		B128	
B129		B130	
B131		B132	
B133		B134	

B135		B136	
B137		B138	
B139		B140	
B141		B142	
B143		B144	
B145		B146	
B147		B148	

B149		B150	
B151		B152	
B153		B154	
B155		B156	
B157		B158	
B159		B160	
B161		B162	

B163		B164	
B165		B166	
B167		B168	
B169			

Particular compounds of the invention of formula (Ix) denoted as the product of the combination of group A1 to A110 in Table 1 with B1 to B169 in Table 2 are illustrated below:

A1-B1;	A1-B2;	A1-B3;	A1-B4;	A1-B5;	A1-B6;
A1-B7;	A1-B8;	A1-B9;	A1-B10;	A1-B11;	A1-B12;
A1-B13;	A1-B14;	A1-B15;	A1-B16;	A1-B17;	A1-B18;
A1-B19;	A1-B20;	A1-B21;	A1-B22;	A1-B23;	A1-B24;
A1-B25;	A1-B26;	A1-B27;	A1-B28;	A1-B29;	A1-B30;
A1-B31;	A1-B32;	A1-B33;	A1-B34;	A1-B35;	A1-B36;
A1-B37;	A1-B38;	A1-B39;	A1-B40;	A1-B41;	A1-B42;
A1-B43;	A1-B44;	A1-B45;	A1-B46;	A1-B47;	A1-B48;
A1-B49;	A1-B50;	A1-B51;	A1-B52;	A1-B53;	A1-B54;
A1-B55;	A1-B56;	A1-B57;	A1-B58;	A1-B59;	A1-B60;
A1-B61;	A1-B62;	A1-B63;	A1-B64;	A1-B65;	A1-B66;
A1-B67;	A1-B68;	A1-B69;	A1-B70;	A1-B71;	A1-B72;
A1-B73;	A1-B74;	A1-B75;	A1-B76;	A1-B77;	A1-B78;
A1-B79;	A1-B80;	A1-B81;	A1-B82;	A1-B83;	A1-B84;
A1-B85;	A1-B86;	A1-B87;	A1-B88;	A1-B89;	A1-B90;

A1-B91;	A1-B92;	A1-B93;	A1-B94;	A1-B95;	A1-B96;
A1-B97;	A1-B98;	A1-B99;	A1-B100;	A1-B101;	A1-B102;
A1-B103;	A1-B104;	A1-B105;	A1-B106;	A1-B107;	A1-B108;
A1-B109;	A1-B110;	A1-B111;	A1-B112;	A1-B113;	A1-B114;
A1-B115;	A1-B116;	A1-B117;	A1-B118;	A1-B119;	A1-B120;
A1-B121;	A1-B122;	A1-B123;	A1-B124;	A1-B125;	A1-B126;
A1-B127;	A1-B128;	A1-B129;	A1-B130;	A1-B131;	A1-B132;
A1-B133;	A1-B134;	A1-B135;	A1-B136;	A1-B137;	A1-B138;
A1-B139;	A1-B140;	A1-B141;	A1-B142;	A1-B143;	A1-B144;
A1-B145;	A1-B146;	A1-B147;	A1-B148;	A1-B149;	A1-B150;
A1-B151;	A1-B152;	A1-B153;	A1-B154;	A1-B155;	A1-B156;
A1-B157;	A1-B158;	A1-B159;	A1-B160;	A1-B161;	A1-B162;
A1-B163;	A1-B164;	A1-B165;	A1-B166;	A1-B167;	A1-B168;
A1-B169;	A2-B1;	A2-B2;	A2-B3;	A2-B4;	A2-B5;
A2-B6;	A2-B7;	A2-B8;	A2-B9;	A2-B10;	A2-B11;
A2-B12;	A2-B13;	A2-B14;	A2-B15;	A2-B16;	A2-B17;
A2-B18;	A2-B19;	A2-B20;	A2-B21;	A2-B22;	A2-B23;
A2-B24;	A2-B25;	A2-B26;	A2-B27;	A2-B28;	A2-B29;
A2-B30;	A2-B31;	A2-B32;	A2-B33;	A2-B34;	A2-B35;
A2-B36;	A2-B37;	A2-B38;	A2-B39;	A2-B40;	A2-B41;
A2-B42;	A2-B43;	A2-B44;	A2-B45;	A2-B46;	A2-B47;
A2-B48;	A2-B49;	A2-B50;	A2-B51;	A2-B52;	A2-B53;
A2-B54;	A2-B55;	A2-B56;	A2-B57;	A2-B58;	A2-B59;
A2-B60;	A2-B61;	A2-B62;	A2-B63;	A2-B64;	A2-B65;
A2-B66;	A2-B67;	A2-B68;	A2-B69;	A2-B70;	A2-B71;
A2-B72;	A2-B73;	A2-B74;	A2-B75;	A2-B76;	A2-B77;
A2-B78;	A2-B79;	A2-B80;	A2-B81;	A2-B82;	A2-B83;
A2-B84;	A2-B85;	A2-B86;	A2-B87;	A2-B88;	A2-B89;
A2-B90;	A2-B91;	A2-B92;	A2-B93;	A2-B94;	A2-B95;
A2-B96;	A2-B97;	A2-B98;	A2-B99;	A2-B100;	A2-B101;
A2-B102;	A2-B103;	A2-B104;	A2-B105;	A2-B106;	A2-B107;
A2-B108;	A2-B109;	A2-B110;	A2-B111;	A2-B112;	A2-B113;
A2-B114;	A2-B115;	A2-B116;	A2-B117;	A2-B118;	A2-B119;
A2-B120;	A2-B121;	A2-B122;	A2-B123;	A2-B124;	A2-B125;
A2-B126;	A2-B127;	A2-B128;	A2-B129;	A2-B130;	A2-B131;

A2-B132;	A2-B133;	A2-B134;	A2-B135;	A2-B136;	A2-B137;
A2-B138;	A2-B139;	A2-B140;	A2-B141;	A2-B142;	A2-B143;
A2-B144;	A2-B145;	A2-B146;	A2-B147;	A2-B148;	A2-B149;
A2-B150;	A2-B151;	A2-B152;	A2-B153;	A2-B154;	A2-B155;
A2-B156;	A2-B157;	A2-B158;	A2-B159;	A2-B160;	A2-B161;
A2-B162;	A2-B163;	A2-B164;	A2-B165;	A2-B166;	A2-B167;
A2-B168;	A2-B169;	A3-B1;	A3-B2;	A3-B3;	A3-B4;
A3-B5;	A3-B6;	A3-B7;	A3-B8;	A3-B9;	A3-B10;
A3-B11;	A3-B12;	A3-B13;	A3-B14;	A3-B15;	A3-B16;
A3-B17;	A3-B18;	A3-B19;	A3-B20;	A3-B21;	A3-B22;
A3-B23;	A3-B24;	A3-B25;	A3-B26;	A3-B27;	A3-B28;
A3-B29;	A3-B30;	A3-B31;	A3-B32;	A3-B33;	A3-B34;
A3-B35;	A3-B36;	A3-B37;	A3-B38;	A3-B39;	A3-B40;
A3-B41;	A3-B42;	A3-B43;	A3-B44;	A3-B45;	A3-B46;
A3-B47;	A3-B48;	A3-B49;	A3-B50;	A3-B51;	A3-B52;
A3-B53;	A3-B54;	A3-B55;	A3-B56;	A3-B57;	A3-B58;
A3-B59;	A3-B60;	A3-B61;	A3-B62;	A3-B63;	A3-B64;
A3-B65;	A3-B66;	A3-B67;	A3-B68;	A3-B69;	A3-B70;
A3-B71;	A3-B72;	A3-B73;	A3-B74;	A3-B75;	A3-B76;
A3-B77;	A3-B78;	A3-B79;	A3-B80;	A3-B81;	A3-B82;
A3-B83;	A3-B84;	A3-B85;	A3-B86;	A3-B87;	A3-B88;
A3-B89;	A3-B90;	A3-B91;	A3-B92;	A3-B93;	A3-B94;
A3-B95;	A3-B96;	A3-B97;	A3-B98;	A3-B99;	A3-B100;
A3-B101;	A3-B102;	A3-B103;	A3-B104;	A3-B105;	A3-B106;
A3-B107;	A3-B108;	A3-B109;	A3-B110;	A3-B111;	A3-B112;
A3-B113;	A3-B114;	A3-B115;	A3-B116;	A3-B117;	A3-B118;
A3-B119;	A3-B120;	A3-B121;	A3-B122;	A3-B123;	A3-B124;
A3-B125;	A3-B126;	A3-B127;	A3-B128;	A3-B129;	A3-B130;
A3-B131;	A3-B132;	A3-B133;	A3-B134;	A3-B135;	A3-B136;
A3-B137;	A3-B138;	A3-B139;	A3-B140;	A3-B141;	A3-B142;
A3-B143;	A3-B144;	A3-B145;	A3-B146;	A3-B147;	A3-B148;
A3-B149;	A3-B150;	A3-B151;	A3-B152;	A3-B153;	A3-B154;
A3-B155;	A3-B156;	A3-B157;	A3-B158;	A3-B159;	A3-B160;
A3-B161;	A3-B162;	A3-B163;	A3-B164;	A3-B165;	A3-B166;
A3-B167;	A3-B168;	A3-B169;	A4-B1;	A4-B2;	A4-B3;

A4-B4;	A4-B5;	A4-B6;	A4-B7;	A4-B8;	A4-B9;
A4-B10;	A4-B11;	A4-B12;	A4-B13;	A4-B14;	A4-B15;
A4-B16;	A4-B17;	A4-B18;	A4-B19;	A4-B20;	A4-B21;
A4-B22;	A4-B23;	A4-B24;	A4-B25;	A4-B26;	A4-B27;
A4-B28;	A4-B29;	A4-B30;	A4-B31;	A4-B32;	A4-B33;
A4-B34;	A4-B35;	A4-B36;	A4-B37;	A4-B38;	A4-B39;
A4-B40;	A4-B41;	A4-B42;	A4-B43;	A4-B44;	A4-B45;
A4-B46;	A4-B47;	A4-B48;	A4-B49;	A4-B50;	A4-B51;
A4-B52;	A4-B53;	A4-B54;	A4-B55;	A4-B56;	A4-B57;
A4-B58;	A4-B59;	A4-B60;	A4-B61;	A4-B62;	A4-B63;
A4-B64;	A4-B65;	A4-B66;	A4-B67;	A4-B68;	A4-B69;
A4-B70;	A4-B71;	A4-B72;	A4-B73;	A4-B74;	A4-B75;
A4-B76;	A4-B77;	A4-B78;	A4-B79;	A4-B80;	A4-B81;
A4-B82;	A4-B83;	A4-B84;	A4-B85;	A4-B86;	A4-B87;
A4-B88;	A4-B89;	A4-B90;	A4-B91;	A4-B92;	A4-B93;
A4-B94;	A4-B95;	A4-B96;	A4-B97;	A4-B98;	A4-B99;
A4-B100;	A4-B101;	A4-B102;	A4-B103;	A4-B104;	A4-B105;
A4-B106;	A4-B107;	A4-B108;	A4-B109;	A4-B110;	A4-B111;
A4-B112;	A4-B113;	A4-B114;	A4-B115;	A4-B116;	A4-B117;
A4-B118;	A4-B119;	A4-B120;	A4-B121;	A4-B122;	A4-B123;
A4-B124;	A4-B125;	A4-B126;	A4-B127;	A4-B128;	A4-B129;
A4-B130;	A4-B131;	A4-B132;	A4-B133;	A4-B134;	A4-B135;
A4-B136;	A4-B137;	A4-B138;	A4-B139;	A4-B140;	A4-B141;
A4-B142;	A4-B143;	A4-B144;	A4-B145;	A4-B146;	A4-B147;
A4-B148;	A4-B149;	A4-B150;	A4-B151;	A4-B152;	A4-B153;
A4-B154;	A4-B155;	A4-B156;	A4-B157;	A4-B158;	A4-B159;
A4-B160;	A4-B161;	A4-B162;	A4-B163;	A4-B164;	A4-B165;
A4-B166;	A4-B167;	A4-B168;	A4-B169;	A5-B1;	A5-B2;
A5-B3;	A5-B4;	A5-B5;	A5-B6;	A5-B7;	A5-B8;
A5-B9;	A5-B10;	A5-B11;	A5-B12;	A5-B13;	A5-B14;
A5-B15;	A5-B16;	A5-B17;	A5-B18;	A5-B19;	A5-B20;
A5-B21;	A5-B22;	A5-B23;	A5-B24;	A5-B25;	A5-B26;
A5-B27;	A5-B28;	A5-B29;	A5-B30;	A5-B31;	A5-B32;
A5-B33;	A5-B34;	A5-B35;	A5-B36;	A5-B37;	A5-B38;
A5-B39;	A5-B40;	A5-B41;	A5-B42;	A5-B43;	A5-B44;

A5-B45;	A5-B46;	A5-B47;	A5-B48;	A5-B49;	A5-B50;
A5-B51;	A5-B52;	A5-B53;	A5-B54;	A5-B55;	A5-B56;
A5-B57;	A5-B58;	A5-B59;	A5-B60;	A5-B61;	A5-B62;
A5-B63;	A5-B64;	A5-B65;	A5-B66;	A5-B67;	A5-B68;
A5-B69;	A5-B70;	A5-B71;	A5-B72;	A5-B73;	A5-B74;
A5-B75;	A5-B76;	A5-B77;	A5-B78;	A5-B79;	A5-B80;
A5-B81;	A5-B82;	A5-B83;	A5-B84;	A5-B85;	A5-B86;
A5-B87;	A5-B88;	A5-B89;	A5-B90;	A5-B91;	A5-B92;
A5-B93;	A5-B94;	A5-B95;	A5-B96;	A5-B97;	A5-B98;
A5-B99;	A5-B100;	A5-B101;	A5-B102;	A5-B103;	A5-B104;
A5-B105;	A5-B106;	A5-B107;	A5-B108;	A5-B109;	A5-B110;
A5-B111;	A5-B112;	A5-B113;	A5-B114;	A5-B115;	A5-B116;
A5-B117;	A5-B118;	A5-B119;	A5-B120;	A5-B121;	A5-B122;
A5-B123;	A5-B124;	A5-B125;	A5-B126;	A5-B127;	A5-B128;
A5-B129;	A5-B130;	A5-B131;	A5-B132;	A5-B133;	A5-B134;
A5-B135;	A5-B136;	A5-B137;	A5-B138;	A5-B139;	A5-B140;
A5-B141;	A5-B142;	A5-B143;	A5-B144;	A5-B145;	A5-B146;
A5-B147;	A5-B148;	A5-B149;	A5-B150;	A5-B151;	A5-B152;
A5-B153;	A5-B154;	A5-B155;	A5-B156;	A5-B157;	A5-B158;
A5-B159;	A5-B160;	A5-B161;	A5-B162;	A5-B163;	A5-B164;
A5-B165;	A5-B166;	A5-B167;	A5-B168;	A5-B169;	A6-B1;
A6-B2;	A6-B3;	A6-B4;	A6-B5;	A6-B6;	A6-B7;
A6-B8;	A6-B9;	A6-B10;	A6-B11;	A6-B12;	A6-B13;
A6-B14;	A6-B15;	A6-B16;	A6-B17;	A6-B18;	A6-B19;
A6-B20;	A6-B21;	A6-B22;	A6-B23;	A6-B24;	A6-B25;
A6-B26;	A6-B27;	A6-B28;	A6-B29;	A6-B30;	A6-B31;
A6-B32;	A6-B33;	A6-B34;	A6-B35;	A6-B36;	A6-B37;
A6-B38;	A6-B39;	A6-B40;	A6-B41;	A6-B42;	A6-B43;
A6-B44;	A6-B45;	A6-B46;	A6-B47;	A6-B48;	A6-B49;
A6-B50;	A6-B51;	A6-B52;	A6-B53;	A6-B54;	A6-B55;
A6-B56;	A6-B57;	A6-B58;	A6-B59;	A6-B60;	A6-B61;
A6-B62;	A6-B63;	A6-B64;	A6-B65;	A6-B66;	A6-B67;
A6-B68;	A6-B69;	A6-B70;	A6-B71;	A6-B72;	A6-B73;
A6-B74;	A6-B75;	A6-B76;	A6-B77;	A6-B78;	A6-B79;
A6-B80;	A6-B81;	A6-B82;	A6-B83;	A6-B84;	A6-B85;

A6-B86;	A6-B87;	A6-B88;	A6-B89;	A6-B90;	A6-B91;
A6-B92;	A6-B93;	A6-B94;	A6-B95;	A6-B96;	A6-B97;
A6-B98;	A6-B99;	A6-B100;	A6-B101;	A6-B102;	A6-B103;
A6-B104;	A6-B105;	A6-B106;	A6-B107;	A6-B108;	A6-B109;
A6-B110;	A6-B111;	A6-B112;	A6-B113;	A6-B114;	A6-B115;
A6-B116;	A6-B117;	A6-B118;	A6-B119;	A6-B120;	A6-B121;
A6-B122;	A6-B123;	A6-B124;	A6-B125;	A6-B126;	A6-B127;
A6-B128;	A6-B129;	A6-B130;	A6-B131;	A6-B132;	A6-B133;
A6-B134;	A6-B135;	A6-B136;	A6-B137;	A6-B138;	A6-B139;
A6-B140;	A6-B141;	A6-B142;	A6-B143;	A6-B144;	A6-B145;
A6-B146;	A6-B147;	A6-B148;	A6-B149;	A6-B150;	A6-B151;
A6-B152;	A6-B153;	A6-B154;	A6-B155;	A6-B156;	A6-B157;
A6-B158;	A6-B159;	A6-B160;	A6-B161;	A6-B162;	A6-B163;
A6-B164;	A6-B165;	A6-B166;	A6-B167;	A6-B168;	A6-B169;
A7-B1;	A7-B2;	A7-B3;	A7-B4;	A7-B5;	A7-B6;
A7-B7;	A7-B8;	A7-B9;	A7-B10;	A7-B11;	A7-B12;
A7-B13;	A7-B14;	A7-B15;	A7-B16;	A7-B17;	A7-B18;
A7-B19;	A7-B20;	A7-B21;	A7-B22;	A7-B23;	A7-B24;
A7-B25;	A7-B26;	A7-B27;	A7-B28;	A7-B29;	A7-B30;
A7-B31;	A7-B32;	A7-B33;	A7-B34;	A7-B35;	A7-B36;
A7-B37;	A7-B38;	A7-B39;	A7-B40;	A7-B41;	A7-B42;
A7-B43;	A7-B44;	A7-B45;	A7-B46;	A7-B47;	A7-B48;
A7-B49;	A7-B50;	A7-B51;	A7-B52;	A7-B53;	A7-B54;
A7-B55;	A7-B56;	A7-B57;	A7-B58;	A7-B59;	A7-B60;
A7-B61;	A7-B62;	A7-B63;	A7-B64;	A7-B65;	A7-B66;
A7-B67;	A7-B68;	A7-B69;	A7-B70;	A7-B71;	A7-B72;
A7-B73;	A7-B74;	A7-B75;	A7-B76;	A7-B77;	A7-B78;
A7-B79;	A7-B80;	A7-B81;	A7-B82;	A7-B83;	A7-B84;
A7-B85;	A7-B86;	A7-B87;	A7-B88;	A7-B89;	A7-B90;
A7-B91;	A7-B92;	A7-B93;	A7-B94;	A7-B95;	A7-B96;
A7-B97;	A7-B98;	A7-B99;	A7-B100;	A7-B101;	A7-B102;
A7-B103;	A7-B104;	A7-B105;	A7-B106;	A7-B107;	A7-B108;
A7-B109;	A7-B110;	A7-B111;	A7-B112;	A7-B113;	A7-B114;
A7-B115;	A7-B116;	A7-B117;	A7-B118;	A7-B119;	A7-B120;
A7-B121;	A7-B122;	A7-B123;	A7-B124;	A7-B125;	A7-B126;

A7-B127;	A7-B128;	A7-B129;	A7-B130;	A7-B131;	A7-B132;
A7-B133;	A7-B134;	A7-B135;	A7-B136;	A7-B137;	A7-B138;
A7-B139;	A7-B140;	A7-B141;	A7-B142;	A7-B143;	A7-B144;
A7-B145;	A7-B146;	A7-B147;	A7-B148;	A7-B149;	A7-B150;
A7-B151;	A7-B152;	A7-B153;	A7-B154;	A7-B155;	A7-B156;
A7-B157;	A7-B158;	A7-B159;	A7-B160;	A7-B161;	A7-B162;
A7-B163;	A7-B164;	A7-B165;	A7-B166;	A7-B167;	A7-B168;
A7-B169;	A8-B1;	A8-B2;	A8-B3;	A8-B4;	A8-B5;
A8-B6;	A8-B7;	A8-B8;	A8-B9;	A8-B10;	A8-B11;
A8-B12;	A8-B13;	A8-B14;	A8-B15;	A8-B16;	A8-B17;
A8-B18;	A8-B19;	A8-B20;	A8-B21;	A8-B22;	A8-B23;
A8-B24;	A8-B25;	A8-B26;	A8-B27;	A8-B28;	A8-B29;
A8-B30;	A8-B31;	A8-B32;	A8-B33;	A8-B34;	A8-B35;
A8-B36;	A8-B37;	A8-B38;	A8-B39;	A8-B40;	A8-B41;
A8-B42;	A8-B43;	A8-B44;	A8-B45;	A8-B46;	A8-B47;
A8-B48;	A8-B49;	A8-B50;	A8-B51;	A8-B52;	A8-B53;
A8-B54;	A8-B55;	A8-B56;	A8-B57;	A8-B58;	A8-B59;
A8-B60;	A8-B61;	A8-B62;	A8-B63;	A8-B64;	A8-B65;
A8-B66;	A8-B67;	A8-B68;	A8-B69;	A8-B70;	A8-B71;
A8-B72;	A8-B73;	A8-B74;	A8-B75;	A8-B76;	A8-B77;
A8-B78;	A8-B79;	A8-B80;	A8-B81;	A8-B82;	A8-B83;
A8-B84;	A8-B85;	A8-B86;	A8-B87;	A8-B88;	A8-B89;
A8-B90;	A8-B91;	A8-B92;	A8-B93;	A8-B94;	A8-B95;
A8-B96;	A8-B97;	A8-B98;	A8-B99;	A8-B100;	A8-B101;
A8-B102;	A8-B103;	A8-B104;	A8-B105;	A8-B106;	A8-B107;
A8-B108;	A8-B109;	A8-B110;	A8-B111;	A8-B112;	A8-B113;
A8-B114;	A8-B115;	A8-B116;	A8-B117;	A8-B118;	A8-B119;
A8-B120;	A8-B121;	A8-B122;	A8-B123;	A8-B124;	A8-B125;
A8-B126;	A8-B127;	A8-B128;	A8-B129;	A8-B130;	A8-B131;
A8-B132;	A8-B133;	A8-B134;	A8-B135;	A8-B136;	A8-B137;
A8-B138;	A8-B139;	A8-B140;	A8-B141;	A8-B142;	A8-B143;
A8-B144;	A8-B145;	A8-B146;	A8-B147;	A8-B148;	A8-B149;
A8-B150;	A8-B151;	A8-B152;	A8-B153;	A8-B154;	A8-B155;
A8-B156;	A8-B157;	A8-B158;	A8-B159;	A8-B160;	A8-B161;
A8-B162;	A8-B163;	A8-B164;	A8-B165;	A8-B166;	A8-B167;

A8-B168;	A8-B169;	A9-B1;	A9-B2;	A9-B3;	A9-B4;
A9-B5;	A9-B6;	A9-B7;	A9-B8;	A9-B9;	A9-B10;
A9-B11;	A9-B12;	A9-B13;	A9-B14;	A9-B15;	A9-B16;
A9-B17;	A9-B18;	A9-B19;	A9-B20;	A9-B21;	A9-B22;
A9-B23;	A9-B24;	A9-B25;	A9-B26;	A9-B27;	A9-B28;
A9-B29;	A9-B30;	A9-B31;	A9-B32;	A9-B33;	A9-B34;
A9-B35;	A9-B36;	A9-B37;	A9-B38;	A9-B39;	A9-B40;
A9-B41;	A9-B42;	A9-B43;	A9-B44;	A9-B45;	A9-B46;
A9-B47;	A9-B48;	A9-B49;	A9-B50;	A9-B51;	A9-B52;
A9-B53;	A9-B54;	A9-B55;	A9-B56;	A9-B57;	A9-B58;
A9-B59;	A9-B60;	A9-B61;	A9-B62;	A9-B63;	A9-B64;
A9-B65;	A9-B66;	A9-B67;	A9-B68;	A9-B69;	A9-B70;
A9-B71;	A9-B72;	A9-B73;	A9-B74;	A9-B75;	A9-B76;
A9-B77;	A9-B78;	A9-B79;	A9-B80;	A9-B81;	A9-B82;
A9-B83;	A9-B84;	A9-B85;	A9-B86;	A9-B87;	A9-B88;
A9-B89;	A9-B90;	A9-B91;	A9-B92;	A9-B93;	A9-B94;
A9-B95;	A9-B96;	A9-B97;	A9-B98;	A9-B99;	A9-B100;
A9-B101;	A9-B102;	A9-B103;	A9-B104;	A9-B105;	A9-B106;
A9-B107;	A9-B108;	A9-B109;	A9-B110;	A9-B111;	A9-B112;
A9-B113;	A9-B114;	A9-B115;	A9-B116;	A9-B117;	A9-B118;
A9-B119;	A9-B120;	A9-B121;	A9-B122;	A9-B123;	A9-B124;
A9-B125;	A9-B126;	A9-B127;	A9-B128;	A9-B129;	A9-B130;
A9-B131;	A9-B132;	A9-B133;	A9-B134;	A9-B135;	A9-B136;
A9-B137;	A9-B138;	A9-B139;	A9-B140;	A9-B141;	A9-B142;
A9-B143;	A9-B144;	A9-B145;	A9-B146;	A9-B147;	A9-B148;
A9-B149;	A9-B150;	A9-B151;	A9-B152;	A9-B153;	A9-B154;
A9-B155;	A9-B156;	A9-B157;	A9-B158;	A9-B159;	A9-B160;
A9-B161;	A9-B162;	A9-B163;	A9-B164;	A9-B165;	A9-B166;
A9-B167;	A9-B168;	A9-B169;	A10-B1;	A10-B2;	A10-B3;
A10-B4;	A10-B5;	A10-B6;	A10-B7;	A10-B8;	A10-B9;
A10-B10;	A10-B11;	A10-B12;	A10-B13;	A10-B14;	A10-B15;
A10-B16;	A10-B17;	A10-B18;	A10-B19;	A10-B20;	A10-B21;
A10-B22;	A10-B23;	A10-B24;	A10-B25;	A10-B26;	A10-B27;
A10-B28;	A10-B29;	A10-B30;	A10-B31;	A10-B32;	A10-B33;
A10-B34;	A10-B35;	A10-B36;	A10-B37;	A10-B38;	A10-B39;

A10-B40;	A10-B41;	A10-B42;	A10-B43;	A10-B44;	A10-B45;
A10-B46;	A10-B47;	A10-B48;	A10-B49;	A10-B50;	A10-B51;
A10-B52;	A10-B53;	A10-B54;	A10-B55;	A10-B56;	A10-B57;
A10-B58;	A10-B59;	A10-B60;	A10-B61;	A10-B62;	A10-B63;
A10-B64;	A10-B65;	A10-B66;	A10-B67;	A10-B68;	A10-B69;
A10-B70;	A10-B71;	A10-B72;	A10-B73;	A10-B74;	A10-B75;
A10-B76;	A10-B77;	A10-B78;	A10-B79;	A10-B80;	A10-B81;
A10-B82;	A10-B83;	A10-B84;	A10-B85;	A10-B86;	A10-B87;
A10-B88;	A10-B89;	A10-B90;	A10-B91;	A10-B92;	A10-B93;
A10-B94;	A10-B95;	A10-B96;	A10-B97;	A10-B98;	A10-B99;
A10-B100;	A10-B101;	A10-B102;	A10-B103;	A10-B104;	A10-B105;
A10-B106;	A10-B107;	A10-B108;	A10-B109;	A10-B110;	A10-B111;
A10-B112;	A10-B113;	A10-B114;	A10-B115;	A10-B116;	A10-B117;
A10-B118;	A10-B119;	A10-B120;	A10-B121;	A10-B122;	A10-B123;
A10-B124;	A10-B125;	A10-B126;	A10-B127;	A10-B128;	A10-B129;
A10-B130;	A10-B131;	A10-B132;	A10-B133;	A10-B134;	A10-B135;
A10-B136;	A10-B137;	A10-B138;	A10-B139;	A10-B140;	A10-B141;
A10-B142;	A10-B143;	A10-B144;	A10-B145;	A10-B146;	A10-B147;
A10-B148;	A10-B149;	A10-B150;	A10-B151;	A10-B152;	A10-B153;
A10-B154;	A10-B155;	A10-B156;	A10-B157;	A10-B158;	A10-B159;
A10-B160;	A10-B161;	A10-B162;	A10-B163;	A10-B164;	A10-B165;
A10-B166;	A10-B167;	A10-B168;	A10-B169;	A11-B1;	A11-B2;
A11-B3;	A11-B4;	A11-B5;	A11-B6;	A11-B7;	A11-B8;
A11-B9;	A11-B10;	A11-B11;	A11-B12;	A11-B13;	A11-B14;
A11-B15;	A11-B16;	A11-B17;	A11-B18;	A11-B19;	A11-B20;
A11-B21;	A11-B22;	A11-B23;	A11-B24;	A11-B25;	A11-B26;
A11-B27;	A11-B28;	A11-B29;	A11-B30;	A11-B31;	A11-B32;
A11-B33;	A11-B34;	A11-B35;	A11-B36;	A11-B37;	A11-B38;
A11-B39;	A11-B40;	A11-B41;	A11-B42;	A11-B43;	A11-B44;
A11-B45;	A11-B46;	A11-B47;	A11-B48;	A11-B49;	A11-B50;
A11-B51;	A11-B52;	A11-B53;	A11-B54;	A11-B55;	A11-B56;
A11-B57;	A11-B58;	A11-B59;	A11-B60;	A11-B61;	A11-B62;
A11-B63;	A11-B64;	A11-B65;	A11-B66;	A11-B67;	A11-B68;
A11-B69;	A11-B70;	A11-B71;	A11-B72;	A11-B73;	A11-B74;
A11-B75;	A11-B76;	A11-B77;	A11-B78;	A11-B79;	A11-B80;

A11-B81;	A11-B82;	A11-B83;	A11-B84;	A11-B85;	A11-B86;
A11-B87;	A11-B88;	A11-B89;	A11-B90;	A11-B91;	A11-B92;
A11-B93;	A11-B94;	A11-B95;	A11-B96;	A11-B97;	A11-B98;
A11-B99;	A11-B100;	A11-B101;	A11-B102;	A11-B103;	A11-B104;
A11-B105;	A11-B106;	A11-B107;	A11-B108;	A11-B109;	A11-B110;
A11-B111;	A11-B112;	A11-B113;	A11-B114;	A11-B115;	A11-B116;
A11-B117;	A11-B118;	A11-B119;	A11-B120;	A11-B121;	A11-B122;
A11-B123;	A11-B124;	A11-B125;	A11-B126;	A11-B127;	A11-B128;
A11-B129;	A11-B130;	A11-B131;	A11-B132;	A11-B133;	A11-B134;
A11-B135;	A11-B136;	A11-B137;	A11-B138;	A11-B139;	A11-B140;
A11-B141;	A11-B142;	A11-B143;	A11-B144;	A11-B145;	A11-B146;
A11-B147;	A11-B148;	A11-B149;	A11-B150;	A11-B151;	A11-B152;
A11-B153;	A11-B154;	A11-B155;	A11-B156;	A11-B157;	A11-B158;
A11-B159;	A11-B160;	A11-B161;	A11-B162;	A11-B163;	A11-B164;
A11-B165;	A11-B166;	A11-B167;	A11-B168;	A11-B169;	A12-B1;
A12-B2;	A12-B3;	A12-B4;	A12-B5;	A12-B6;	A12-B7;
A12-B8;	A12-B9;	A12-B10;	A12-B11;	A12-B12;	A12-B13;
A12-B14;	A12-B15;	A12-B16;	A12-B17;	A12-B18;	A12-B19;
A12-B20;	A12-B21;	A12-B22;	A12-B23;	A12-B24;	A12-B25;
A12-B26;	A12-B27;	A12-B28;	A12-B29;	A12-B30;	A12-B31;
A12-B32;	A12-B33;	A12-B34;	A12-B35;	A12-B36;	A12-B37;
A12-B38;	A12-B39;	A12-B40;	A12-B41;	A12-B42;	A12-B43;
A12-B44;	A12-B45;	A12-B46;	A12-B47;	A12-B48;	A12-B49;
A12-B50;	A12-B51;	A12-B52;	A12-B53;	A12-B54;	A12-B55;
A12-B56;	A12-B57;	A12-B58;	A12-B59;	A12-B60;	A12-B61;
A12-B62;	A12-B63;	A12-B64;	A12-B65;	A12-B66;	A12-B67;
A12-B68;	A12-B69;	A12-B70;	A12-B71;	A12-B72;	A12-B73;
A12-B74;	A12-B75;	A12-B76;	A12-B77;	A12-B78;	A12-B79;
A12-B80;	A12-B81;	A12-B82;	A12-B83;	A12-B84;	A12-B85;
A12-B86;	A12-B87;	A12-B88;	A12-B89;	A12-B90;	A12-B91;
A12-B92;	A12-B93;	A12-B94;	A12-B95;	A12-B96;	A12-B97;
A12-B98;	A12-B99;	A12-B100;	A12-B101;	A12-B102;	A12-B103;
A12-B104;	A12-B105;	A12-B106;	A12-B107;	A12-B108;	A12-B109;
A12-B110;	A12-B111;	A12-B112;	A12-B113;	A12-B114;	A12-B115;
A12-B116;	A12-B117;	A12-B118;	A12-B119;	A12-B120;	A12-B121;

A12-B122;	A12-B123;	A12-B124;	A12-B125;	A12-B126;	A12-B127;
A12-B128;	A12-B129;	A12-B130;	A12-B131;	A12-B132;	A12-B133;
A12-B134;	A12-B135;	A12-B136;	A12-B137;	A12-B138;	A12-B139;
A12-B140;	A12-B141;	A12-B142;	A12-B143;	A12-B144;	A12-B145;
A12-B146;	A12-B147;	A12-B148;	A12-B149;	A12-B150;	A12-B151;
A12-B152;	A12-B153;	A12-B154;	A12-B155;	A12-B156;	A12-B157;
A12-B158;	A12-B159;	A12-B160;	A12-B161;	A12-B162;	A12-B163;
A12-B164;	A12-B165;	A12-B166;	A12-B167;	A12-B168;	A12-B169;
A13-B1;	A13-B2;	A13-B3;	A13-B4;	A13-B5;	A13-B6;
A13-B7;	A13-B8;	A13-B9;	A13-B10;	A13-B11;	A13-B12;
A13-B13;	A13-B14;	A13-B15;	A13-B16;	A13-B17;	A13-B18;
A13-B19;	A13-B20;	A13-B21;	A13-B22;	A13-B23;	A13-B24;
A13-B25;	A13-B26;	A13-B27;	A13-B28;	A13-B29;	A13-B30;
A13-B31;	A13-B32;	A13-B33;	A13-B34;	A13-B35;	A13-B36;
A13-B37;	A13-B38;	A13-B39;	A13-B40;	A13-B41;	A13-B42;
A13-B43;	A13-B44;	A13-B45;	A13-B46;	A13-B47;	A13-B48;
A13-B49;	A13-B50;	A13-B51;	A13-B52;	A13-B53;	A13-B54;
A13-B55;	A13-B56;	A13-B57;	A13-B58;	A13-B59;	A13-B60;
A13-B61;	A13-B62;	A13-B63;	A13-B64;	A13-B65;	A13-B66;
A13-B67;	A13-B68;	A13-B69;	A13-B70;	A13-B71;	A13-B72;
A13-B73;	A13-B74;	A13-B75;	A13-B76;	A13-B77;	A13-B78;
A13-B79;	A13-B80;	A13-B81;	A13-B82;	A13-B83;	A13-B84;
A13-B85;	A13-B86;	A13-B87;	A13-B88;	A13-B89;	A13-B90;
A13-B91;	A13-B92;	A13-B93;	A13-B94;	A13-B95;	A13-B96;
A13-B97;	A13-B98;	A13-B99;	A13-B100;	A13-B101;	A13-B102;
A13-B103;	A13-B104;	A13-B105;	A13-B106;	A13-B107;	A13-B108;
A13-B109;	A13-B110;	A13-B111;	A13-B112;	A13-B113;	A13-B114;
A13-B115;	A13-B116;	A13-B117;	A13-B118;	A13-B119;	A13-B120;
A13-B121;	A13-B122;	A13-B123;	A13-B124;	A13-B125;	A13-B126;
A13-B127;	A13-B128;	A13-B129;	A13-B130;	A13-B131;	A13-B132;
A13-B133;	A13-B134;	A13-B135;	A13-B136;	A13-B137;	A13-B138;
A13-B139;	A13-B140;	A13-B141;	A13-B142;	A13-B143;	A13-B144;
A13-B145;	A13-B146;	A13-B147;	A13-B148;	A13-B149;	A13-B150;
A13-B151;	A13-B152;	A13-B153;	A13-B154;	A13-B155;	A13-B156;
A13-B157;	A13-B158;	A13-B159;	A13-B160;	A13-B161;	A13-B162;

A13-B163;	A13-B164;	A13-B165;	A13-B166;	A13-B167;	A13-B168;
A13-B169;	A14-B1;	A14-B2;	A14-B3;	A14-B4;	A14-B5;
A14-B6;	A14-B7;	A14-B8;	A14-B9;	A14-B10;	A14-B11;
A14-B12;	A14-B13;	A14-B14;	A14-B15;	A14-B16;	A14-B17;
A14-B18;	A14-B19;	A14-B20;	A14-B21;	A14-B22;	A14-B23;
A14-B24;	A14-B25;	A14-B26;	A14-B27;	A14-B28;	A14-B29;
A14-B30;	A14-B31;	A14-B32;	A14-B33;	A14-B34;	A14-B35;
A14-B36;	A14-B37;	A14-B38;	A14-B39;	A14-B40;	A14-B41;
A14-B42;	A14-B43;	A14-B44;	A14-B45;	A14-B46;	A14-B47;
A14-B48;	A14-B49;	A14-B50;	A14-B51;	A14-B52;	A14-B53;
A14-B54;	A14-B55;	A14-B56;	A14-B57;	A14-B58;	A14-B59;
A14-B60;	A14-B61;	A14-B62;	A14-B63;	A14-B64;	A14-B65;
A14-B66;	A14-B67;	A14-B68;	A14-B69;	A14-B70;	A14-B71;
A14-B72;	A14-B73;	A14-B74;	A14-B75;	A14-B76;	A14-B77;
A14-B78;	A14-B79;	A14-B80;	A14-B81;	A14-B82;	A14-B83;
A14-B84;	A14-B85;	A14-B86;	A14-B87;	A14-B88;	A14-B89;
A14-B90;	A14-B91;	A14-B92;	A14-B93;	A14-B94;	A14-B95;
A14-B96;	A14-B97;	A14-B98;	A14-B99;	A14-B100;	A14-B101;
A14-B102;	A14-B103;	A14-B104;	A14-B105;	A14-B106;	A14-B107;
A14-B108;	A14-B109;	A14-B110;	A14-B111;	A14-B112;	A14-B113;
A14-B114;	A14-B115;	A14-B116;	A14-B117;	A14-B118;	A14-B119;
A14-B120;	A14-B121;	A14-B122;	A14-B123;	A14-B124;	A14-B125;
A14-B126;	A14-B127;	A14-B128;	A14-B129;	A14-B130;	A14-B131;
A14-B132;	A14-B133;	A14-B134;	A14-B135;	A14-B136;	A14-B137;
A14-B138;	A14-B139;	A14-B140;	A14-B141;	A14-B142;	A14-B143;
A14-B144;	A14-B145;	A14-B146;	A14-B147;	A14-B148;	A14-B149;
A14-B150;	A14-B151;	A14-B152;	A14-B153;	A14-B154;	A14-B155;
A14-B156;	A14-B157;	A14-B158;	A14-B159;	A14-B160;	A14-B161;
A14-B162;	A14-B163;	A14-B164;	A14-B165;	A14-B166;	A14-B167;
A14-B168;	A14-B169;	A15-B1;	A15-B2;	A15-B3;	A15-B4;
A15-B5;	A15-B6;	A15-B7;	A15-B8;	A15-B9;	A15-B10;
A15-B11;	A15-B12;	A15-B13;	A15-B14;	A15-B15;	A15-B16;
A15-B17;	A15-B18;	A15-B19;	A15-B20;	A15-B21;	A15-B22;
A15-B23;	A15-B24;	A15-B25;	A15-B26;	A15-B27;	A15-B28;
A15-B29;	A15-B30;	A15-B31;	A15-B32;	A15-B33;	A15-B34;

A15-B35;	A15-B36;	A15-B37;	A15-B38;	A15-B39;	A15-B40;
A15-B41;	A15-B42;	A15-B43;	A15-B44;	A15-B45;	A15-B46;
A15-B47;	A15-B48;	A15-B49;	A15-B50;	A15-B51;	A15-B52;
A15-B53;	A15-B54;	A15-B55;	A15-B56;	A15-B57;	A15-B58;
A15-B59;	A15-B60;	A15-B61;	A15-B62;	A15-B63;	A15-B64;
A15-B65;	A15-B66;	A15-B67;	A15-B68;	A15-B69;	A15-B70;
A15-B71;	A15-B72;	A15-B73;	A15-B74;	A15-B75;	A15-B76;
A15-B77;	A15-B78;	A15-B79;	A15-B80;	A15-B81;	A15-B82;
A15-B83;	A15-B84;	A15-B85;	A15-B86;	A15-B87;	A15-B88;
A15-B89;	A15-B90;	A15-B91;	A15-B92;	A15-B93;	A15-B94;
A15-B95;	A15-B96;	A15-B97;	A15-B98;	A15-B99;	A15-B100;
A15-B101;	A15-B102;	A15-B103;	A15-B104;	A15-B105;	A15-B106;
A15-B107;	A15-B108;	A15-B109;	A15-B110;	A15-B111;	A15-B112;
A15-B113;	A15-B114;	A15-B115;	A15-B116;	A15-B117;	A15-B118;
A15-B119;	A15-B120;	A15-B121;	A15-B122;	A15-B123;	A15-B124;
A15-B125;	A15-B126;	A15-B127;	A15-B128;	A15-B129;	A15-B130;
A15-B131;	A15-B132;	A15-B133;	A15-B134;	A15-B135;	A15-B136;
A15-B137;	A15-B138;	A15-B139;	A15-B140;	A15-B141;	A15-B142;
A15-B143;	A15-B144;	A15-B145;	A15-B146;	A15-B147;	A15-B148;
A15-B149;	A15-B150;	A15-B151;	A15-B152;	A15-B153;	A15-B154;
A15-B155;	A15-B156;	A15-B157;	A15-B158;	A15-B159;	A15-B160;
A15-B161;	A15-B162;	A15-B163;	A15-B164;	A15-B165;	A15-B166;
A15-B167;	A15-B168;	A15-B169;	A16-B1;	A16-B2;	A16-B3;
A16-B4;	A16-B5;	A16-B6;	A16-B7;	A16-B8;	A16-B9;
A16-B10;	A16-B11;	A16-B12;	A16-B13;	A16-B14;	A16-B15;
A16-B16;	A16-B17;	A16-B18;	A16-B19;	A16-B20;	A16-B21;
A16-B22;	A16-B23;	A16-B24;	A16-B25;	A16-B26;	A16-B27;
A16-B28;	A16-B29;	A16-B30;	A16-B31;	A16-B32;	A16-B33;
A16-B34;	A16-B35;	A16-B36;	A16-B37;	A16-B38;	A16-B39;
A16-B40;	A16-B41;	A16-B42;	A16-B43;	A16-B44;	A16-B45;
A16-B46;	A16-B47;	A16-B48;	A16-B49;	A16-B50;	A16-B51;
A16-B52;	A16-B53;	A16-B54;	A16-B55;	A16-B56;	A16-B57;
A16-B58;	A16-B59;	A16-B60;	A16-B61;	A16-B62;	A16-B63;
A16-B64;	A16-B65;	A16-B66;	A16-B67;	A16-B68;	A16-B69;
A16-B70;	A16-B71;	A16-B72;	A16-B73;	A16-B74;	A16-B75;

A16-B76;	A16-B77;	A16-B78;	A16-B79;	A16-B80;	A16-B81;
A16-B82;	A16-B83;	A16-B84;	A16-B85;	A16-B86;	A16-B87;
A16-B88;	A16-B89;	A16-B90;	A16-B91;	A16-B92;	A16-B93;
A16-B94;	A16-B95;	A16-B96;	A16-B97;	A16-B98;	A16-B99;
A16-B100;	A16-B101;	A16-B102;	A16-B103;	A16-B104;	A16-B105;
A16-B106;	A16-B107;	A16-B108;	A16-B109;	A16-B110;	A16-B111;
A16-B112;	A16-B113;	A16-B114;	A16-B115;	A16-B116;	A16-B117;
A16-B118;	A16-B119;	A16-B120;	A16-B121;	A16-B122;	A16-B123;
A16-B124;	A16-B125;	A16-B126;	A16-B127;	A16-B128;	A16-B129;
A16-B130;	A16-B131;	A16-B132;	A16-B133;	A16-B134;	A16-B135;
A16-B136;	A16-B137;	A16-B138;	A16-B139;	A16-B140;	A16-B141;
A16-B142;	A16-B143;	A16-B144;	A16-B145;	A16-B146;	A16-B147;
A16-B148;	A16-B149;	A16-B150;	A16-B151;	A16-B152;	A16-B153;
A16-B154;	A16-B155;	A16-B156;	A16-B157;	A16-B158;	A16-B159;
A16-B160;	A16-B161;	A16-B162;	A16-B163;	A16-B164;	A16-B165;
A16-B166;	A16-B167;	A16-B168;	A16-B169;	A17-B1;	A17-B2;
A17-B3;	A17-B4;	A17-B5;	A17-B6;	A17-B7;	A17-B8;
A17-B9;	A17-B10;	A17-B11;	A17-B12;	A17-B13;	A17-B14;
A17-B15;	A17-B16;	A17-B17;	A17-B18;	A17-B19;	A17-B20;
A17-B21;	A17-B22;	A17-B23;	A17-B24;	A17-B25;	A17-B26;
A17-B27;	A17-B28;	A17-B29;	A17-B30;	A17-B31;	A17-B32;
A17-B33;	A17-B34;	A17-B35;	A17-B36;	A17-B37;	A17-B38;
A17-B39;	A17-B40;	A17-B41;	A17-B42;	A17-B43;	A17-B44;
A17-B45;	A17-B46;	A17-B47;	A17-B48;	A17-B49;	A17-B50;
A17-B51;	A17-B52;	A17-B53;	A17-B54;	A17-B55;	A17-B56;
A17-B57;	A17-B58;	A17-B59;	A17-B60;	A17-B61;	A17-B62;
A17-B63;	A17-B64;	A17-B65;	A17-B66;	A17-B67;	A17-B68;
A17-B69;	A17-B70;	A17-B71;	A17-B72;	A17-B73;	A17-B74;
A17-B75;	A17-B76;	A17-B77;	A17-B78;	A17-B79;	A17-B80;
A17-B81;	A17-B82;	A17-B83;	A17-B84;	A17-B85;	A17-B86;
A17-B87;	A17-B88;	A17-B89;	A17-B90;	A17-B91;	A17-B92;
A17-B93;	A17-B94;	A17-B95;	A17-B96;	A17-B97;	A17-B98;
A17-B99;	A17-B100;	A17-B101;	A17-B102;	A17-B103;	A17-B104;
A17-B105;	A17-B106;	A17-B107;	A17-B108;	A17-B109;	A17-B110;
A17-B111;	A17-B112;	A17-B113;	A17-B114;	A17-B115;	A17-B116;

A17-B117;	A17-B118;	A17-B119;	A17-B120;	A17-B121;	A17-B122;
A17-B123;	A17-B124;	A17-B125;	A17-B126;	A17-B127;	A17-B128;
A17-B129;	A17-B130;	A17-B131;	A17-B132;	A17-B133;	A17-B134;
A17-B135;	A17-B136;	A17-B137;	A17-B138;	A17-B139;	A17-B140;
A17-B141;	A17-B142;	A17-B143;	A17-B144;	A17-B145;	A17-B146;
A17-B147;	A17-B148;	A17-B149;	A17-B150;	A17-B151;	A17-B152;
A17-B153;	A17-B154;	A17-B155;	A17-B156;	A17-B157;	A17-B158;
A17-B159;	A17-B160;	A17-B161;	A17-B162;	A17-B163;	A17-B164;
A17-B165;	A17-B166;	A17-B167;	A17-B168;	A17-B169;	A18-B1;
A18-B2;	A18-B3;	A18-B4;	A18-B5;	A18-B6;	A18-B7;
A18-B8;	A18-B9;	A18-B10;	A18-B11;	A18-B12;	A18-B13;
A18-B14;	A18-B15;	A18-B16;	A18-B17;	A18-B18;	A18-B19;
A18-B20;	A18-B21;	A18-B22;	A18-B23;	A18-B24;	A18-B25;
A18-B26;	A18-B27;	A18-B28;	A18-B29;	A18-B30;	A18-B31;
A18-B32;	A18-B33;	A18-B34;	A18-B35;	A18-B36;	A18-B37;
A18-B38;	A18-B39;	A18-B40;	A18-B41;	A18-B42;	A18-B43;
A18-B44;	A18-B45;	A18-B46;	A18-B47;	A18-B48;	A18-B49;
A18-B50;	A18-B51;	A18-B52;	A18-B53;	A18-B54;	A18-B55;
A18-B56;	A18-B57;	A18-B58;	A18-B59;	A18-B60;	A18-B61;
A18-B62;	A18-B63;	A18-B64;	A18-B65;	A18-B66;	A18-B67;
A18-B68;	A18-B69;	A18-B70;	A18-B71;	A18-B72;	A18-B73;
A18-B74;	A18-B75;	A18-B76;	A18-B77;	A18-B78;	A18-B79;
A18-B80;	A18-B81;	A18-B82;	A18-B83;	A18-B84;	A18-B85;
A18-B86;	A18-B87;	A18-B88;	A18-B89;	A18-B90;	A18-B91;
A18-B92;	A18-B93;	A18-B94;	A18-B95;	A18-B96;	A18-B97;
A18-B98;	A18-B99;	A18-B100;	A18-B101;	A18-B102;	A18-B103;
A18-B104;	A18-B105;	A18-B106;	A18-B107;	A18-B108;	A18-B109;
A18-B110;	A18-B111;	A18-B112;	A18-B113;	A18-B114;	A18-B115;
A18-B116;	A18-B117;	A18-B118;	A18-B119;	A18-B120;	A18-B121;
A18-B122;	A18-B123;	A18-B124;	A18-B125;	A18-B126;	A18-B127;
A18-B128;	A18-B129;	A18-B130;	A18-B131;	A18-B132;	A18-B133;
A18-B134;	A18-B135;	A18-B136;	A18-B137;	A18-B138;	A18-B139;
A18-B140;	A18-B141;	A18-B142;	A18-B143;	A18-B144;	A18-B145;
A18-B146;	A18-B147;	A18-B148;	A18-B149;	A18-B150;	A18-B151;
A18-B152;	A18-B153;	A18-B154;	A18-B155;	A18-B156;	A18-B157;

A18-B158;	A18-B159;	A18-B160;	A18-B161;	A18-B162;	A18-B163;
A18-B164;	A18-B165;	A18-B166;	A18-B167;	A18-B168;	A18-B169;
A19-B1;	A19-B2;	A19-B3;	A19-B4;	A19-B5;	A19-B6;
A19-B7;	A19-B8;	A19-B9;	A19-B10;	A19-B11;	A19-B12;
A19-B13;	A19-B14;	A19-B15;	A19-B16;	A19-B17;	A19-B18;
A19-B19;	A19-B20;	A19-B21;	A19-B22;	A19-B23;	A19-B24;
A19-B25;	A19-B26;	A19-B27;	A19-B28;	A19-B29;	A19-B30;
A19-B31;	A19-B32;	A19-B33;	A19-B34;	A19-B35;	A19-B36;
A19-B37;	A19-B38;	A19-B39;	A19-B40;	A19-B41;	A19-B42;
A19-B43;	A19-B44;	A19-B45;	A19-B46;	A19-B47;	A19-B48;
A19-B49;	A19-B50;	A19-B51;	A19-B52;	A19-B53;	A19-B54;
A19-B55;	A19-B56;	A19-B57;	A19-B58;	A19-B59;	A19-B60;
A19-B61;	A19-B62;	A19-B63;	A19-B64;	A19-B65;	A19-B66;
A19-B67;	A19-B68;	A19-B69;	A19-B70;	A19-B71;	A19-B72;
A19-B73;	A19-B74;	A19-B75;	A19-B76;	A19-B77;	A19-B78;
A19-B79;	A19-B80;	A19-B81;	A19-B82;	A19-B83;	A19-B84;
A19-B85;	A19-B86;	A19-B87;	A19-B88;	A19-B89;	A19-B90;
A19-B91;	A19-B92;	A19-B93;	A19-B94;	A19-B95;	A19-B96;
A19-B97;	A19-B98;	A19-B99;	A19-B100;	A19-B101;	A19-B102;
A19-B103;	A19-B104;	A19-B105;	A19-B106;	A19-B107;	A19-B108;
A19-B109;	A19-B110;	A19-B111;	A19-B112;	A19-B113;	A19-B114;
A19-B115;	A19-B116;	A19-B117;	A19-B118;	A19-B119;	A19-B120;
A19-B121;	A19-B122;	A19-B123;	A19-B124;	A19-B125;	A19-B126;
A19-B127;	A19-B128;	A19-B129;	A19-B130;	A19-B131;	A19-B132;
A19-B133;	A19-B134;	A19-B135;	A19-B136;	A19-B137;	A19-B138;
A19-B139;	A19-B140;	A19-B141;	A19-B142;	A19-B143;	A19-B144;
A19-B145;	A19-B146;	A19-B147;	A19-B148;	A19-B149;	A19-B150;
A19-B151;	A19-B152;	A19-B153;	A19-B154;	A19-B155;	A19-B156;
A19-B157;	A19-B158;	A19-B159;	A19-B160;	A19-B161;	A19-B162;
A19-B163;	A19-B164;	A19-B165;	A19-B166;	A19-B167;	A19-B168;
A19-B169;	A20-B1;	A20-B2;	A20-B3;	A20-B4;	A20-B5;
A20-B6;	A20-B7;	A20-B8;	A20-B9;	A20-B10;	A20-B11;
A20-B12;	A20-B13;	A20-B14;	A20-B15;	A20-B16;	A20-B17;
A20-B18;	A20-B19;	A20-B20;	A20-B21;	A20-B22;	A20-B23;
A20-B24;	A20-B25;	A20-B26;	A20-B27;	A20-B28;	A20-B29;

A20-B30;	A20-B31;	A20-B32;	A20-B33;	A20-B34;	A20-B35;
A20-B36;	A20-B37;	A20-B38;	A20-B39;	A20-B40;	A20-B41;
A20-B42;	A20-B43;	A20-B44;	A20-B45;	A20-B46;	A20-B47;
A20-B48;	A20-B49;	A20-B50;	A20-B51;	A20-B52;	A20-B53;
A20-B54;	A20-B55;	A20-B56;	A20-B57;	A20-B58;	A20-B59;
A20-B60;	A20-B61;	A20-B62;	A20-B63;	A20-B64;	A20-B65;
A20-B66;	A20-B67;	A20-B68;	A20-B69;	A20-B70;	A20-B71;
A20-B72;	A20-B73;	A20-B74;	A20-B75;	A20-B76;	A20-B77;
A20-B78;	A20-B79;	A20-B80;	A20-B81;	A20-B82;	A20-B83;
A20-B84;	A20-B85;	A20-B86;	A20-B87;	A20-B88;	A20-B89;
A20-B90;	A20-B91;	A20-B92;	A20-B93;	A20-B94;	A20-B95;
A20-B96;	A20-B97;	A20-B98;	A20-B99;	A20-B100;	A20-B101;
A20-B102;	A20-B103;	A20-B104;	A20-B105;	A20-B106;	A20-B107;
A20-B108;	A20-B109;	A20-B110;	A20-B111;	A20-B112;	A20-B113;
A20-B114;	A20-B115;	A20-B116;	A20-B117;	A20-B118;	A20-B119;
A20-B120;	A20-B121;	A20-B122;	A20-B123;	A20-B124;	A20-B125;
A20-B126;	A20-B127;	A20-B128;	A20-B129;	A20-B130;	A20-B131;
A20-B132;	A20-B133;	A20-B134;	A20-B135;	A20-B136;	A20-B137;
A20-B138;	A20-B139;	A20-B140;	A20-B141;	A20-B142;	A20-B143;
A20-B144;	A20-B145;	A20-B146;	A20-B147;	A20-B148;	A20-B149;
A20-B150;	A20-B151;	A20-B152;	A20-B153;	A20-B154;	A20-B155;
A20-B156;	A20-B157;	A20-B158;	A20-B159;	A20-B160;	A20-B161;
A20-B162;	A20-B163;	A20-B164;	A20-B165;	A20-B166;	A20-B167;
A20-B168;	A20-B169;	A21-B1;	A21-B2;	A21-B3;	A21-B4;
A21-B5;	A21-B6;	A21-B7;	A21-B8;	A21-B9;	A21-B10;
A21-B11;	A21-B12;	A21-B13;	A21-B14;	A21-B15;	A21-B16;
A21-B17;	A21-B18;	A21-B19;	A21-B20;	A21-B21;	A21-B22;
A21-B23;	A21-B24;	A21-B25;	A21-B26;	A21-B27;	A21-B28;
A21-B29;	A21-B30;	A21-B31;	A21-B32;	A21-B33;	A21-B34;
A21-B35;	A21-B36;	A21-B37;	A21-B38;	A21-B39;	A21-B40;
A21-B41;	A21-B42;	A21-B43;	A21-B44;	A21-B45;	A21-B46;
A21-B47;	A21-B48;	A21-B49;	A21-B50;	A21-B51;	A21-B52;
A21-B53;	A21-B54;	A21-B55;	A21-B56;	A21-B57;	A21-B58;
A21-B59;	A21-B60;	A21-B61;	A21-B62;	A21-B63;	A21-B64;
A21-B65;	A21-B66;	A21-B67;	A21-B68;	A21-B69;	A21-B70;

A21-B71;	A21-B72;	A21-B73;	A21-B74;	A21-B75;	A21-B76;
A21-B77;	A21-B78;	A21-B79;	A21-B80;	A21-B81;	A21-B82;
A21-B83;	A21-B84;	A21-B85;	A21-B86;	A21-B87;	A21-B88;
A21-B89;	A21-B90;	A21-B91;	A21-B92;	A21-B93;	A21-B94;
A21-B95;	A21-B96;	A21-B97;	A21-B98;	A21-B99;	A21-B100;
A21-B101;	A21-B102;	A21-B103;	A21-B104;	A21-B105;	A21-B106;
A21-B107;	A21-B108;	A21-B109;	A21-B110;	A21-B111;	A21-B112;
A21-B113;	A21-B114;	A21-B115;	A21-B116;	A21-B117;	A21-B118;
A21-B119;	A21-B120;	A21-B121;	A21-B122;	A21-B123;	A21-B124;
A21-B125;	A21-B126;	A21-B127;	A21-B128;	A21-B129;	A21-B130;
A21-B131;	A21-B132;	A21-B133;	A21-B134;	A21-B135;	A21-B136;
A21-B137;	A21-B138;	A21-B139;	A21-B140;	A21-B141;	A21-B142;
A21-B143;	A21-B144;	A21-B145;	A21-B146;	A21-B147;	A21-B148;
A21-B149;	A21-B150;	A21-B151;	A21-B152;	A21-B153;	A21-B154;
A21-B155;	A21-B156;	A21-B157;	A21-B158;	A21-B159;	A21-B160;
A21-B161;	A21-B162;	A21-B163;	A21-B164;	A21-B165;	A21-B166;
A21-B167;	A21-B168;	A21-B169;	A22-B1;	A22-B2;	A22-B3;
A22-B4;	A22-B5;	A22-B6;	A22-B7;	A22-B8;	A22-B9;
A22-B10;	A22-B11;	A22-B12;	A22-B13;	A22-B14;	A22-B15;
A22-B16;	A22-B17;	A22-B18;	A22-B19;	A22-B20;	A22-B21;
A22-B22;	A22-B23;	A22-B24;	A22-B25;	A22-B26;	A22-B27;
A22-B28;	A22-B29;	A22-B30;	A22-B31;	A22-B32;	A22-B33;
A22-B34;	A22-B35;	A22-B36;	A22-B37;	A22-B38;	A22-B39;
A22-B40;	A22-B41;	A22-B42;	A22-B43;	A22-B44;	A22-B45;
A22-B46;	A22-B47;	A22-B48;	A22-B49;	A22-B50;	A22-B51;
A22-B52;	A22-B53;	A22-B54;	A22-B55;	A22-B56;	A22-B57;
A22-B58;	A22-B59;	A22-B60;	A22-B61;	A22-B62;	A22-B63;
A22-B64;	A22-B65;	A22-B66;	A22-B67;	A22-B68;	A22-B69;
A22-B70;	A22-B71;	A22-B72;	A22-B73;	A22-B74;	A22-B75;
A22-B76;	A22-B77;	A22-B78;	A22-B79;	A22-B80;	A22-B81;
A22-B82;	A22-B83;	A22-B84;	A22-B85;	A22-B86;	A22-B87;
A22-B88;	A22-B89;	A22-B90;	A22-B91;	A22-B92;	A22-B93;
A22-B94;	A22-B95;	A22-B96;	A22-B97;	A22-B98;	A22-B99;
A22-B100;	A22-B101;	A22-B102;	A22-B103;	A22-B104;	A22-B105;
A22-B106;	A22-B107;	A22-B108;	A22-B109;	A22-B110;	A22-B111;

A22-B112;	A22-B113;	A22-B114;	A22-B115;	A22-B116;	A22-B117;
A22-B118;	A22-B119;	A22-B120;	A22-B121;	A22-B122;	A22-B123;
A22-B124;	A22-B125;	A22-B126;	A22-B127;	A22-B128;	A22-B129;
A22-B130;	A22-B131;	A22-B132;	A22-B133;	A22-B134;	A22-B135;
A22-B136;	A22-B137;	A22-B138;	A22-B139;	A22-B140;	A22-B141;
A22-B142;	A22-B143;	A22-B144;	A22-B145;	A22-B146;	A22-B147;
A22-B148;	A22-B149;	A22-B150;	A22-B151;	A22-B152;	A22-B153;
A22-B154;	A22-B155;	A22-B156;	A22-B157;	A22-B158;	A22-B159;
A22-B160;	A22-B161;	A22-B162;	A22-B163;	A22-B164;	A22-B165;
A22-B166;	A22-B167;	A22-B168;	A22-B169;	A23-B1;	A23-B2;
A23-B3;	A23-B4;	A23-B5;	A23-B6;	A23-B7;	A23-B8;
A23-B9;	A23-B10;	A23-B11;	A23-B12;	A23-B13;	A23-B14;
A23-B15;	A23-B16;	A23-B17;	A23-B18;	A23-B19;	A23-B20;
A23-B21;	A23-B22;	A23-B23;	A23-B24;	A23-B25;	A23-B26;
A23-B27;	A23-B28;	A23-B29;	A23-B30;	A23-B31;	A23-B32;
A23-B33;	A23-B34;	A23-B35;	A23-B36;	A23-B37;	A23-B38;
A23-B39;	A23-B40;	A23-B41;	A23-B42;	A23-B43;	A23-B44;
A23-B45;	A23-B46;	A23-B47;	A23-B48;	A23-B49;	A23-B50;
A23-B51;	A23-B52;	A23-B53;	A23-B54;	A23-B55;	A23-B56;
A23-B57;	A23-B58;	A23-B59;	A23-B60;	A23-B61;	A23-B62;
A23-B63;	A23-B64;	A23-B65;	A23-B66;	A23-B67;	A23-B68;
A23-B69;	A23-B70;	A23-B71;	A23-B72;	A23-B73;	A23-B74;
A23-B75;	A23-B76;	A23-B77;	A23-B78;	A23-B79;	A23-B80;
A23-B81;	A23-B82;	A23-B83;	A23-B84;	A23-B85;	A23-B86;
A23-B87;	A23-B88;	A23-B89;	A23-B90;	A23-B91;	A23-B92;
A23-B93;	A23-B94;	A23-B95;	A23-B96;	A23-B97;	A23-B98;
A23-B99;	A23-B100;	A23-B101;	A23-B102;	A23-B103;	A23-B104;
A23-B105;	A23-B106;	A23-B107;	A23-B108;	A23-B109;	A23-B110;
A23-B111;	A23-B112;	A23-B113;	A23-B114;	A23-B115;	A23-B116;
A23-B117;	A23-B118;	A23-B119;	A23-B120;	A23-B121;	A23-B122;
A23-B123;	A23-B124;	A23-B125;	A23-B126;	A23-B127;	A23-B128;
A23-B129;	A23-B130;	A23-B131;	A23-B132;	A23-B133;	A23-B134;
A23-B135;	A23-B136;	A23-B137;	A23-B138;	A23-B139;	A23-B140;
A23-B141;	A23-B142;	A23-B143;	A23-B144;	A23-B145;	A23-B146;
A23-B147;	A23-B148;	A23-B149;	A23-B150;	A23-B151;	A23-B152;

A23-B153;	A23-B154;	A23-B155;	A23-B156;	A23-B157;	A23-B158;
A23-B159;	A23-B160;	A23-B161;	A23-B162;	A23-B163;	A23-B164;
A23-B165;	A23-B166;	A23-B167;	A23-B168;	A23-B169;	A24-B1;
A24-B2;	A24-B3;	A24-B4;	A24-B5;	A24-B6;	A24-B7;
A24-B8;	A24-B9;	A24-B10;	A24-B11;	A24-B12;	A24-B13;
A24-B14;	A24-B15;	A24-B16;	A24-B17;	A24-B18;	A24-B19;
A24-B20;	A24-B21;	A24-B22;	A24-B23;	A24-B24;	A24-B25;
A24-B26;	A24-B27;	A24-B28;	A24-B29;	A24-B30;	A24-B31;
A24-B32;	A24-B33;	A24-B34;	A24-B35;	A24-B36;	A24-B37;
A24-B38;	A24-B39;	A24-B40;	A24-B41;	A24-B42;	A24-B43;
A24-B44;	A24-B45;	A24-B46;	A24-B47;	A24-B48;	A24-B49;
A24-B50;	A24-B51;	A24-B52;	A24-B53;	A24-B54;	A24-B55;
A24-B56;	A24-B57;	A24-B58;	A24-B59;	A24-B60;	A24-B61;
A24-B62;	A24-B63;	A24-B64;	A24-B65;	A24-B66;	A24-B67;
A24-B68;	A24-B69;	A24-B70;	A24-B71;	A24-B72;	A24-B73;
A24-B74;	A24-B75;	A24-B76;	A24-B77;	A24-B78;	A24-B79;
A24-B80;	A24-B81;	A24-B82;	A24-B83;	A24-B84;	A24-B85;
A24-B86;	A24-B87;	A24-B88;	A24-B89;	A24-B90;	A24-B91;
A24-B92;	A24-B93;	A24-B94;	A24-B95;	A24-B96;	A24-B97;
A24-B98;	A24-B99;	A24-B100;	A24-B101;	A24-B102;	A24-B103;
A24-B104;	A24-B105;	A24-B106;	A24-B107;	A24-B108;	A24-B109;
A24-B110;	A24-B111;	A24-B112;	A24-B113;	A24-B114;	A24-B115;
A24-B116;	A24-B117;	A24-B118;	A24-B119;	A24-B120;	A24-B121;
A24-B122;	A24-B123;	A24-B124;	A24-B125;	A24-B126;	A24-B127;
A24-B128;	A24-B129;	A24-B130;	A24-B131;	A24-B132;	A24-B133;
A24-B134;	A24-B135;	A24-B136;	A24-B137;	A24-B138;	A24-B139;
A24-B140;	A24-B141;	A24-B142;	A24-B143;	A24-B144;	A24-B145;
A24-B146;	A24-B147;	A24-B148;	A24-B149;	A24-B150;	A24-B151;
A24-B152;	A24-B153;	A24-B154;	A24-B155;	A24-B156;	A24-B157;
A24-B158;	A24-B159;	A24-B160;	A24-B161;	A24-B162;	A24-B163;
A24-B164;	A24-B165;	A24-B166;	A24-B167;	A24-B168;	A24-B169;
A25-B1;	A25-B2;	A25-B3;	A25-B4;	A25-B5;	A25-B6;
A25-B7;	A25-B8;	A25-B9;	A25-B10;	A25-B11;	A25-B12;
A25-B13;	A25-B14;	A25-B15;	A25-B16;	A25-B17;	A25-B18;
A25-B19;	A25-B20;	A25-B21;	A25-B22;	A25-B23;	A25-B24;

A25-B25;	A25-B26;	A25-B27;	A25-B28;	A25-B29;	A25-B30;
A25-B31;	A25-B32;	A25-B33;	A25-B34;	A25-B35;	A25-B36;
A25-B37;	A25-B38;	A25-B39;	A25-B40;	A25-B41;	A25-B42;
A25-B43;	A25-B44;	A25-B45;	A25-B46;	A25-B47;	A25-B48;
A25-B49;	A25-B50;	A25-B51;	A25-B52;	A25-B53;	A25-B54;
A25-B55;	A25-B56;	A25-B57;	A25-B58;	A25-B59;	A25-B60;
A25-B61;	A25-B62;	A25-B63;	A25-B64;	A25-B65;	A25-B66;
A25-B67;	A25-B68;	A25-B69;	A25-B70;	A25-B71;	A25-B72;
A25-B73;	A25-B74;	A25-B75;	A25-B76;	A25-B77;	A25-B78;
A25-B79;	A25-B80;	A25-B81;	A25-B82;	A25-B83;	A25-B84;
A25-B85;	A25-B86;	A25-B87;	A25-B88;	A25-B89;	A25-B90;
A25-B91;	A25-B92;	A25-B93;	A25-B94;	A25-B95;	A25-B96;
A25-B97;	A25-B98;	A25-B99;	A25-B100;	A25-B101;	A25-B102;
A25-B103;	A25-B104;	A25-B105;	A25-B106;	A25-B107;	A25-B108;
A25-B109;	A25-B110;	A25-B111;	A25-B112;	A25-B113;	A25-B114;
A25-B115;	A25-B116;	A25-B117;	A25-B118;	A25-B119;	A25-B120;
A25-B121;	A25-B122;	A25-B123;	A25-B124;	A25-B125;	A25-B126;
A25-B127;	A25-B128;	A25-B129;	A25-B130;	A25-B131;	A25-B132;
A25-B133;	A25-B134;	A25-B135;	A25-B136;	A25-B137;	A25-B138;
A25-B139;	A25-B140;	A25-B141;	A25-B142;	A25-B143;	A25-B144;
A25-B145;	A25-B146;	A25-B147;	A25-B148;	A25-B149;	A25-B150;
A25-B151;	A25-B152;	A25-B153;	A25-B154;	A25-B155;	A25-B156;
A25-B157;	A25-B158;	A25-B159;	A25-B160;	A25-B161;	A25-B162;
A25-B163;	A25-B164;	A25-B165;	A25-B166;	A25-B167;	A25-B168;
A25-B169;	A26-B1;	A26-B2;	A26-B3;	A26-B4;	A26-B5;
A26-B6;	A26-B7;	A26-B8;	A26-B9;	A26-B10;	A26-B11;
A26-B12;	A26-B13;	A26-B14;	A26-B15;	A26-B16;	A26-B17;
A26-B18;	A26-B19;	A26-B20;	A26-B21;	A26-B22;	A26-B23;
A26-B24;	A26-B25;	A26-B26;	A26-B27;	A26-B28;	A26-B29;
A26-B30;	A26-B31;	A26-B32;	A26-B33;	A26-B34;	A26-B35;
A26-B36;	A26-B37;	A26-B38;	A26-B39;	A26-B40;	A26-B41;
A26-B42;	A26-B43;	A26-B44;	A26-B45;	A26-B46;	A26-B47;
A26-B48;	A26-B49;	A26-B50;	A26-B51;	A26-B52;	A26-B53;
A26-B54;	A26-B55;	A26-B56;	A26-B57;	A26-B58;	A26-B59;
A26-B60;	A26-B61;	A26-B62;	A26-B63;	A26-B64;	A26-B65;

A26-B66;	A26-B67;	A26-B68;	A26-B69;	A26-B70;	A26-B71;
A26-B72;	A26-B73;	A26-B74;	A26-B75;	A26-B76;	A26-B77;
A26-B78;	A26-B79;	A26-B80;	A26-B81;	A26-B82;	A26-B83;
A26-B84;	A26-B85;	A26-B86;	A26-B87;	A26-B88;	A26-B89;
A26-B90;	A26-B91;	A26-B92;	A26-B93;	A26-B94;	A26-B95;
A26-B96;	A26-B97;	A26-B98;	A26-B99;	A26-B100;	A26-B101;
A26-B102;	A26-B103;	A26-B104;	A26-B105;	A26-B106;	A26-B107;
A26-B108;	A26-B109;	A26-B110;	A26-B111;	A26-B112;	A26-B113;
A26-B114;	A26-B115;	A26-B116;	A26-B117;	A26-B118;	A26-B119;
A26-B120;	A26-B121;	A26-B122;	A26-B123;	A26-B124;	A26-B125;
A26-B126;	A26-B127;	A26-B128;	A26-B129;	A26-B130;	A26-B131;
A26-B132;	A26-B133;	A26-B134;	A26-B135;	A26-B136;	A26-B137;
A26-B138;	A26-B139;	A26-B140;	A26-B141;	A26-B142;	A26-B143;
A26-B144;	A26-B145;	A26-B146;	A26-B147;	A26-B148;	A26-B149;
A26-B150;	A26-B151;	A26-B152;	A26-B153;	A26-B154;	A26-B155;
A26-B156;	A26-B157;	A26-B158;	A26-B159;	A26-B160;	A26-B161;
A26-B162;	A26-B163;	A26-B164;	A26-B165;	A26-B166;	A26-B167;
A26-B168;	A26-B169;	A27-B1;	A27-B2;	A27-B3;	A27-B4;
A27-B5;	A27-B6;	A27-B7;	A27-B8;	A27-B9;	A27-B10;
A27-B11;	A27-B12;	A27-B13;	A27-B14;	A27-B15;	A27-B16;
A27-B17;	A27-B18;	A27-B19;	A27-B20;	A27-B21;	A27-B22;
A27-B23;	A27-B24;	A27-B25;	A27-B26;	A27-B27;	A27-B28;
A27-B29;	A27-B30;	A27-B31;	A27-B32;	A27-B33;	A27-B34;
A27-B35;	A27-B36;	A27-B37;	A27-B38;	A27-B39;	A27-B40;
A27-B41;	A27-B42;	A27-B43;	A27-B44;	A27-B45;	A27-B46;
A27-B47;	A27-B48;	A27-B49;	A27-B50;	A27-B51;	A27-B52;
A27-B53;	A27-B54;	A27-B55;	A27-B56;	A27-B57;	A27-B58;
A27-B59;	A27-B60;	A27-B61;	A27-B62;	A27-B63;	A27-B64;
A27-B65;	A27-B66;	A27-B67;	A27-B68;	A27-B69;	A27-B70;
A27-B71;	A27-B72;	A27-B73;	A27-B74;	A27-B75;	A27-B76;
A27-B77;	A27-B78;	A27-B79;	A27-B80;	A27-B81;	A27-B82;
A27-B83;	A27-B84;	A27-B85;	A27-B86;	A27-B87;	A27-B88;
A27-B89;	A27-B90;	A27-B91;	A27-B92;	A27-B93;	A27-B94;
A27-B95;	A27-B96;	A27-B97;	A27-B98;	A27-B99;	A27-B100;
A27-B101;	A27-B102;	A27-B103;	A27-B104;	A27-B105;	A27-B106;

A27-B107;	A27-B108;	A27-B109;	A27-B110;	A27-B111;	A27-B112;
A27-B113;	A27-B114;	A27-B115;	A27-B116;	A27-B117;	A27-B118;
A27-B119;	A27-B120;	A27-B121;	A27-B122;	A27-B123;	A27-B124;
A27-B125;	A27-B126;	A27-B127;	A27-B128;	A27-B129;	A27-B130;
A27-B131;	A27-B132;	A27-B133;	A27-B134;	A27-B135;	A27-B136;
A27-B137;	A27-B138;	A27-B139;	A27-B140;	A27-B141;	A27-B142;
A27-B143;	A27-B144;	A27-B145;	A27-B146;	A27-B147;	A27-B148;
A27-B149;	A27-B150;	A27-B151;	A27-B152;	A27-B153;	A27-B154;
A27-B155;	A27-B156;	A27-B157;	A27-B158;	A27-B159;	A27-B160;
A27-B161;	A27-B162;	A27-B163;	A27-B164;	A27-B165;	A27-B166;
A27-B167;	A27-B168;	A27-B169;	A28-B1;	A28-B2;	A28-B3;
A28-B4;	A28-B5;	A28-B6;	A28-B7;	A28-B8;	A28-B9;
A28-B10;	A28-B11;	A28-B12;	A28-B13;	A28-B14;	A28-B15;
A28-B16;	A28-B17;	A28-B18;	A28-B19;	A28-B20;	A28-B21;
A28-B22;	A28-B23;	A28-B24;	A28-B25;	A28-B26;	A28-B27;
A28-B28;	A28-B29;	A28-B30;	A28-B31;	A28-B32;	A28-B33;
A28-B34;	A28-B35;	A28-B36;	A28-B37;	A28-B38;	A28-B39;
A28-B40;	A28-B41;	A28-B42;	A28-B43;	A28-B44;	A28-B45;
A28-B46;	A28-B47;	A28-B48;	A28-B49;	A28-B50;	A28-B51;
A28-B52;	A28-B53;	A28-B54;	A28-B55;	A28-B56;	A28-B57;
A28-B58;	A28-B59;	A28-B60;	A28-B61;	A28-B62;	A28-B63;
A28-B64;	A28-B65;	A28-B66;	A28-B67;	A28-B68;	A28-B69;
A28-B70;	A28-B71;	A28-B72;	A28-B73;	A28-B74;	A28-B75;
A28-B76;	A28-B77;	A28-B78;	A28-B79;	A28-B80;	A28-B81;
A28-B82;	A28-B83;	A28-B84;	A28-B85;	A28-B86;	A28-B87;
A28-B88;	A28-B89;	A28-B90;	A28-B91;	A28-B92;	A28-B93;
A28-B94;	A28-B95;	A28-B96;	A28-B97;	A28-B98;	A28-B99;
A28-B100;	A28-B101;	A28-B102;	A28-B103;	A28-B104;	A28-B105;
A28-B106;	A28-B107;	A28-B108;	A28-B109;	A28-B110;	A28-B111;
A28-B112;	A28-B113;	A28-B114;	A28-B115;	A28-B116;	A28-B117;
A28-B118;	A28-B119;	A28-B120;	A28-B121;	A28-B122;	A28-B123;
A28-B124;	A28-B125;	A28-B126;	A28-B127;	A28-B128;	A28-B129;
A28-B130;	A28-B131;	A28-B132;	A28-B133;	A28-B134;	A28-B135;
A28-B136;	A28-B137;	A28-B138;	A28-B139;	A28-B140;	A28-B141;
A28-B142;	A28-B143;	A28-B144;	A28-B145;	A28-B146;	A28-B147;

A28-B148;	A28-B149;	A28-B150;	A28-B151;	A28-B152;	A28-B153;
A28-B154;	A28-B155;	A28-B156;	A28-B157;	A28-B158;	A28-B159;
A28-B160;	A28-B161;	A28-B162;	A28-B163;	A28-B164;	A28-B165;
A28-B166;	A28-B167;	A28-B168;	A28-B169;	A29-B1;	A29-B2;
A29-B3;	A29-B4;	A29-B5;	A29-B6;	A29-B7;	A29-B8;
A29-B9;	A29-B10;	A29-B11;	A29-B12;	A29-B13;	A29-B14;
A29-B15;	A29-B16;	A29-B17;	A29-B18;	A29-B19;	A29-B20;
A29-B21;	A29-B22;	A29-B23;	A29-B24;	A29-B25;	A29-B26;
A29-B27;	A29-B28;	A29-B29;	A29-B30;	A29-B31;	A29-B32;
A29-B33;	A29-B34;	A29-B35;	A29-B36;	A29-B37;	A29-B38;
A29-B39;	A29-B40;	A29-B41;	A29-B42;	A29-B43;	A29-B44;
A29-B45;	A29-B46;	A29-B47;	A29-B48;	A29-B49;	A29-B50;
A29-B51;	A29-B52;	A29-B53;	A29-B54;	A29-B55;	A29-B56;
A29-B57;	A29-B58;	A29-B59;	A29-B60;	A29-B61;	A29-B62;
A29-B63;	A29-B64;	A29-B65;	A29-B66;	A29-B67;	A29-B68;
A29-B69;	A29-B70;	A29-B71;	A29-B72;	A29-B73;	A29-B74;
A29-B75;	A29-B76;	A29-B77;	A29-B78;	A29-B79;	A29-B80;
A29-B81;	A29-B82;	A29-B83;	A29-B84;	A29-B85;	A29-B86;
A29-B87;	A29-B88;	A29-B89;	A29-B90;	A29-B91;	A29-B92;
A29-B93;	A29-B94;	A29-B95;	A29-B96;	A29-B97;	A29-B98;
A29-B99;	A29-B100;	A29-B101;	A29-B102;	A29-B103;	A29-B104;
A29-B105;	A29-B106;	A29-B107;	A29-B108;	A29-B109;	A29-B110;
A29-B111;	A29-B112;	A29-B113;	A29-B114;	A29-B115;	A29-B116;
A29-B117;	A29-B118;	A29-B119;	A29-B120;	A29-B121;	A29-B122;
A29-B123;	A29-B124;	A29-B125;	A29-B126;	A29-B127;	A29-B128;
A29-B129;	A29-B130;	A29-B131;	A29-B132;	A29-B133;	A29-B134;
A29-B135;	A29-B136;	A29-B137;	A29-B138;	A29-B139;	A29-B140;
A29-B141;	A29-B142;	A29-B143;	A29-B144;	A29-B145;	A29-B146;
A29-B147;	A29-B148;	A29-B149;	A29-B150;	A29-B151;	A29-B152;
A29-B153;	A29-B154;	A29-B155;	A29-B156;	A29-B157;	A29-B158;
A29-B159;	A29-B160;	A29-B161;	A29-B162;	A29-B163;	A29-B164;
A29-B165;	A29-B166;	A29-B167;	A29-B168;	A29-B169;	A30-B1;
A30-B2;	A30-B3;	A30-B4;	A30-B5;	A30-B6;	A30-B7;
A30-B8;	A30-B9;	A30-B10;	A30-B11;	A30-B12;	A30-B13;
A30-B14;	A30-B15;	A30-B16;	A30-B17;	A30-B18;	A30-B19;

A30-B20;	A30-B21;	A30-B22;	A30-B23;	A30-B24;	A30-B25;
A30-B26;	A30-B27;	A30-B28;	A30-B29;	A30-B30;	A30-B31;
A30-B32;	A30-B33;	A30-B34;	A30-B35;	A30-B36;	A30-B37;
A30-B38;	A30-B39;	A30-B40;	A30-B41;	A30-B42;	A30-B43;
A30-B44;	A30-B45;	A30-B46;	A30-B47;	A30-B48;	A30-B49;
A30-B50;	A30-B51;	A30-B52;	A30-B53;	A30-B54;	A30-B55;
A30-B56;	A30-B57;	A30-B58;	A30-B59;	A30-B60;	A30-B61;
A30-B62;	A30-B63;	A30-B64;	A30-B65;	A30-B66;	A30-B67;
A30-B68;	A30-B69;	A30-B70;	A30-B71;	A30-B72;	A30-B73;
A30-B74;	A30-B75;	A30-B76;	A30-B77;	A30-B78;	A30-B79;
A30-B80;	A30-B81;	A30-B82;	A30-B83;	A30-B84;	A30-B85;
A30-B86;	A30-B87;	A30-B88;	A30-B89;	A30-B90;	A30-B91;
A30-B92;	A30-B93;	A30-B94;	A30-B95;	A30-B96;	A30-B97;
A30-B98;	A30-B99;	A30-B100;	A30-B101;	A30-B102;	A30-B103;
A30-B104;	A30-B105;	A30-B106;	A30-B107;	A30-B108;	A30-B109;
A30-B110;	A30-B111;	A30-B112;	A30-B113;	A30-B114;	A30-B115;
A30-B116;	A30-B117;	A30-B118;	A30-B119;	A30-B120;	A30-B121;
A30-B122;	A30-B123;	A30-B124;	A30-B125;	A30-B126;	A30-B127;
A30-B128;	A30-B129;	A30-B130;	A30-B131;	A30-B132;	A30-B133;
A30-B134;	A30-B135;	A30-B136;	A30-B137;	A30-B138;	A30-B139;
A30-B140;	A30-B141;	A30-B142;	A30-B143;	A30-B144;	A30-B145;
A30-B146;	A30-B147;	A30-B148;	A30-B149;	A30-B150;	A30-B151;
A30-B152;	A30-B153;	A30-B154;	A30-B155;	A30-B156;	A30-B157;
A30-B158;	A30-B159;	A30-B160;	A30-B161;	A30-B162;	A30-B163;
A30-B164;	A30-B165;	A30-B166;	A30-B167;	A30-B168;	A30-B169;
A31-B1;	A31-B2;	A31-B3;	A31-B4;	A31-B5;	A31-B6;
A31-B7;	A31-B8;	A31-B9;	A31-B10;	A31-B11;	A31-B12;
A31-B13;	A31-B14;	A31-B15;	A31-B16;	A31-B17;	A31-B18;
A31-B19;	A31-B20;	A31-B21;	A31-B22;	A31-B23;	A31-B24;
A31-B25;	A31-B26;	A31-B27;	A31-B28;	A31-B29;	A31-B30;
A31-B31;	A31-B32;	A31-B33;	A31-B34;	A31-B35;	A31-B36;
A31-B37;	A31-B38;	A31-B39;	A31-B40;	A31-B41;	A31-B42;
A31-B43;	A31-B44;	A31-B45;	A31-B46;	A31-B47;	A31-B48;
A31-B49;	A31-B50;	A31-B51;	A31-B52;	A31-B53;	A31-B54;
A31-B55;	A31-B56;	A31-B57;	A31-B58;	A31-B59;	A31-B60;

A31-B61;	A31-B62;	A31-B63;	A31-B64;	A31-B65;	A31-B66;
A31-B67;	A31-B68;	A31-B69;	A31-B70;	A31-B71;	A31-B72;
A31-B73;	A31-B74;	A31-B75;	A31-B76;	A31-B77;	A31-B78;
A31-B79;	A31-B80;	A31-B81;	A31-B82;	A31-B83;	A31-B84;
A31-B85;	A31-B86;	A31-B87;	A31-B88;	A31-B89;	A31-B90;
A31-B91;	A31-B92;	A31-B93;	A31-B94;	A31-B95;	A31-B96;
A31-B97;	A31-B98;	A31-B99;	A31-B100;	A31-B101;	A31-B102;
A31-B103;	A31-B104;	A31-B105;	A31-B106;	A31-B107;	A31-B108;
A31-B109;	A31-B110;	A31-B111;	A31-B112;	A31-B113;	A31-B114;
A31-B115;	A31-B116;	A31-B117;	A31-B118;	A31-B119;	A31-B120;
A31-B121;	A31-B122;	A31-B123;	A31-B124;	A31-B125;	A31-B126;
A31-B127;	A31-B128;	A31-B129;	A31-B130;	A31-B131;	A31-B132;
A31-B133;	A31-B134;	A31-B135;	A31-B136;	A31-B137;	A31-B138;
A31-B139;	A31-B140;	A31-B141;	A31-B142;	A31-B143;	A31-B144;
A31-B145;	A31-B146;	A31-B147;	A31-B148;	A31-B149;	A31-B150;
A31-B151;	A31-B152;	A31-B153;	A31-B154;	A31-B155;	A31-B156;
A31-B157;	A31-B158;	A31-B159;	A31-B160;	A31-B161;	A31-B162;
A31-B163;	A31-B164;	A31-B165;	A31-B166;	A31-B167;	A31-B168;
A31-B169;	A32-B1;	A32-B2;	A32-B3;	A32-B4;	A32-B5;
A32-B6;	A32-B7;	A32-B8;	A32-B9;	A32-B10;	A32-B11;
A32-B12;	A32-B13;	A32-B14;	A32-B15;	A32-B16;	A32-B17;
A32-B18;	A32-B19;	A32-B20;	A32-B21;	A32-B22;	A32-B23;
A32-B24;	A32-B25;	A32-B26;	A32-B27;	A32-B28;	A32-B29;
A32-B30;	A32-B31;	A32-B32;	A32-B33;	A32-B34;	A32-B35;
A32-B36;	A32-B37;	A32-B38;	A32-B39;	A32-B40;	A32-B41;
A32-B42;	A32-B43;	A32-B44;	A32-B45;	A32-B46;	A32-B47;
A32-B48;	A32-B49;	A32-B50;	A32-B51;	A32-B52;	A32-B53;
A32-B54;	A32-B55;	A32-B56;	A32-B57;	A32-B58;	A32-B59;
A32-B60;	A32-B61;	A32-B62;	A32-B63;	A32-B64;	A32-B65;
A32-B66;	A32-B67;	A32-B68;	A32-B69;	A32-B70;	A32-B71;
A32-B72;	A32-B73;	A32-B74;	A32-B75;	A32-B76;	A32-B77;
A32-B78;	A32-B79;	A32-B80;	A32-B81;	A32-B82;	A32-B83;
A32-B84;	A32-B85;	A32-B86;	A32-B87;	A32-B88;	A32-B89;
A32-B90;	A32-B91;	A32-B92;	A32-B93;	A32-B94;	A32-B95;
A32-B96;	A32-B97;	A32-B98;	A32-B99;	A32-B100;	A32-B101;

A32-B102;	A32-B103;	A32-B104;	A32-B105;	A32-B106;	A32-B107;
A32-B108;	A32-B109;	A32-B110;	A32-B111;	A32-B112;	A32-B113;
A32-B114;	A32-B115;	A32-B116;	A32-B117;	A32-B118;	A32-B119;
A32-B120;	A32-B121;	A32-B122;	A32-B123;	A32-B124;	A32-B125;
A32-B126;	A32-B127;	A32-B128;	A32-B129;	A32-B130;	A32-B131;
A32-B132;	A32-B133;	A32-B134;	A32-B135;	A32-B136;	A32-B137;
A32-B138;	A32-B139;	A32-B140;	A32-B141;	A32-B142;	A32-B143;
A32-B144;	A32-B145;	A32-B146;	A32-B147;	A32-B148;	A32-B149;
A32-B150;	A32-B151;	A32-B152;	A32-B153;	A32-B154;	A32-B155;
A32-B156;	A32-B157;	A32-B158;	A32-B159;	A32-B160;	A32-B161;
A32-B162;	A32-B163;	A32-B164;	A32-B165;	A32-B166;	A32-B167;
A32-B168;	A32-B169;	A33-B1;	A33-B2;	A33-B3;	A33-B4;
A33-B5;	A33-B6;	A33-B7;	A33-B8;	A33-B9;	A33-B10;
A33-B11;	A33-B12;	A33-B13;	A33-B14;	A33-B15;	A33-B16;
A33-B17;	A33-B18;	A33-B19;	A33-B20;	A33-B21;	A33-B22;
A33-B23;	A33-B24;	A33-B25;	A33-B26;	A33-B27;	A33-B28;
A33-B29;	A33-B30;	A33-B31;	A33-B32;	A33-B33;	A33-B34;
A33-B35;	A33-B36;	A33-B37;	A33-B38;	A33-B39;	A33-B40;
A33-B41;	A33-B42;	A33-B43;	A33-B44;	A33-B45;	A33-B46;
A33-B47;	A33-B48;	A33-B49;	A33-B50;	A33-B51;	A33-B52;
A33-B53;	A33-B54;	A33-B55;	A33-B56;	A33-B57;	A33-B58;
A33-B59;	A33-B60;	A33-B61;	A33-B62;	A33-B63;	A33-B64;
A33-B65;	A33-B66;	A33-B67;	A33-B68;	A33-B69;	A33-B70;
A33-B71;	A33-B72;	A33-B73;	A33-B74;	A33-B75;	A33-B76;
A33-B77;	A33-B78;	A33-B79;	A33-B80;	A33-B81;	A33-B82;
A33-B83;	A33-B84;	A33-B85;	A33-B86;	A33-B87;	A33-B88;
A33-B89;	A33-B90;	A33-B91;	A33-B92;	A33-B93;	A33-B94;
A33-B95;	A33-B96;	A33-B97;	A33-B98;	A33-B99;	A33-B100;
A33-B101;	A33-B102;	A33-B103;	A33-B104;	A33-B105;	A33-B106;
A33-B107;	A33-B108;	A33-B109;	A33-B110;	A33-B111;	A33-B112;
A33-B113;	A33-B114;	A33-B115;	A33-B116;	A33-B117;	A33-B118;
A33-B119;	A33-B120;	A33-B121;	A33-B122;	A33-B123;	A33-B124;
A33-B125;	A33-B126;	A33-B127;	A33-B128;	A33-B129;	A33-B130;
A33-B131;	A33-B132;	A33-B133;	A33-B134;	A33-B135;	A33-B136;
A33-B137;	A33-B138;	A33-B139;	A33-B140;	A33-B141;	A33-B142;

A33-B143;	A33-B144;	A33-B145;	A33-B146;	A33-B147;	A33-B148;
A33-B149;	A33-B150;	A33-B151;	A33-B152;	A33-B153;	A33-B154;
A33-B155;	A33-B156;	A33-B157;	A33-B158;	A33-B159;	A33-B160;
A33-B161;	A33-B162;	A33-B163;	A33-B164;	A33-B165;	A33-B166;
A33-B167;	A33-B168;	A33-B169;	A34-B1;	A34-B2;	A34-B3;
A34-B4;	A34-B5;	A34-B6;	A34-B7;	A34-B8;	A34-B9;
A34-B10;	A34-B11;	A34-B12;	A34-B13;	A34-B14;	A34-B15;
A34-B16;	A34-B17;	A34-B18;	A34-B19;	A34-B20;	A34-B21;
A34-B22;	A34-B23;	A34-B24;	A34-B25;	A34-B26;	A34-B27;
A34-B28;	A34-B29;	A34-B30;	A34-B31;	A34-B32;	A34-B33;
A34-B34;	A34-B35;	A34-B36;	A34-B37;	A34-B38;	A34-B39;
A34-B40;	A34-B41;	A34-B42;	A34-B43;	A34-B44;	A34-B45;
A34-B46;	A34-B47;	A34-B48;	A34-B49;	A34-B50;	A34-B51;
A34-B52;	A34-B53;	A34-B54;	A34-B55;	A34-B56;	A34-B57;
A34-B58;	A34-B59;	A34-B60;	A34-B61;	A34-B62;	A34-B63;
A34-B64;	A34-B65;	A34-B66;	A34-B67;	A34-B68;	A34-B69;
A34-B70;	A34-B71;	A34-B72;	A34-B73;	A34-B74;	A34-B75;
A34-B76;	A34-B77;	A34-B78;	A34-B79;	A34-B80;	A34-B81;
A34-B82;	A34-B83;	A34-B84;	A34-B85;	A34-B86;	A34-B87;
A34-B88;	A34-B89;	A34-B90;	A34-B91;	A34-B92;	A34-B93;
A34-B94;	A34-B95;	A34-B96;	A34-B97;	A34-B98;	A34-B99;
A34-B100;	A34-B101;	A34-B102;	A34-B103;	A34-B104;	A34-B105;
A34-B106;	A34-B107;	A34-B108;	A34-B109;	A34-B110;	A34-B111;
A34-B112;	A34-B113;	A34-B114;	A34-B115;	A34-B116;	A34-B117;
A34-B118;	A34-B119;	A34-B120;	A34-B121;	A34-B122;	A34-B123;
A34-B124;	A34-B125;	A34-B126;	A34-B127;	A34-B128;	A34-B129;
A34-B130;	A34-B131;	A34-B132;	A34-B133;	A34-B134;	A34-B135;
A34-B136;	A34-B137;	A34-B138;	A34-B139;	A34-B140;	A34-B141;
A34-B142;	A34-B143;	A34-B144;	A34-B145;	A34-B146;	A34-B147;
A34-B148;	A34-B149;	A34-B150;	A34-B151;	A34-B152;	A34-B153;
A34-B154;	A34-B155;	A34-B156;	A34-B157;	A34-B158;	A34-B159;
A34-B160;	A34-B161;	A34-B162;	A34-B163;	A34-B164;	A34-B165;
A34-B166;	A34-B167;	A34-B168;	A34-B169;	A35-B1;	A35-B2;
A35-B3;	A35-B4;	A35-B5;	A35-B6;	A35-B7;	A35-B8;
A35-B9;	A35-B10;	A35-B11;	A35-B12;	A35-B13;	A35-B14;

A35-B15;	A35-B16;	A35-B17;	A35-B18;	A35-B19;	A35-B20;
A35-B21;	A35-B22;	A35-B23;	A35-B24;	A35-B25;	A35-B26;
A35-B27;	A35-B28;	A35-B29;	A35-B30;	A35-B31;	A35-B32;
A35-B33;	A35-B34;	A35-B35;	A35-B36;	A35-B37;	A35-B38;
A35-B39;	A35-B40;	A35-B41;	A35-B42;	A35-B43;	A35-B44;
A35-B45;	A35-B46;	A35-B47;	A35-B48;	A35-B49;	A35-B50;
A35-B51;	A35-B52;	A35-B53;	A35-B54;	A35-B55;	A35-B56;
A35-B57;	A35-B58;	A35-B59;	A35-B60;	A35-B61;	A35-B62;
A35-B63;	A35-B64;	A35-B65;	A35-B66;	A35-B67;	A35-B68;
A35-B69;	A35-B70;	A35-B71;	A35-B72;	A35-B73;	A35-B74;
A35-B75;	A35-B76;	A35-B77;	A35-B78;	A35-B79;	A35-B80;
A35-B81;	A35-B82;	A35-B83;	A35-B84;	A35-B85;	A35-B86;
A35-B87;	A35-B88;	A35-B89;	A35-B90;	A35-B91;	A35-B92;
A35-B93;	A35-B94;	A35-B95;	A35-B96;	A35-B97;	A35-B98;
A35-B99;	A35-B100;	A35-B101;	A35-B102;	A35-B103;	A35-B104;
A35-B105;	A35-B106;	A35-B107;	A35-B108;	A35-B109;	A35-B110;
A35-B111;	A35-B112;	A35-B113;	A35-B114;	A35-B115;	A35-B116;
A35-B117;	A35-B118;	A35-B119;	A35-B120;	A35-B121;	A35-B122;
A35-B123;	A35-B124;	A35-B125;	A35-B126;	A35-B127;	A35-B128;
A35-B129;	A35-B130;	A35-B131;	A35-B132;	A35-B133;	A35-B134;
A35-B135;	A35-B136;	A35-B137;	A35-B138;	A35-B139;	A35-B140;
A35-B141;	A35-B142;	A35-B143;	A35-B144;	A35-B145;	A35-B146;
A35-B147;	A35-B148;	A35-B149;	A35-B150;	A35-B151;	A35-B152;
A35-B153;	A35-B154;	A35-B155;	A35-B156;	A35-B157;	A35-B158;
A35-B159;	A35-B160;	A35-B161;	A35-B162;	A35-B163;	A35-B164;
A35-B165;	A35-B166;	A35-B167;	A35-B168;	A35-B169;	A36-B1;
A36-B2;	A36-B3;	A36-B4;	A36-B5;	A36-B6;	A36-B7;
A36-B8;	A36-B9;	A36-B10;	A36-B11;	A36-B12;	A36-B13;
A36-B14;	A36-B15;	A36-B16;	A36-B17;	A36-B18;	A36-B19;
A36-B20;	A36-B21;	A36-B22;	A36-B23;	A36-B24;	A36-B25;
A36-B26;	A36-B27;	A36-B28;	A36-B29;	A36-B30;	A36-B31;
A36-B32;	A36-B33;	A36-B34;	A36-B35;	A36-B36;	A36-B37;
A36-B38;	A36-B39;	A36-B40;	A36-B41;	A36-B42;	A36-B43;
A36-B44;	A36-B45;	A36-B46;	A36-B47;	A36-B48;	A36-B49;
A36-B50;	A36-B51;	A36-B52;	A36-B53;	A36-B54;	A36-B55;

A36-B56;	A36-B57;	A36-B58;	A36-B59;	A36-B60;	A36-B61;
A36-B62;	A36-B63;	A36-B64;	A36-B65;	A36-B66;	A36-B67;
A36-B68;	A36-B69;	A36-B70;	A36-B71;	A36-B72;	A36-B73;
A36-B74;	A36-B75;	A36-B76;	A36-B77;	A36-B78;	A36-B79;
A36-B80;	A36-B81;	A36-B82;	A36-B83;	A36-B84;	A36-B85;
A36-B86;	A36-B87;	A36-B88;	A36-B89;	A36-B90;	A36-B91;
A36-B92;	A36-B93;	A36-B94;	A36-B95;	A36-B96;	A36-B97;
A36-B98;	A36-B99;	A36-B100;	A36-B101;	A36-B102;	A36-B103;
A36-B104;	A36-B105;	A36-B106;	A36-B107;	A36-B108;	A36-B109;
A36-B110;	A36-B111;	A36-B112;	A36-B113;	A36-B114;	A36-B115;
A36-B116;	A36-B117;	A36-B118;	A36-B119;	A36-B120;	A36-B121;
A36-B122;	A36-B123;	A36-B124;	A36-B125;	A36-B126;	A36-B127;
A36-B128;	A36-B129;	A36-B130;	A36-B131;	A36-B132;	A36-B133;
A36-B134;	A36-B135;	A36-B136;	A36-B137;	A36-B138;	A36-B139;
A36-B140;	A36-B141;	A36-B142;	A36-B143;	A36-B144;	A36-B145;
A36-B146;	A36-B147;	A36-B148;	A36-B149;	A36-B150;	A36-B151;
A36-B152;	A36-B153;	A36-B154;	A36-B155;	A36-B156;	A36-B157;
A36-B158;	A36-B159;	A36-B160;	A36-B161;	A36-B162;	A36-B163;
A36-B164;	A36-B165;	A36-B166;	A36-B167;	A36-B168;	A36-B169;
A37-B1;	A37-B2;	A37-B3;	A37-B4;	A37-B5;	A37-B6;
A37-B7;	A37-B8;	A37-B9;	A37-B10;	A37-B11;	A37-B12;
A37-B13;	A37-B14;	A37-B15;	A37-B16;	A37-B17;	A37-B18;
A37-B19;	A37-B20;	A37-B21;	A37-B22;	A37-B23;	A37-B24;
A37-B25;	A37-B26;	A37-B27;	A37-B28;	A37-B29;	A37-B30;
A37-B31;	A37-B32;	A37-B33;	A37-B34;	A37-B35;	A37-B36;
A37-B37;	A37-B38;	A37-B39;	A37-B40;	A37-B41;	A37-B42;
A37-B43;	A37-B44;	A37-B45;	A37-B46;	A37-B47;	A37-B48;
A37-B49;	A37-B50;	A37-B51;	A37-B52;	A37-B53;	A37-B54;
A37-B55;	A37-B56;	A37-B57;	A37-B58;	A37-B59;	A37-B60;
A37-B61;	A37-B62;	A37-B63;	A37-B64;	A37-B65;	A37-B66;
A37-B67;	A37-B68;	A37-B69;	A37-B70;	A37-B71;	A37-B72;
A37-B73;	A37-B74;	A37-B75;	A37-B76;	A37-B77;	A37-B78;
A37-B79;	A37-B80;	A37-B81;	A37-B82;	A37-B83;	A37-B84;
A37-B85;	A37-B86;	A37-B87;	A37-B88;	A37-B89;	A37-B90;
A37-B91;	A37-B92;	A37-B93;	A37-B94;	A37-B95;	A37-B96;

A37-B97;	A37-B98;	A37-B99;	A37-B100;	A37-B101;	A37-B102;
A37-B103;	A37-B104;	A37-B105;	A37-B106;	A37-B107;	A37-B108;
A37-B109;	A37-B110;	A37-B111;	A37-B112;	A37-B113;	A37-B114;
A37-B115;	A37-B116;	A37-B117;	A37-B118;	A37-B119;	A37-B120;
A37-B121;	A37-B122;	A37-B123;	A37-B124;	A37-B125;	A37-B126;
A37-B127;	A37-B128;	A37-B129;	A37-B130;	A37-B131;	A37-B132;
A37-B133;	A37-B134;	A37-B135;	A37-B136;	A37-B137;	A37-B138;
A37-B139;	A37-B140;	A37-B141;	A37-B142;	A37-B143;	A37-B144;
A37-B145;	A37-B146;	A37-B147;	A37-B148;	A37-B149;	A37-B150;
A37-B151;	A37-B152;	A37-B153;	A37-B154;	A37-B155;	A37-B156;
A37-B157;	A37-B158;	A37-B159;	A37-B160;	A37-B161;	A37-B162;
A37-B163;	A37-B164;	A37-B165;	A37-B166;	A37-B167;	A37-B168;
A37-B169;	A38-B1;	A38-B2;	A38-B3;	A38-B4;	A38-B5;
A38-B6;	A38-B7;	A38-B8;	A38-B9;	A38-B10;	A38-B11;
A38-B12;	A38-B13;	A38-B14;	A38-B15;	A38-B16;	A38-B17;
A38-B18;	A38-B19;	A38-B20;	A38-B21;	A38-B22;	A38-B23;
A38-B24;	A38-B25;	A38-B26;	A38-B27;	A38-B28;	A38-B29;
A38-B30;	A38-B31;	A38-B32;	A38-B33;	A38-B34;	A38-B35;
A38-B36;	A38-B37;	A38-B38;	A38-B39;	A38-B40;	A38-B41;
A38-B42;	A38-B43;	A38-B44;	A38-B45;	A38-B46;	A38-B47;
A38-B48;	A38-B49;	A38-B50;	A38-B51;	A38-B52;	A38-B53;
A38-B54;	A38-B55;	A38-B56;	A38-B57;	A38-B58;	A38-B59;
A38-B60;	A38-B61;	A38-B62;	A38-B63;	A38-B64;	A38-B65;
A38-B66;	A38-B67;	A38-B68;	A38-B69;	A38-B70;	A38-B71;
A38-B72;	A38-B73;	A38-B74;	A38-B75;	A38-B76;	A38-B77;
A38-B78;	A38-B79;	A38-B80;	A38-B81;	A38-B82;	A38-B83;
A38-B84;	A38-B85;	A38-B86;	A38-B87;	A38-B88;	A38-B89;
A38-B90;	A38-B91;	A38-B92;	A38-B93;	A38-B94;	A38-B95;
A38-B96;	A38-B97;	A38-B98;	A38-B99;	A38-B100;	A38-B101;
A38-B102;	A38-B103;	A38-B104;	A38-B105;	A38-B106;	A38-B107;
A38-B108;	A38-B109;	A38-B110;	A38-B111;	A38-B112;	A38-B113;
A38-B114;	A38-B115;	A38-B116;	A38-B117;	A38-B118;	A38-B119;
A38-B120;	A38-B121;	A38-B122;	A38-B123;	A38-B124;	A38-B125;
A38-B126;	A38-B127;	A38-B128;	A38-B129;	A38-B130;	A38-B131;
A38-B132;	A38-B133;	A38-B134;	A38-B135;	A38-B136;	A38-B137;

A38-B138;	A38-B139;	A38-B140;	A38-B141;	A38-B142;	A38-B143;
A38-B144;	A38-B145;	A38-B146;	A38-B147;	A38-B148;	A38-B149;
A38-B150;	A38-B151;	A38-B152;	A38-B153;	A38-B154;	A38-B155;
A38-B156;	A38-B157;	A38-B158;	A38-B159;	A38-B160;	A38-B161;
A38-B162;	A38-B163;	A38-B164;	A38-B165;	A38-B166;	A38-B167;
A38-B168;	A38-B169;	A39-B1;	A39-B2;	A39-B3;	A39-B4;
A39-B5;	A39-B6;	A39-B7;	A39-B8;	A39-B9;	A39-B10;
A39-B11;	A39-B12;	A39-B13;	A39-B14;	A39-B15;	A39-B16;
A39-B17;	A39-B18;	A39-B19;	A39-B20;	A39-B21;	A39-B22;
A39-B23;	A39-B24;	A39-B25;	A39-B26;	A39-B27;	A39-B28;
A39-B29;	A39-B30;	A39-B31;	A39-B32;	A39-B33;	A39-B34;
A39-B35;	A39-B36;	A39-B37;	A39-B38;	A39-B39;	A39-B40;
A39-B41;	A39-B42;	A39-B43;	A39-B44;	A39-B45;	A39-B46;
A39-B47;	A39-B48;	A39-B49;	A39-B50;	A39-B51;	A39-B52;
A39-B53;	A39-B54;	A39-B55;	A39-B56;	A39-B57;	A39-B58;
A39-B59;	A39-B60;	A39-B61;	A39-B62;	A39-B63;	A39-B64;
A39-B65;	A39-B66;	A39-B67;	A39-B68;	A39-B69;	A39-B70;
A39-B71;	A39-B72;	A39-B73;	A39-B74;	A39-B75;	A39-B76;
A39-B77;	A39-B78;	A39-B79;	A39-B80;	A39-B81;	A39-B82;
A39-B83;	A39-B84;	A39-B85;	A39-B86;	A39-B87;	A39-B88;
A39-B89;	A39-B90;	A39-B91;	A39-B92;	A39-B93;	A39-B94;
A39-B95;	A39-B96;	A39-B97;	A39-B98;	A39-B99;	A39-B100;
A39-B101;	A39-B102;	A39-B103;	A39-B104;	A39-B105;	A39-B106;
A39-B107;	A39-B108;	A39-B109;	A39-B110;	A39-B111;	A39-B112;
A39-B113;	A39-B114;	A39-B115;	A39-B116;	A39-B117;	A39-B118;
A39-B119;	A39-B120;	A39-B121;	A39-B122;	A39-B123;	A39-B124;
A39-B125;	A39-B126;	A39-B127;	A39-B128;	A39-B129;	A39-B130;
A39-B131;	A39-B132;	A39-B133;	A39-B134;	A39-B135;	A39-B136;
A39-B137;	A39-B138;	A39-B139;	A39-B140;	A39-B141;	A39-B142;
A39-B143;	A39-B144;	A39-B145;	A39-B146;	A39-B147;	A39-B148;
A39-B149;	A39-B150;	A39-B151;	A39-B152;	A39-B153;	A39-B154;
A39-B155;	A39-B156;	A39-B157;	A39-B158;	A39-B159;	A39-B160;
A39-B161;	A39-B162;	A39-B163;	A39-B164;	A39-B165;	A39-B166;
A39-B167;	A39-B168;	A39-B169;	A40-B1;	A40-B2;	A40-B3;
A40-B4;	A40-B5;	A40-B6;	A40-B7;	A40-B8;	A40-B9;

A40-B10;	A40-B11;	A40-B12;	A40-B13;	A40-B14;	A40-B15;
A40-B16;	A40-B17;	A40-B18;	A40-B19;	A40-B20;	A40-B21;
A40-B22;	A40-B23;	A40-B24;	A40-B25;	A40-B26;	A40-B27;
A40-B28;	A40-B29;	A40-B30;	A40-B31;	A40-B32;	A40-B33;
A40-B34;	A40-B35;	A40-B36;	A40-B37;	A40-B38;	A40-B39;
A40-B40;	A40-B41;	A40-B42;	A40-B43;	A40-B44;	A40-B45;
A40-B46;	A40-B47;	A40-B48;	A40-B49;	A40-B50;	A40-B51;
A40-B52;	A40-B53;	A40-B54;	A40-B55;	A40-B56;	A40-B57;
A40-B58;	A40-B59;	A40-B60;	A40-B61;	A40-B62;	A40-B63;
A40-B64;	A40-B65;	A40-B66;	A40-B67;	A40-B68;	A40-B69;
A40-B70;	A40-B71;	A40-B72;	A40-B73;	A40-B74;	A40-B75;
A40-B76;	A40-B77;	A40-B78;	A40-B79;	A40-B80;	A40-B81;
A40-B82;	A40-B83;	A40-B84;	A40-B85;	A40-B86;	A40-B87;
A40-B88;	A40-B89;	A40-B90;	A40-B91;	A40-B92;	A40-B93;
A40-B94;	A40-B95;	A40-B96;	A40-B97;	A40-B98;	A40-B99;
A40-B100;	A40-B101;	A40-B102;	A40-B103;	A40-B104;	A40-B105;
A40-B106;	A40-B107;	A40-B108;	A40-B109;	A40-B110;	A40-B111;
A40-B112;	A40-B113;	A40-B114;	A40-B115;	A40-B116;	A40-B117;
A40-B118;	A40-B119;	A40-B120;	A40-B121;	A40-B122;	A40-B123;
A40-B124;	A40-B125;	A40-B126;	A40-B127;	A40-B128;	A40-B129;
A40-B130;	A40-B131;	A40-B132;	A40-B133;	A40-B134;	A40-B135;
A40-B136;	A40-B137;	A40-B138;	A40-B139;	A40-B140;	A40-B141;
A40-B142;	A40-B143;	A40-B144;	A40-B145;	A40-B146;	A40-B147;
A40-B148;	A40-B149;	A40-B150;	A40-B151;	A40-B152;	A40-B153;
A40-B154;	A40-B155;	A40-B156;	A40-B157;	A40-B158;	A40-B159;
A40-B160;	A40-B161;	A40-B162;	A40-B163;	A40-B164;	A40-B165;
A40-B166;	A40-B167;	A40-B168;	A40-B169;	A41-B1;	A41-B2;
A41-B3;	A41-B4;	A41-B5;	A41-B6;	A41-B7;	A41-B8;
A41-B9;	A41-B10;	A41-B11;	A41-B12;	A41-B13;	A41-B14;
A41-B15;	A41-B16;	A41-B17;	A41-B18;	A41-B19;	A41-B20;
A41-B21;	A41-B22;	A41-B23;	A41-B24;	A41-B25;	A41-B26;
A41-B27;	A41-B28;	A41-B29;	A41-B30;	A41-B31;	A41-B32;
A41-B33;	A41-B34;	A41-B35;	A41-B36;	A41-B37;	A41-B38;
A41-B39;	A41-B40;	A41-B41;	A41-B42;	A41-B43;	A41-B44;
A41-B45;	A41-B46;	A41-B47;	A41-B48;	A41-B49;	A41-B50;

A41-B51;	A41-B52;	A41-B53;	A41-B54;	A41-B55;	A41-B56;
A41-B57;	A41-B58;	A41-B59;	A41-B60;	A41-B61;	A41-B62;
A41-B63;	A41-B64;	A41-B65;	A41-B66;	A41-B67;	A41-B68;
A41-B69;	A41-B70;	A41-B71;	A41-B72;	A41-B73;	A41-B74;
A41-B75;	A41-B76;	A41-B77;	A41-B78;	A41-B79;	A41-B80;
A41-B81;	A41-B82;	A41-B83;	A41-B84;	A41-B85;	A41-B86;
A41-B87;	A41-B88;	A41-B89;	A41-B90;	A41-B91;	A41-B92;
A41-B93;	A41-B94;	A41-B95;	A41-B96;	A41-B97;	A41-B98;
A41-B99;	A41-B100;	A41-B101;	A41-B102;	A41-B103;	A41-B104;
A41-B105;	A41-B106;	A41-B107;	A41-B108;	A41-B109;	A41-B110;
A41-B111;	A41-B112;	A41-B113;	A41-B114;	A41-B115;	A41-B116;
A41-B117;	A41-B118;	A41-B119;	A41-B120;	A41-B121;	A41-B122;
A41-B123;	A41-B124;	A41-B125;	A41-B126;	A41-B127;	A41-B128;
A41-B129;	A41-B130;	A41-B131;	A41-B132;	A41-B133;	A41-B134;
A41-B135;	A41-B136;	A41-B137;	A41-B138;	A41-B139;	A41-B140;
A41-B141;	A41-B142;	A41-B143;	A41-B144;	A41-B145;	A41-B146;
A41-B147;	A41-B148;	A41-B149;	A41-B150;	A41-B151;	A41-B152;
A41-B153;	A41-B154;	A41-B155;	A41-B156;	A41-B157;	A41-B158;
A41-B159;	A41-B160;	A41-B161;	A41-B162;	A41-B163;	A41-B164;
A41-B165;	A41-B166;	A41-B167;	A41-B168;	A41-B169;	A42-B1;
A42-B2;	A42-B3;	A42-B4;	A42-B5;	A42-B6;	A42-B7;
A42-B8;	A42-B9;	A42-B10;	A42-B11;	A42-B12;	A42-B13;
A42-B14;	A42-B15;	A42-B16;	A42-B17;	A42-B18;	A42-B19;
A42-B20;	A42-B21;	A42-B22;	A42-B23;	A42-B24;	A42-B25;
A42-B26;	A42-B27;	A42-B28;	A42-B29;	A42-B30;	A42-B31;
A42-B32;	A42-B33;	A42-B34;	A42-B35;	A42-B36;	A42-B37;
A42-B38;	A42-B39;	A42-B40;	A42-B41;	A42-B42;	A42-B43;
A42-B44;	A42-B45;	A42-B46;	A42-B47;	A42-B48;	A42-B49;
A42-B50;	A42-B51;	A42-B52;	A42-B53;	A42-B54;	A42-B55;
A42-B56;	A42-B57;	A42-B58;	A42-B59;	A42-B60;	A42-B61;
A42-B62;	A42-B63;	A42-B64;	A42-B65;	A42-B66;	A42-B67;
A42-B68;	A42-B69;	A42-B70;	A42-B71;	A42-B72;	A42-B73;
A42-B74;	A42-B75;	A42-B76;	A42-B77;	A42-B78;	A42-B79;
A42-B80;	A42-B81;	A42-B82;	A42-B83;	A42-B84;	A42-B85;
A42-B86;	A42-B87;	A42-B88;	A42-B89;	A42-B90;	A42-B91;

A42-B92;	A42-B93;	A42-B94;	A42-B95;	A42-B96;	A42-B97;
A42-B98;	A42-B99;	A42-B100;	A42-B101;	A42-B102;	A42-B103;
A42-B104;	A42-B105;	A42-B106;	A42-B107;	A42-B108;	A42-B109;
A42-B110;	A42-B111;	A42-B112;	A42-B113;	A42-B114;	A42-B115;
A42-B116;	A42-B117;	A42-B118;	A42-B119;	A42-B120;	A42-B121;
A42-B122;	A42-B123;	A42-B124;	A42-B125;	A42-B126;	A42-B127;
A42-B128;	A42-B129;	A42-B130;	A42-B131;	A42-B132;	A42-B133;
A42-B134;	A42-B135;	A42-B136;	A42-B137;	A42-B138;	A42-B139;
A42-B140;	A42-B141;	A42-B142;	A42-B143;	A42-B144;	A42-B145;
A42-B146;	A42-B147;	A42-B148;	A42-B149;	A42-B150;	A42-B151;
A42-B152;	A42-B153;	A42-B154;	A42-B155;	A42-B156;	A42-B157;
A42-B158;	A42-B159;	A42-B160;	A42-B161;	A42-B162;	A42-B163;
A42-B164;	A42-B165;	A42-B166;	A42-B167;	A42-B168;	A42-B169;
A43-B1;	A43-B2;	A43-B3;	A43-B4;	A43-B5;	A43-B6;
A43-B7;	A43-B8;	A43-B9;	A43-B10;	A43-B11;	A43-B12;
A43-B13;	A43-B14;	A43-B15;	A43-B16;	A43-B17;	A43-B18;
A43-B19;	A43-B20;	A43-B21;	A43-B22;	A43-B23;	A43-B24;
A43-B25;	A43-B26;	A43-B27;	A43-B28;	A43-B29;	A43-B30;
A43-B31;	A43-B32;	A43-B33;	A43-B34;	A43-B35;	A43-B36;
A43-B37;	A43-B38;	A43-B39;	A43-B40;	A43-B41;	A43-B42;
A43-B43;	A43-B44;	A43-B45;	A43-B46;	A43-B47;	A43-B48;
A43-B49;	A43-B50;	A43-B51;	A43-B52;	A43-B53;	A43-B54;
A43-B55;	A43-B56;	A43-B57;	A43-B58;	A43-B59;	A43-B60;
A43-B61;	A43-B62;	A43-B63;	A43-B64;	A43-B65;	A43-B66;
A43-B67;	A43-B68;	A43-B69;	A43-B70;	A43-B71;	A43-B72;
A43-B73;	A43-B74;	A43-B75;	A43-B76;	A43-B77;	A43-B78;
A43-B79;	A43-B80;	A43-B81;	A43-B82;	A43-B83;	A43-B84;
A43-B85;	A43-B86;	A43-B87;	A43-B88;	A43-B89;	A43-B90;
A43-B91;	A43-B92;	A43-B93;	A43-B94;	A43-B95;	A43-B96;
A43-B97;	A43-B98;	A43-B99;	A43-B100;	A43-B101;	A43-B102;
A43-B103;	A43-B104;	A43-B105;	A43-B106;	A43-B107;	A43-B108;
A43-B109;	A43-B110;	A43-B111;	A43-B112;	A43-B113;	A43-B114;
A43-B115;	A43-B116;	A43-B117;	A43-B118;	A43-B119;	A43-B120;
A43-B121;	A43-B122;	A43-B123;	A43-B124;	A43-B125;	A43-B126;
A43-B127;	A43-B128;	A43-B129;	A43-B130;	A43-B131;	A43-B132;

A43-B133;	A43-B134;	A43-B135;	A43-B136;	A43-B137;	A43-B138;
A43-B139;	A43-B140;	A43-B141;	A43-B142;	A43-B143;	A43-B144;
A43-B145;	A43-B146;	A43-B147;	A43-B148;	A43-B149;	A43-B150;
A43-B151;	A43-B152;	A43-B153;	A43-B154;	A43-B155;	A43-B156;
A43-B157;	A43-B158;	A43-B159;	A43-B160;	A43-B161;	A43-B162;
A43-B163;	A43-B164;	A43-B165;	A43-B166;	A43-B167;	A43-B168;
A43-B169;	A44-B1;	A44-B2;	A44-B3;	A44-B4;	A44-B5;
A44-B6;	A44-B7;	A44-B8;	A44-B9;	A44-B10;	A44-B11;
A44-B12;	A44-B13;	A44-B14;	A44-B15;	A44-B16;	A44-B17;
A44-B18;	A44-B19;	A44-B20;	A44-B21;	A44-B22;	A44-B23;
A44-B24;	A44-B25;	A44-B26;	A44-B27;	A44-B28;	A44-B29;
A44-B30;	A44-B31;	A44-B32;	A44-B33;	A44-B34;	A44-B35;
A44-B36;	A44-B37;	A44-B38;	A44-B39;	A44-B40;	A44-B41;
A44-B42;	A44-B43;	A44-B44;	A44-B45;	A44-B46;	A44-B47;
A44-B48;	A44-B49;	A44-B50;	A44-B51;	A44-B52;	A44-B53;
A44-B54;	A44-B55;	A44-B56;	A44-B57;	A44-B58;	A44-B59;
A44-B60;	A44-B61;	A44-B62;	A44-B63;	A44-B64;	A44-B65;
A44-B66;	A44-B67;	A44-B68;	A44-B69;	A44-B70;	A44-B71;
A44-B72;	A44-B73;	A44-B74;	A44-B75;	A44-B76;	A44-B77;
A44-B78;	A44-B79;	A44-B80;	A44-B81;	A44-B82;	A44-B83;
A44-B84;	A44-B85;	A44-B86;	A44-B87;	A44-B88;	A44-B89;
A44-B90;	A44-B91;	A44-B92;	A44-B93;	A44-B94;	A44-B95;
A44-B96;	A44-B97;	A44-B98;	A44-B99;	A44-B100;	A44-B101;
A44-B102;	A44-B103;	A44-B104;	A44-B105;	A44-B106;	A44-B107;
A44-B108;	A44-B109;	A44-B110;	A44-B111;	A44-B112;	A44-B113;
A44-B114;	A44-B115;	A44-B116;	A44-B117;	A44-B118;	A44-B119;
A44-B120;	A44-B121;	A44-B122;	A44-B123;	A44-B124;	A44-B125;
A44-B126;	A44-B127;	A44-B128;	A44-B129;	A44-B130;	A44-B131;
A44-B132;	A44-B133;	A44-B134;	A44-B135;	A44-B136;	A44-B137;
A44-B138;	A44-B139;	A44-B140;	A44-B141;	A44-B142;	A44-B143;
A44-B144;	A44-B145;	A44-B146;	A44-B147;	A44-B148;	A44-B149;
A44-B150;	A44-B151;	A44-B152;	A44-B153;	A44-B154;	A44-B155;
A44-B156;	A44-B157;	A44-B158;	A44-B159;	A44-B160;	A44-B161;
A44-B162;	A44-B163;	A44-B164;	A44-B165;	A44-B166;	A44-B167;
A44-B168;	A44-B169;	A45-B1;	A45-B2;	A45-B3;	A45-B4;

A45-B5;	A45-B6;	A45-B7;	A45-B8;	A45-B9;	A45-B10;
A45-B11;	A45-B12;	A45-B13;	A45-B14;	A45-B15;	A45-B16;
A45-B17;	A45-B18;	A45-B19;	A45-B20;	A45-B21;	A45-B22;
A45-B23;	A45-B24;	A45-B25;	A45-B26;	A45-B27;	A45-B28;
A45-B29;	A45-B30;	A45-B31;	A45-B32;	A45-B33;	A45-B34;
A45-B35;	A45-B36;	A45-B37;	A45-B38;	A45-B39;	A45-B40;
A45-B41;	A45-B42;	A45-B43;	A45-B44;	A45-B45;	A45-B46;
A45-B47;	A45-B48;	A45-B49;	A45-B50;	A45-B51;	A45-B52;
A45-B53;	A45-B54;	A45-B55;	A45-B56;	A45-B57;	A45-B58;
A45-B59;	A45-B60;	A45-B61;	A45-B62;	A45-B63;	A45-B64;
A45-B65;	A45-B66;	A45-B67;	A45-B68;	A45-B69;	A45-B70;
A45-B71;	A45-B72;	A45-B73;	A45-B74;	A45-B75;	A45-B76;
A45-B77;	A45-B78;	A45-B79;	A45-B80;	A45-B81;	A45-B82;
A45-B83;	A45-B84;	A45-B85;	A45-B86;	A45-B87;	A45-B88;
A45-B89;	A45-B90;	A45-B91;	A45-B92;	A45-B93;	A45-B94;
A45-B95;	A45-B96;	A45-B97;	A45-B98;	A45-B99;	A45-B100;
A45-B101;	A45-B102;	A45-B103;	A45-B104;	A45-B105;	A45-B106;
A45-B107;	A45-B108;	A45-B109;	A45-B110;	A45-B111;	A45-B112;
A45-B113;	A45-B114;	A45-B115;	A45-B116;	A45-B117;	A45-B118;
A45-B119;	A45-B120;	A45-B121;	A45-B122;	A45-B123;	A45-B124;
A45-B125;	A45-B126;	A45-B127;	A45-B128;	A45-B129;	A45-B130;
A45-B131;	A45-B132;	A45-B133;	A45-B134;	A45-B135;	A45-B136;
A45-B137;	A45-B138;	A45-B139;	A45-B140;	A45-B141;	A45-B142;
A45-B143;	A45-B144;	A45-B145;	A45-B146;	A45-B147;	A45-B148;
A45-B149;	A45-B150;	A45-B151;	A45-B152;	A45-B153;	A45-B154;
A45-B155;	A45-B156;	A45-B157;	A45-B158;	A45-B159;	A45-B160;
A45-B161;	A45-B162;	A45-B163;	A45-B164;	A45-B165;	A45-B166;
A45-B167;	A45-B168;	A45-B169;	A46-B1;	A46-B2;	A46-B3;
A46-B4;	A46-B5;	A46-B6;	A46-B7;	A46-B8;	A46-B9;
A46-B10;	A46-B11;	A46-B12;	A46-B13;	A46-B14;	A46-B15;
A46-B16;	A46-B17;	A46-B18;	A46-B19;	A46-B20;	A46-B21;
A46-B22;	A46-B23;	A46-B24;	A46-B25;	A46-B26;	A46-B27;
A46-B28;	A46-B29;	A46-B30;	A46-B31;	A46-B32;	A46-B33;
A46-B34;	A46-B35;	A46-B36;	A46-B37;	A46-B38;	A46-B39;
A46-B40;	A46-B41;	A46-B42;	A46-B43;	A46-B44;	A46-B45;

A46-B46;	A46-B47;	A46-B48;	A46-B49;	A46-B50;	A46-B51;
A46-B52;	A46-B53;	A46-B54;	A46-B55;	A46-B56;	A46-B57;
A46-B58;	A46-B59;	A46-B60;	A46-B61;	A46-B62;	A46-B63;
A46-B64;	A46-B65;	A46-B66;	A46-B67;	A46-B68;	A46-B69;
A46-B70;	A46-B71;	A46-B72;	A46-B73;	A46-B74;	A46-B75;
A46-B76;	A46-B77;	A46-B78;	A46-B79;	A46-B80;	A46-B81;
A46-B82;	A46-B83;	A46-B84;	A46-B85;	A46-B86;	A46-B87;
A46-B88;	A46-B89;	A46-B90;	A46-B91;	A46-B92;	A46-B93;
A46-B94;	A46-B95;	A46-B96;	A46-B97;	A46-B98;	A46-B99;
A46-B100;	A46-B101;	A46-B102;	A46-B103;	A46-B104;	A46-B105;
A46-B106;	A46-B107;	A46-B108;	A46-B109;	A46-B110;	A46-B111;
A46-B112;	A46-B113;	A46-B114;	A46-B115;	A46-B116;	A46-B117;
A46-B118;	A46-B119;	A46-B120;	A46-B121;	A46-B122;	A46-B123;
A46-B124;	A46-B125;	A46-B126;	A46-B127;	A46-B128;	A46-B129;
A46-B130;	A46-B131;	A46-B132;	A46-B133;	A46-B134;	A46-B135;
A46-B136;	A46-B137;	A46-B138;	A46-B139;	A46-B140;	A46-B141;
A46-B142;	A46-B143;	A46-B144;	A46-B145;	A46-B146;	A46-B147;
A46-B148;	A46-B149;	A46-B150;	A46-B151;	A46-B152;	A46-B153;
A46-B154;	A46-B155;	A46-B156;	A46-B157;	A46-B158;	A46-B159;
A46-B160;	A46-B161;	A46-B162;	A46-B163;	A46-B164;	A46-B165;
A46-B166;	A46-B167;	A46-B168;	A46-B169;	A47-B1;	A47-B2;
A47-B3;	A47-B4;	A47-B5;	A47-B6;	A47-B7;	A47-B8;
A47-B9;	A47-B10;	A47-B11;	A47-B12;	A47-B13;	A47-B14;
A47-B15;	A47-B16;	A47-B17;	A47-B18;	A47-B19;	A47-B20;
A47-B21;	A47-B22;	A47-B23;	A47-B24;	A47-B25;	A47-B26;
A47-B27;	A47-B28;	A47-B29;	A47-B30;	A47-B31;	A47-B32;
A47-B33;	A47-B34;	A47-B35;	A47-B36;	A47-B37;	A47-B38;
A47-B39;	A47-B40;	A47-B41;	A47-B42;	A47-B43;	A47-B44;
A47-B45;	A47-B46;	A47-B47;	A47-B48;	A47-B49;	A47-B50;
A47-B51;	A47-B52;	A47-B53;	A47-B54;	A47-B55;	A47-B56;
A47-B57;	A47-B58;	A47-B59;	A47-B60;	A47-B61;	A47-B62;
A47-B63;	A47-B64;	A47-B65;	A47-B66;	A47-B67;	A47-B68;
A47-B69;	A47-B70;	A47-B71;	A47-B72;	A47-B73;	A47-B74;
A47-B75;	A47-B76;	A47-B77;	A47-B78;	A47-B79;	A47-B80;
A47-B81;	A47-B82;	A47-B83;	A47-B84;	A47-B85;	A47-B86;

A47-B87;	A47-B88;	A47-B89;	A47-B90;	A47-B91;	A47-B92;
A47-B93;	A47-B94;	A47-B95;	A47-B96;	A47-B97;	A47-B98;
A47-B99;	A47-B100;	A47-B101;	A47-B102;	A47-B103;	A47-B104;
A47-B105;	A47-B106;	A47-B107;	A47-B108;	A47-B109;	A47-B110;
A47-B111;	A47-B112;	A47-B113;	A47-B114;	A47-B115;	A47-B116;
A47-B117;	A47-B118;	A47-B119;	A47-B120;	A47-B121;	A47-B122;
A47-B123;	A47-B124;	A47-B125;	A47-B126;	A47-B127;	A47-B128;
A47-B129;	A47-B130;	A47-B131;	A47-B132;	A47-B133;	A47-B134;
A47-B135;	A47-B136;	A47-B137;	A47-B138;	A47-B139;	A47-B140;
A47-B141;	A47-B142;	A47-B143;	A47-B144;	A47-B145;	A47-B146;
A47-B147;	A47-B148;	A47-B149;	A47-B150;	A47-B151;	A47-B152;
A47-B153;	A47-B154;	A47-B155;	A47-B156;	A47-B157;	A47-B158;
A47-B159;	A47-B160;	A47-B161;	A47-B162;	A47-B163;	A47-B164;
A47-B165;	A47-B166;	A47-B167;	A47-B168;	A47-B169;	A48-B1;
A48-B2;	A48-B3;	A48-B4;	A48-B5;	A48-B6;	A48-B7;
A48-B8;	A48-B9;	A48-B10;	A48-B11;	A48-B12;	A48-B13;
A48-B14;	A48-B15;	A48-B16;	A48-B17;	A48-B18;	A48-B19;
A48-B20;	A48-B21;	A48-B22;	A48-B23;	A48-B24;	A48-B25;
A48-B26;	A48-B27;	A48-B28;	A48-B29;	A48-B30;	A48-B31;
A48-B32;	A48-B33;	A48-B34;	A48-B35;	A48-B36;	A48-B37;
A48-B38;	A48-B39;	A48-B40;	A48-B41;	A48-B42;	A48-B43;
A48-B44;	A48-B45;	A48-B46;	A48-B47;	A48-B48;	A48-B49;
A48-B50;	A48-B51;	A48-B52;	A48-B53;	A48-B54;	A48-B55;
A48-B56;	A48-B57;	A48-B58;	A48-B59;	A48-B60;	A48-B61;
A48-B62;	A48-B63;	A48-B64;	A48-B65;	A48-B66;	A48-B67;
A48-B68;	A48-B69;	A48-B70;	A48-B71;	A48-B72;	A48-B73;
A48-B74;	A48-B75;	A48-B76;	A48-B77;	A48-B78;	A48-B79;
A48-B80;	A48-B81;	A48-B82;	A48-B83;	A48-B84;	A48-B85;
A48-B86;	A48-B87;	A48-B88;	A48-B89;	A48-B90;	A48-B91;
A48-B92;	A48-B93;	A48-B94;	A48-B95;	A48-B96;	A48-B97;
A48-B98;	A48-B99;	A48-B100;	A48-B101;	A48-B102;	A48-B103;
A48-B104;	A48-B105;	A48-B106;	A48-B107;	A48-B108;	A48-B109;
A48-B110;	A48-B111;	A48-B112;	A48-B113;	A48-B114;	A48-B115;
A48-B116;	A48-B117;	A48-B118;	A48-B119;	A48-B120;	A48-B121;
A48-B122;	A48-B123;	A48-B124;	A48-B125;	A48-B126;	A48-B127;

A48-B128;	A48-B129;	A48-B130;	A48-B131;	A48-B132;	A48-B133;
A48-B134;	A48-B135;	A48-B136;	A48-B137;	A48-B138;	A48-B139;
A48-B140;	A48-B141;	A48-B142;	A48-B143;	A48-B144;	A48-B145;
A48-B146;	A48-B147;	A48-B148;	A48-B149;	A48-B150;	A48-B151;
A48-B152;	A48-B153;	A48-B154;	A48-B155;	A48-B156;	A48-B157;
A48-B158;	A48-B159;	A48-B160;	A48-B161;	A48-B162;	A48-B163;
A48-B164;	A48-B165;	A48-B166;	A48-B167;	A48-B168;	A48-B169;
A49-B1;	A49-B2;	A49-B3;	A49-B4;	A49-B5;	A49-B6;
A49-B7;	A49-B8;	A49-B9;	A49-B10;	A49-B11;	A49-B12;
A49-B13;	A49-B14;	A49-B15;	A49-B16;	A49-B17;	A49-B18;
A49-B19;	A49-B20;	A49-B21;	A49-B22;	A49-B23;	A49-B24;
A49-B25;	A49-B26;	A49-B27;	A49-B28;	A49-B29;	A49-B30;
A49-B31;	A49-B32;	A49-B33;	A49-B34;	A49-B35;	A49-B36;
A49-B37;	A49-B38;	A49-B39;	A49-B40;	A49-B41;	A49-B42;
A49-B43;	A49-B44;	A49-B45;	A49-B46;	A49-B47;	A49-B48;
A49-B49;	A49-B50;	A49-B51;	A49-B52;	A49-B53;	A49-B54;
A49-B55;	A49-B56;	A49-B57;	A49-B58;	A49-B59;	A49-B60;
A49-B61;	A49-B62;	A49-B63;	A49-B64;	A49-B65;	A49-B66;
A49-B67;	A49-B68;	A49-B69;	A49-B70;	A49-B71;	A49-B72;
A49-B73;	A49-B74;	A49-B75;	A49-B76;	A49-B77;	A49-B78;
A49-B79;	A49-B80;	A49-B81;	A49-B82;	A49-B83;	A49-B84;
A49-B85;	A49-B86;	A49-B87;	A49-B88;	A49-B89;	A49-B90;
A49-B91;	A49-B92;	A49-B93;	A49-B94;	A49-B95;	A49-B96;
A49-B97;	A49-B98;	A49-B99;	A49-B100;	A49-B101;	A49-B102;
A49-B103;	A49-B104;	A49-B105;	A49-B106;	A49-B107;	A49-B108;
A49-B109;	A49-B110;	A49-B111;	A49-B112;	A49-B113;	A49-B114;
A49-B115;	A49-B116;	A49-B117;	A49-B118;	A49-B119;	A49-B120;
A49-B121;	A49-B122;	A49-B123;	A49-B124;	A49-B125;	A49-B126;
A49-B127;	A49-B128;	A49-B129;	A49-B130;	A49-B131;	A49-B132;
A49-B133;	A49-B134;	A49-B135;	A49-B136;	A49-B137;	A49-B138;
A49-B139;	A49-B140;	A49-B141;	A49-B142;	A49-B143;	A49-B144;
A49-B145;	A49-B146;	A49-B147;	A49-B148;	A49-B149;	A49-B150;
A49-B151;	A49-B152;	A49-B153;	A49-B154;	A49-B155;	A49-B156;
A49-B157;	A49-B158;	A49-B159;	A49-B160;	A49-B161;	A49-B162;
A49-B163;	A49-B164;	A49-B165;	A49-B166;	A49-B167;	A49-B168;

A49-B169;	A50-B1;	A50-B2;	A50-B3;	A50-B4;	A50-B5;
A50-B6;	A50-B7;	A50-B8;	A50-B9;	A50-B10;	A50-B11;
A50-B12;	A50-B13;	A50-B14;	A50-B15;	A50-B16;	A50-B17;
A50-B18;	A50-B19;	A50-B20;	A50-B21;	A50-B22;	A50-B23;
A50-B24;	A50-B25;	A50-B26;	A50-B27;	A50-B28;	A50-B29;
A50-B30;	A50-B31;	A50-B32;	A50-B33;	A50-B34;	A50-B35;
A50-B36;	A50-B37;	A50-B38;	A50-B39;	A50-B40;	A50-B41;
A50-B42;	A50-B43;	A50-B44;	A50-B45;	A50-B46;	A50-B47;
A50-B48;	A50-B49;	A50-B50;	A50-B51;	A50-B52;	A50-B53;
A50-B54;	A50-B55;	A50-B56;	A50-B57;	A50-B58;	A50-B59;
A50-B60;	A50-B61;	A50-B62;	A50-B63;	A50-B64;	A50-B65;
A50-B66;	A50-B67;	A50-B68;	A50-B69;	A50-B70;	A50-B71;
A50-B72;	A50-B73;	A50-B74;	A50-B75;	A50-B76;	A50-B77;
A50-B78;	A50-B79;	A50-B80;	A50-B81;	A50-B82;	A50-B83;
A50-B84;	A50-B85;	A50-B86;	A50-B87;	A50-B88;	A50-B89;
A50-B90;	A50-B91;	A50-B92;	A50-B93;	A50-B94;	A50-B95;
A50-B96;	A50-B97;	A50-B98;	A50-B99;	A50-B100;	A50-B101;
A50-B102;	A50-B103;	A50-B104;	A50-B105;	A50-B106;	A50-B107;
A50-B108;	A50-B109;	A50-B110;	A50-B111;	A50-B112;	A50-B113;
A50-B114;	A50-B115;	A50-B116;	A50-B117;	A50-B118;	A50-B119;
A50-B120;	A50-B121;	A50-B122;	A50-B123;	A50-B124;	A50-B125;
A50-B126;	A50-B127;	A50-B128;	A50-B129;	A50-B130;	A50-B131;
A50-B132;	A50-B133;	A50-B134;	A50-B135;	A50-B136;	A50-B137;
A50-B138;	A50-B139;	A50-B140;	A50-B141;	A50-B142;	A50-B143;
A50-B144;	A50-B145;	A50-B146;	A50-B147;	A50-B148;	A50-B149;
A50-B150;	A50-B151;	A50-B152;	A50-B153;	A50-B154;	A50-B155;
A50-B156;	A50-B157;	A50-B158;	A50-B159;	A50-B160;	A50-B161;
A50-B162;	A50-B163;	A50-B164;	A50-B165;	A50-B166;	A50-B167;
A50-B168;	A50-B169;	A51-B1;	A51-B2;	A51-B3;	A51-B4;
A51-B5;	A51-B6;	A51-B7;	A51-B8;	A51-B9;	A51-B10;
A51-B11;	A51-B12;	A51-B13;	A51-B14;	A51-B15;	A51-B16;
A51-B17;	A51-B18;	A51-B19;	A51-B20;	A51-B21;	A51-B22;
A51-B23;	A51-B24;	A51-B25;	A51-B26;	A51-B27;	A51-B28;
A51-B29;	A51-B30;	A51-B31;	A51-B32;	A51-B33;	A51-B34;
A51-B35;	A51-B36;	A51-B37;	A51-B38;	A51-B39;	A51-B40;

A51-B41;	A51-B42;	A51-B43;	A51-B44;	A51-B45;	A51-B46;
A51-B47;	A51-B48;	A51-B49;	A51-B50;	A51-B51;	A51-B52;
A51-B53;	A51-B54;	A51-B55;	A51-B56;	A51-B57;	A51-B58;
A51-B59;	A51-B60;	A51-B61;	A51-B62;	A51-B63;	A51-B64;
A51-B65;	A51-B66;	A51-B67;	A51-B68;	A51-B69;	A51-B70;
A51-B71;	A51-B72;	A51-B73;	A51-B74;	A51-B75;	A51-B76;
A51-B77;	A51-B78;	A51-B79;	A51-B80;	A51-B81;	A51-B82;
A51-B83;	A51-B84;	A51-B85;	A51-B86;	A51-B87;	A51-B88;
A51-B89;	A51-B90;	A51-B91;	A51-B92;	A51-B93;	A51-B94;
A51-B95;	A51-B96;	A51-B97;	A51-B98;	A51-B99;	A51-B100;
A51-B101;	A51-B102;	A51-B103;	A51-B104;	A51-B105;	A51-B106;
A51-B107;	A51-B108;	A51-B109;	A51-B110;	A51-B111;	A51-B112;
A51-B113;	A51-B114;	A51-B115;	A51-B116;	A51-B117;	A51-B118;
A51-B119;	A51-B120;	A51-B121;	A51-B122;	A51-B123;	A51-B124;
A51-B125;	A51-B126;	A51-B127;	A51-B128;	A51-B129;	A51-B130;
A51-B131;	A51-B132;	A51-B133;	A51-B134;	A51-B135;	A51-B136;
A51-B137;	A51-B138;	A51-B139;	A51-B140;	A51-B141;	A51-B142;
A51-B143;	A51-B144;	A51-B145;	A51-B146;	A51-B147;	A51-B148;
A51-B149;	A51-B150;	A51-B151;	A51-B152;	A51-B153;	A51-B154;
A51-B155;	A51-B156;	A51-B157;	A51-B158;	A51-B159;	A51-B160;
A51-B161;	A51-B162;	A51-B163;	A51-B164;	A51-B165;	A51-B166;
A51-B167;	A51-B168;	A51-B169;	A52-B1;	A52-B2;	A52-B3;
A52-B4;	A52-B5;	A52-B6;	A52-B7;	A52-B8;	A52-B9;
A52-B10;	A52-B11;	A52-B12;	A52-B13;	A52-B14;	A52-B15;
A52-B16;	A52-B17;	A52-B18;	A52-B19;	A52-B20;	A52-B21;
A52-B22;	A52-B23;	A52-B24;	A52-B25;	A52-B26;	A52-B27;
A52-B28;	A52-B29;	A52-B30;	A52-B31;	A52-B32;	A52-B33;
A52-B34;	A52-B35;	A52-B36;	A52-B37;	A52-B38;	A52-B39;
A52-B40;	A52-B41;	A52-B42;	A52-B43;	A52-B44;	A52-B45;
A52-B46;	A52-B47;	A52-B48;	A52-B49;	A52-B50;	A52-B51;
A52-B52;	A52-B53;	A52-B54;	A52-B55;	A52-B56;	A52-B57;
A52-B58;	A52-B59;	A52-B60;	A52-B61;	A52-B62;	A52-B63;
A52-B64;	A52-B65;	A52-B66;	A52-B67;	A52-B68;	A52-B69;
A52-B70;	A52-B71;	A52-B72;	A52-B73;	A52-B74;	A52-B75;
A52-B76;	A52-B77;	A52-B78;	A52-B79;	A52-B80;	A52-B81;

A52-B82;	A52-B83;	A52-B84;	A52-B85;	A52-B86;	A52-B87;
A52-B88;	A52-B89;	A52-B90;	A52-B91;	A52-B92;	A52-B93;
A52-B94;	A52-B95;	A52-B96;	A52-B97;	A52-B98;	A52-B99;
A52-B100;	A52-B101;	A52-B102;	A52-B103;	A52-B104;	A52-B105;
A52-B106;	A52-B107;	A52-B108;	A52-B109;	A52-B110;	A52-B111;
A52-B112;	A52-B113;	A52-B114;	A52-B115;	A52-B116;	A52-B117;
A52-B118;	A52-B119;	A52-B120;	A52-B121;	A52-B122;	A52-B123;
A52-B124;	A52-B125;	A52-B126;	A52-B127;	A52-B128;	A52-B129;
A52-B130;	A52-B131;	A52-B132;	A52-B133;	A52-B134;	A52-B135;
A52-B136;	A52-B137;	A52-B138;	A52-B139;	A52-B140;	A52-B141;
A52-B142;	A52-B143;	A52-B144;	A52-B145;	A52-B146;	A52-B147;
A52-B148;	A52-B149;	A52-B150;	A52-B151;	A52-B152;	A52-B153;
A52-B154;	A52-B155;	A52-B156;	A52-B157;	A52-B158;	A52-B159;
A52-B160;	A52-B161;	A52-B162;	A52-B163;	A52-B164;	A52-B165;
A52-B166;	A52-B167;	A52-B168;	A52-B169;	A53-B1;	A53-B2;
A53-B3;	A53-B4;	A53-B5;	A53-B6;	A53-B7;	A53-B8;
A53-B9;	A53-B10;	A53-B11;	A53-B12;	A53-B13;	A53-B14;
A53-B15;	A53-B16;	A53-B17;	A53-B18;	A53-B19;	A53-B20;
A53-B21;	A53-B22;	A53-B23;	A53-B24;	A53-B25;	A53-B26;
A53-B27;	A53-B28;	A53-B29;	A53-B30;	A53-B31;	A53-B32;
A53-B33;	A53-B34;	A53-B35;	A53-B36;	A53-B37;	A53-B38;
A53-B39;	A53-B40;	A53-B41;	A53-B42;	A53-B43;	A53-B44;
A53-B45;	A53-B46;	A53-B47;	A53-B48;	A53-B49;	A53-B50;
A53-B51;	A53-B52;	A53-B53;	A53-B54;	A53-B55;	A53-B56;
A53-B57;	A53-B58;	A53-B59;	A53-B60;	A53-B61;	A53-B62;
A53-B63;	A53-B64;	A53-B65;	A53-B66;	A53-B67;	A53-B68;
A53-B69;	A53-B70;	A53-B71;	A53-B72;	A53-B73;	A53-B74;
A53-B75;	A53-B76;	A53-B77;	A53-B78;	A53-B79;	A53-B80;
A53-B81;	A53-B82;	A53-B83;	A53-B84;	A53-B85;	A53-B86;
A53-B87;	A53-B88;	A53-B89;	A53-B90;	A53-B91;	A53-B92;
A53-B93;	A53-B94;	A53-B95;	A53-B96;	A53-B97;	A53-B98;
A53-B99;	A53-B100;	A53-B101;	A53-B102;	A53-B103;	A53-B104;
A53-B105;	A53-B106;	A53-B107;	A53-B108;	A53-B109;	A53-B110;
A53-B111;	A53-B112;	A53-B113;	A53-B114;	A53-B115;	A53-B116;
A53-B117;	A53-B118;	A53-B119;	A53-B120;	A53-B121;	A53-B122;

A53-B123;	A53-B124;	A53-B125;	A53-B126;	A53-B127;	A53-B128;
A53-B129;	A53-B130;	A53-B131;	A53-B132;	A53-B133;	A53-B134;
A53-B135;	A53-B136;	A53-B137;	A53-B138;	A53-B139;	A53-B140;
A53-B141;	A53-B142;	A53-B143;	A53-B144;	A53-B145;	A53-B146;
A53-B147;	A53-B148;	A53-B149;	A53-B150;	A53-B151;	A53-B152;
A53-B153;	A53-B154;	A53-B155;	A53-B156;	A53-B157;	A53-B158;
A53-B159;	A53-B160;	A53-B161;	A53-B162;	A53-B163;	A53-B164;
A53-B165;	A53-B166;	A53-B167;	A53-B168;	A53-B169;	A54-B1;
A54-B2;	A54-B3;	A54-B4;	A54-B5;	A54-B6;	A54-B7;
A54-B8;	A54-B9;	A54-B10;	A54-B11;	A54-B12;	A54-B13;
A54-B14;	A54-B15;	A54-B16;	A54-B17;	A54-B18;	A54-B19;
A54-B20;	A54-B21;	A54-B22;	A54-B23;	A54-B24;	A54-B25;
A54-B26;	A54-B27;	A54-B28;	A54-B29;	A54-B30;	A54-B31;
A54-B32;	A54-B33;	A54-B34;	A54-B35;	A54-B36;	A54-B37;
A54-B38;	A54-B39;	A54-B40;	A54-B41;	A54-B42;	A54-B43;
A54-B44;	A54-B45;	A54-B46;	A54-B47;	A54-B48;	A54-B49;
A54-B50;	A54-B51;	A54-B52;	A54-B53;	A54-B54;	A54-B55;
A54-B56;	A54-B57;	A54-B58;	A54-B59;	A54-B60;	A54-B61;
A54-B62;	A54-B63;	A54-B64;	A54-B65;	A54-B66;	A54-B67;
A54-B68;	A54-B69;	A54-B70;	A54-B71;	A54-B72;	A54-B73;
A54-B74;	A54-B75;	A54-B76;	A54-B77;	A54-B78;	A54-B79;
A54-B80;	A54-B81;	A54-B82;	A54-B83;	A54-B84;	A54-B85;
A54-B86;	A54-B87;	A54-B88;	A54-B89;	A54-B90;	A54-B91;
A54-B92;	A54-B93;	A54-B94;	A54-B95;	A54-B96;	A54-B97;
A54-B98;	A54-B99;	A54-B100;	A54-B101;	A54-B102;	A54-B103;
A54-B104;	A54-B105;	A54-B106;	A54-B107;	A54-B108;	A54-B109;
A54-B110;	A54-B111;	A54-B112;	A54-B113;	A54-B114;	A54-B115;
A54-B116;	A54-B117;	A54-B118;	A54-B119;	A54-B120;	A54-B121;
A54-B122;	A54-B123;	A54-B124;	A54-B125;	A54-B126;	A54-B127;
A54-B128;	A54-B129;	A54-B130;	A54-B131;	A54-B132;	A54-B133;
A54-B134;	A54-B135;	A54-B136;	A54-B137;	A54-B138;	A54-B139;
A54-B140;	A54-B141;	A54-B142;	A54-B143;	A54-B144;	A54-B145;
A54-B146;	A54-B147;	A54-B148;	A54-B149;	A54-B150;	A54-B151;
A54-B152;	A54-B153;	A54-B154;	A54-B155;	A54-B156;	A54-B157;
A54-B158;	A54-B159;	A54-B160;	A54-B161;	A54-B162;	A54-B163;

A54-B164;	A54-B165;	A54-B166;	A54-B167;	A54-B168;	A54-B169;
A55-B1;	A55-B2;	A55-B3;	A55-B4;	A55-B5;	A55-B6;
A55-B7;	A55-B8;	A55-B9;	A55-B10;	A55-B11;	A55-B12;
A55-B13;	A55-B14;	A55-B15;	A55-B16;	A55-B17;	A55-B18;
A55-B19;	A55-B20;	A55-B21;	A55-B22;	A55-B23;	A55-B24;
A55-B25;	A55-B26;	A55-B27;	A55-B28;	A55-B29;	A55-B30;
A55-B31;	A55-B32;	A55-B33;	A55-B34;	A55-B35;	A55-B36;
A55-B37;	A55-B38;	A55-B39;	A55-B40;	A55-B41;	A55-B42;
A55-B43;	A55-B44;	A55-B45;	A55-B46;	A55-B47;	A55-B48;
A55-B49;	A55-B50;	A55-B51;	A55-B52;	A55-B53;	A55-B54;
A55-B55;	A55-B56;	A55-B57;	A55-B58;	A55-B59;	A55-B60;
A55-B61;	A55-B62;	A55-B63;	A55-B64;	A55-B65;	A55-B66;
A55-B67;	A55-B68;	A55-B69;	A55-B70;	A55-B71;	A55-B72;
A55-B73;	A55-B74;	A55-B75;	A55-B76;	A55-B77;	A55-B78;
A55-B79;	A55-B80;	A55-B81;	A55-B82;	A55-B83;	A55-B84;
A55-B85;	A55-B86;	A55-B87;	A55-B88;	A55-B89;	A55-B90;
A55-B91;	A55-B92;	A55-B93;	A55-B94;	A55-B95;	A55-B96;
A55-B97;	A55-B98;	A55-B99;	A55-B100;	A55-B101;	A55-B102;
A55-B103;	A55-B104;	A55-B105;	A55-B106;	A55-B107;	A55-B108;
A55-B109;	A55-B110;	A55-B111;	A55-B112;	A55-B113;	A55-B114;
A55-B115;	A55-B116;	A55-B117;	A55-B118;	A55-B119;	A55-B120;
A55-B121;	A55-B122;	A55-B123;	A55-B124;	A55-B125;	A55-B126;
A55-B127;	A55-B128;	A55-B129;	A55-B130;	A55-B131;	A55-B132;
A55-B133;	A55-B134;	A55-B135;	A55-B136;	A55-B137;	A55-B138;
A55-B139;	A55-B140;	A55-B141;	A55-B142;	A55-B143;	A55-B144;
A55-B145;	A55-B146;	A55-B147;	A55-B148;	A55-B149;	A55-B150;
A55-B151;	A55-B152;	A55-B153;	A55-B154;	A55-B155;	A55-B156;
A55-B157;	A55-B158;	A55-B159;	A55-B160;	A55-B161;	A55-B162;
A55-B163;	A55-B164;	A55-B165;	A55-B166;	A55-B167;	A55-B168;
A55-B169;	A56-B1;	A56-B2;	A56-B3;	A56-B4;	A56-B5;
A56-B6;	A56-B7;	A56-B8;	A56-B9;	A56-B10;	A56-B11;
A56-B12;	A56-B13;	A56-B14;	A56-B15;	A56-B16;	A56-B17;
A56-B18;	A56-B19;	A56-B20;	A56-B21;	A56-B22;	A56-B23;
A56-B24;	A56-B25;	A56-B26;	A56-B27;	A56-B28;	A56-B29;
A56-B30;	A56-B31;	A56-B32;	A56-B33;	A56-B34;	A56-B35;

A56-B36;	A56-B37;	A56-B38;	A56-B39;	A56-B40;	A56-B41;
A56-B42;	A56-B43;	A56-B44;	A56-B45;	A56-B46;	A56-B47;
A56-B48;	A56-B49;	A56-B50;	A56-B51;	A56-B52;	A56-B53;
A56-B54;	A56-B55;	A56-B56;	A56-B57;	A56-B58;	A56-B59;
A56-B60;	A56-B61;	A56-B62;	A56-B63;	A56-B64;	A56-B65;
A56-B66;	A56-B67;	A56-B68;	A56-B69;	A56-B70;	A56-B71;
A56-B72;	A56-B73;	A56-B74;	A56-B75;	A56-B76;	A56-B77;
A56-B78;	A56-B79;	A56-B80;	A56-B81;	A56-B82;	A56-B83;
A56-B84;	A56-B85;	A56-B86;	A56-B87;	A56-B88;	A56-B89;
A56-B90;	A56-B91;	A56-B92;	A56-B93;	A56-B94;	A56-B95;
A56-B96;	A56-B97;	A56-B98;	A56-B99;	A56-B100;	A56-B101;
A56-B102;	A56-B103;	A56-B104;	A56-B105;	A56-B106;	A56-B107;
A56-B108;	A56-B109;	A56-B110;	A56-B111;	A56-B112;	A56-B113;
A56-B114;	A56-B115;	A56-B116;	A56-B117;	A56-B118;	A56-B119;
A56-B120;	A56-B121;	A56-B122;	A56-B123;	A56-B124;	A56-B125;
A56-B126;	A56-B127;	A56-B128;	A56-B129;	A56-B130;	A56-B131;
A56-B132;	A56-B133;	A56-B134;	A56-B135;	A56-B136;	A56-B137;
A56-B138;	A56-B139;	A56-B140;	A56-B141;	A56-B142;	A56-B143;
A56-B144;	A56-B145;	A56-B146;	A56-B147;	A56-B148;	A56-B149;
A56-B150;	A56-B151;	A56-B152;	A56-B153;	A56-B154;	A56-B155;
A56-B156;	A56-B157;	A56-B158;	A56-B159;	A56-B160;	A56-B161;
A56-B162;	A56-B163;	A56-B164;	A56-B165;	A56-B166;	A56-B167;
A56-B168;	A56-B169;	A57-B1;	A57-B2;	A57-B3;	A57-B4;
A57-B5;	A57-B6;	A57-B7;	A57-B8;	A57-B9;	A57-B10;
A57-B11;	A57-B12;	A57-B13;	A57-B14;	A57-B15;	A57-B16;
A57-B17;	A57-B18;	A57-B19;	A57-B20;	A57-B21;	A57-B22;
A57-B23;	A57-B24;	A57-B25;	A57-B26;	A57-B27;	A57-B28;
A57-B29;	A57-B30;	A57-B31;	A57-B32;	A57-B33;	A57-B34;
A57-B35;	A57-B36;	A57-B37;	A57-B38;	A57-B39;	A57-B40;
A57-B41;	A57-B42;	A57-B43;	A57-B44;	A57-B45;	A57-B46;
A57-B47;	A57-B48;	A57-B49;	A57-B50;	A57-B51;	A57-B52;
A57-B53;	A57-B54;	A57-B55;	A57-B56;	A57-B57;	A57-B58;
A57-B59;	A57-B60;	A57-B61;	A57-B62;	A57-B63;	A57-B64;
A57-B65;	A57-B66;	A57-B67;	A57-B68;	A57-B69;	A57-B70;
A57-B71;	A57-B72;	A57-B73;	A57-B74;	A57-B75;	A57-B76;

A57-B77;	A57-B78;	A57-B79;	A57-B80;	A57-B81;	A57-B82;
A57-B83;	A57-B84;	A57-B85;	A57-B86;	A57-B87;	A57-B88;
A57-B89;	A57-B90;	A57-B91;	A57-B92;	A57-B93;	A57-B94;
A57-B95;	A57-B96;	A57-B97;	A57-B98;	A57-B99;	A57-B100;
A57-B101;	A57-B102;	A57-B103;	A57-B104;	A57-B105;	A57-B106;
A57-B107;	A57-B108;	A57-B109;	A57-B110;	A57-B111;	A57-B112;
A57-B113;	A57-B114;	A57-B115;	A57-B116;	A57-B117;	A57-B118;
A57-B119;	A57-B120;	A57-B121;	A57-B122;	A57-B123;	A57-B124;
A57-B125;	A57-B126;	A57-B127;	A57-B128;	A57-B129;	A57-B130;
A57-B131;	A57-B132;	A57-B133;	A57-B134;	A57-B135;	A57-B136;
A57-B137;	A57-B138;	A57-B139;	A57-B140;	A57-B141;	A57-B142;
A57-B143;	A57-B144;	A57-B145;	A57-B146;	A57-B147;	A57-B148;
A57-B149;	A57-B150;	A57-B151;	A57-B152;	A57-B153;	A57-B154;
A57-B155;	A57-B156;	A57-B157;	A57-B158;	A57-B159;	A57-B160;
A57-B161;	A57-B162;	A57-B163;	A57-B164;	A57-B165;	A57-B166;
A57-B167;	A57-B168;	A57-B169;	A58-B1;	A58-B2;	A58-B3;
A58-B4;	A58-B5;	A58-B6;	A58-B7;	A58-B8;	A58-B9;
A58-B10;	A58-B11;	A58-B12;	A58-B13;	A58-B14;	A58-B15;
A58-B16;	A58-B17;	A58-B18;	A58-B19;	A58-B20;	A58-B21;
A58-B22;	A58-B23;	A58-B24;	A58-B25;	A58-B26;	A58-B27;
A58-B28;	A58-B29;	A58-B30;	A58-B31;	A58-B32;	A58-B33;
A58-B34;	A58-B35;	A58-B36;	A58-B37;	A58-B38;	A58-B39;
A58-B40;	A58-B41;	A58-B42;	A58-B43;	A58-B44;	A58-B45;
A58-B46;	A58-B47;	A58-B48;	A58-B49;	A58-B50;	A58-B51;
A58-B52;	A58-B53;	A58-B54;	A58-B55;	A58-B56;	A58-B57;
A58-B58;	A58-B59;	A58-B60;	A58-B61;	A58-B62;	A58-B63;
A58-B64;	A58-B65;	A58-B66;	A58-B67;	A58-B68;	A58-B69;
A58-B70;	A58-B71;	A58-B72;	A58-B73;	A58-B74;	A58-B75;
A58-B76;	A58-B77;	A58-B78;	A58-B79;	A58-B80;	A58-B81;
A58-B82;	A58-B83;	A58-B84;	A58-B85;	A58-B86;	A58-B87;
A58-B88;	A58-B89;	A58-B90;	A58-B91;	A58-B92;	A58-B93;
A58-B94;	A58-B95;	A58-B96;	A58-B97;	A58-B98;	A58-B99;
A58-B100;	A58-B101;	A58-B102;	A58-B103;	A58-B104;	A58-B105;
A58-B106;	A58-B107;	A58-B108;	A58-B109;	A58-B110;	A58-B111;
A58-B112;	A58-B113;	A58-B114;	A58-B115;	A58-B116;	A58-B117;

A58-B118;	A58-B119;	A58-B120;	A58-B121;	A58-B122;	A58-B123;
A58-B124;	A58-B125;	A58-B126;	A58-B127;	A58-B128;	A58-B129;
A58-B130;	A58-B131;	A58-B132;	A58-B133;	A58-B134;	A58-B135;
A58-B136;	A58-B137;	A58-B138;	A58-B139;	A58-B140;	A58-B141;
A58-B142;	A58-B143;	A58-B144;	A58-B145;	A58-B146;	A58-B147;
A58-B148;	A58-B149;	A58-B150;	A58-B151;	A58-B152;	A58-B153;
A58-B154;	A58-B155;	A58-B156;	A58-B157;	A58-B158;	A58-B159;
A58-B160;	A58-B161;	A58-B162;	A58-B163;	A58-B164;	A58-B165;
A58-B166;	A58-B167;	A58-B168;	A58-B169;	A59-B1;	A59-B2;
A59-B3;	A59-B4;	A59-B5;	A59-B6;	A59-B7;	A59-B8;
A59-B9;	A59-B10;	A59-B11;	A59-B12;	A59-B13;	A59-B14;
A59-B15;	A59-B16;	A59-B17;	A59-B18;	A59-B19;	A59-B20;
A59-B21;	A59-B22;	A59-B23;	A59-B24;	A59-B25;	A59-B26;
A59-B27;	A59-B28;	A59-B29;	A59-B30;	A59-B31;	A59-B32;
A59-B33;	A59-B34;	A59-B35;	A59-B36;	A59-B37;	A59-B38;
A59-B39;	A59-B40;	A59-B41;	A59-B42;	A59-B43;	A59-B44;
A59-B45;	A59-B46;	A59-B47;	A59-B48;	A59-B49;	A59-B50;
A59-B51;	A59-B52;	A59-B53;	A59-B54;	A59-B55;	A59-B56;
A59-B57;	A59-B58;	A59-B59;	A59-B60;	A59-B61;	A59-B62;
A59-B63;	A59-B64;	A59-B65;	A59-B66;	A59-B67;	A59-B68;
A59-B69;	A59-B70;	A59-B71;	A59-B72;	A59-B73;	A59-B74;
A59-B75;	A59-B76;	A59-B77;	A59-B78;	A59-B79;	A59-B80;
A59-B81;	A59-B82;	A59-B83;	A59-B84;	A59-B85;	A59-B86;
A59-B87;	A59-B88;	A59-B89;	A59-B90;	A59-B91;	A59-B92;
A59-B93;	A59-B94;	A59-B95;	A59-B96;	A59-B97;	A59-B98;
A59-B99;	A59-B100;	A59-B101;	A59-B102;	A59-B103;	A59-B104;
A59-B105;	A59-B106;	A59-B107;	A59-B108;	A59-B109;	A59-B110;
A59-B111;	A59-B112;	A59-B113;	A59-B114;	A59-B115;	A59-B116;
A59-B117;	A59-B118;	A59-B119;	A59-B120;	A59-B121;	A59-B122;
A59-B123;	A59-B124;	A59-B125;	A59-B126;	A59-B127;	A59-B128;
A59-B129;	A59-B130;	A59-B131;	A59-B132;	A59-B133;	A59-B134;
A59-B135;	A59-B136;	A59-B137;	A59-B138;	A59-B139;	A59-B140;
A59-B141;	A59-B142;	A59-B143;	A59-B144;	A59-B145;	A59-B146;
A59-B147;	A59-B148;	A59-B149;	A59-B150;	A59-B151;	A59-B152;
A59-B153;	A59-B154;	A59-B155;	A59-B156;	A59-B157;	A59-B158;

A59-B159;	A59-B160;	A59-B161;	A59-B162;	A59-B163;	A59-B164;
A59-B165;	A59-B166;	A59-B167;	A59-B168;	A59-B169;	A60-B1;
A60-B2;	A60-B3;	A60-B4;	A60-B5;	A60-B6;	A60-B7;
A60-B8;	A60-B9;	A60-B10;	A60-B11;	A60-B12;	A60-B13;
A60-B14;	A60-B15;	A60-B16;	A60-B17;	A60-B18;	A60-B19;
A60-B20;	A60-B21;	A60-B22;	A60-B23;	A60-B24;	A60-B25;
A60-B26;	A60-B27;	A60-B28;	A60-B29;	A60-B30;	A60-B31;
A60-B32;	A60-B33;	A60-B34;	A60-B35;	A60-B36;	A60-B37;
A60-B38;	A60-B39;	A60-B40;	A60-B41;	A60-B42;	A60-B43;
A60-B44;	A60-B45;	A60-B46;	A60-B47;	A60-B48;	A60-B49;
A60-B50;	A60-B51;	A60-B52;	A60-B53;	A60-B54;	A60-B55;
A60-B56;	A60-B57;	A60-B58;	A60-B59;	A60-B60;	A60-B61;
A60-B62;	A60-B63;	A60-B64;	A60-B65;	A60-B66;	A60-B67;
A60-B68;	A60-B69;	A60-B70;	A60-B71;	A60-B72;	A60-B73;
A60-B74;	A60-B75;	A60-B76;	A60-B77;	A60-B78;	A60-B79;
A60-B80;	A60-B81;	A60-B82;	A60-B83;	A60-B84;	A60-B85;
A60-B86;	A60-B87;	A60-B88;	A60-B89;	A60-B90;	A60-B91;
A60-B92;	A60-B93;	A60-B94;	A60-B95;	A60-B96;	A60-B97;
A60-B98;	A60-B99;	A60-B100;	A60-B101;	A60-B102;	A60-B103;
A60-B104;	A60-B105;	A60-B106;	A60-B107;	A60-B108;	A60-B109;
A60-B110;	A60-B111;	A60-B112;	A60-B113;	A60-B114;	A60-B115;
A60-B116;	A60-B117;	A60-B118;	A60-B119;	A60-B120;	A60-B121;
A60-B122;	A60-B123;	A60-B124;	A60-B125;	A60-B126;	A60-B127;
A60-B128;	A60-B129;	A60-B130;	A60-B131;	A60-B132;	A60-B133;
A60-B134;	A60-B135;	A60-B136;	A60-B137;	A60-B138;	A60-B139;
A60-B140;	A60-B141;	A60-B142;	A60-B143;	A60-B144;	A60-B145;
A60-B146;	A60-B147;	A60-B148;	A60-B149;	A60-B150;	A60-B151;
A60-B152;	A60-B153;	A60-B154;	A60-B155;	A60-B156;	A60-B157;
A60-B158;	A60-B159;	A60-B160;	A60-B161;	A60-B162;	A60-B163;
A60-B164;	A60-B165;	A60-B166;	A60-B167;	A60-B168;	A60-B169;
A61-B1;	A61-B2;	A61-B3;	A61-B4;	A61-B5;	A61-B6;
A61-B7;	A61-B8;	A61-B9;	A61-B10;	A61-B11;	A61-B12;
A61-B13;	A61-B14;	A61-B15;	A61-B16;	A61-B17;	A61-B18;
A61-B19;	A61-B20;	A61-B21;	A61-B22;	A61-B23;	A61-B24;
A61-B25;	A61-B26;	A61-B27;	A61-B28;	A61-B29;	A61-B30;

A61-B31;	A61-B32;	A61-B33;	A61-B34;	A61-B35;	A61-B36;
A61-B37;	A61-B38;	A61-B39;	A61-B40;	A61-B41;	A61-B42;
A61-B43;	A61-B44;	A61-B45;	A61-B46;	A61-B47;	A61-B48;
A61-B49;	A61-B50;	A61-B51;	A61-B52;	A61-B53;	A61-B54;
A61-B55;	A61-B56;	A61-B57;	A61-B58;	A61-B59;	A61-B60;
A61-B61;	A61-B62;	A61-B63;	A61-B64;	A61-B65;	A61-B66;
A61-B67;	A61-B68;	A61-B69;	A61-B70;	A61-B71;	A61-B72;
A61-B73;	A61-B74;	A61-B75;	A61-B76;	A61-B77;	A61-B78;
A61-B79;	A61-B80;	A61-B81;	A61-B82;	A61-B83;	A61-B84;
A61-B85;	A61-B86;	A61-B87;	A61-B88;	A61-B89;	A61-B90;
A61-B91;	A61-B92;	A61-B93;	A61-B94;	A61-B95;	A61-B96;
A61-B97;	A61-B98;	A61-B99;	A61-B100;	A61-B101;	A61-B102;
A61-B103;	A61-B104;	A61-B105;	A61-B106;	A61-B107;	A61-B108;
A61-B109;	A61-B110;	A61-B111;	A61-B112;	A61-B113;	A61-B114;
A61-B115;	A61-B116;	A61-B117;	A61-B118;	A61-B119;	A61-B120;
A61-B121;	A61-B122;	A61-B123;	A61-B124;	A61-B125;	A61-B126;
A61-B127;	A61-B128;	A61-B129;	A61-B130;	A61-B131;	A61-B132;
A61-B133;	A61-B134;	A61-B135;	A61-B136;	A61-B137;	A61-B138;
A61-B139;	A61-B140;	A61-B141;	A61-B142;	A61-B143;	A61-B144;
A61-B145;	A61-B146;	A61-B147;	A61-B148;	A61-B149;	A61-B150;
A61-B151;	A61-B152;	A61-B153;	A61-B154;	A61-B155;	A61-B156;
A61-B157;	A61-B158;	A61-B159;	A61-B160;	A61-B161;	A61-B162;
A61-B163;	A61-B164;	A61-B165;	A61-B166;	A61-B167;	A61-B168;
A61-B169;	A62-B1;	A62-B2;	A62-B3;	A62-B4;	A62-B5;
A62-B6;	A62-B7;	A62-B8;	A62-B9;	A62-B10;	A62-B11;
A62-B12;	A62-B13;	A62-B14;	A62-B15;	A62-B16;	A62-B17;
A62-B18;	A62-B19;	A62-B20;	A62-B21;	A62-B22;	A62-B23;
A62-B24;	A62-B25;	A62-B26;	A62-B27;	A62-B28;	A62-B29;
A62-B30;	A62-B31;	A62-B32;	A62-B33;	A62-B34;	A62-B35;
A62-B36;	A62-B37;	A62-B38;	A62-B39;	A62-B40;	A62-B41;
A62-B42;	A62-B43;	A62-B44;	A62-B45;	A62-B46;	A62-B47;
A62-B48;	A62-B49;	A62-B50;	A62-B51;	A62-B52;	A62-B53;
A62-B54;	A62-B55;	A62-B56;	A62-B57;	A62-B58;	A62-B59;
A62-B60;	A62-B61;	A62-B62;	A62-B63;	A62-B64;	A62-B65;
A62-B66;	A62-B67;	A62-B68;	A62-B69;	A62-B70;	A62-B71;

A62-B72;	A62-B73;	A62-B74;	A62-B75;	A62-B76;	A62-B77;
A62-B78;	A62-B79;	A62-B80;	A62-B81;	A62-B82;	A62-B83;
A62-B84;	A62-B85;	A62-B86;	A62-B87;	A62-B88;	A62-B89;
A62-B90;	A62-B91;	A62-B92;	A62-B93;	A62-B94;	A62-B95;
A62-B96;	A62-B97;	A62-B98;	A62-B99;	A62-B100;	A62-B101;
A62-B102;	A62-B103;	A62-B104;	A62-B105;	A62-B106;	A62-B107;
A62-B108;	A62-B109;	A62-B110;	A62-B111;	A62-B112;	A62-B113;
A62-B114;	A62-B115;	A62-B116;	A62-B117;	A62-B118;	A62-B119;
A62-B120;	A62-B121;	A62-B122;	A62-B123;	A62-B124;	A62-B125;
A62-B126;	A62-B127;	A62-B128;	A62-B129;	A62-B130;	A62-B131;
A62-B132;	A62-B133;	A62-B134;	A62-B135;	A62-B136;	A62-B137;
A62-B138;	A62-B139;	A62-B140;	A62-B141;	A62-B142;	A62-B143;
A62-B144;	A62-B145;	A62-B146;	A62-B147;	A62-B148;	A62-B149;
A62-B150;	A62-B151;	A62-B152;	A62-B153;	A62-B154;	A62-B155;
A62-B156;	A62-B157;	A62-B158;	A62-B159;	A62-B160;	A62-B161;
A62-B162;	A62-B163;	A62-B164;	A62-B165;	A62-B166;	A62-B167;
A62-B168;	A62-B169;	A63-B1;	A63-B2;	A63-B3;	A63-B4;
A63-B5;	A63-B6;	A63-B7;	A63-B8;	A63-B9;	A63-B10;
A63-B11;	A63-B12;	A63-B13;	A63-B14;	A63-B15;	A63-B16;
A63-B17;	A63-B18;	A63-B19;	A63-B20;	A63-B21;	A63-B22;
A63-B23;	A63-B24;	A63-B25;	A63-B26;	A63-B27;	A63-B28;
A63-B29;	A63-B30;	A63-B31;	A63-B32;	A63-B33;	A63-B34;
A63-B35;	A63-B36;	A63-B37;	A63-B38;	A63-B39;	A63-B40;
A63-B41;	A63-B42;	A63-B43;	A63-B44;	A63-B45;	A63-B46;
A63-B47;	A63-B48;	A63-B49;	A63-B50;	A63-B51;	A63-B52;
A63-B53;	A63-B54;	A63-B55;	A63-B56;	A63-B57;	A63-B58;
A63-B59;	A63-B60;	A63-B61;	A63-B62;	A63-B63;	A63-B64;
A63-B65;	A63-B66;	A63-B67;	A63-B68;	A63-B69;	A63-B70;
A63-B71;	A63-B72;	A63-B73;	A63-B74;	A63-B75;	A63-B76;
A63-B77;	A63-B78;	A63-B79;	A63-B80;	A63-B81;	A63-B82;
A63-B83;	A63-B84;	A63-B85;	A63-B86;	A63-B87;	A63-B88;
A63-B89;	A63-B90;	A63-B91;	A63-B92;	A63-B93;	A63-B94;
A63-B95;	A63-B96;	A63-B97;	A63-B98;	A63-B99;	A63-B100;
A63-B101;	A63-B102;	A63-B103;	A63-B104;	A63-B105;	A63-B106;
A63-B107;	A63-B108;	A63-B109;	A63-B110;	A63-B111;	A63-B112;

A63-B113;	A63-B114;	A63-B115;	A63-B116;	A63-B117;	A63-B118;
A63-B119;	A63-B120;	A63-B121;	A63-B122;	A63-B123;	A63-B124;
A63-B125;	A63-B126;	A63-B127;	A63-B128;	A63-B129;	A63-B130;
A63-B131;	A63-B132;	A63-B133;	A63-B134;	A63-B135;	A63-B136;
A63-B137;	A63-B138;	A63-B139;	A63-B140;	A63-B141;	A63-B142;
A63-B143;	A63-B144;	A63-B145;	A63-B146;	A63-B147;	A63-B148;
A63-B149;	A63-B150;	A63-B151;	A63-B152;	A63-B153;	A63-B154;
A63-B155;	A63-B156;	A63-B157;	A63-B158;	A63-B159;	A63-B160;
A63-B161;	A63-B162;	A63-B163;	A63-B164;	A63-B165;	A63-B166;
A63-B167;	A63-B168;	A63-B169;	A64-B1;	A64-B2;	A64-B3;
A64-B4;	A64-B5;	A64-B6;	A64-B7;	A64-B8;	A64-B9;
A64-B10;	A64-B11;	A64-B12;	A64-B13;	A64-B14;	A64-B15;
A64-B16;	A64-B17;	A64-B18;	A64-B19;	A64-B20;	A64-B21;
A64-B22;	A64-B23;	A64-B24;	A64-B25;	A64-B26;	A64-B27;
A64-B28;	A64-B29;	A64-B30;	A64-B31;	A64-B32;	A64-B33;
A64-B34;	A64-B35;	A64-B36;	A64-B37;	A64-B38;	A64-B39;
A64-B40;	A64-B41;	A64-B42;	A64-B43;	A64-B44;	A64-B45;
A64-B46;	A64-B47;	A64-B48;	A64-B49;	A64-B50;	A64-B51;
A64-B52;	A64-B53;	A64-B54;	A64-B55;	A64-B56;	A64-B57;
A64-B58;	A64-B59;	A64-B60;	A64-B61;	A64-B62;	A64-B63;
A64-B64;	A64-B65;	A64-B66;	A64-B67;	A64-B68;	A64-B69;
A64-B70;	A64-B71;	A64-B72;	A64-B73;	A64-B74;	A64-B75;
A64-B76;	A64-B77;	A64-B78;	A64-B79;	A64-B80;	A64-B81;
A64-B82;	A64-B83;	A64-B84;	A64-B85;	A64-B86;	A64-B87;
A64-B88;	A64-B89;	A64-B90;	A64-B91;	A64-B92;	A64-B93;
A64-B94;	A64-B95;	A64-B96;	A64-B97;	A64-B98;	A64-B99;
A64-B100;	A64-B101;	A64-B102;	A64-B103;	A64-B104;	A64-B105;
A64-B106;	A64-B107;	A64-B108;	A64-B109;	A64-B110;	A64-B111;
A64-B112;	A64-B113;	A64-B114;	A64-B115;	A64-B116;	A64-B117;
A64-B118;	A64-B119;	A64-B120;	A64-B121;	A64-B122;	A64-B123;
A64-B124;	A64-B125;	A64-B126;	A64-B127;	A64-B128;	A64-B129;
A64-B130;	A64-B131;	A64-B132;	A64-B133;	A64-B134;	A64-B135;
A64-B136;	A64-B137;	A64-B138;	A64-B139;	A64-B140;	A64-B141;
A64-B142;	A64-B143;	A64-B144;	A64-B145;	A64-B146;	A64-B147;
A64-B148;	A64-B149;	A64-B150;	A64-B151;	A64-B152;	A64-B153;

A64-B154;	A64-B155;	A64-B156;	A64-B157;	A64-B158;	A64-B159;
A64-B160;	A64-B161;	A64-B162;	A64-B163;	A64-B164;	A64-B165;
A64-B166;	A64-B167;	A64-B168;	A64-B169;	A65-B1;	A65-B2;
A65-B3;	A65-B4;	A65-B5;	A65-B6;	A65-B7;	A65-B8;
A65-B9;	A65-B10;	A65-B11;	A65-B12;	A65-B13;	A65-B14;
A65-B15;	A65-B16;	A65-B17;	A65-B18;	A65-B19;	A65-B20;
A65-B21;	A65-B22;	A65-B23;	A65-B24;	A65-B25;	A65-B26;
A65-B27;	A65-B28;	A65-B29;	A65-B30;	A65-B31;	A65-B32;
A65-B33;	A65-B34;	A65-B35;	A65-B36;	A65-B37;	A65-B38;
A65-B39;	A65-B40;	A65-B41;	A65-B42;	A65-B43;	A65-B44;
A65-B45;	A65-B46;	A65-B47;	A65-B48;	A65-B49;	A65-B50;
A65-B51;	A65-B52;	A65-B53;	A65-B54;	A65-B55;	A65-B56;
A65-B57;	A65-B58;	A65-B59;	A65-B60;	A65-B61;	A65-B62;
A65-B63;	A65-B64;	A65-B65;	A65-B66;	A65-B67;	A65-B68;
A65-B69;	A65-B70;	A65-B71;	A65-B72;	A65-B73;	A65-B74;
A65-B75;	A65-B76;	A65-B77;	A65-B78;	A65-B79;	A65-B80;
A65-B81;	A65-B82;	A65-B83;	A65-B84;	A65-B85;	A65-B86;
A65-B87;	A65-B88;	A65-B89;	A65-B90;	A65-B91;	A65-B92;
A65-B93;	A65-B94;	A65-B95;	A65-B96;	A65-B97;	A65-B98;
A65-B99;	A65-B100;	A65-B101;	A65-B102;	A65-B103;	A65-B104;
A65-B105;	A65-B106;	A65-B107;	A65-B108;	A65-B109;	A65-B110;
A65-B111;	A65-B112;	A65-B113;	A65-B114;	A65-B115;	A65-B116;
A65-B117;	A65-B118;	A65-B119;	A65-B120;	A65-B121;	A65-B122;
A65-B123;	A65-B124;	A65-B125;	A65-B126;	A65-B127;	A65-B128;
A65-B129;	A65-B130;	A65-B131;	A65-B132;	A65-B133;	A65-B134;
A65-B135;	A65-B136;	A65-B137;	A65-B138;	A65-B139;	A65-B140;
A65-B141;	A65-B142;	A65-B143;	A65-B144;	A65-B145;	A65-B146;
A65-B147;	A65-B148;	A65-B149;	A65-B150;	A65-B151;	A65-B152;
A65-B153;	A65-B154;	A65-B155;	A65-B156;	A65-B157;	A65-B158;
A65-B159;	A65-B160;	A65-B161;	A65-B162;	A65-B163;	A65-B164;
A65-B165;	A65-B166;	A65-B167;	A65-B168;	A65-B169;	A66-B1;
A66-B2;	A66-B3;	A66-B4;	A66-B5;	A66-B6;	A66-B7;
A66-B8;	A66-B9;	A66-B10;	A66-B11;	A66-B12;	A66-B13;
A66-B14;	A66-B15;	A66-B16;	A66-B17;	A66-B18;	A66-B19;
A66-B20;	A66-B21;	A66-B22;	A66-B23;	A66-B24;	A66-B25;

A66-B26;	A66-B27;	A66-B28;	A66-B29;	A66-B30;	A66-B31;
A66-B32;	A66-B33;	A66-B34;	A66-B35;	A66-B36;	A66-B37;
A66-B38;	A66-B39;	A66-B40;	A66-B41;	A66-B42;	A66-B43;
A66-B44;	A66-B45;	A66-B46;	A66-B47;	A66-B48;	A66-B49;
A66-B50;	A66-B51;	A66-B52;	A66-B53;	A66-B54;	A66-B55;
A66-B56;	A66-B57;	A66-B58;	A66-B59;	A66-B60;	A66-B61;
A66-B62;	A66-B63;	A66-B64;	A66-B65;	A66-B66;	A66-B67;
A66-B68;	A66-B69;	A66-B70;	A66-B71;	A66-B72;	A66-B73;
A66-B74;	A66-B75;	A66-B76;	A66-B77;	A66-B78;	A66-B79;
A66-B80;	A66-B81;	A66-B82;	A66-B83;	A66-B84;	A66-B85;
A66-B86;	A66-B87;	A66-B88;	A66-B89;	A66-B90;	A66-B91;
A66-B92;	A66-B93;	A66-B94;	A66-B95;	A66-B96;	A66-B97;
A66-B98;	A66-B99;	A66-B100;	A66-B101;	A66-B102;	A66-B103;
A66-B104;	A66-B105;	A66-B106;	A66-B107;	A66-B108;	A66-B109;
A66-B110;	A66-B111;	A66-B112;	A66-B113;	A66-B114;	A66-B115;
A66-B116;	A66-B117;	A66-B118;	A66-B119;	A66-B120;	A66-B121;
A66-B122;	A66-B123;	A66-B124;	A66-B125;	A66-B126;	A66-B127;
A66-B128;	A66-B129;	A66-B130;	A66-B131;	A66-B132;	A66-B133;
A66-B134;	A66-B135;	A66-B136;	A66-B137;	A66-B138;	A66-B139;
A66-B140;	A66-B141;	A66-B142;	A66-B143;	A66-B144;	A66-B145;
A66-B146;	A66-B147;	A66-B148;	A66-B149;	A66-B150;	A66-B151;
A66-B152;	A66-B153;	A66-B154;	A66-B155;	A66-B156;	A66-B157;
A66-B158;	A66-B159;	A66-B160;	A66-B161;	A66-B162;	A66-B163;
A66-B164;	A66-B165;	A66-B166;	A66-B167;	A66-B168;	A66-B169;
A67-B1;	A67-B2;	A67-B3;	A67-B4;	A67-B5;	A67-B6;
A67-B7;	A67-B8;	A67-B9;	A67-B10;	A67-B11;	A67-B12;
A67-B13;	A67-B14;	A67-B15;	A67-B16;	A67-B17;	A67-B18;
A67-B19;	A67-B20;	A67-B21;	A67-B22;	A67-B23;	A67-B24;
A67-B25;	A67-B26;	A67-B27;	A67-B28;	A67-B29;	A67-B30;
A67-B31;	A67-B32;	A67-B33;	A67-B34;	A67-B35;	A67-B36;
A67-B37;	A67-B38;	A67-B39;	A67-B40;	A67-B41;	A67-B42;
A67-B43;	A67-B44;	A67-B45;	A67-B46;	A67-B47;	A67-B48;
A67-B49;	A67-B50;	A67-B51;	A67-B52;	A67-B53;	A67-B54;
A67-B55;	A67-B56;	A67-B57;	A67-B58;	A67-B59;	A67-B60;
A67-B61;	A67-B62;	A67-B63;	A67-B64;	A67-B65;	A67-B66;

A67-B67;	A67-B68;	A67-B69;	A67-B70;	A67-B71;	A67-B72;
A67-B73;	A67-B74;	A67-B75;	A67-B76;	A67-B77;	A67-B78;
A67-B79;	A67-B80;	A67-B81;	A67-B82;	A67-B83;	A67-B84;
A67-B85;	A67-B86;	A67-B87;	A67-B88;	A67-B89;	A67-B90;
A67-B91;	A67-B92;	A67-B93;	A67-B94;	A67-B95;	A67-B96;
A67-B97;	A67-B98;	A67-B99;	A67-B100;	A67-B101;	A67-B102;
A67-B103;	A67-B104;	A67-B105;	A67-B106;	A67-B107;	A67-B108;
A67-B109;	A67-B110;	A67-B111;	A67-B112;	A67-B113;	A67-B114;
A67-B115;	A67-B116;	A67-B117;	A67-B118;	A67-B119;	A67-B120;
A67-B121;	A67-B122;	A67-B123;	A67-B124;	A67-B125;	A67-B126;
A67-B127;	A67-B128;	A67-B129;	A67-B130;	A67-B131;	A67-B132;
A67-B133;	A67-B134;	A67-B135;	A67-B136;	A67-B137;	A67-B138;
A67-B139;	A67-B140;	A67-B141;	A67-B142;	A67-B143;	A67-B144;
A67-B145;	A67-B146;	A67-B147;	A67-B148;	A67-B149;	A67-B150;
A67-B151;	A67-B152;	A67-B153;	A67-B154;	A67-B155;	A67-B156;
A67-B157;	A67-B158;	A67-B159;	A67-B160;	A67-B161;	A67-B162;
A67-B163;	A67-B164;	A67-B165;	A67-B166;	A67-B167;	A67-B168;
A67-B169;	A68-B1;	A68-B2;	A68-B3;	A68-B4;	A68-B5;
A68-B6;	A68-B7;	A68-B8;	A68-B9;	A68-B10;	A68-B11;
A68-B12;	A68-B13;	A68-B14;	A68-B15;	A68-B16;	A68-B17;
A68-B18;	A68-B19;	A68-B20;	A68-B21;	A68-B22;	A68-B23;
A68-B24;	A68-B25;	A68-B26;	A68-B27;	A68-B28;	A68-B29;
A68-B30;	A68-B31;	A68-B32;	A68-B33;	A68-B34;	A68-B35;
A68-B36;	A68-B37;	A68-B38;	A68-B39;	A68-B40;	A68-B41;
A68-B42;	A68-B43;	A68-B44;	A68-B45;	A68-B46;	A68-B47;
A68-B48;	A68-B49;	A68-B50;	A68-B51;	A68-B52;	A68-B53;
A68-B54;	A68-B55;	A68-B56;	A68-B57;	A68-B58;	A68-B59;
A68-B60;	A68-B61;	A68-B62;	A68-B63;	A68-B64;	A68-B65;
A68-B66;	A68-B67;	A68-B68;	A68-B69;	A68-B70;	A68-B71;
A68-B72;	A68-B73;	A68-B74;	A68-B75;	A68-B76;	A68-B77;
A68-B78;	A68-B79;	A68-B80;	A68-B81;	A68-B82;	A68-B83;
A68-B84;	A68-B85;	A68-B86;	A68-B87;	A68-B88;	A68-B89;
A68-B90;	A68-B91;	A68-B92;	A68-B93;	A68-B94;	A68-B95;
A68-B96;	A68-B97;	A68-B98;	A68-B99;	A68-B100;	A68-B101;
A68-B102;	A68-B103;	A68-B104;	A68-B105;	A68-B106;	A68-B107;

A68-B108;	A68-B109;	A68-B110;	A68-B111;	A68-B112;	A68-B113;
A68-B114;	A68-B115;	A68-B116;	A68-B117;	A68-B118;	A68-B119;
A68-B120;	A68-B121;	A68-B122;	A68-B123;	A68-B124;	A68-B125;
A68-B126;	A68-B127;	A68-B128;	A68-B129;	A68-B130;	A68-B131;
A68-B132;	A68-B133;	A68-B134;	A68-B135;	A68-B136;	A68-B137;
A68-B138;	A68-B139;	A68-B140;	A68-B141;	A68-B142;	A68-B143;
A68-B144;	A68-B145;	A68-B146;	A68-B147;	A68-B148;	A68-B149;
A68-B150;	A68-B151;	A68-B152;	A68-B153;	A68-B154;	A68-B155;
A68-B156;	A68-B157;	A68-B158;	A68-B159;	A68-B160;	A68-B161;
A68-B162;	A68-B163;	A68-B164;	A68-B165;	A68-B166;	A68-B167;
A68-B168;	A68-B169;	A69-B1;	A69-B2;	A69-B3;	A69-B4;
A69-B5;	A69-B6;	A69-B7;	A69-B8;	A69-B9;	A69-B10;
A69-B11;	A69-B12;	A69-B13;	A69-B14;	A69-B15;	A69-B16;
A69-B17;	A69-B18;	A69-B19;	A69-B20;	A69-B21;	A69-B22;
A69-B23;	A69-B24;	A69-B25;	A69-B26;	A69-B27;	A69-B28;
A69-B29;	A69-B30;	A69-B31;	A69-B32;	A69-B33;	A69-B34;
A69-B35;	A69-B36;	A69-B37;	A69-B38;	A69-B39;	A69-B40;
A69-B41;	A69-B42;	A69-B43;	A69-B44;	A69-B45;	A69-B46;
A69-B47;	A69-B48;	A69-B49;	A69-B50;	A69-B51;	A69-B52;
A69-B53;	A69-B54;	A69-B55;	A69-B56;	A69-B57;	A69-B58;
A69-B59;	A69-B60;	A69-B61;	A69-B62;	A69-B63;	A69-B64;
A69-B65;	A69-B66;	A69-B67;	A69-B68;	A69-B69;	A69-B70;
A69-B71;	A69-B72;	A69-B73;	A69-B74;	A69-B75;	A69-B76;
A69-B77;	A69-B78;	A69-B79;	A69-B80;	A69-B81;	A69-B82;
A69-B83;	A69-B84;	A69-B85;	A69-B86;	A69-B87;	A69-B88;
A69-B89;	A69-B90;	A69-B91;	A69-B92;	A69-B93;	A69-B94;
A69-B95;	A69-B96;	A69-B97;	A69-B98;	A69-B99;	A69-B100;
A69-B101;	A69-B102;	A69-B103;	A69-B104;	A69-B105;	A69-B106;
A69-B107;	A69-B108;	A69-B109;	A69-B110;	A69-B111;	A69-B112;
A69-B113;	A69-B114;	A69-B115;	A69-B116;	A69-B117;	A69-B118;
A69-B119;	A69-B120;	A69-B121;	A69-B122;	A69-B123;	A69-B124;
A69-B125;	A69-B126;	A69-B127;	A69-B128;	A69-B129;	A69-B130;
A69-B131;	A69-B132;	A69-B133;	A69-B134;	A69-B135;	A69-B136;
A69-B137;	A69-B138;	A69-B139;	A69-B140;	A69-B141;	A69-B142;
A69-B143;	A69-B144;	A69-B145;	A69-B146;	A69-B147;	A69-B148;

A69-B149;	A69-B150;	A69-B151;	A69-B152;	A69-B153;	A69-B154;
A69-B155;	A69-B156;	A69-B157;	A69-B158;	A69-B159;	A69-B160;
A69-B161;	A69-B162;	A69-B163;	A69-B164;	A69-B165;	A69-B166;
A69-B167;	A69-B168;	A69-B169;	A70-B1;	A70-B2;	A70-B3;
A70-B4;	A70-B5;	A70-B6;	A70-B7;	A70-B8;	A70-B9;
A70-B10;	A70-B11;	A70-B12;	A70-B13;	A70-B14;	A70-B15;
A70-B16;	A70-B17;	A70-B18;	A70-B19;	A70-B20;	A70-B21;
A70-B22;	A70-B23;	A70-B24;	A70-B25;	A70-B26;	A70-B27;
A70-B28;	A70-B29;	A70-B30;	A70-B31;	A70-B32;	A70-B33;
A70-B34;	A70-B35;	A70-B36;	A70-B37;	A70-B38;	A70-B39;
A70-B40;	A70-B41;	A70-B42;	A70-B43;	A70-B44;	A70-B45;
A70-B46;	A70-B47;	A70-B48;	A70-B49;	A70-B50;	A70-B51;
A70-B52;	A70-B53;	A70-B54;	A70-B55;	A70-B56;	A70-B57;
A70-B58;	A70-B59;	A70-B60;	A70-B61;	A70-B62;	A70-B63;
A70-B64;	A70-B65;	A70-B66;	A70-B67;	A70-B68;	A70-B69;
A70-B70;	A70-B71;	A70-B72;	A70-B73;	A70-B74;	A70-B75;
A70-B76;	A70-B77;	A70-B78;	A70-B79;	A70-B80;	A70-B81;
A70-B82;	A70-B83;	A70-B84;	A70-B85;	A70-B86;	A70-B87;
A70-B88;	A70-B89;	A70-B90;	A70-B91;	A70-B92;	A70-B93;
A70-B94;	A70-B95;	A70-B96;	A70-B97;	A70-B98;	A70-B99;
A70-B100;	A70-B101;	A70-B102;	A70-B103;	A70-B104;	A70-B105;
A70-B106;	A70-B107;	A70-B108;	A70-B109;	A70-B110;	A70-B111;
A70-B112;	A70-B113;	A70-B114;	A70-B115;	A70-B116;	A70-B117;
A70-B118;	A70-B119;	A70-B120;	A70-B121;	A70-B122;	A70-B123;
A70-B124;	A70-B125;	A70-B126;	A70-B127;	A70-B128;	A70-B129;
A70-B130;	A70-B131;	A70-B132;	A70-B133;	A70-B134;	A70-B135;
A70-B136;	A70-B137;	A70-B138;	A70-B139;	A70-B140;	A70-B141;
A70-B142;	A70-B143;	A70-B144;	A70-B145;	A70-B146;	A70-B147;
A70-B148;	A70-B149;	A70-B150;	A70-B151;	A70-B152;	A70-B153;
A70-B154;	A70-B155;	A70-B156;	A70-B157;	A70-B158;	A70-B159;
A70-B160;	A70-B161;	A70-B162;	A70-B163;	A70-B164;	A70-B165;
A70-B166;	A70-B167;	A70-B168;	A70-B169;	A71-B1;	A71-B2;
A71-B3;	A71-B4;	A71-B5;	A71-B6;	A71-B7;	A71-B8;
A71-B9;	A71-B10;	A71-B11;	A71-B12;	A71-B13;	A71-B14;
A71-B15;	A71-B16;	A71-B17;	A71-B18;	A71-B19;	A71-B20;

A71-B21;	A71-B22;	A71-B23;	A71-B24;	A71-B25;	A71-B26;
A71-B27;	A71-B28;	A71-B29;	A71-B30;	A71-B31;	A71-B32;
A71-B33;	A71-B34;	A71-B35;	A71-B36;	A71-B37;	A71-B38;
A71-B39;	A71-B40;	A71-B41;	A71-B42;	A71-B43;	A71-B44;
A71-B45;	A71-B46;	A71-B47;	A71-B48;	A71-B49;	A71-B50;
A71-B51;	A71-B52;	A71-B53;	A71-B54;	A71-B55;	A71-B56;
A71-B57;	A71-B58;	A71-B59;	A71-B60;	A71-B61;	A71-B62;
A71-B63;	A71-B64;	A71-B65;	A71-B66;	A71-B67;	A71-B68;
A71-B69;	A71-B70;	A71-B71;	A71-B72;	A71-B73;	A71-B74;
A71-B75;	A71-B76;	A71-B77;	A71-B78;	A71-B79;	A71-B80;
A71-B81;	A71-B82;	A71-B83;	A71-B84;	A71-B85;	A71-B86;
A71-B87;	A71-B88;	A71-B89;	A71-B90;	A71-B91;	A71-B92;
A71-B93;	A71-B94;	A71-B95;	A71-B96;	A71-B97;	A71-B98;
A71-B99;	A71-B100;	A71-B101;	A71-B102;	A71-B103;	A71-B104;
A71-B105;	A71-B106;	A71-B107;	A71-B108;	A71-B109;	A71-B110;
A71-B111;	A71-B112;	A71-B113;	A71-B114;	A71-B115;	A71-B116;
A71-B117;	A71-B118;	A71-B119;	A71-B120;	A71-B121;	A71-B122;
A71-B123;	A71-B124;	A71-B125;	A71-B126;	A71-B127;	A71-B128;
A71-B129;	A71-B130;	A71-B131;	A71-B132;	A71-B133;	A71-B134;
A71-B135;	A71-B136;	A71-B137;	A71-B138;	A71-B139;	A71-B140;
A71-B141;	A71-B142;	A71-B143;	A71-B144;	A71-B145;	A71-B146;
A71-B147;	A71-B148;	A71-B149;	A71-B150;	A71-B151;	A71-B152;
A71-B153;	A71-B154;	A71-B155;	A71-B156;	A71-B157;	A71-B158;
A71-B159;	A71-B160;	A71-B161;	A71-B162;	A71-B163;	A71-B164;
A71-B165;	A71-B166;	A71-B167;	A71-B168;	A71-B169;	A72-B1;
A72-B2;	A72-B3;	A72-B4;	A72-B5;	A72-B6;	A72-B7;
A72-B8;	A72-B9;	A72-B10;	A72-B11;	A72-B12;	A72-B13;
A72-B14;	A72-B15;	A72-B16;	A72-B17;	A72-B18;	A72-B19;
A72-B20;	A72-B21;	A72-B22;	A72-B23;	A72-B24;	A72-B25;
A72-B26;	A72-B27;	A72-B28;	A72-B29;	A72-B30;	A72-B31;
A72-B32;	A72-B33;	A72-B34;	A72-B35;	A72-B36;	A72-B37;
A72-B38;	A72-B39;	A72-B40;	A72-B41;	A72-B42;	A72-B43;
A72-B44;	A72-B45;	A72-B46;	A72-B47;	A72-B48;	A72-B49;
A72-B50;	A72-B51;	A72-B52;	A72-B53;	A72-B54;	A72-B55;
A72-B56;	A72-B57;	A72-B58;	A72-B59;	A72-B60;	A72-B61;

A72-B62;	A72-B63;	A72-B64;	A72-B65;	A72-B66;	A72-B67;
A72-B68;	A72-B69;	A72-B70;	A72-B71;	A72-B72;	A72-B73;
A72-B74;	A72-B75;	A72-B76;	A72-B77;	A72-B78;	A72-B79;
A72-B80;	A72-B81;	A72-B82;	A72-B83;	A72-B84;	A72-B85;
A72-B86;	A72-B87;	A72-B88;	A72-B89;	A72-B90;	A72-B91;
A72-B92;	A72-B93;	A72-B94;	A72-B95;	A72-B96;	A72-B97;
A72-B98;	A72-B99;	A72-B100;	A72-B101;	A72-B102;	A72-B103;
A72-B104;	A72-B105;	A72-B106;	A72-B107;	A72-B108;	A72-B109;
A72-B110;	A72-B111;	A72-B112;	A72-B113;	A72-B114;	A72-B115;
A72-B116;	A72-B117;	A72-B118;	A72-B119;	A72-B120;	A72-B121;
A72-B122;	A72-B123;	A72-B124;	A72-B125;	A72-B126;	A72-B127;
A72-B128;	A72-B129;	A72-B130;	A72-B131;	A72-B132;	A72-B133;
A72-B134;	A72-B135;	A72-B136;	A72-B137;	A72-B138;	A72-B139;
A72-B140;	A72-B141;	A72-B142;	A72-B143;	A72-B144;	A72-B145;
A72-B146;	A72-B147;	A72-B148;	A72-B149;	A72-B150;	A72-B151;
A72-B152;	A72-B153;	A72-B154;	A72-B155;	A72-B156;	A72-B157;
A72-B158;	A72-B159;	A72-B160;	A72-B161;	A72-B162;	A72-B163;
A72-B164;	A72-B165;	A72-B166;	A72-B167;	A72-B168;	A72-B169;
A73-B1;	A73-B2;	A73-B3;	A73-B4;	A73-B5;	A73-B6;
A73-B7;	A73-B8;	A73-B9;	A73-B10;	A73-B11;	A73-B12;
A73-B13;	A73-B14;	A73-B15;	A73-B16;	A73-B17;	A73-B18;
A73-B19;	A73-B20;	A73-B21;	A73-B22;	A73-B23;	A73-B24;
A73-B25;	A73-B26;	A73-B27;	A73-B28;	A73-B29;	A73-B30;
A73-B31;	A73-B32;	A73-B33;	A73-B34;	A73-B35;	A73-B36;
A73-B37;	A73-B38;	A73-B39;	A73-B40;	A73-B41;	A73-B42;
A73-B43;	A73-B44;	A73-B45;	A73-B46;	A73-B47;	A73-B48;
A73-B49;	A73-B50;	A73-B51;	A73-B52;	A73-B53;	A73-B54;
A73-B55;	A73-B56;	A73-B57;	A73-B58;	A73-B59;	A73-B60;
A73-B61;	A73-B62;	A73-B63;	A73-B64;	A73-B65;	A73-B66;
A73-B67;	A73-B68;	A73-B69;	A73-B70;	A73-B71;	A73-B72;
A73-B73;	A73-B74;	A73-B75;	A73-B76;	A73-B77;	A73-B78;
A73-B79;	A73-B80;	A73-B81;	A73-B82;	A73-B83;	A73-B84;
A73-B85;	A73-B86;	A73-B87;	A73-B88;	A73-B89;	A73-B90;
A73-B91;	A73-B92;	A73-B93;	A73-B94;	A73-B95;	A73-B96;
A73-B97;	A73-B98;	A73-B99;	A73-B100;	A73-B101;	A73-B102;

A73-B103;	A73-B104;	A73-B105;	A73-B106;	A73-B107;	A73-B108;
A73-B109;	A73-B110;	A73-B111;	A73-B112;	A73-B113;	A73-B114;
A73-B115;	A73-B116;	A73-B117;	A73-B118;	A73-B119;	A73-B120;
A73-B121;	A73-B122;	A73-B123;	A73-B124;	A73-B125;	A73-B126;
A73-B127;	A73-B128;	A73-B129;	A73-B130;	A73-B131;	A73-B132;
A73-B133;	A73-B134;	A73-B135;	A73-B136;	A73-B137;	A73-B138;
A73-B139;	A73-B140;	A73-B141;	A73-B142;	A73-B143;	A73-B144;
A73-B145;	A73-B146;	A73-B147;	A73-B148;	A73-B149;	A73-B150;
A73-B151;	A73-B152;	A73-B153;	A73-B154;	A73-B155;	A73-B156;
A73-B157;	A73-B158;	A73-B159;	A73-B160;	A73-B161;	A73-B162;
A73-B163;	A73-B164;	A73-B165;	A73-B166;	A73-B167;	A73-B168;
A73-B169;	A74-B1;	A74-B2;	A74-B3;	A74-B4;	A74-B5;
A74-B6;	A74-B7;	A74-B8;	A74-B9;	A74-B10;	A74-B11;
A74-B12;	A74-B13;	A74-B14;	A74-B15;	A74-B16;	A74-B17;
A74-B18;	A74-B19;	A74-B20;	A74-B21;	A74-B22;	A74-B23;
A74-B24;	A74-B25;	A74-B26;	A74-B27;	A74-B28;	A74-B29;
A74-B30;	A74-B31;	A74-B32;	A74-B33;	A74-B34;	A74-B35;
A74-B36;	A74-B37;	A74-B38;	A74-B39;	A74-B40;	A74-B41;
A74-B42;	A74-B43;	A74-B44;	A74-B45;	A74-B46;	A74-B47;
A74-B48;	A74-B49;	A74-B50;	A74-B51;	A74-B52;	A74-B53;
A74-B54;	A74-B55;	A74-B56;	A74-B57;	A74-B58;	A74-B59;
A74-B60;	A74-B61;	A74-B62;	A74-B63;	A74-B64;	A74-B65;
A74-B66;	A74-B67;	A74-B68;	A74-B69;	A74-B70;	A74-B71;
A74-B72;	A74-B73;	A74-B74;	A74-B75;	A74-B76;	A74-B77;
A74-B78;	A74-B79;	A74-B80;	A74-B81;	A74-B82;	A74-B83;
A74-B84;	A74-B85;	A74-B86;	A74-B87;	A74-B88;	A74-B89;
A74-B90;	A74-B91;	A74-B92;	A74-B93;	A74-B94;	A74-B95;
A74-B96;	A74-B97;	A74-B98;	A74-B99;	A74-B100;	A74-B101;
A74-B102;	A74-B103;	A74-B104;	A74-B105;	A74-B106;	A74-B107;
A74-B108;	A74-B109;	A74-B110;	A74-B111;	A74-B112;	A74-B113;
A74-B114;	A74-B115;	A74-B116;	A74-B117;	A74-B118;	A74-B119;
A74-B120;	A74-B121;	A74-B122;	A74-B123;	A74-B124;	A74-B125;
A74-B126;	A74-B127;	A74-B128;	A74-B129;	A74-B130;	A74-B131;
A74-B132;	A74-B133;	A74-B134;	A74-B135;	A74-B136;	A74-B137;
A74-B138;	A74-B139;	A74-B140;	A74-B141;	A74-B142;	A74-B143;

A74-B144;	A74-B145;	A74-B146;	A74-B147;	A74-B148;	A74-B149;
A74-B150;	A74-B151;	A74-B152;	A74-B153;	A74-B154;	A74-B155;
A74-B156;	A74-B157;	A74-B158;	A74-B159;	A74-B160;	A74-B161;
A74-B162;	A74-B163;	A74-B164;	A74-B165;	A74-B166;	A74-B167;
A74-B168;	A74-B169;	A75-B1;	A75-B2;	A75-B3;	A75-B4;
A75-B5;	A75-B6;	A75-B7;	A75-B8;	A75-B9;	A75-B10;
A75-B11;	A75-B12;	A75-B13;	A75-B14;	A75-B15;	A75-B16;
A75-B17;	A75-B18;	A75-B19;	A75-B20;	A75-B21;	A75-B22;
A75-B23;	A75-B24;	A75-B25;	A75-B26;	A75-B27;	A75-B28;
A75-B29;	A75-B30;	A75-B31;	A75-B32;	A75-B33;	A75-B34;
A75-B35;	A75-B36;	A75-B37;	A75-B38;	A75-B39;	A75-B40;
A75-B41;	A75-B42;	A75-B43;	A75-B44;	A75-B45;	A75-B46;
A75-B47;	A75-B48;	A75-B49;	A75-B50;	A75-B51;	A75-B52;
A75-B53;	A75-B54;	A75-B55;	A75-B56;	A75-B57;	A75-B58;
A75-B59;	A75-B60;	A75-B61;	A75-B62;	A75-B63;	A75-B64;
A75-B65;	A75-B66;	A75-B67;	A75-B68;	A75-B69;	A75-B70;
A75-B71;	A75-B72;	A75-B73;	A75-B74;	A75-B75;	A75-B76;
A75-B77;	A75-B78;	A75-B79;	A75-B80;	A75-B81;	A75-B82;
A75-B83;	A75-B84;	A75-B85;	A75-B86;	A75-B87;	A75-B88;
A75-B89;	A75-B90;	A75-B91;	A75-B92;	A75-B93;	A75-B94;
A75-B95;	A75-B96;	A75-B97;	A75-B98;	A75-B99;	A75-B100;
A75-B101;	A75-B102;	A75-B103;	A75-B104;	A75-B105;	A75-B106;
A75-B107;	A75-B108;	A75-B109;	A75-B110;	A75-B111;	A75-B112;
A75-B113;	A75-B114;	A75-B115;	A75-B116;	A75-B117;	A75-B118;
A75-B119;	A75-B120;	A75-B121;	A75-B122;	A75-B123;	A75-B124;
A75-B125;	A75-B126;	A75-B127;	A75-B128;	A75-B129;	A75-B130;
A75-B131;	A75-B132;	A75-B133;	A75-B134;	A75-B135;	A75-B136;
A75-B137;	A75-B138;	A75-B139;	A75-B140;	A75-B141;	A75-B142;
A75-B143;	A75-B144;	A75-B145;	A75-B146;	A75-B147;	A75-B148;
A75-B149;	A75-B150;	A75-B151;	A75-B152;	A75-B153;	A75-B154;
A75-B155;	A75-B156;	A75-B157;	A75-B158;	A75-B159;	A75-B160;
A75-B161;	A75-B162;	A75-B163;	A75-B164;	A75-B165;	A75-B166;
A75-B167;	A75-B168;	A75-B169;	A76-B1;	A76-B2;	A76-B3;
A76-B4;	A76-B5;	A76-B6;	A76-B7;	A76-B8;	A76-B9;
A76-B10;	A76-B11;	A76-B12;	A76-B13;	A76-B14;	A76-B15;

A76-B16;	A76-B17;	A76-B18;	A76-B19;	A76-B20;	A76-B21;
A76-B22;	A76-B23;	A76-B24;	A76-B25;	A76-B26;	A76-B27;
A76-B28;	A76-B29;	A76-B30;	A76-B31;	A76-B32;	A76-B33;
A76-B34;	A76-B35;	A76-B36;	A76-B37;	A76-B38;	A76-B39;
A76-B40;	A76-B41;	A76-B42;	A76-B43;	A76-B44;	A76-B45;
A76-B46;	A76-B47;	A76-B48;	A76-B49;	A76-B50;	A76-B51;
A76-B52;	A76-B53;	A76-B54;	A76-B55;	A76-B56;	A76-B57;
A76-B58;	A76-B59;	A76-B60;	A76-B61;	A76-B62;	A76-B63;
A76-B64;	A76-B65;	A76-B66;	A76-B67;	A76-B68;	A76-B69;
A76-B70;	A76-B71;	A76-B72;	A76-B73;	A76-B74;	A76-B75;
A76-B76;	A76-B77;	A76-B78;	A76-B79;	A76-B80;	A76-B81;
A76-B82;	A76-B83;	A76-B84;	A76-B85;	A76-B86;	A76-B87;
A76-B88;	A76-B89;	A76-B90;	A76-B91;	A76-B92;	A76-B93;
A76-B94;	A76-B95;	A76-B96;	A76-B97;	A76-B98;	A76-B99;
A76-B100;	A76-B101;	A76-B102;	A76-B103;	A76-B104;	A76-B105;
A76-B106;	A76-B107;	A76-B108;	A76-B109;	A76-B110;	A76-B111;
A76-B112;	A76-B113;	A76-B114;	A76-B115;	A76-B116;	A76-B117;
A76-B118;	A76-B119;	A76-B120;	A76-B121;	A76-B122;	A76-B123;
A76-B124;	A76-B125;	A76-B126;	A76-B127;	A76-B128;	A76-B129;
A76-B130;	A76-B131;	A76-B132;	A76-B133;	A76-B134;	A76-B135;
A76-B136;	A76-B137;	A76-B138;	A76-B139;	A76-B140;	A76-B141;
A76-B142;	A76-B143;	A76-B144;	A76-B145;	A76-B146;	A76-B147;
A76-B148;	A76-B149;	A76-B150;	A76-B151;	A76-B152;	A76-B153;
A76-B154;	A76-B155;	A76-B156;	A76-B157;	A76-B158;	A76-B159;
A76-B160;	A76-B161;	A76-B162;	A76-B163;	A76-B164;	A76-B165;
A76-B166;	A76-B167;	A76-B168;	A76-B169;	A77-B1;	A77-B2;
A77-B3;	A77-B4;	A77-B5;	A77-B6;	A77-B7;	A77-B8;
A77-B9;	A77-B10;	A77-B11;	A77-B12;	A77-B13;	A77-B14;
A77-B15;	A77-B16;	A77-B17;	A77-B18;	A77-B19;	A77-B20;
A77-B21;	A77-B22;	A77-B23;	A77-B24;	A77-B25;	A77-B26;
A77-B27;	A77-B28;	A77-B29;	A77-B30;	A77-B31;	A77-B32;
A77-B33;	A77-B34;	A77-B35;	A77-B36;	A77-B37;	A77-B38;
A77-B39;	A77-B40;	A77-B41;	A77-B42;	A77-B43;	A77-B44;
A77-B45;	A77-B46;	A77-B47;	A77-B48;	A77-B49;	A77-B50;
A77-B51;	A77-B52;	A77-B53;	A77-B54;	A77-B55;	A77-B56;

A77-B57;	A77-B58;	A77-B59;	A77-B60;	A77-B61;	A77-B62;
A77-B63;	A77-B64;	A77-B65;	A77-B66;	A77-B67;	A77-B68;
A77-B69;	A77-B70;	A77-B71;	A77-B72;	A77-B73;	A77-B74;
A77-B75;	A77-B76;	A77-B77;	A77-B78;	A77-B79;	A77-B80;
A77-B81;	A77-B82;	A77-B83;	A77-B84;	A77-B85;	A77-B86;
A77-B87;	A77-B88;	A77-B89;	A77-B90;	A77-B91;	A77-B92;
A77-B93;	A77-B94;	A77-B95;	A77-B96;	A77-B97;	A77-B98;
A77-B99;	A77-B100;	A77-B101;	A77-B102;	A77-B103;	A77-B104;
A77-B105;	A77-B106;	A77-B107;	A77-B108;	A77-B109;	A77-B110;
A77-B111;	A77-B112;	A77-B113;	A77-B114;	A77-B115;	A77-B116;
A77-B117;	A77-B118;	A77-B119;	A77-B120;	A77-B121;	A77-B122;
A77-B123;	A77-B124;	A77-B125;	A77-B126;	A77-B127;	A77-B128;
A77-B129;	A77-B130;	A77-B131;	A77-B132;	A77-B133;	A77-B134;
A77-B135;	A77-B136;	A77-B137;	A77-B138;	A77-B139;	A77-B140;
A77-B141;	A77-B142;	A77-B143;	A77-B144;	A77-B145;	A77-B146;
A77-B147;	A77-B148;	A77-B149;	A77-B150;	A77-B151;	A77-B152;
A77-B153;	A77-B154;	A77-B155;	A77-B156;	A77-B157;	A77-B158;
A77-B159;	A77-B160;	A77-B161;	A77-B162;	A77-B163;	A77-B164;
A77-B165;	A77-B166;	A77-B167;	A77-B168;	A77-B169;	A78-B1;
A78-B2;	A78-B3;	A78-B4;	A78-B5;	A78-B6;	A78-B7;
A78-B8;	A78-B9;	A78-B10;	A78-B11;	A78-B12;	A78-B13;
A78-B14;	A78-B15;	A78-B16;	A78-B17;	A78-B18;	A78-B19;
A78-B20;	A78-B21;	A78-B22;	A78-B23;	A78-B24;	A78-B25;
A78-B26;	A78-B27;	A78-B28;	A78-B29;	A78-B30;	A78-B31;
A78-B32;	A78-B33;	A78-B34;	A78-B35;	A78-B36;	A78-B37;
A78-B38;	A78-B39;	A78-B40;	A78-B41;	A78-B42;	A78-B43;
A78-B44;	A78-B45;	A78-B46;	A78-B47;	A78-B48;	A78-B49;
A78-B50;	A78-B51;	A78-B52;	A78-B53;	A78-B54;	A78-B55;
A78-B56;	A78-B57;	A78-B58;	A78-B59;	A78-B60;	A78-B61;
A78-B62;	A78-B63;	A78-B64;	A78-B65;	A78-B66;	A78-B67;
A78-B68;	A78-B69;	A78-B70;	A78-B71;	A78-B72;	A78-B73;
A78-B74;	A78-B75;	A78-B76;	A78-B77;	A78-B78;	A78-B79;
A78-B80;	A78-B81;	A78-B82;	A78-B83;	A78-B84;	A78-B85;
A78-B86;	A78-B87;	A78-B88;	A78-B89;	A78-B90;	A78-B91;
A78-B92;	A78-B93;	A78-B94;	A78-B95;	A78-B96;	A78-B97;

A78-B98;	A78-B99;	A78-B100;	A78-B101;	A78-B102;	A78-B103;
A78-B104;	A78-B105;	A78-B106;	A78-B107;	A78-B108;	A78-B109;
A78-B110;	A78-B111;	A78-B112;	A78-B113;	A78-B114;	A78-B115;
A78-B116;	A78-B117;	A78-B118;	A78-B119;	A78-B120;	A78-B121;
A78-B122;	A78-B123;	A78-B124;	A78-B125;	A78-B126;	A78-B127;
A78-B128;	A78-B129;	A78-B130;	A78-B131;	A78-B132;	A78-B133;
A78-B134;	A78-B135;	A78-B136;	A78-B137;	A78-B138;	A78-B139;
A78-B140;	A78-B141;	A78-B142;	A78-B143;	A78-B144;	A78-B145;
A78-B146;	A78-B147;	A78-B148;	A78-B149;	A78-B150;	A78-B151;
A78-B152;	A78-B153;	A78-B154;	A78-B155;	A78-B156;	A78-B157;
A78-B158;	A78-B159;	A78-B160;	A78-B161;	A78-B162;	A78-B163;
A78-B164;	A78-B165;	A78-B166;	A78-B167;	A78-B168;	A78-B169;
A79-B1;	A79-B2;	A79-B3;	A79-B4;	A79-B5;	A79-B6;
A79-B7;	A79-B8;	A79-B9;	A79-B10;	A79-B11;	A79-B12;
A79-B13;	A79-B14;	A79-B15;	A79-B16;	A79-B17;	A79-B18;
A79-B19;	A79-B20;	A79-B21;	A79-B22;	A79-B23;	A79-B24;
A79-B25;	A79-B26;	A79-B27;	A79-B28;	A79-B29;	A79-B30;
A79-B31;	A79-B32;	A79-B33;	A79-B34;	A79-B35;	A79-B36;
A79-B37;	A79-B38;	A79-B39;	A79-B40;	A79-B41;	A79-B42;
A79-B43;	A79-B44;	A79-B45;	A79-B46;	A79-B47;	A79-B48;
A79-B49;	A79-B50;	A79-B51;	A79-B52;	A79-B53;	A79-B54;
A79-B55;	A79-B56;	A79-B57;	A79-B58;	A79-B59;	A79-B60;
A79-B61;	A79-B62;	A79-B63;	A79-B64;	A79-B65;	A79-B66;
A79-B67;	A79-B68;	A79-B69;	A79-B70;	A79-B71;	A79-B72;
A79-B73;	A79-B74;	A79-B75;	A79-B76;	A79-B77;	A79-B78;
A79-B79;	A79-B80;	A79-B81;	A79-B82;	A79-B83;	A79-B84;
A79-B85;	A79-B86;	A79-B87;	A79-B88;	A79-B89;	A79-B90;
A79-B91;	A79-B92;	A79-B93;	A79-B94;	A79-B95;	A79-B96;
A79-B97;	A79-B98;	A79-B99;	A79-B100;	A79-B101;	A79-B102;
A79-B103;	A79-B104;	A79-B105;	A79-B106;	A79-B107;	A79-B108;
A79-B109;	A79-B110;	A79-B111;	A79-B112;	A79-B113;	A79-B114;
A79-B115;	A79-B116;	A79-B117;	A79-B118;	A79-B119;	A79-B120;
A79-B121;	A79-B122;	A79-B123;	A79-B124;	A79-B125;	A79-B126;
A79-B127;	A79-B128;	A79-B129;	A79-B130;	A79-B131;	A79-B132;
A79-B133;	A79-B134;	A79-B135;	A79-B136;	A79-B137;	A79-B138;

A79-B139;	A79-B140;	A79-B141;	A79-B142;	A79-B143;	A79-B144;
A79-B145;	A79-B146;	A79-B147;	A79-B148;	A79-B149;	A79-B150;
A79-B151;	A79-B152;	A79-B153;	A79-B154;	A79-B155;	A79-B156;
A79-B157;	A79-B158;	A79-B159;	A79-B160;	A79-B161;	A79-B162;
A79-B163;	A79-B164;	A79-B165;	A79-B166;	A79-B167;	A79-B168;
A79-B169;	A80-B1;	A80-B2;	A80-B3;	A80-B4;	A80-B5;
A80-B6;	A80-B7;	A80-B8;	A80-B9;	A80-B10;	A80-B11;
A80-B12;	A80-B13;	A80-B14;	A80-B15;	A80-B16;	A80-B17;
A80-B18;	A80-B19;	A80-B20;	A80-B21;	A80-B22;	A80-B23;
A80-B24;	A80-B25;	A80-B26;	A80-B27;	A80-B28;	A80-B29;
A80-B30;	A80-B31;	A80-B32;	A80-B33;	A80-B34;	A80-B35;
A80-B36;	A80-B37;	A80-B38;	A80-B39;	A80-B40;	A80-B41;
A80-B42;	A80-B43;	A80-B44;	A80-B45;	A80-B46;	A80-B47;
A80-B48;	A80-B49;	A80-B50;	A80-B51;	A80-B52;	A80-B53;
A80-B54;	A80-B55;	A80-B56;	A80-B57;	A80-B58;	A80-B59;
A80-B60;	A80-B61;	A80-B62;	A80-B63;	A80-B64;	A80-B65;
A80-B66;	A80-B67;	A80-B68;	A80-B69;	A80-B70;	A80-B71;
A80-B72;	A80-B73;	A80-B74;	A80-B75;	A80-B76;	A80-B77;
A80-B78;	A80-B79;	A80-B80;	A80-B81;	A80-B82;	A80-B83;
A80-B84;	A80-B85;	A80-B86;	A80-B87;	A80-B88;	A80-B89;
A80-B90;	A80-B91;	A80-B92;	A80-B93;	A80-B94;	A80-B95;
A80-B96;	A80-B97;	A80-B98;	A80-B99;	A80-B100;	A80-B101;
A80-B102;	A80-B103;	A80-B104;	A80-B105;	A80-B106;	A80-B107;
A80-B108;	A80-B109;	A80-B110;	A80-B111;	A80-B112;	A80-B113;
A80-B114;	A80-B115;	A80-B116;	A80-B117;	A80-B118;	A80-B119;
A80-B120;	A80-B121;	A80-B122;	A80-B123;	A80-B124;	A80-B125;
A80-B126;	A80-B127;	A80-B128;	A80-B129;	A80-B130;	A80-B131;
A80-B132;	A80-B133;	A80-B134;	A80-B135;	A80-B136;	A80-B137;
A80-B138;	A80-B139;	A80-B140;	A80-B141;	A80-B142;	A80-B143;
A80-B144;	A80-B145;	A80-B146;	A80-B147;	A80-B148;	A80-B149;
A80-B150;	A80-B151;	A80-B152;	A80-B153;	A80-B154;	A80-B155;
A80-B156;	A80-B157;	A80-B158;	A80-B159;	A80-B160;	A80-B161;
A80-B162;	A80-B163;	A80-B164;	A80-B165;	A80-B166;	A80-B167;
A80-B168;	A80-B169;	A81-B1;	A81-B2;	A81-B3;	A81-B4;
A81-B5;	A81-B6;	A81-B7;	A81-B8;	A81-B9;	A81-B10;

A81-B11;	A81-B12;	A81-B13;	A81-B14;	A81-B15;	A81-B16;
A81-B17;	A81-B18;	A81-B19;	A81-B20;	A81-B21;	A81-B22;
A81-B23;	A81-B24;	A81-B25;	A81-B26;	A81-B27;	A81-B28;
A81-B29;	A81-B30;	A81-B31;	A81-B32;	A81-B33;	A81-B34;
A81-B35;	A81-B36;	A81-B37;	A81-B38;	A81-B39;	A81-B40;
A81-B41;	A81-B42;	A81-B43;	A81-B44;	A81-B45;	A81-B46;
A81-B47;	A81-B48;	A81-B49;	A81-B50;	A81-B51;	A81-B52;
A81-B53;	A81-B54;	A81-B55;	A81-B56;	A81-B57;	A81-B58;
A81-B59;	A81-B60;	A81-B61;	A81-B62;	A81-B63;	A81-B64;
A81-B65;	A81-B66;	A81-B67;	A81-B68;	A81-B69;	A81-B70;
A81-B71;	A81-B72;	A81-B73;	A81-B74;	A81-B75;	A81-B76;
A81-B77;	A81-B78;	A81-B79;	A81-B80;	A81-B81;	A81-B82;
A81-B83;	A81-B84;	A81-B85;	A81-B86;	A81-B87;	A81-B88;
A81-B89;	A81-B90;	A81-B91;	A81-B92;	A81-B93;	A81-B94;
A81-B95;	A81-B96;	A81-B97;	A81-B98;	A81-B99;	A81-B100;
A81-B101;	A81-B102;	A81-B103;	A81-B104;	A81-B105;	A81-B106;
A81-B107;	A81-B108;	A81-B109;	A81-B110;	A81-B111;	A81-B112;
A81-B113;	A81-B114;	A81-B115;	A81-B116;	A81-B117;	A81-B118;
A81-B119;	A81-B120;	A81-B121;	A81-B122;	A81-B123;	A81-B124;
A81-B125;	A81-B126;	A81-B127;	A81-B128;	A81-B129;	A81-B130;
A81-B131;	A81-B132;	A81-B133;	A81-B134;	A81-B135;	A81-B136;
A81-B137;	A81-B138;	A81-B139;	A81-B140;	A81-B141;	A81-B142;
A81-B143;	A81-B144;	A81-B145;	A81-B146;	A81-B147;	A81-B148;
A81-B149;	A81-B150;	A81-B151;	A81-B152;	A81-B153;	A81-B154;
A81-B155;	A81-B156;	A81-B157;	A81-B158;	A81-B159;	A81-B160;
A81-B161;	A81-B162;	A81-B163;	A81-B164;	A81-B165;	A81-B166;
A81-B167;	A81-B168;	A81-B169;	A82-B1;	A82-B2;	A82-B3;
A82-B4;	A82-B5;	A82-B6;	A82-B7;	A82-B8;	A82-B9;
A82-B10;	A82-B11;	A82-B12;	A82-B13;	A82-B14;	A82-B15;
A82-B16;	A82-B17;	A82-B18;	A82-B19;	A82-B20;	A82-B21;
A82-B22;	A82-B23;	A82-B24;	A82-B25;	A82-B26;	A82-B27;
A82-B28;	A82-B29;	A82-B30;	A82-B31;	A82-B32;	A82-B33;
A82-B34;	A82-B35;	A82-B36;	A82-B37;	A82-B38;	A82-B39;
A82-B40;	A82-B41;	A82-B42;	A82-B43;	A82-B44;	A82-B45;
A82-B46;	A82-B47;	A82-B48;	A82-B49;	A82-B50;	A82-B51;

A82-B52;	A82-B53;	A82-B54;	A82-B55;	A82-B56;	A82-B57;
A82-B58;	A82-B59;	A82-B60;	A82-B61;	A82-B62;	A82-B63;
A82-B64;	A82-B65;	A82-B66;	A82-B67;	A82-B68;	A82-B69;
A82-B70;	A82-B71;	A82-B72;	A82-B73;	A82-B74;	A82-B75;
A82-B76;	A82-B77;	A82-B78;	A82-B79;	A82-B80;	A82-B81;
A82-B82;	A82-B83;	A82-B84;	A82-B85;	A82-B86;	A82-B87;
A82-B88;	A82-B89;	A82-B90;	A82-B91;	A82-B92;	A82-B93;
A82-B94;	A82-B95;	A82-B96;	A82-B97;	A82-B98;	A82-B99;
A82-B100;	A82-B101;	A82-B102;	A82-B103;	A82-B104;	A82-B105;
A82-B106;	A82-B107;	A82-B108;	A82-B109;	A82-B110;	A82-B111;
A82-B112;	A82-B113;	A82-B114;	A82-B115;	A82-B116;	A82-B117;
A82-B118;	A82-B119;	A82-B120;	A82-B121;	A82-B122;	A82-B123;
A82-B124;	A82-B125;	A82-B126;	A82-B127;	A82-B128;	A82-B129;
A82-B130;	A82-B131;	A82-B132;	A82-B133;	A82-B134;	A82-B135;
A82-B136;	A82-B137;	A82-B138;	A82-B139;	A82-B140;	A82-B141;
A82-B142;	A82-B143;	A82-B144;	A82-B145;	A82-B146;	A82-B147;
A82-B148;	A82-B149;	A82-B150;	A82-B151;	A82-B152;	A82-B153;
A82-B154;	A82-B155;	A82-B156;	A82-B157;	A82-B158;	A82-B159;
A82-B160;	A82-B161;	A82-B162;	A82-B163;	A82-B164;	A82-B165;
A82-B166;	A82-B167;	A82-B168;	A82-B169;	A83-B1;	A83-B2;
A83-B3;	A83-B4;	A83-B5;	A83-B6;	A83-B7;	A83-B8;
A83-B9;	A83-B10;	A83-B11;	A83-B12;	A83-B13;	A83-B14;
A83-B15;	A83-B16;	A83-B17;	A83-B18;	A83-B19;	A83-B20;
A83-B21;	A83-B22;	A83-B23;	A83-B24;	A83-B25;	A83-B26;
A83-B27;	A83-B28;	A83-B29;	A83-B30;	A83-B31;	A83-B32;
A83-B33;	A83-B34;	A83-B35;	A83-B36;	A83-B37;	A83-B38;
A83-B39;	A83-B40;	A83-B41;	A83-B42;	A83-B43;	A83-B44;
A83-B45;	A83-B46;	A83-B47;	A83-B48;	A83-B49;	A83-B50;
A83-B51;	A83-B52;	A83-B53;	A83-B54;	A83-B55;	A83-B56;
A83-B57;	A83-B58;	A83-B59;	A83-B60;	A83-B61;	A83-B62;
A83-B63;	A83-B64;	A83-B65;	A83-B66;	A83-B67;	A83-B68;
A83-B69;	A83-B70;	A83-B71;	A83-B72;	A83-B73;	A83-B74;
A83-B75;	A83-B76;	A83-B77;	A83-B78;	A83-B79;	A83-B80;
A83-B81;	A83-B82;	A83-B83;	A83-B84;	A83-B85;	A83-B86;
A83-B87;	A83-B88;	A83-B89;	A83-B90;	A83-B91;	A83-B92;

A83-B93;	A83-B94;	A83-B95;	A83-B96;	A83-B97;	A83-B98;
A83-B99;	A83-B100;	A83-B101;	A83-B102;	A83-B103;	A83-B104;
A83-B105;	A83-B106;	A83-B107;	A83-B108;	A83-B109;	A83-B110;
A83-B111;	A83-B112;	A83-B113;	A83-B114;	A83-B115;	A83-B116;
A83-B117;	A83-B118;	A83-B119;	A83-B120;	A83-B121;	A83-B122;
A83-B123;	A83-B124;	A83-B125;	A83-B126;	A83-B127;	A83-B128;
A83-B129;	A83-B130;	A83-B131;	A83-B132;	A83-B133;	A83-B134;
A83-B135;	A83-B136;	A83-B137;	A83-B138;	A83-B139;	A83-B140;
A83-B141;	A83-B142;	A83-B143;	A83-B144;	A83-B145;	A83-B146;
A83-B147;	A83-B148;	A83-B149;	A83-B150;	A83-B151;	A83-B152;
A83-B153;	A83-B154;	A83-B155;	A83-B156;	A83-B157;	A83-B158;
A83-B159;	A83-B160;	A83-B161;	A83-B162;	A83-B163;	A83-B164;
A83-B165;	A83-B166;	A83-B167;	A83-B168;	A83-B169;	A84-B1;
A84-B2;	A84-B3;	A84-B4;	A84-B5;	A84-B6;	A84-B7;
A84-B8;	A84-B9;	A84-B10;	A84-B11;	A84-B12;	A84-B13;
A84-B14;	A84-B15;	A84-B16;	A84-B17;	A84-B18;	A84-B19;
A84-B20;	A84-B21;	A84-B22;	A84-B23;	A84-B24;	A84-B25;
A84-B26;	A84-B27;	A84-B28;	A84-B29;	A84-B30;	A84-B31;
A84-B32;	A84-B33;	A84-B34;	A84-B35;	A84-B36;	A84-B37;
A84-B38;	A84-B39;	A84-B40;	A84-B41;	A84-B42;	A84-B43;
A84-B44;	A84-B45;	A84-B46;	A84-B47;	A84-B48;	A84-B49;
A84-B50;	A84-B51;	A84-B52;	A84-B53;	A84-B54;	A84-B55;
A84-B56;	A84-B57;	A84-B58;	A84-B59;	A84-B60;	A84-B61;
A84-B62;	A84-B63;	A84-B64;	A84-B65;	A84-B66;	A84-B67;
A84-B68;	A84-B69;	A84-B70;	A84-B71;	A84-B72;	A84-B73;
A84-B74;	A84-B75;	A84-B76;	A84-B77;	A84-B78;	A84-B79;
A84-B80;	A84-B81;	A84-B82;	A84-B83;	A84-B84;	A84-B85;
A84-B86;	A84-B87;	A84-B88;	A84-B89;	A84-B90;	A84-B91;
A84-B92;	A84-B93;	A84-B94;	A84-B95;	A84-B96;	A84-B97;
A84-B98;	A84-B99;	A84-B100;	A84-B101;	A84-B102;	A84-B103;
A84-B104;	A84-B105;	A84-B106;	A84-B107;	A84-B108;	A84-B109;
A84-B110;	A84-B111;	A84-B112;	A84-B113;	A84-B114;	A84-B115;
A84-B116;	A84-B117;	A84-B118;	A84-B119;	A84-B120;	A84-B121;
A84-B122;	A84-B123;	A84-B124;	A84-B125;	A84-B126;	A84-B127;
A84-B128;	A84-B129;	A84-B130;	A84-B131;	A84-B132;	A84-B133;

A84-B134;	A84-B135;	A84-B136;	A84-B137;	A84-B138;	A84-B139;
A84-B140;	A84-B141;	A84-B142;	A84-B143;	A84-B144;	A84-B145;
A84-B146;	A84-B147;	A84-B148;	A84-B149;	A84-B150;	A84-B151;
A84-B152;	A84-B153;	A84-B154;	A84-B155;	A84-B156;	A84-B157;
A84-B158;	A84-B159;	A84-B160;	A84-B161;	A84-B162;	A84-B163;
A84-B164;	A84-B165;	A84-B166;	A84-B167;	A84-B168;	A84-B169;
A85-B1;	A85-B2;	A85-B3;	A85-B4;	A85-B5;	A85-B6;
A85-B7;	A85-B8;	A85-B9;	A85-B10;	A85-B11;	A85-B12;
A85-B13;	A85-B14;	A85-B15;	A85-B16;	A85-B17;	A85-B18;
A85-B19;	A85-B20;	A85-B21;	A85-B22;	A85-B23;	A85-B24;
A85-B25;	A85-B26;	A85-B27;	A85-B28;	A85-B29;	A85-B30;
A85-B31;	A85-B32;	A85-B33;	A85-B34;	A85-B35;	A85-B36;
A85-B37;	A85-B38;	A85-B39;	A85-B40;	A85-B41;	A85-B42;
A85-B43;	A85-B44;	A85-B45;	A85-B46;	A85-B47;	A85-B48;
A85-B49;	A85-B50;	A85-B51;	A85-B52;	A85-B53;	A85-B54;
A85-B55;	A85-B56;	A85-B57;	A85-B58;	A85-B59;	A85-B60;
A85-B61;	A85-B62;	A85-B63;	A85-B64;	A85-B65;	A85-B66;
A85-B67;	A85-B68;	A85-B69;	A85-B70;	A85-B71;	A85-B72;
A85-B73;	A85-B74;	A85-B75;	A85-B76;	A85-B77;	A85-B78;
A85-B79;	A85-B80;	A85-B81;	A85-B82;	A85-B83;	A85-B84;
A85-B85;	A85-B86;	A85-B87;	A85-B88;	A85-B89;	A85-B90;
A85-B91;	A85-B92;	A85-B93;	A85-B94;	A85-B95;	A85-B96;
A85-B97;	A85-B98;	A85-B99;	A85-B100;	A85-B101;	A85-B102;
A85-B103;	A85-B104;	A85-B105;	A85-B106;	A85-B107;	A85-B108;
A85-B109;	A85-B110;	A85-B111;	A85-B112;	A85-B113;	A85-B114;
A85-B115;	A85-B116;	A85-B117;	A85-B118;	A85-B119;	A85-B120;
A85-B121;	A85-B122;	A85-B123;	A85-B124;	A85-B125;	A85-B126;
A85-B127;	A85-B128;	A85-B129;	A85-B130;	A85-B131;	A85-B132;
A85-B133;	A85-B134;	A85-B135;	A85-B136;	A85-B137;	A85-B138;
A85-B139;	A85-B140;	A85-B141;	A85-B142;	A85-B143;	A85-B144;
A85-B145;	A85-B146;	A85-B147;	A85-B148;	A85-B149;	A85-B150;
A85-B151;	A85-B152;	A85-B153;	A85-B154;	A85-B155;	A85-B156;
A85-B157;	A85-B158;	A85-B159;	A85-B160;	A85-B161;	A85-B162;
A85-B163;	A85-B164;	A85-B165;	A85-B166;	A85-B167;	A85-B168;
A85-B169;	A86-B1;	A86-B2;	A86-B3;	A86-B4;	A86-B5;

A86-B6;	A86-B7;	A86-B8;	A86-B9;	A86-B10;	A86-B11;
A86-B12;	A86-B13;	A86-B14;	A86-B15;	A86-B16;	A86-B17;
A86-B18;	A86-B19;	A86-B20;	A86-B21;	A86-B22;	A86-B23;
A86-B24;	A86-B25;	A86-B26;	A86-B27;	A86-B28;	A86-B29;
A86-B30;	A86-B31;	A86-B32;	A86-B33;	A86-B34;	A86-B35;
A86-B36;	A86-B37;	A86-B38;	A86-B39;	A86-B40;	A86-B41;
A86-B42;	A86-B43;	A86-B44;	A86-B45;	A86-B46;	A86-B47;
A86-B48;	A86-B49;	A86-B50;	A86-B51;	A86-B52;	A86-B53;
A86-B54;	A86-B55;	A86-B56;	A86-B57;	A86-B58;	A86-B59;
A86-B60;	A86-B61;	A86-B62;	A86-B63;	A86-B64;	A86-B65;
A86-B66;	A86-B67;	A86-B68;	A86-B69;	A86-B70;	A86-B71;
A86-B72;	A86-B73;	A86-B74;	A86-B75;	A86-B76;	A86-B77;
A86-B78;	A86-B79;	A86-B80;	A86-B81;	A86-B82;	A86-B83;
A86-B84;	A86-B85;	A86-B86;	A86-B87;	A86-B88;	A86-B89;
A86-B90;	A86-B91;	A86-B92;	A86-B93;	A86-B94;	A86-B95;
A86-B96;	A86-B97;	A86-B98;	A86-B99;	A86-B100;	A86-B101;
A86-B102;	A86-B103;	A86-B104;	A86-B105;	A86-B106;	A86-B107;
A86-B108;	A86-B109;	A86-B110;	A86-B111;	A86-B112;	A86-B113;
A86-B114;	A86-B115;	A86-B116;	A86-B117;	A86-B118;	A86-B119;
A86-B120;	A86-B121;	A86-B122;	A86-B123;	A86-B124;	A86-B125;
A86-B126;	A86-B127;	A86-B128;	A86-B129;	A86-B130;	A86-B131;
A86-B132;	A86-B133;	A86-B134;	A86-B135;	A86-B136;	A86-B137;
A86-B138;	A86-B139;	A86-B140;	A86-B141;	A86-B142;	A86-B143;
A86-B144;	A86-B145;	A86-B146;	A86-B147;	A86-B148;	A86-B149;
A86-B150;	A86-B151;	A86-B152;	A86-B153;	A86-B154;	A86-B155;
A86-B156;	A86-B157;	A86-B158;	A86-B159;	A86-B160;	A86-B161;
A86-B162;	A86-B163;	A86-B164;	A86-B165;	A86-B166;	A86-B167;
A86-B168;	A86-B169;	A87-B1;	A87-B2;	A87-B3;	A87-B4;
A87-B5;	A87-B6;	A87-B7;	A87-B8;	A87-B9;	A87-B10;
A87-B11;	A87-B12;	A87-B13;	A87-B14;	A87-B15;	A87-B16;
A87-B17;	A87-B18;	A87-B19;	A87-B20;	A87-B21;	A87-B22;
A87-B23;	A87-B24;	A87-B25;	A87-B26;	A87-B27;	A87-B28;
A87-B29;	A87-B30;	A87-B31;	A87-B32;	A87-B33;	A87-B34;
A87-B35;	A87-B36;	A87-B37;	A87-B38;	A87-B39;	A87-B40;
A87-B41;	A87-B42;	A87-B43;	A87-B44;	A87-B45;	A87-B46;

A87-B47;	A87-B48;	A87-B49;	A87-B50;	A87-B51;	A87-B52;
A87-B53;	A87-B54;	A87-B55;	A87-B56;	A87-B57;	A87-B58;
A87-B59;	A87-B60;	A87-B61;	A87-B62;	A87-B63;	A87-B64;
A87-B65;	A87-B66;	A87-B67;	A87-B68;	A87-B69;	A87-B70;
A87-B71;	A87-B72;	A87-B73;	A87-B74;	A87-B75;	A87-B76;
A87-B77;	A87-B78;	A87-B79;	A87-B80;	A87-B81;	A87-B82;
A87-B83;	A87-B84;	A87-B85;	A87-B86;	A87-B87;	A87-B88;
A87-B89;	A87-B90;	A87-B91;	A87-B92;	A87-B93;	A87-B94;
A87-B95;	A87-B96;	A87-B97;	A87-B98;	A87-B99;	A87-B100;
A87-B101;	A87-B102;	A87-B103;	A87-B104;	A87-B105;	A87-B106;
A87-B107;	A87-B108;	A87-B109;	A87-B110;	A87-B111;	A87-B112;
A87-B113;	A87-B114;	A87-B115;	A87-B116;	A87-B117;	A87-B118;
A87-B119;	A87-B120;	A87-B121;	A87-B122;	A87-B123;	A87-B124;
A87-B125;	A87-B126;	A87-B127;	A87-B128;	A87-B129;	A87-B130;
A87-B131;	A87-B132;	A87-B133;	A87-B134;	A87-B135;	A87-B136;
A87-B137;	A87-B138;	A87-B139;	A87-B140;	A87-B141;	A87-B142;
A87-B143;	A87-B144;	A87-B145;	A87-B146;	A87-B147;	A87-B148;
A87-B149;	A87-B150;	A87-B151;	A87-B152;	A87-B153;	A87-B154;
A87-B155;	A87-B156;	A87-B157;	A87-B158;	A87-B159;	A87-B160;
A87-B161;	A87-B162;	A87-B163;	A87-B164;	A87-B165;	A87-B166;
A87-B167;	A87-B168;	A87-B169;	A88-B1;	A88-B2;	A88-B3;
A88-B4;	A88-B5;	A88-B6;	A88-B7;	A88-B8;	A88-B9;
A88-B10;	A88-B11;	A88-B12;	A88-B13;	A88-B14;	A88-B15;
A88-B16;	A88-B17;	A88-B18;	A88-B19;	A88-B20;	A88-B21;
A88-B22;	A88-B23;	A88-B24;	A88-B25;	A88-B26;	A88-B27;
A88-B28;	A88-B29;	A88-B30;	A88-B31;	A88-B32;	A88-B33;
A88-B34;	A88-B35;	A88-B36;	A88-B37;	A88-B38;	A88-B39;
A88-B40;	A88-B41;	A88-B42;	A88-B43;	A88-B44;	A88-B45;
A88-B46;	A88-B47;	A88-B48;	A88-B49;	A88-B50;	A88-B51;
A88-B52;	A88-B53;	A88-B54;	A88-B55;	A88-B56;	A88-B57;
A88-B58;	A88-B59;	A88-B60;	A88-B61;	A88-B62;	A88-B63;
A88-B64;	A88-B65;	A88-B66;	A88-B67;	A88-B68;	A88-B69;
A88-B70;	A88-B71;	A88-B72;	A88-B73;	A88-B74;	A88-B75;
A88-B76;	A88-B77;	A88-B78;	A88-B79;	A88-B80;	A88-B81;
A88-B82;	A88-B83;	A88-B84;	A88-B85;	A88-B86;	A88-B87;

A88-B88;	A88-B89;	A88-B90;	A88-B91;	A88-B92;	A88-B93;
A88-B94;	A88-B95;	A88-B96;	A88-B97;	A88-B98;	A88-B99;
A88-B100;	A88-B101;	A88-B102;	A88-B103;	A88-B104;	A88-B105;
A88-B106;	A88-B107;	A88-B108;	A88-B109;	A88-B110;	A88-B111;
A88-B112;	A88-B113;	A88-B114;	A88-B115;	A88-B116;	A88-B117;
A88-B118;	A88-B119;	A88-B120;	A88-B121;	A88-B122;	A88-B123;
A88-B124;	A88-B125;	A88-B126;	A88-B127;	A88-B128;	A88-B129;
A88-B130;	A88-B131;	A88-B132;	A88-B133;	A88-B134;	A88-B135;
A88-B136;	A88-B137;	A88-B138;	A88-B139;	A88-B140;	A88-B141;
A88-B142;	A88-B143;	A88-B144;	A88-B145;	A88-B146;	A88-B147;
A88-B148;	A88-B149;	A88-B150;	A88-B151;	A88-B152;	A88-B153;
A88-B154;	A88-B155;	A88-B156;	A88-B157;	A88-B158;	A88-B159;
A88-B160;	A88-B161;	A88-B162;	A88-B163;	A88-B164;	A88-B165;
A88-B166;	A88-B167;	A88-B168;	A88-B169;	A89-B1;	A89-B2;
A89-B3;	A89-B4;	A89-B5;	A89-B6;	A89-B7;	A89-B8;
A89-B9;	A89-B10;	A89-B11;	A89-B12;	A89-B13;	A89-B14;
A89-B15;	A89-B16;	A89-B17;	A89-B18;	A89-B19;	A89-B20;
A89-B21;	A89-B22;	A89-B23;	A89-B24;	A89-B25;	A89-B26;
A89-B27;	A89-B28;	A89-B29;	A89-B30;	A89-B31;	A89-B32;
A89-B33;	A89-B34;	A89-B35;	A89-B36;	A89-B37;	A89-B38;
A89-B39;	A89-B40;	A89-B41;	A89-B42;	A89-B43;	A89-B44;
A89-B45;	A89-B46;	A89-B47;	A89-B48;	A89-B49;	A89-B50;
A89-B51;	A89-B52;	A89-B53;	A89-B54;	A89-B55;	A89-B56;
A89-B57;	A89-B58;	A89-B59;	A89-B60;	A89-B61;	A89-B62;
A89-B63;	A89-B64;	A89-B65;	A89-B66;	A89-B67;	A89-B68;
A89-B69;	A89-B70;	A89-B71;	A89-B72;	A89-B73;	A89-B74;
A89-B75;	A89-B76;	A89-B77;	A89-B78;	A89-B79;	A89-B80;
A89-B81;	A89-B82;	A89-B83;	A89-B84;	A89-B85;	A89-B86;
A89-B87;	A89-B88;	A89-B89;	A89-B90;	A89-B91;	A89-B92;
A89-B93;	A89-B94;	A89-B95;	A89-B96;	A89-B97;	A89-B98;
A89-B99;	A89-B100;	A89-B101;	A89-B102;	A89-B103;	A89-B104;
A89-B105;	A89-B106;	A89-B107;	A89-B108;	A89-B109;	A89-B110;
A89-B111;	A89-B112;	A89-B113;	A89-B114;	A89-B115;	A89-B116;
A89-B117;	A89-B118;	A89-B119;	A89-B120;	A89-B121;	A89-B122;
A89-B123;	A89-B124;	A89-B125;	A89-B126;	A89-B127;	A89-B128;

A89-B129;	A89-B130;	A89-B131;	A89-B132;	A89-B133;	A89-B134;
A89-B135;	A89-B136;	A89-B137;	A89-B138;	A89-B139;	A89-B140;
A89-B141;	A89-B142;	A89-B143;	A89-B144;	A89-B145;	A89-B146;
A89-B147;	A89-B148;	A89-B149;	A89-B150;	A89-B151;	A89-B152;
A89-B153;	A89-B154;	A89-B155;	A89-B156;	A89-B157;	A89-B158;
A89-B159;	A89-B160;	A89-B161;	A89-B162;	A89-B163;	A89-B164;
A89-B165;	A89-B166;	A89-B167;	A89-B168;	A89-B169;	A90-B1;
A90-B2;	A90-B3;	A90-B4;	A90-B5;	A90-B6;	A90-B7;
A90-B8;	A90-B9;	A90-B10;	A90-B11;	A90-B12;	A90-B13;
A90-B14;	A90-B15;	A90-B16;	A90-B17;	A90-B18;	A90-B19;
A90-B20;	A90-B21;	A90-B22;	A90-B23;	A90-B24;	A90-B25;
A90-B26;	A90-B27;	A90-B28;	A90-B29;	A90-B30;	A90-B31;
A90-B32;	A90-B33;	A90-B34;	A90-B35;	A90-B36;	A90-B37;
A90-B38;	A90-B39;	A90-B40;	A90-B41;	A90-B42;	A90-B43;
A90-B44;	A90-B45;	A90-B46;	A90-B47;	A90-B48;	A90-B49;
A90-B50;	A90-B51;	A90-B52;	A90-B53;	A90-B54;	A90-B55;
A90-B56;	A90-B57;	A90-B58;	A90-B59;	A90-B60;	A90-B61;
A90-B62;	A90-B63;	A90-B64;	A90-B65;	A90-B66;	A90-B67;
A90-B68;	A90-B69;	A90-B70;	A90-B71;	A90-B72;	A90-B73;
A90-B74;	A90-B75;	A90-B76;	A90-B77;	A90-B78;	A90-B79;
A90-B80;	A90-B81;	A90-B82;	A90-B83;	A90-B84;	A90-B85;
A90-B86;	A90-B87;	A90-B88;	A90-B89;	A90-B90;	A90-B91;
A90-B92;	A90-B93;	A90-B94;	A90-B95;	A90-B96;	A90-B97;
A90-B98;	A90-B99;	A90-B100;	A90-B101;	A90-B102;	A90-B103;
A90-B104;	A90-B105;	A90-B106;	A90-B107;	A90-B108;	A90-B109;
A90-B110;	A90-B111;	A90-B112;	A90-B113;	A90-B114;	A90-B115;
A90-B116;	A90-B117;	A90-B118;	A90-B119;	A90-B120;	A90-B121;
A90-B122;	A90-B123;	A90-B124;	A90-B125;	A90-B126;	A90-B127;
A90-B128;	A90-B129;	A90-B130;	A90-B131;	A90-B132;	A90-B133;
A90-B134;	A90-B135;	A90-B136;	A90-B137;	A90-B138;	A90-B139;
A90-B140;	A90-B141;	A90-B142;	A90-B143;	A90-B144;	A90-B145;
A90-B146;	A90-B147;	A90-B148;	A90-B149;	A90-B150;	A90-B151;
A90-B152;	A90-B153;	A90-B154;	A90-B155;	A90-B156;	A90-B157;
A90-B158;	A90-B159;	A90-B160;	A90-B161;	A90-B162;	A90-B163;
A90-B164;	A90-B165;	A90-B166;	A90-B167;	A90-B168;	A90-B169;

A91-B1;	A91-B2;	A91-B3;	A91-B4;	A91-B5;	A91-B6;
A91-B7;	A91-B8;	A91-B9;	A91-B10;	A91-B11;	A91-B12;
A91-B13;	A91-B14;	A91-B15;	A91-B16;	A91-B17;	A91-B18;
A91-B19;	A91-B20;	A91-B21;	A91-B22;	A91-B23;	A91-B24;
A91-B25;	A91-B26;	A91-B27;	A91-B28;	A91-B29;	A91-B30;
A91-B31;	A91-B32;	A91-B33;	A91-B34;	A91-B35;	A91-B36;
A91-B37;	A91-B38;	A91-B39;	A91-B40;	A91-B41;	A91-B42;
A91-B43;	A91-B44;	A91-B45;	A91-B46;	A91-B47;	A91-B48;
A91-B49;	A91-B50;	A91-B51;	A91-B52;	A91-B53;	A91-B54;
A91-B55;	A91-B56;	A91-B57;	A91-B58;	A91-B59;	A91-B60;
A91-B61;	A91-B62;	A91-B63;	A91-B64;	A91-B65;	A91-B66;
A91-B67;	A91-B68;	A91-B69;	A91-B70;	A91-B71;	A91-B72;
A91-B73;	A91-B74;	A91-B75;	A91-B76;	A91-B77;	A91-B78;
A91-B79;	A91-B80;	A91-B81;	A91-B82;	A91-B83;	A91-B84;
A91-B85;	A91-B86;	A91-B87;	A91-B88;	A91-B89;	A91-B90;
A91-B91;	A91-B92;	A91-B93;	A91-B94;	A91-B95;	A91-B96;
A91-B97;	A91-B98;	A91-B99;	A91-B100;	A91-B101;	A91-B102;
A91-B103;	A91-B104;	A91-B105;	A91-B106;	A91-B107;	A91-B108;
A91-B109;	A91-B110;	A91-B111;	A91-B112;	A91-B113;	A91-B114;
A91-B115;	A91-B116;	A91-B117;	A91-B118;	A91-B119;	A91-B120;
A91-B121;	A91-B122;	A91-B123;	A91-B124;	A91-B125;	A91-B126;
A91-B127;	A91-B128;	A91-B129;	A91-B130;	A91-B131;	A91-B132;
A91-B133;	A91-B134;	A91-B135;	A91-B136;	A91-B137;	A91-B138;
A91-B139;	A91-B140;	A91-B141;	A91-B142;	A91-B143;	A91-B144;
A91-B145;	A91-B146;	A91-B147;	A91-B148;	A91-B149;	A91-B150;
A91-B151;	A91-B152;	A91-B153;	A91-B154;	A91-B155;	A91-B156;
A91-B157;	A91-B158;	A91-B159;	A91-B160;	A91-B161;	A91-B162;
A91-B163;	A91-B164;	A91-B165;	A91-B166;	A91-B167;	A91-B168;
A91-B169;	A92-B1;	A92-B2;	A92-B3;	A92-B4;	A92-B5;
A92-B6;	A92-B7;	A92-B8;	A92-B9;	A92-B10;	A92-B11;
A92-B12;	A92-B13;	A92-B14;	A92-B15;	A92-B16;	A92-B17;
A92-B18;	A92-B19;	A92-B20;	A92-B21;	A92-B22;	A92-B23;
A92-B24;	A92-B25;	A92-B26;	A92-B27;	A92-B28;	A92-B29;
A92-B30;	A92-B31;	A92-B32;	A92-B33;	A92-B34;	A92-B35;
A92-B36;	A92-B37;	A92-B38;	A92-B39;	A92-B40;	A92-B41;

A92-B42;	A92-B43;	A92-B44;	A92-B45;	A92-B46;	A92-B47;
A92-B48;	A92-B49;	A92-B50;	A92-B51;	A92-B52;	A92-B53;
A92-B54;	A92-B55;	A92-B56;	A92-B57;	A92-B58;	A92-B59;
A92-B60;	A92-B61;	A92-B62;	A92-B63;	A92-B64;	A92-B65;
A92-B66;	A92-B67;	A92-B68;	A92-B69;	A92-B70;	A92-B71;
A92-B72;	A92-B73;	A92-B74;	A92-B75;	A92-B76;	A92-B77;
A92-B78;	A92-B79;	A92-B80;	A92-B81;	A92-B82;	A92-B83;
A92-B84;	A92-B85;	A92-B86;	A92-B87;	A92-B88;	A92-B89;
A92-B90;	A92-B91;	A92-B92;	A92-B93;	A92-B94;	A92-B95;
A92-B96;	A92-B97;	A92-B98;	A92-B99;	A92-B100;	A92-B101;
A92-B102;	A92-B103;	A92-B104;	A92-B105;	A92-B106;	A92-B107;
A92-B108;	A92-B109;	A92-B110;	A92-B111;	A92-B112;	A92-B113;
A92-B114;	A92-B115;	A92-B116;	A92-B117;	A92-B118;	A92-B119;
A92-B120;	A92-B121;	A92-B122;	A92-B123;	A92-B124;	A92-B125;
A92-B126;	A92-B127;	A92-B128;	A92-B129;	A92-B130;	A92-B131;
A92-B132;	A92-B133;	A92-B134;	A92-B135;	A92-B136;	A92-B137;
A92-B138;	A92-B139;	A92-B140;	A92-B141;	A92-B142;	A92-B143;
A92-B144;	A92-B145;	A92-B146;	A92-B147;	A92-B148;	A92-B149;
A92-B150;	A92-B151;	A92-B152;	A92-B153;	A92-B154;	A92-B155;
A92-B156;	A92-B157;	A92-B158;	A92-B159;	A92-B160;	A92-B161;
A92-B162;	A92-B163;	A92-B164;	A92-B165;	A92-B166;	A92-B167;
A92-B168;	A92-B169;	A93-B1;	A93-B2;	A93-B3;	A93-B4;
A93-B5;	A93-B6;	A93-B7;	A93-B8;	A93-B9;	A93-B10;
A93-B11;	A93-B12;	A93-B13;	A93-B14;	A93-B15;	A93-B16;
A93-B17;	A93-B18;	A93-B19;	A93-B20;	A93-B21;	A93-B22;
A93-B23;	A93-B24;	A93-B25;	A93-B26;	A93-B27;	A93-B28;
A93-B29;	A93-B30;	A93-B31;	A93-B32;	A93-B33;	A93-B34;
A93-B35;	A93-B36;	A93-B37;	A93-B38;	A93-B39;	A93-B40;
A93-B41;	A93-B42;	A93-B43;	A93-B44;	A93-B45;	A93-B46;
A93-B47;	A93-B48;	A93-B49;	A93-B50;	A93-B51;	A93-B52;
A93-B53;	A93-B54;	A93-B55;	A93-B56;	A93-B57;	A93-B58;
A93-B59;	A93-B60;	A93-B61;	A93-B62;	A93-B63;	A93-B64;
A93-B65;	A93-B66;	A93-B67;	A93-B68;	A93-B69;	A93-B70;
A93-B71;	A93-B72;	A93-B73;	A93-B74;	A93-B75;	A93-B76;
A93-B77;	A93-B78;	A93-B79;	A93-B80;	A93-B81;	A93-B82;

A93-B83;	A93-B84;	A93-B85;	A93-B86;	A93-B87;	A93-B88;
A93-B89;	A93-B90;	A93-B91;	A93-B92;	A93-B93;	A93-B94;
A93-B95;	A93-B96;	A93-B97;	A93-B98;	A93-B99;	A93-B100;
A93-B101;	A93-B102;	A93-B103;	A93-B104;	A93-B105;	A93-B106;
A93-B107;	A93-B108;	A93-B109;	A93-B110;	A93-B111;	A93-B112;
A93-B113;	A93-B114;	A93-B115;	A93-B116;	A93-B117;	A93-B118;
A93-B119;	A93-B120;	A93-B121;	A93-B122;	A93-B123;	A93-B124;
A93-B125;	A93-B126;	A93-B127;	A93-B128;	A93-B129;	A93-B130;
A93-B131;	A93-B132;	A93-B133;	A93-B134;	A93-B135;	A93-B136;
A93-B137;	A93-B138;	A93-B139;	A93-B140;	A93-B141;	A93-B142;
A93-B143;	A93-B144;	A93-B145;	A93-B146;	A93-B147;	A93-B148;
A93-B149;	A93-B150;	A93-B151;	A93-B152;	A93-B153;	A93-B154;
A93-B155;	A93-B156;	A93-B157;	A93-B158;	A93-B159;	A93-B160;
A93-B161;	A93-B162;	A93-B163;	A93-B164;	A93-B165;	A93-B166;
A93-B167;	A93-B168;	A93-B169;	A94-B1;	A94-B2;	A94-B3;
A94-B4;	A94-B5;	A94-B6;	A94-B7;	A94-B8;	A94-B9;
A94-B10;	A94-B11;	A94-B12;	A94-B13;	A94-B14;	A94-B15;
A94-B16;	A94-B17;	A94-B18;	A94-B19;	A94-B20;	A94-B21;
A94-B22;	A94-B23;	A94-B24;	A94-B25;	A94-B26;	A94-B27;
A94-B28;	A94-B29;	A94-B30;	A94-B31;	A94-B32;	A94-B33;
A94-B34;	A94-B35;	A94-B36;	A94-B37;	A94-B38;	A94-B39;
A94-B40;	A94-B41;	A94-B42;	A94-B43;	A94-B44;	A94-B45;
A94-B46;	A94-B47;	A94-B48;	A94-B49;	A94-B50;	A94-B51;
A94-B52;	A94-B53;	A94-B54;	A94-B55;	A94-B56;	A94-B57;
A94-B58;	A94-B59;	A94-B60;	A94-B61;	A94-B62;	A94-B63;
A94-B64;	A94-B65;	A94-B66;	A94-B67;	A94-B68;	A94-B69;
A94-B70;	A94-B71;	A94-B72;	A94-B73;	A94-B74;	A94-B75;
A94-B76;	A94-B77;	A94-B78;	A94-B79;	A94-B80;	A94-B81;
A94-B82;	A94-B83;	A94-B84;	A94-B85;	A94-B86;	A94-B87;
A94-B88;	A94-B89;	A94-B90;	A94-B91;	A94-B92;	A94-B93;
A94-B94;	A94-B95;	A94-B96;	A94-B97;	A94-B98;	A94-B99;
A94-B100;	A94-B101;	A94-B102;	A94-B103;	A94-B104;	A94-B105;
A94-B106;	A94-B107;	A94-B108;	A94-B109;	A94-B110;	A94-B111;
A94-B112;	A94-B113;	A94-B114;	A94-B115;	A94-B116;	A94-B117;
A94-B118;	A94-B119;	A94-B120;	A94-B121;	A94-B122;	A94-B123;

A94-B124;	A94-B125;	A94-B126;	A94-B127;	A94-B128;	A94-B129;
A94-B130;	A94-B131;	A94-B132;	A94-B133;	A94-B134;	A94-B135;
A94-B136;	A94-B137;	A94-B138;	A94-B139;	A94-B140;	A94-B141;
A94-B142;	A94-B143;	A94-B144;	A94-B145;	A94-B146;	A94-B147;
A94-B148;	A94-B149;	A94-B150;	A94-B151;	A94-B152;	A94-B153;
A94-B154;	A94-B155;	A94-B156;	A94-B157;	A94-B158;	A94-B159;
A94-B160;	A94-B161;	A94-B162;	A94-B163;	A94-B164;	A94-B165;
A94-B166;	A94-B167;	A94-B168;	A94-B169;	A95-B1;	A95-B2;
A95-B3;	A95-B4;	A95-B5;	A95-B6;	A95-B7;	A95-B8;
A95-B9;	A95-B10;	A95-B11;	A95-B12;	A95-B13;	A95-B14;
A95-B15;	A95-B16;	A95-B17;	A95-B18;	A95-B19;	A95-B20;
A95-B21;	A95-B22;	A95-B23;	A95-B24;	A95-B25;	A95-B26;
A95-B27;	A95-B28;	A95-B29;	A95-B30;	A95-B31;	A95-B32;
A95-B33;	A95-B34;	A95-B35;	A95-B36;	A95-B37;	A95-B38;
A95-B39;	A95-B40;	A95-B41;	A95-B42;	A95-B43;	A95-B44;
A95-B45;	A95-B46;	A95-B47;	A95-B48;	A95-B49;	A95-B50;
A95-B51;	A95-B52;	A95-B53;	A95-B54;	A95-B55;	A95-B56;
A95-B57;	A95-B58;	A95-B59;	A95-B60;	A95-B61;	A95-B62;
A95-B63;	A95-B64;	A95-B65;	A95-B66;	A95-B67;	A95-B68;
A95-B69;	A95-B70;	A95-B71;	A95-B72;	A95-B73;	A95-B74;
A95-B75;	A95-B76;	A95-B77;	A95-B78;	A95-B79;	A95-B80;
A95-B81;	A95-B82;	A95-B83;	A95-B84;	A95-B85;	A95-B86;
A95-B87;	A95-B88;	A95-B89;	A95-B90;	A95-B91;	A95-B92;
A95-B93;	A95-B94;	A95-B95;	A95-B96;	A95-B97;	A95-B98;
A95-B99;	A95-B100;	A95-B101;	A95-B102;	A95-B103;	A95-B104;
A95-B105;	A95-B106;	A95-B107;	A95-B108;	A95-B109;	A95-B110;
A95-B111;	A95-B112;	A95-B113;	A95-B114;	A95-B115;	A95-B116;
A95-B117;	A95-B118;	A95-B119;	A95-B120;	A95-B121;	A95-B122;
A95-B123;	A95-B124;	A95-B125;	A95-B126;	A95-B127;	A95-B128;
A95-B129;	A95-B130;	A95-B131;	A95-B132;	A95-B133;	A95-B134;
A95-B135;	A95-B136;	A95-B137;	A95-B138;	A95-B139;	A95-B140;
A95-B141;	A95-B142;	A95-B143;	A95-B144;	A95-B145;	A95-B146;
A95-B147;	A95-B148;	A95-B149;	A95-B150;	A95-B151;	A95-B152;
A95-B153;	A95-B154;	A95-B155;	A95-B156;	A95-B157;	A95-B158;
A95-B159;	A95-B160;	A95-B161;	A95-B162;	A95-B163;	A95-B164;

A95-B165;	A95-B166;	A95-B167;	A95-B168;	A95-B169;	A96-B1;
A96-B2;	A96-B3;	A96-B4;	A96-B5;	A96-B6;	A96-B7;
A96-B8;	A96-B9;	A96-B10;	A96-B11;	A96-B12;	A96-B13;
A96-B14;	A96-B15;	A96-B16;	A96-B17;	A96-B18;	A96-B19;
A96-B20;	A96-B21;	A96-B22;	A96-B23;	A96-B24;	A96-B25;
A96-B26;	A96-B27;	A96-B28;	A96-B29;	A96-B30;	A96-B31;
A96-B32;	A96-B33;	A96-B34;	A96-B35;	A96-B36;	A96-B37;
A96-B38;	A96-B39;	A96-B40;	A96-B41;	A96-B42;	A96-B43;
A96-B44;	A96-B45;	A96-B46;	A96-B47;	A96-B48;	A96-B49;
A96-B50;	A96-B51;	A96-B52;	A96-B53;	A96-B54;	A96-B55;
A96-B56;	A96-B57;	A96-B58;	A96-B59;	A96-B60;	A96-B61;
A96-B62;	A96-B63;	A96-B64;	A96-B65;	A96-B66;	A96-B67;
A96-B68;	A96-B69;	A96-B70;	A96-B71;	A96-B72;	A96-B73;
A96-B74;	A96-B75;	A96-B76;	A96-B77;	A96-B78;	A96-B79;
A96-B80;	A96-B81;	A96-B82;	A96-B83;	A96-B84;	A96-B85;
A96-B86;	A96-B87;	A96-B88;	A96-B89;	A96-B90;	A96-B91;
A96-B92;	A96-B93;	A96-B94;	A96-B95;	A96-B96;	A96-B97;
A96-B98;	A96-B99;	A96-B100;	A96-B101;	A96-B102;	A96-B103;
A96-B104;	A96-B105;	A96-B106;	A96-B107;	A96-B108;	A96-B109;
A96-B110;	A96-B111;	A96-B112;	A96-B113;	A96-B114;	A96-B115;
A96-B116;	A96-B117;	A96-B118;	A96-B119;	A96-B120;	A96-B121;
A96-B122;	A96-B123;	A96-B124;	A96-B125;	A96-B126;	A96-B127;
A96-B128;	A96-B129;	A96-B130;	A96-B131;	A96-B132;	A96-B133;
A96-B134;	A96-B135;	A96-B136;	A96-B137;	A96-B138;	A96-B139;
A96-B140;	A96-B141;	A96-B142;	A96-B143;	A96-B144;	A96-B145;
A96-B146;	A96-B147;	A96-B148;	A96-B149;	A96-B150;	A96-B151;
A96-B152;	A96-B153;	A96-B154;	A96-B155;	A96-B156;	A96-B157;
A96-B158;	A96-B159;	A96-B160;	A96-B161;	A96-B162;	A96-B163;
A96-B164;	A96-B165;	A96-B166;	A96-B167;	A96-B168;	A96-B169;
A97-B1;	A97-B2;	A97-B3;	A97-B4;	A97-B5;	A97-B6;
A97-B7;	A97-B8;	A97-B9;	A97-B10;	A97-B11;	A97-B12;
A97-B13;	A97-B14;	A97-B15;	A97-B16;	A97-B17;	A97-B18;
A97-B19;	A97-B20;	A97-B21;	A97-B22;	A97-B23;	A97-B24;
A97-B25;	A97-B26;	A97-B27;	A97-B28;	A97-B29;	A97-B30;
A97-B31;	A97-B32;	A97-B33;	A97-B34;	A97-B35;	A97-B36;

A97-B37;	A97-B38;	A97-B39;	A97-B40;	A97-B41;	A97-B42;
A97-B43;	A97-B44;	A97-B45;	A97-B46;	A97-B47;	A97-B48;
A97-B49;	A97-B50;	A97-B51;	A97-B52;	A97-B53;	A97-B54;
A97-B55;	A97-B56;	A97-B57;	A97-B58;	A97-B59;	A97-B60;
A97-B61;	A97-B62;	A97-B63;	A97-B64;	A97-B65;	A97-B66;
A97-B67;	A97-B68;	A97-B69;	A97-B70;	A97-B71;	A97-B72;
A97-B73;	A97-B74;	A97-B75;	A97-B76;	A97-B77;	A97-B78;
A97-B79;	A97-B80;	A97-B81;	A97-B82;	A97-B83;	A97-B84;
A97-B85;	A97-B86;	A97-B87;	A97-B88;	A97-B89;	A97-B90;
A97-B91;	A97-B92;	A97-B93;	A97-B94;	A97-B95;	A97-B96;
A97-B97;	A97-B98;	A97-B99;	A97-B100;	A97-B101;	A97-B102;
A97-B103;	A97-B104;	A97-B105;	A97-B106;	A97-B107;	A97-B108;
A97-B109;	A97-B110;	A97-B111;	A97-B112;	A97-B113;	A97-B114;
A97-B115;	A97-B116;	A97-B117;	A97-B118;	A97-B119;	A97-B120;
A97-B121;	A97-B122;	A97-B123;	A97-B124;	A97-B125;	A97-B126;
A97-B127;	A97-B128;	A97-B129;	A97-B130;	A97-B131;	A97-B132;
A97-B133;	A97-B134;	A97-B135;	A97-B136;	A97-B137;	A97-B138;
A97-B139;	A97-B140;	A97-B141;	A97-B142;	A97-B143;	A97-B144;
A97-B145;	A97-B146;	A97-B147;	A97-B148;	A97-B149;	A97-B150;
A97-B151;	A97-B152;	A97-B153;	A97-B154;	A97-B155;	A97-B156;
A97-B157;	A97-B158;	A97-B159;	A97-B160;	A97-B161;	A97-B162;
A97-B163;	A97-B164;	A97-B165;	A97-B166;	A97-B167;	A97-B168;
A97-B169;	A98-B1;	A98-B2;	A98-B3;	A98-B4;	A98-B5;
A98-B6;	A98-B7;	A98-B8;	A98-B9;	A98-B10;	A98-B11;
A98-B12;	A98-B13;	A98-B14;	A98-B15;	A98-B16;	A98-B17;
A98-B18;	A98-B19;	A98-B20;	A98-B21;	A98-B22;	A98-B23;
A98-B24;	A98-B25;	A98-B26;	A98-B27;	A98-B28;	A98-B29;
A98-B30;	A98-B31;	A98-B32;	A98-B33;	A98-B34;	A98-B35;
A98-B36;	A98-B37;	A98-B38;	A98-B39;	A98-B40;	A98-B41;
A98-B42;	A98-B43;	A98-B44;	A98-B45;	A98-B46;	A98-B47;
A98-B48;	A98-B49;	A98-B50;	A98-B51;	A98-B52;	A98-B53;
A98-B54;	A98-B55;	A98-B56;	A98-B57;	A98-B58;	A98-B59;
A98-B60;	A98-B61;	A98-B62;	A98-B63;	A98-B64;	A98-B65;
A98-B66;	A98-B67;	A98-B68;	A98-B69;	A98-B70;	A98-B71;
A98-B72;	A98-B73;	A98-B74;	A98-B75;	A98-B76;	A98-B77;

A98-B78;	A98-B79;	A98-B80;	A98-B81;	A98-B82;	A98-B83;
A98-B84;	A98-B85;	A98-B86;	A98-B87;	A98-B88;	A98-B89;
A98-B90;	A98-B91;	A98-B92;	A98-B93;	A98-B94;	A98-B95;
A98-B96;	A98-B97;	A98-B98;	A98-B99;	A98-B100;	A98-B101;
A98-B102;	A98-B103;	A98-B104;	A98-B105;	A98-B106;	A98-B107;
A98-B108;	A98-B109;	A98-B110;	A98-B111;	A98-B112;	A98-B113;
A98-B114;	A98-B115;	A98-B116;	A98-B117;	A98-B118;	A98-B119;
A98-B120;	A98-B121;	A98-B122;	A98-B123;	A98-B124;	A98-B125;
A98-B126;	A98-B127;	A98-B128;	A98-B129;	A98-B130;	A98-B131;
A98-B132;	A98-B133;	A98-B134;	A98-B135;	A98-B136;	A98-B137;
A98-B138;	A98-B139;	A98-B140;	A98-B141;	A98-B142;	A98-B143;
A98-B144;	A98-B145;	A98-B146;	A98-B147;	A98-B148;	A98-B149;
A98-B150;	A98-B151;	A98-B152;	A98-B153;	A98-B154;	A98-B155;
A98-B156;	A98-B157;	A98-B158;	A98-B159;	A98-B160;	A98-B161;
A98-B162;	A98-B163;	A98-B164;	A98-B165;	A98-B166;	A98-B167;
A98-B168;	A98-B169;	A99-B1;	A99-B2;	A99-B3;	A99-B4;
A99-B5;	A99-B6;	A99-B7;	A99-B8;	A99-B9;	A99-B10;
A99-B11;	A99-B12;	A99-B13;	A99-B14;	A99-B15;	A99-B16;
A99-B17;	A99-B18;	A99-B19;	A99-B20;	A99-B21;	A99-B22;
A99-B23;	A99-B24;	A99-B25;	A99-B26;	A99-B27;	A99-B28;
A99-B29;	A99-B30;	A99-B31;	A99-B32;	A99-B33;	A99-B34;
A99-B35;	A99-B36;	A99-B37;	A99-B38;	A99-B39;	A99-B40;
A99-B41;	A99-B42;	A99-B43;	A99-B44;	A99-B45;	A99-B46;
A99-B47;	A99-B48;	A99-B49;	A99-B50;	A99-B51;	A99-B52;
A99-B53;	A99-B54;	A99-B55;	A99-B56;	A99-B57;	A99-B58;
A99-B59;	A99-B60;	A99-B61;	A99-B62;	A99-B63;	A99-B64;
A99-B65;	A99-B66;	A99-B67;	A99-B68;	A99-B69;	A99-B70;
A99-B71;	A99-B72;	A99-B73;	A99-B74;	A99-B75;	A99-B76;
A99-B77;	A99-B78;	A99-B79;	A99-B80;	A99-B81;	A99-B82;
A99-B83;	A99-B84;	A99-B85;	A99-B86;	A99-B87;	A99-B88;
A99-B89;	A99-B90;	A99-B91;	A99-B92;	A99-B93;	A99-B94;
A99-B95;	A99-B96;	A99-B97;	A99-B98;	A99-B99;	A99-B100;
A99-B101;	A99-B102;	A99-B103;	A99-B104;	A99-B105;	A99-B106;
A99-B107;	A99-B108;	A99-B109;	A99-B110;	A99-B111;	A99-B112;
A99-B113;	A99-B114;	A99-B115;	A99-B116;	A99-B117;	A99-B118;

A99-B119;	A99-B120;	A99-B121;	A99-B122;	A99-B123;	A99-B124;
A99-B125;	A99-B126;	A99-B127;	A99-B128;	A99-B129;	A99-B130;
A99-B131;	A99-B132;	A99-B133;	A99-B134;	A99-B135;	A99-B136;
A99-B137;	A99-B138;	A99-B139;	A99-B140;	A99-B141;	A99-B142;
A99-B143;	A99-B144;	A99-B145;	A99-B146;	A99-B147;	A99-B148;
A99-B149;	A99-B150;	A99-B151;	A99-B152;	A99-B153;	A99-B154;
A99-B155;	A99-B156;	A99-B157;	A99-B158;	A99-B159;	A99-B160;
A99-B161;	A99-B162;	A99-B163;	A99-B164;	A99-B165;	A99-B166;
A99-B167;	A99-B168;	A99-B169;	A100-B1;	A100-B2;	A100-B3;
A100-B4;	A100-B5;	A100-B6;	A100-B7;	A100-B8;	A100-B9;
A100-B10;	A100-B11;	A100-B12;	A100-B13;	A100-B14;	A100-B15;
A100-B16;	A100-B17;	A100-B18;	A100-B19;	A100-B20;	A100-B21;
A100-B22;	A100-B23;	A100-B24;	A100-B25;	A100-B26;	A100-B27;
A100-B28;	A100-B29;	A100-B30;	A100-B31;	A100-B32;	A100-B33;
A100-B34;	A100-B35;	A100-B36;	A100-B37;	A100-B38;	A100-B39;
A100-B40;	A100-B41;	A100-B42;	A100-B43;	A100-B44;	A100-B45;
A100-B46;	A100-B47;	A100-B48;	A100-B49;	A100-B50;	A100-B51;
A100-B52;	A100-B53;	A100-B54;	A100-B55;	A100-B56;	A100-B57;
A100-B58;	A100-B59;	A100-B60;	A100-B61;	A100-B62;	A100-B63;
A100-B64;	A100-B65;	A100-B66;	A100-B67;	A100-B68;	A100-B69;
A100-B70;	A100-B71;	A100-B72;	A100-B73;	A100-B74;	A100-B75;
A100-B76;	A100-B77;	A100-B78;	A100-B79;	A100-B80;	A100-B81;
A100-B82;	A100-B83;	A100-B84;	A100-B85;	A100-B86;	A100-B87;
A100-B88;	A100-B89;	A100-B90;	A100-B91;	A100-B92;	A100-B93;
A100-B94;	A100-B95;	A100-B96;	A100-B97;	A100-B98;	A100-B99;
A100-B100;	A100-B101;	A100-B102;	A100-B103;	A100-B104;	A100-B105;
A100-B106;	A100-B107;	A100-B108;	A100-B109;	A100-B110;	A100-B111;
A100-B112;	A100-B113;	A100-B114;	A100-B115;	A100-B116;	A100-B117;
A100-B118;	A100-B119;	A100-B120;	A100-B121;	A100-B122;	A100-B123;
A100-B124;	A100-B125;	A100-B126;	A100-B127;	A100-B128;	A100-B129;
A100-B130;	A100-B131;	A100-B132;	A100-B133;	A100-B134;	A100-B135;
A100-B136;	A100-B137;	A100-B138;	A100-B139;	A100-B140;	A100-B141;
A100-B142;	A100-B143;	A100-B144;	A100-B145;	A100-B146;	A100-B147;
A100-B148;	A100-B149;	A100-B150;	A100-B151;	A100-B152;	A100-B153;
A100-B154;	A100-B155;	A100-B156;	A100-B157;	A100-B158;	A100-B159;

A100-B160;	A100-B161;	A100-B162;	A100-B163;	A100-B164;	A100-B165;
A100-B166;	A100-B167;	A100-B168;	A100-B169;	A101-B1;	A101-B2;
A101-B3;	A101-B4;	A101-B5;	A101-B6;	A101-B7;	A101-B8;
A101-B9;	A101-B10;	A101-B11;	A101-B12;	A101-B13;	A101-B14;
A101-B15;	A101-B16;	A101-B17;	A101-B18;	A101-B19;	A101-B20;
A101-B21;	A101-B22;	A101-B23;	A101-B24;	A101-B25;	A101-B26;
A101-B27;	A101-B28;	A101-B29;	A101-B30;	A101-B31;	A101-B32;
A101-B33;	A101-B34;	A101-B35;	A101-B36;	A101-B37;	A101-B38;
A101-B39;	A101-B40;	A101-B41;	A101-B42;	A101-B43;	A101-B44;
A101-B45;	A101-B46;	A101-B47;	A101-B48;	A101-B49;	A101-B50;
A101-B51;	A101-B52;	A101-B53;	A101-B54;	A101-B55;	A101-B56;
A101-B57;	A101-B58;	A101-B59;	A101-B60;	A101-B61;	A101-B62;
A101-B63;	A101-B64;	A101-B65;	A101-B66;	A101-B67;	A101-B68;
A101-B69;	A101-B70;	A101-B71;	A101-B72;	A101-B73;	A101-B74;
A101-B75;	A101-B76;	A101-B77;	A101-B78;	A101-B79;	A101-B80;
A101-B81;	A101-B82;	A101-B83;	A101-B84;	A101-B85;	A101-B86;
A101-B87;	A101-B88;	A101-B89;	A101-B90;	A101-B91;	A101-B92;
A101-B93;	A101-B94;	A101-B95;	A101-B96;	A101-B97;	A101-B98;
A101-B99;	A101-B100;	A101-B101;	A101-B102;	A101-B103;	A101-B104;
A101-B105;	A101-B106;	A101-B107;	A101-B108;	A101-B109;	A101-B110;
A101-B111;	A101-B112;	A101-B113;	A101-B114;	A101-B115;	A101-B116;
A101-B117;	A101-B118;	A101-B119;	A101-B120;	A101-B121;	A101-B122;
A101-B123;	A101-B124;	A101-B125;	A101-B126;	A101-B127;	A101-B128;
A101-B129;	A101-B130;	A101-B131;	A101-B132;	A101-B133;	A101-B134;
A101-B135;	A101-B136;	A101-B137;	A101-B138;	A101-B139;	A101-B140;
A101-B141;	A101-B142;	A101-B143;	A101-B144;	A101-B145;	A101-B146;
A101-B147;	A101-B148;	A101-B149;	A101-B150;	A101-B151;	A101-B152;
A101-B153;	A101-B154;	A101-B155;	A101-B156;	A101-B157;	A101-B158;
A101-B159;	A101-B160;	A101-B161;	A101-B162;	A101-B163;	A101-B164;
A101-B165;	A101-B166;	A101-B167;	A101-B168;	A101-B169;	A102-B1;
A102-B2;	A102-B3;	A102-B4;	A102-B5;	A102-B6;	A102-B7;
A102-B8;	A102-B9;	A102-B10;	A102-B11;	A102-B12;	A102-B13;
A102-B14;	A102-B15;	A102-B16;	A102-B17;	A102-B18;	A102-B19;
A102-B20;	A102-B21;	A102-B22;	A102-B23;	A102-B24;	A102-B25;
A102-B26;	A102-B27;	A102-B28;	A102-B29;	A102-B30;	A102-B31;

A102-B32;	A102-B33;	A102-B34;	A102-B35;	A102-B36;	A102-B37;
A102-B38;	A102-B39;	A102-B40;	A102-B41;	A102-B42;	A102-B43;
A102-B44;	A102-B45;	A102-B46;	A102-B47;	A102-B48;	A102-B49;
A102-B50;	A102-B51;	A102-B52;	A102-B53;	A102-B54;	A102-B55;
A102-B56;	A102-B57;	A102-B58;	A102-B59;	A102-B60;	A102-B61;
A102-B62;	A102-B63;	A102-B64;	A102-B65;	A102-B66;	A102-B67;
A102-B68;	A102-B69;	A102-B70;	A102-B71;	A102-B72;	A102-B73;
A102-B74;	A102-B75;	A102-B76;	A102-B77;	A102-B78;	A102-B79;
A102-B80;	A102-B81;	A102-B82;	A102-B83;	A102-B84;	A102-B85;
A102-B86;	A102-B87;	A102-B88;	A102-B89;	A102-B90;	A102-B91;
A102-B92;	A102-B93;	A102-B94;	A102-B95;	A102-B96;	A102-B97;
A102-B98;	A102-B99;	A102-B100;	A102-B101;	A102-B102;	A102-B103;
A102-B104;	A102-B105;	A102-B106;	A102-B107;	A102-B108;	A102-B109;
A102-B110;	A102-B111;	A102-B112;	A102-B113;	A102-B114;	A102-B115;
A102-B116;	A102-B117;	A102-B118;	A102-B119;	A102-B120;	A102-B121;
A102-B122;	A102-B123;	A102-B124;	A102-B125;	A102-B126;	A102-B127;
A102-B128;	A102-B129;	A102-B130;	A102-B131;	A102-B132;	A102-B133;
A102-B134;	A102-B135;	A102-B136;	A102-B137;	A102-B138;	A102-B139;
A102-B140;	A102-B141;	A102-B142;	A102-B143;	A102-B144;	A102-B145;
A102-B146;	A102-B147;	A102-B148;	A102-B149;	A102-B150;	A102-B151;
A102-B152;	A102-B153;	A102-B154;	A102-B155;	A102-B156;	A102-B157;
A102-B158;	A102-B159;	A102-B160;	A102-B161;	A102-B162;	A102-B163;
A102-B164;	A102-B165;	A102-B166;	A102-B167;	A102-B168;	A102-B169;
A103-B1;	A103-B2;	A103-B3;	A103-B4;	A103-B5;	A103-B6;
A103-B7;	A103-B8;	A103-B9;	A103-B10;	A103-B11;	A103-B12;
A103-B13;	A103-B14;	A103-B15;	A103-B16;	A103-B17;	A103-B18;
A103-B19;	A103-B20;	A103-B21;	A103-B22;	A103-B23;	A103-B24;
A103-B25;	A103-B26;	A103-B27;	A103-B28;	A103-B29;	A103-B30;
A103-B31;	A103-B32;	A103-B33;	A103-B34;	A103-B35;	A103-B36;
A103-B37;	A103-B38;	A103-B39;	A103-B40;	A103-B41;	A103-B42;
A103-B43;	A103-B44;	A103-B45;	A103-B46;	A103-B47;	A103-B48;
A103-B49;	A103-B50;	A103-B51;	A103-B52;	A103-B53;	A103-B54;
A103-B55;	A103-B56;	A103-B57;	A103-B58;	A103-B59;	A103-B60;
A103-B61;	A103-B62;	A103-B63;	A103-B64;	A103-B65;	A103-B66;
A103-B67;	A103-B68;	A103-B69;	A103-B70;	A103-B71;	A103-B72;

A103-B73;	A103-B74;	A103-B75;	A103-B76;	A103-B77;	A103-B78;
A103-B79;	A103-B80;	A103-B81;	A103-B82;	A103-B83;	A103-B84;
A103-B85;	A103-B86;	A103-B87;	A103-B88;	A103-B89;	A103-B90;
A103-B91;	A103-B92;	A103-B93;	A103-B94;	A103-B95;	A103-B96;
A103-B97;	A103-B98;	A103-B99;	A103-B100;	A103-B101;	A103-B102;
A103-B103;	A103-B104;	A103-B105;	A103-B106;	A103-B107;	A103-B108;
A103-B109;	A103-B110;	A103-B111;	A103-B112;	A103-B113;	A103-B114;
A103-B115;	A103-B116;	A103-B117;	A103-B118;	A103-B119;	A103-B120;
A103-B121;	A103-B122;	A103-B123;	A103-B124;	A103-B125;	A103-B126;
A103-B127;	A103-B128;	A103-B129;	A103-B130;	A103-B131;	A103-B132;
A103-B133;	A103-B134;	A103-B135;	A103-B136;	A103-B137;	A103-B138;
A103-B139;	A103-B140;	A103-B141;	A103-B142;	A103-B143;	A103-B144;
A103-B145;	A103-B146;	A103-B147;	A103-B148;	A103-B149;	A103-B150;
A103-B151;	A103-B152;	A103-B153;	A103-B154;	A103-B155;	A103-B156;
A103-B157;	A103-B158;	A103-B159;	A103-B160;	A103-B161;	A103-B162;
A103-B163;	A103-B164;	A103-B165;	A103-B166;	A103-B167;	A103-B168;
A103-B169;	A104-B1;	A104-B2;	A104-B3;	A104-B4;	A104-B5;
A104-B6;	A104-B7;	A104-B8;	A104-B9;	A104-B10;	A104-B11;
A104-B12;	A104-B13;	A104-B14;	A104-B15;	A104-B16;	A104-B17;
A104-B18;	A104-B19;	A104-B20;	A104-B21;	A104-B22;	A104-B23;
A104-B24;	A104-B25;	A104-B26;	A104-B27;	A104-B28;	A104-B29;
A104-B30;	A104-B31;	A104-B32;	A104-B33;	A104-B34;	A104-B35;
A104-B36;	A104-B37;	A104-B38;	A104-B39;	A104-B40;	A104-B41;
A104-B42;	A104-B43;	A104-B44;	A104-B45;	A104-B46;	A104-B47;
A104-B48;	A104-B49;	A104-B50;	A104-B51;	A104-B52;	A104-B53;
A104-B54;	A104-B55;	A104-B56;	A104-B57;	A104-B58;	A104-B59;
A104-B60;	A104-B61;	A104-B62;	A104-B63;	A104-B64;	A104-B65;
A104-B66;	A104-B67;	A104-B68;	A104-B69;	A104-B70;	A104-B71;
A104-B72;	A104-B73;	A104-B74;	A104-B75;	A104-B76;	A104-B77;
A104-B78;	A104-B79;	A104-B80;	A104-B81;	A104-B82;	A104-B83;
A104-B84;	A104-B85;	A104-B86;	A104-B87;	A104-B88;	A104-B89;
A104-B90;	A104-B91;	A104-B92;	A104-B93;	A104-B94;	A104-B95;
A104-B96;	A104-B97;	A104-B98;	A104-B99;	A104-B100;	A104-B101;
A104-B102;	A104-B103;	A104-B104;	A104-B105;	A104-B106;	A104-B107;
A104-B108;	A104-B109;	A104-B110;	A104-B111;	A104-B112;	A104-B113;

A104-B114;	A104-B115;	A104-B116;	A104-B117;	A104-B118;	A104-B119;
A104-B120;	A104-B121;	A104-B122;	A104-B123;	A104-B124;	A104-B125;
A104-B126;	A104-B127;	A104-B128;	A104-B129;	A104-B130;	A104-B131;
A104-B132;	A104-B133;	A104-B134;	A104-B135;	A104-B136;	A104-B137;
A104-B138;	A104-B139;	A104-B140;	A104-B141;	A104-B142;	A104-B143;
A104-B144;	A104-B145;	A104-B146;	A104-B147;	A104-B148;	A104-B149;
A104-B150;	A104-B151;	A104-B152;	A104-B153;	A104-B154;	A104-B155;
A104-B156;	A104-B157;	A104-B158;	A104-B159;	A104-B160;	A104-B161;
A104-B162;	A104-B163;	A104-B164;	A104-B165;	A104-B166;	A104-B167;
A104-B168;	A104-B169;	A105-B1;	A105-B2;	A105-B3;	A105-B4;
A105-B5;	A105-B6;	A105-B7;	A105-B8;	A105-B9;	A105-B10;
A105-B11;	A105-B12;	A105-B13;	A105-B14;	A105-B15;	A105-B16;
A105-B17;	A105-B18;	A105-B19;	A105-B20;	A105-B21;	A105-B22;
A105-B23;	A105-B24;	A105-B25;	A105-B26;	A105-B27;	A105-B28;
A105-B29;	A105-B30;	A105-B31;	A105-B32;	A105-B33;	A105-B34;
A105-B35;	A105-B36;	A105-B37;	A105-B38;	A105-B39;	A105-B40;
A105-B41;	A105-B42;	A105-B43;	A105-B44;	A105-B45;	A105-B46;
A105-B47;	A105-B48;	A105-B49;	A105-B50;	A105-B51;	A105-B52;
A105-B53;	A105-B54;	A105-B55;	A105-B56;	A105-B57;	A105-B58;
A105-B59;	A105-B60;	A105-B61;	A105-B62;	A105-B63;	A105-B64;
A105-B65;	A105-B66;	A105-B67;	A105-B68;	A105-B69;	A105-B70;
A105-B71;	A105-B72;	A105-B73;	A105-B74;	A105-B75;	A105-B76;
A105-B77;	A105-B78;	A105-B79;	A105-B80;	A105-B81;	A105-B82;
A105-B83;	A105-B84;	A105-B85;	A105-B86;	A105-B87;	A105-B88;
A105-B89;	A105-B90;	A105-B91;	A105-B92;	A105-B93;	A105-B94;
A105-B95;	A105-B96;	A105-B97;	A105-B98;	A105-B99;	A105-B100;
A105-B101;	A105-B102;	A105-B103;	A105-B104;	A105-B105;	A105-B106;
A105-B107;	A105-B108;	A105-B109;	A105-B110;	A105-B111;	A105-B112;
A105-B113;	A105-B114;	A105-B115;	A105-B116;	A105-B117;	A105-B118;
A105-B119;	A105-B120;	A105-B121;	A105-B122;	A105-B123;	A105-B124;
A105-B125;	A105-B126;	A105-B127;	A105-B128;	A105-B129;	A105-B130;
A105-B131;	A105-B132;	A105-B133;	A105-B134;	A105-B135;	A105-B136;
A105-B137;	A105-B138;	A105-B139;	A105-B140;	A105-B141;	A105-B142;
A105-B143;	A105-B144;	A105-B145;	A105-B146;	A105-B147;	A105-B148;
A105-B149;	A105-B150;	A105-B151;	A105-B152;	A105-B153;	A105-B154;

A105-B155;	A105-B156;	A105-B157;	A105-B158;	A105-B159;	A105-B160;
A105-B161;	A105-B162;	A105-B163;	A105-B164;	A105-B165;	A105-B166;
A105-B167;	A105-B168;	A105-B169;	A106-B1;	A106-B2;	A106-B3;
A106-B4;	A106-B5;	A106-B6;	A106-B7;	A106-B8;	A106-B9;
A106-B10;	A106-B11;	A106-B12;	A106-B13;	A106-B14;	A106-B15;
A106-B16;	A106-B17;	A106-B18;	A106-B19;	A106-B20;	A106-B21;
A106-B22;	A106-B23;	A106-B24;	A106-B25;	A106-B26;	A106-B27;
A106-B28;	A106-B29;	A106-B30;	A106-B31;	A106-B32;	A106-B33;
A106-B34;	A106-B35;	A106-B36;	A106-B37;	A106-B38;	A106-B39;
A106-B40;	A106-B41;	A106-B42;	A106-B43;	A106-B44;	A106-B45;
A106-B46;	A106-B47;	A106-B48;	A106-B49;	A106-B50;	A106-B51;
A106-B52;	A106-B53;	A106-B54;	A106-B55;	A106-B56;	A106-B57;
A106-B58;	A106-B59;	A106-B60;	A106-B61;	A106-B62;	A106-B63;
A106-B64;	A106-B65;	A106-B66;	A106-B67;	A106-B68;	A106-B69;
A106-B70;	A106-B71;	A106-B72;	A106-B73;	A106-B74;	A106-B75;
A106-B76;	A106-B77;	A106-B78;	A106-B79;	A106-B80;	A106-B81;
A106-B82;	A106-B83;	A106-B84;	A106-B85;	A106-B86;	A106-B87;
A106-B88;	A106-B89;	A106-B90;	A106-B91;	A106-B92;	A106-B93;
A106-B94;	A106-B95;	A106-B96;	A106-B97;	A106-B98;	A106-B99;
A106-B100;	A106-B101;	A106-B102;	A106-B103;	A106-B104;	A106-B105;
A106-B106;	A106-B107;	A106-B108;	A106-B109;	A106-B110;	A106-B111;
A106-B112;	A106-B113;	A106-B114;	A106-B115;	A106-B116;	A106-B117;
A106-B118;	A106-B119;	A106-B120;	A106-B121;	A106-B122;	A106-B123;
A106-B124;	A106-B125;	A106-B126;	A106-B127;	A106-B128;	A106-B129;
A106-B130;	A106-B131;	A106-B132;	A106-B133;	A106-B134;	A106-B135;
A106-B136;	A106-B137;	A106-B138;	A106-B139;	A106-B140;	A106-B141;
A106-B142;	A106-B143;	A106-B144;	A106-B145;	A106-B146;	A106-B147;
A106-B148;	A106-B149;	A106-B150;	A106-B151;	A106-B152;	A106-B153;
A106-B154;	A106-B155;	A106-B156;	A106-B157;	A106-B158;	A106-B159;
A106-B160;	A106-B161;	A106-B162;	A106-B163;	A106-B164;	A106-B165;
A106-B166;	A106-B167;	A106-B168;	A106-B169;	A107-B1;	A107-B2;
A107-B3;	A107-B4;	A107-B5;	A107-B6;	A107-B7;	A107-B8;
A107-B9;	A107-B10;	A107-B11;	A107-B12;	A107-B13;	A107-B14;
A107-B15;	A107-B16;	A107-B17;	A107-B18;	A107-B19;	A107-B20;
A107-B21;	A107-B22;	A107-B23;	A107-B24;	A107-B25;	A107-B26;

A107-B27;	A107-B28;	A107-B29;	A107-B30;	A107-B31;	A107-B32;
A107-B33;	A107-B34;	A107-B35;	A107-B36;	A107-B37;	A107-B38;
A107-B39;	A107-B40;	A107-B41;	A107-B42;	A107-B43;	A107-B44;
A107-B45;	A107-B46;	A107-B47;	A107-B48;	A107-B49;	A107-B50;
A107-B51;	A107-B52;	A107-B53;	A107-B54;	A107-B55;	A107-B56;
A107-B57;	A107-B58;	A107-B59;	A107-B60;	A107-B61;	A107-B62;
A107-B63;	A107-B64;	A107-B65;	A107-B66;	A107-B67;	A107-B68;
A107-B69;	A107-B70;	A107-B71;	A107-B72;	A107-B73;	A107-B74;
A107-B75;	A107-B76;	A107-B77;	A107-B78;	A107-B79;	A107-B80;
A107-B81;	A107-B82;	A107-B83;	A107-B84;	A107-B85;	A107-B86;
A107-B87;	A107-B88;	A107-B89;	A107-B90;	A107-B91;	A107-B92;
A107-B93;	A107-B94;	A107-B95;	A107-B96;	A107-B97;	A107-B98;
A107-B99;	A107-B100;	A107-B101;	A107-B102;	A107-B103;	A107-B104;
A107-B105;	A107-B106;	A107-B107;	A107-B108;	A107-B109;	A107-B110;
A107-B111;	A107-B112;	A107-B113;	A107-B114;	A107-B115;	A107-B116;
A107-B117;	A107-B118;	A107-B119;	A107-B120;	A107-B121;	A107-B122;
A107-B123;	A107-B124;	A107-B125;	A107-B126;	A107-B127;	A107-B128;
A107-B129;	A107-B130;	A107-B131;	A107-B132;	A107-B133;	A107-B134;
A107-B135;	A107-B136;	A107-B137;	A107-B138;	A107-B139;	A107-B140;
A107-B141;	A107-B142;	A107-B143;	A107-B144;	A107-B145;	A107-B146;
A107-B147;	A107-B148;	A107-B149;	A107-B150;	A107-B151;	A107-B152;
A107-B153;	A107-B154;	A107-B155;	A107-B156;	A107-B157;	A107-B158;
A107-B159;	A107-B160;	A107-B161;	A107-B162;	A107-B163;	A107-B164;
A107-B165;	A107-B166;	A107-B167;	A107-B168;	A107-B169;	A108-B1;
A108-B2;	A108-B3;	A108-B4;	A108-B5;	A108-B6;	A108-B7;
A108-B8;	A108-B9;	A108-B10;	A108-B11;	A108-B12;	A108-B13;
A108-B14;	A108-B15;	A108-B16;	A108-B17;	A108-B18;	A108-B19;
A108-B20;	A108-B21;	A108-B22;	A108-B23;	A108-B24;	A108-B25;
A108-B26;	A108-B27;	A108-B28;	A108-B29;	A108-B30;	A108-B31;
A108-B32;	A108-B33;	A108-B34;	A108-B35;	A108-B36;	A108-B37;
A108-B38;	A108-B39;	A108-B40;	A108-B41;	A108-B42;	A108-B43;
A108-B44;	A108-B45;	A108-B46;	A108-B47;	A108-B48;	A108-B49;
A108-B50;	A108-B51;	A108-B52;	A108-B53;	A108-B54;	A108-B55;
A108-B56;	A108-B57;	A108-B58;	A108-B59;	A108-B60;	A108-B61;
A108-B62;	A108-B63;	A108-B64;	A108-B65;	A108-B66;	A108-B67;

A108-B68;	A108-B69;	A108-B70;	A108-B71;	A108-B72;	A108-B73;
A108-B74;	A108-B75;	A108-B76;	A108-B77;	A108-B78;	A108-B79;
A108-B80;	A108-B81;	A108-B82;	A108-B83;	A108-B84;	A108-B85;
A108-B86;	A108-B87;	A108-B88;	A108-B89;	A108-B90;	A108-B91;
A108-B92;	A108-B93;	A108-B94;	A108-B95;	A108-B96;	A108-B97;
A108-B98;	A108-B99;	A108-B100;	A108-B101;	A108-B102;	A108-B103;
A108-B104;	A108-B105;	A108-B106;	A108-B107;	A108-B108;	A108-B109;
A108-B110;	A108-B111;	A108-B112;	A108-B113;	A108-B114;	A108-B115;
A108-B116;	A108-B117;	A108-B118;	A108-B119;	A108-B120;	A108-B121;
A108-B122;	A108-B123;	A108-B124;	A108-B125;	A108-B126;	A108-B127;
A108-B128;	A108-B129;	A108-B130;	A108-B131;	A108-B132;	A108-B133;
A108-B134;	A108-B135;	A108-B136;	A108-B137;	A108-B138;	A108-B139;
A108-B140;	A108-B141;	A108-B142;	A108-B143;	A108-B144;	A108-B145;
A108-B146;	A108-B147;	A108-B148;	A108-B149;	A108-B150;	A108-B151;
A108-B152;	A108-B153;	A108-B154;	A108-B155;	A108-B156;	A108-B157;
A108-B158;	A108-B159;	A108-B160;	A108-B161;	A108-B162;	A108-B163;
A108-B164;	A108-B165;	A108-B166;	A108-B167;	A108-B168;	A108-B169;
A109-B1;	A109-B2;	A109-B3;	A109-B4;	A109-B5;	A109-B6;
A109-B7;	A109-B8;	A109-B9;	A109-B10;	A109-B11;	A109-B12;
A109-B13;	A109-B14;	A109-B15;	A109-B16;	A109-B17;	A109-B18;
A109-B19;	A109-B20;	A109-B21;	A109-B22;	A109-B23;	A109-B24;
A109-B25;	A109-B26;	A109-B27;	A109-B28;	A109-B29;	A109-B30;
A109-B31;	A109-B32;	A109-B33;	A109-B34;	A109-B35;	A109-B36;
A109-B37;	A109-B38;	A109-B39;	A109-B40;	A109-B41;	A109-B42;
A109-B43;	A109-B44;	A109-B45;	A109-B46;	A109-B47;	A109-B48;
A109-B49;	A109-B50;	A109-B51;	A109-B52;	A109-B53;	A109-B54;
A109-B55;	A109-B56;	A109-B57;	A109-B58;	A109-B59;	A109-B60;
A109-B61;	A109-B62;	A109-B63;	A109-B64;	A109-B65;	A109-B66;
A109-B67;	A109-B68;	A109-B69;	A109-B70;	A109-B71;	A109-B72;
A109-B73;	A109-B74;	A109-B75;	A109-B76;	A109-B77;	A109-B78;
A109-B79;	A109-B80;	A109-B81;	A109-B82;	A109-B83;	A109-B84;
A109-B85;	A109-B86;	A109-B87;	A109-B88;	A109-B89;	A109-B90;
A109-B91;	A109-B92;	A109-B93;	A109-B94;	A109-B95;	A109-B96;
A109-B97;	A109-B98;	A109-B99;	A109-B100;	A109-B101;	A109-B102;
A109-B103;	A109-B104;	A109-B105;	A109-B106;	A109-B107;	A109-B108;

A109-B109;	A109-B110;	A109-B111;	A109-B112;	A109-B113;	A109-B114;
A109-B115;	A109-B116;	A109-B117;	A109-B118;	A109-B119;	A109-B120;
A109-B121;	A109-B122;	A109-B123;	A109-B124;	A109-B125;	A109-B126;
A109-B127;	A109-B128;	A109-B129;	A109-B130;	A109-B131;	A109-B132;
A109-B133;	A109-B134;	A109-B135;	A109-B136;	A109-B137;	A109-B138;
A109-B139;	A109-B140;	A109-B141;	A109-B142;	A109-B143;	A109-B144;
A109-B145;	A109-B146;	A109-B147;	A109-B148;	A109-B149;	A109-B150;
A109-B151;	A109-B152;	A109-B153;	A109-B154;	A109-B155;	A109-B156;
A109-B157;	A109-B158;	A109-B159;	A109-B160;	A109-B161;	A109-B162;
A109-B163;	A109-B164;	A109-B165;	A109-B166;	A109-B167;	A109-B168;
A109-B169;	A110-B1;	A110-B2;	A110-B3;	A110-B4;	A110-B5;
A110-B6;	A110-B7;	A110-B8;	A110-B9;	A110-B10;	A110-B11;
A110-B12;	A110-B13;	A110-B14;	A110-B15;	A110-B16;	A110-B17;
A110-B18;	A110-B19;	A110-B20;	A110-B21;	A110-B22;	A110-B23;
A110-B24;	A110-B25;	A110-B26;	A110-B27;	A110-B28;	A110-B29;
A110-B30;	A110-B31;	A110-B32;	A110-B33;	A110-B34;	A110-B35;
A110-B36;	A110-B37;	A110-B38;	A110-B39;	A110-B40;	A110-B41;
A110-B42;	A110-B43;	A110-B44;	A110-B45;	A110-B46;	A110-B47;
A110-B48;	A110-B49;	A110-B50;	A110-B51;	A110-B52;	A110-B53;
A110-B54;	A110-B55;	A110-B56;	A110-B57;	A110-B58;	A110-B59;
A110-B60;	A110-B61;	A110-B62;	A110-B63;	A110-B64;	A110-B65;
A110-B66;	A110-B67;	A110-B68;	A110-B69;	A110-B70;	A110-B71;
A110-B72;	A110-B73;	A110-B74;	A110-B75;	A110-B76;	A110-B77;
A110-B78;	A110-B79;	A110-B80;	A110-B81;	A110-B82;	A110-B83;
A110-B84;	A110-B85;	A110-B86;	A110-B87;	A110-B88;	A110-B89;
A110-B90;	A110-B91;	A110-B92;	A110-B93;	A110-B94;	A110-B95;
A110-B96;	A110-B97;	A110-B98;	A110-B99;	A110-B100;	A110-B101;
A110-B102;	A110-B103;	A110-B104;	A110-B105;	A110-B106;	A110-B107;
A110-B108;	A110-B109;	A110-B110;	A110-B111;	A110-B112;	A110-B113;
A110-B114;	A110-B115;	A110-B116;	A110-B117;	A110-B118;	A110-B119;
A110-B120;	A110-B121;	A110-B122;	A110-B123;	A110-B124;	A110-B125;
A110-B126;	A110-B127;	A110-B128;	A110-B129;	A110-B130;	A110-B131;
A110-B132;	A110-B133;	A110-B134;	A110-B135;	A110-B136;	A110-B137;
A110-B138;	A110-B139;	A110-B140;	A110-B141;	A110-B142;	A110-B143;
A110-B144;	A110-B145;	A110-B146;	A110-B147;	A110-B148;	A110-B149;

A110-B150;	A110-B151;	A110-B152;	A110-B153;	A110-B154;	A110-B155;
A110-B156;	A110-B157;	A110-B158;	A110-B159;	A110-B160;	A110-B161;
A110-B162;	A110-B163;	A110-B164;	A110-B165;	A110-B166;	A110-B167;
A110-B168;	A110-B169.				

Thus, for example, in the above list the compound denoted as A9-B9 is the product of the combination of group A9 in Table 1 and B9 in Table 2, namely



, Example 230(a) hereinafter described.

Particular compounds of the invention of formula (Ix) for the inhibition of SYK are:

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide;
5,6-dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
6-chloro-5-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
6-chloro-2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole;
2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5-trifluoromethyl-1H-benzoimidazole;
2-(5-cyclopropylmethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
5,6-dimethyl-2-[5-(pyridin-3-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole;
5-fluoro-2-[5-methylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole;
5,6-dimethyl-2-(5-phenethylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
4-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
5,6-dimethyl-2-(5-benzylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
6-chloro-5-methyl-2-(5-morpholin-4-yl-1H-pyrazol-3-yl)-1H-benzoimidazole;
5,6-dimethyl-2-[5-(thiophen-2-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole;
2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methoxy-1H-benzoimidazole hydrochloride;
5-methyl-2-(5-methylsulfanyl-4-propyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
2-(5-(4-methoxy-benzylsulfanyl)-4-propyl-1H-pyrazol-3-yl)- 5-methyl-1H-benzoimidazole;

2-(5-benzylsulfanyl-4-isopropyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole;
2-(5-methylsulfanyl-4-methyl-1H-pyrazol-3-yl)-5-methoxy-1H-benzoimidazole;
2-(5-methylsulfanyl-4-methyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole;
3-(5-chloro-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5,6-dichloro-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
2-(4-amino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester;
3-(1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-indazole;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanone;
2-(1H-indazol-3-yl)-3H-benzoimidazol-4-ol;
2-phenyl-1H-imidazol[4,5-b]pyrazine;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole;
2-(1H-indazol-3-yl)-3H-imidazo[4,5-c]pyridine;
2-(1H-indazole-3-yl)-3H-imidazo[4,5-b]pyridine;
2-(1H-pyrazol-3yl)-1H-benzoimidazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methoxy-1H-indazole;
3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-5-methoxy-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-fluoro-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-fluoro-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-methoxy-1H-indazole;
5,6-dimethyl-2-(4-phenyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
3-(5-ethyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-isopropyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-bromo-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-bromo-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(3-cyano)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;

3-(5-(pyrid-3-yl)-1H-benzoimidazol-2-yl)-1H-indazole;
3-(6-methyl-5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(2-fluoro)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(5,6-methylenedioxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(2-methoxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(4-chloro)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(4-methyl)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-benzyloxy-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5,6-methylenedioxy-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5,6-diethyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(4,5-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonitrile;
3-(5-methoxycarbonyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-ethoxy-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-pyrazole-4-carboxylic acid ethyl ester;
2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-pyrazole-4-carboxylic acid ethyl ester;
3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;
3-(5-methoxy-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide;
3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile;
3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;
3-(6-ethyl-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile;
2-(5-methyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
2-(5-ethoxy-1H-pyrazol-3-yl)-1H-benzoimidazole;
2-(5-methylsulfanyl-isoxazol-3-yl)-1H-benzoimidazole;
5-chloro-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;
5,6-dichloro-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;
(benzoimidazol-2-yl)-5-methylthio-3-pyrazole;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-indazole;
2-(5-isopropyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
2-(5-ethyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
5,6-dimethyl-2-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-1H-benzoimidazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4-fluoro-1H-indazole;
4-chloro-3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-chloro-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazol-5-ol;
3-(5-n-propyl-1H-benzoimidazol-2-yl)-1H-indazole;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-sulfonic acid benzylamide;
3-(5-methanesulfonyl-1H-benzoimidazol-2-yl)-1H-indazole;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanol;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, methylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, dimethylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, isopropylamide;
1H-benzoimidazol-5-yl]-carboxylic acid, benzylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide;
2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid cyclopropylamide;
2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide;
2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-morpholin-4-yl-ethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-methoxy-ethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-cyano-ethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide;
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide;

3-(5, 6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid tert-butylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid dimethylamide;
2-(4-isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid;
3-(5,6-dimethyl-1H-benzoimidazol-5-yl)-pyrazole-4-carboxylic acid;
2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-pyrazole-4-carboxylic acid;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide ;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-butyramide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-phenyl-acetamide;
cyclopropanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
methoxyacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopentanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
trimethylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
tert-butylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
butanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
isoxazole-5-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
S(+)-2-methylbutanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethylurea;
cyclopropanecarboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
N-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide;
cyclopropanecarboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3,5-dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide;
furan-3-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide;

5,6-dimethyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;

5-ethyl-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;

6-chloro-5-methoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;

5-fluoro-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;

2-(4-nitro-1H-pyrazol-3-yl)-5-trifluoromethoxy-1H-benzoimidazole;

2-(4-nitro-1H-pyrazol-3-yl)-5-trifluoromethyl-1H-benzoimidazole;

5-chloro-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;

2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide;

cyclopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone;

isopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone;

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-1-one;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid *tert*-butyl ester;

5-methoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;

5-ethoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;

3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester;

3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrano[4,3-c]pyrazole;

3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester;

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide;

2-dimethylamino-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide;

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]- 2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isonicotinamide;
2-cyclopropyl-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-phenyl-urea;
1-benzyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide;
cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide;
3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-ylamine;
4-methylpiperazine-1-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide;
1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea;
cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazole-4-yl]amide;
morpholine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
3-[6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea;
5-methoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;
morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylmethyl]-amide;
3-[3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea;
piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide;
morpholine-4-carboxylic acid[3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
piperidine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
morpholine-4-carboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylie acid diethylamide;

[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyrrolidin-1-yl-methanone;
[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-piperidin-1-yl-methanone;
[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-morpholin-4-yl-methanone;
3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;
morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;
3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [2-(2H-tetrazol-5-yl)-ethyl]-amide;
1-cyclopropyl-3-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
4-methyl-piperazine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
4-methyl-piperazine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-methyl-3-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-[3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
4-methyl-piperazine-1-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-tert-butyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-ethyl-urea;
4-methyl-piperazine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-cyclopropyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isobutyl-urea;
1-cyclopropylmethyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;

3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid amide dihydrochloride;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid;
2-(4-isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid;
3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
3-(5-nitro-1H-benzoimidazol-2-yl)-1H-indazole;
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-piperidin-1-yl-ethyl)-amide;
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide;
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide;
N-[2-(1H-Indazol-3-yl)-1H-benzoimidazol-5-yl]-isobutyramide;
N-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-piperidin-1-yl-acetamide;
2-(1H-indazol-3-yl)-3H-benzoimidazol-5-amine;
piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (Ixa) of the invention for the inhibition of SYK are:-
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide;
5,6-dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
6-chloro-5-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
6-chloro-2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole;
2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5-trifluoromethyl-1H-benzoimidazole;
2-(5-cyclopropylmethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
5,6-dimethyl-2-[5-(pyridin-3-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole;
5-fluoro-2-[5-methylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole;
5,6-dimethyl-2-(5-phenethylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
4-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
5,6-dimethyl-2-(5-benzylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
5,6-dimethyl-2-[5-(thiophen-2-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole;
2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methoxy-1H-benzoimidazole hydrochloride;

5-methyl-2-(5-methylsulfanyl-4-propyl-1H-pyrazol-3-yl)-1H-benzoimidazole;

2-(5-(4-methoxy-benzylsulfanyl)-4-propyl-1H-pyrazol-3-yl)- 5-methyl-1H-benzoimidazole;

2-(5-benzylsulfanyl-4-isopropyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole;

2-(5-methylsulfanyl-4-methyl-1H-pyrazol-3-yl)-5-methoxy-1H-benzoimidazole;

2-(5-methylsulfanyl-4-methyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole;

3-(5-chloro-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;

3-(5,6-dichloro-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;

5,6-dimethyl-2-(4-phenyl-1H-pyrazol-3-yl)-1H-benzoimidazole;

3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;

3-(5-methoxy-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide;

3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;

3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;

3-(6-ethyl-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;

2-(5-ethoxy-1H-pyrazol-3-yl)-1H-benzoimidazole;

(benzoimidazol-2-yl)-5-methylthio-3-pyrazole;

2-(5-isopropyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;

2-(5-ethyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide;

2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid cyclopropylamide;

2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide;

3-(5, 6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid tert-butylamide;

2-(4-isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide;

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide;

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-butyramide;

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-phenyl-acetamide;

cyclopropanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

methoxyacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopentanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
trimethylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
tert-butylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
butanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
isoxazole-5-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
S(+)-2-methylbutanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethylurea;
cyclopropanecarboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
N-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide;
cyclopropanecarboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3,5-dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide;
furan-3-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide;
2-dimethylamino-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]- 2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isonicotinamide;
2-cyclopropyl-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-phenyl-urea;
1-benzyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide;
4-methylpiperazine-1-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide;
1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea;
cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;

tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazole-4-yl]amide;
morpholine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
3-[6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea;
morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylmethyl]-amide;
3-[3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea;
piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide;
morpholine-4-carboxylic acid[3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
piperidine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
morpholine-4-carboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-cyclopropyl-3-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
4-methyl-piperazine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
4-methyl-piperazine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-methyl-3-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-[3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
4-methyl-piperazine-1-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-tert-butyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-ethyl-urea;
4-methyl-piperazine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

1-cyclopropyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isobutyl-urea;
1-cyclopropylmethyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-piperidin-1-yl-ethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide;
N-[2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-isobutyramide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-piperidin-1-yl-acetamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-morpholinoamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(N'-methylpiperazino)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-pyrrolidinoamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(isobutyl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide;
methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5- carboxylate;
5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole;
2-(1H-indazol-3-yl)-3H-benzimidazole-4-carboxylic acid;
2-(5-ethoxy-2H-pyrazol-3-yl)-1H-benzimidazole-4-carboxylic acid;
5,6-dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-1H-benzimidazole;
5,6-dimethyl-2-(5-thiophen-2-yl-2H-pyrazol-3-yl)-1H-benzimidazole;
2-(4-bromo-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-4,5-ethylenedioxy-1H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-5-methoxy-1H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-4-hydroxy-1H-benzimidazole
2-(5-ethyl-2H-pyrazol-3-yl)-5-bromo-1H-benzimidazole;
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Particularly preferred compounds of formula (Ixa) of the invention for the inhibition of SYK are:-
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide, Example 1;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide, Example 2;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide, Example 3;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide, Example 4;

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide, Example 5;

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide, Example 6

5,6-dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole, (compound denoted as A9-B9), Example 230(a);

6-chloro-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole, (compound denoted as A12-B9), Example 230(b);

6-chloro-2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole, (compound denoted as A12-B10), Example 230(c);

2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5-trifluoromethyl-1H-benzoimidazole, (compound denoted as A4-B9), Example 230(d);

2-(5-cyclopropylmethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole, (compound denoted as A9-B11), Example 230(e);

2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole, (compound denoted as A9-B10), Example 230(f);

3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide, Example 235(ah);

3-(5-methoxy-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(ai);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide, Example 235(ak);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide, Example 235(al);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide, Example 235(am);

3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(ao);

3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide, Example 235(ap);

3-(6-ethyl-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(aq);

2-(5-isopropyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole, (compound denoted as A9-B83), Example 241(b);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, (compound denoted as A9-B106), Example 246(g);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide, (compound denoted as A9-B25), Example 246(h);

2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide, (compound denoted as A40-B106), Example 246(i);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid cyclopropylamide, (compound denoted as A9-B105), Example 246(j);

2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide, (compound denoted as A17-B106), Example 246(k);

3-(5, 6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide, Example 246(v);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 246(w);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide, Example 246(x);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid tert-butylamide, Example 246(y);

2-(4-isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide, Example 246(aa);

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide, (compound denoted as A9-B85), Example 248(a);

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-butyramide, (compound denoted as A9-B86), Example 248(b);

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-phenyl-acetamide, (compound denoted as A9-B36), Example 248(c);

cyclopropanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B89), Example 248(d);

methoxyacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B94), Example 248(e);

cyclopentanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B87), Example 248(f);

trimethylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B88), Example 248(g);

tert-butylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B90), Example 248(h);

butanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B91), Example 248(i);

isoxazole-5-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B96), Example 248(j);

S(+)-2-methylbutanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B93), Example 248(k);

cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A55-B89), Example 248(l);

piperidine-1-carboxylic acid[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(m);

3-[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethylurea, Example 248(n);

cyclopropanecarboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(o);

cyclopropanecarboxylic acid [3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(p);

cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(q);

cyclopropanecarboxylic acid [3-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(r);

cyclopropanecarboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(s);

N-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide, Example 248(t);

cyclopropanecarboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(u);

3,5-dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(v);

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide, Example 248(w);

furan-3-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(x);

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide, Example 248(y);

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide, (compound denoted as A9-B99), Example 253;

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]- 2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide, (compound denoted as A9-B97), Example 254(a);

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isonicotinamide; Example 254(b);

2-cyclopropyl-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide; Example 254(c);

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, (compound denoted as A9-B38), Example 255(a);

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea, (compound denoted as A9-B103), Example 255(b);

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-phenyl-urea, (compound denoted as A9-B40), Example 255(c);

1-benzyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, (compound denoted as A9-B39), Example 255(d);

cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 256(a);

4-methylpiperazine-1-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide, Example 256(c);

1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea, Example 256(d);

cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(a);

tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazole-4-yl]amide, Example 257(b);

morpholine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(c);

piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(d);

3-[6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea, Example 257(e);

morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylmethyl]-amide, Example 257(g);

3-[3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 257(h);

piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 257(i);

cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(a);

cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide, Example 258(b);

morpholine-4-carboxylic acid[3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(c);

piperidine-1-carboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(d);

3-[3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(e);

piperidine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(f);

3-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(g);
morpholine-4-carboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(h);
morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(n);
piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(o);
1-cyclopropyl-3-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(a);
1-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(b);
4-methyl-piperazine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(c);
piperidine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(d);
1-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(e);
morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(f);
4-methyl-piperazine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(g);
1-methyl-3-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(h);
1-[3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(i);
4-methyl-piperazine-1-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(j);
1-tert-butyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(k);
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-ethyl-urea, Example 260(l);
4-methyl-piperazine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(m);
1-cyclopropyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(n);
3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 260(o);
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isobutyl-urea, Example 260(p);
1-cyclopropylmethyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(q);
3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(r);
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-piperidin-1-yl-ethyl)-amide, Example 246(ab);
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide, Example 246(ac);

N-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-piperidin-1-yl-acetamide, Example 253(c);

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Especially preferred compounds of formula (Ixa), denoted as the product of the combination of group A1 in Table 1 and B1 in Table 2, of the invention for the inhibition of SYK are:-

3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide, Example 235(ah);

3-(5-methoxy-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(ai);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide, Example 235(ak);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide, Example 235(al);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide, Example 235(am);

3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(ao);

3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide, Example 235(ap);

3-(6-ethyl-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(aq);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, (compound denoted as A9-B106), Example 246(g);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide, (compound denoted as A9-B25), Example 246(h);

2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide, (compound denoted as A40-B106), Example 246(i);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid cyclopropylamide, (compound denoted as A9-B105), Example 246(j);

2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide, (compound denoted as A17-B106), Example 246(k);

3-(5, 6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide, Example 246(v);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 246(w);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide, Example 246(x);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid tert-butylamide, Example 246(y);

2-(4-isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide, Example 246(aa);

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide, (compound denoted as A9-B85), Example 248(a);

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-butyramide, (compound denoted as A9-B86), Example 248(b);

cyclopropanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B89), Example 248(d);

methoxyacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B94), Example 248(e);

cyclopentanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B87), Example 248(f);

trimethylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B88), Example 248(g);

tert-butylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B90), Example 248(h);

butanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B91), Example 248(i);

isoxazole-5-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B96), Example 248(j);

S(+)-2-methylbutanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B93), Example 248(k);

cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A55-B89), Example 248(l);

piperidine-1-carboxylic acid[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(m);

3-[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethylurea, Example 248(n);

cyclopropanecarboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(o);

cyclopropanecarboxylic acid [3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(p);

cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(q);

cyclopropanecarboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(s);

N-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide, Example 248(t);

cyclopropanecarboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(u);

3,5-dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(v);

furan-3-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(x);

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide, (compound denoted as A9-B99), Example 253;

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]- 2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide, (compound denoted as A9-B97), Example 254(a);

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isonicotinamide; Example 254(b);

2-cyclopropyl-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide; Example 254(c);

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, (compound denoted as A9-B38), Example 255(a);

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea, (compound denoted as A9-B103), Example 255(b);

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-phenyl-urea, (compound denoted as A9-B40), Example 255(c);

1-benzyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, (compound denoted as A9-B39), Example 255(d);

cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 256(a);

4-methylpiperazine-1-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide, Example 256(c);

1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea, Example 256(d);

cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(a);

tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazole-4-yl]amide, Example 257(b);

morpholine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(c);

piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(d);

3-[6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea, Example 257(e);

3-[3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 257(h);

piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 257(i);

cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(a);

cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide, Example 258(b);

morpholine-4-carboxylic acid[3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(c);

piperidine-1-carboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(d);

3-[3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(e);

piperidine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(f);

3-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(g);

morpholine-4-carboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(h);

morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(n);

piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(o);

1-cyclopropyl-3-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(a);

1-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(b);

4-methyl-piperazine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(c);

piperidine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(d);

1-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(e);

morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(f);

1-methyl-3-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(h);

1-[3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(i);

4-methyl-piperazine-1-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(j);

1-tert-butyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(k);

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-ethyl-urea, Example 260(l);

4-methyl-piperazine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(m);

1-cyclopropyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(n);

3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 260(o);

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isobutyl-urea, Example 260(p);

1-cyclopropylmethyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(q);

3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, (compound denoted as A9-B142), Example 258(r);

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

More especially preferred compounds of formula (Ixa) of the invention for the inhibition of SYK are:-

3-(5-methoxy-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(ai);

3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide, Example 235(ah);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide, Example 235(am);

3-(5, 6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide, Example 246(v);

cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 256(a);

1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea, Example 256(d);

piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(d);

3-[6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea, Example 257(e);

3-[3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 257(h);

piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 257(i);

cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide, Example 258(b);

piperidine-1-carboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(d);

piperidine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(f);

piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(o);

1-cyclopropyl-3-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(a);

piperidine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(d);

1-tert-butyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(k);

1-cyclopropyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(n);

3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 260(o);

1-cyclopropylmethyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(q);

3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(r);

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (Ixb) of the invention for the inhibition of SYK are:-

3-(1H-benzoimidazol-2-yl)-1H-indazole;

3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-indazole;

[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanone;

2-(1H-indazol-3-yl)-3H-benzoimidazol-4-ol;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole;

2-(1H-indazol-3-yl)-3H-imidazo[4,5-c]pyridine;

2-(1H-indazole-3-yl)-3H-imidazo[4,5-b]pyridine;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methoxy-1H-indazole;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-fluoro-1H-indazole;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-fluoro-1H-indazole;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-indazole;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-methoxy-1H-indazole;

3-(5-ethyl-1H-benzoimidazol-2-yl)-1H-indazole;

3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-isopropyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-bromo-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-bromo-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(3-cyano)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(pyrid-3-yl)-1H-benzoimidazol-2-yl)-1H-indazole;
3-(6-methyl-5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(2-fluoro)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(5,6-methylenedioxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(2-methoxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(4-chloro)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(4-methyl)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-benzyloxy-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5,6-methylenedioxy-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5,6-diethyl-1H-benzoimidazol-2-yl)-1H-indazole;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonitrile;
3-(5-methoxycarbonyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-ethoxy-1H-indazole;
3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1H-indazole;
3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4-fluoro-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-chloro-1H-indazole;
3-(5-n-propyl-1H-benzoimidazol-2-yl)-1H-indazole;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-sulfonic acid benzylamide;
3-(5-methanesulfonyl-1H-benzoimidazol-2-yl)-1H-indazole;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanol;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, methylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, dimethylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, isopropylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methyl-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-morpholin-4-yl-ethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-methoxy-ethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-cyano-ethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide;

2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid dimethylamide;

[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid;

3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid amide dihydrochloride;

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Particularly preferred compounds of formula (Ixb), denoted as the product of the combination of group A1 in Table 1 and B1 in Table 2, of the invention for the inhibition of SYK are:-

3-(1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A1-B63), Example 234(a);

3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A6-B63), Example 234(b);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A9-B63), Example 234(f);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methoxy-1H-indazole, (compound denoted as A9-B68), Example 235(b);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-fluoro-1H-indazole, (compound denoted as A9-B70), Example 235(d);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-fluoro-1H-indazole, (compound denoted as A9-B71), Example 235(e);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-indazole, (compound denoted as A9-B64), Example 235(f);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-methoxy-1H-indazole, (compound denoted as A9-B69), Example 235(g);

3-(5-ethyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A27-B63), Example 235(i);

3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A55-B63), Example 235(j);

3-(5-isopropyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A54-B63), Example 235(k);

3-(5-bromo-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A58-B63), Example 235(l);

3-(5-bromo-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A32-B63), Example 235(m);

3-(5-(3-cyano)phenyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A68-B63), Example 235(n);

3-(5-(pyrid-3-yl)-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A69-B63), Example 235(o);

3-(6-methyl-5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A57-B63), Example 235(p);

3-(5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A60-B63), Example 235(q);

3-(5-(2-fluoro)phenyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A65-B63), Example 235(r);

3-(5-(3,4 -methylenedioxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A66-B63), Example 235(s);

3-(5-benzyloxy-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A74-B63), Example 235(w);

3-(5,6-methylenedioxy-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A22-B63), Example 235(x);

3-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A23-B63), Example 235(y);

3-(5,6-diethyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A56-B63), Example 235(z);

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonitrile, (compound denoted as A33-B63), Example 235(ab);

3-(5-methoxycarbonyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A35-B63), Example 235(ac);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-ethoxy-1H-indazole, (compound denoted as A9-B63), (compound denoted as A9-B112), Example 235(ad);

3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1H-indazole, Example 235(aj);

3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile, Example 235(an);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile, Example 235(ar);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4-fluoro-1H-indazole, (compound denoted as A9-B110), Example 242(a);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-chloro-1H-indazole, (compound denoted as A9-B109), Example 242(c);

3-(5-n-propyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A28-B63), Example 244(a);

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-sulfonic acid benzylamide, Example244(b);

3-(5-methanesulfonyl-1H-benzoimidazol-2-yl)-1H-indazole; Example 244(c)

[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanol, (compound denoted as A34-B63), Example 245;

[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, ethylamide, (compound denoted as A36-B63), Example 246(a);

[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, methylamide, (compound denoted as A15-B63), Example 246(b);

[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, isopropylamide, (compound denoted as A16-B63), Example 246(d);

[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzylamide, (compound denoted as A17-B63), Example 246(e);

[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzamide, (compound denoted as A52-B63), Example 246(f);

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide, Example 246(m);

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide, Example 246(n);

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methyl-benzylamide, Example 246(o);

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide, Example 246(p);

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-morpholin-4-yl-ethyl)-amide, Example 246(q);

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-methoxy-ethyl)-amide, Example 246(r);

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-cyano-ethyl)-amide, Example 246(s);

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide, Example 246(t);

2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide, Example 246(u),

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid dimethylamide, Example 246(x);

[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, (compound denoted as A14-B63), Example 247(a);

3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid amide dihydrochloride, Example 262;

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Especially preferred compounds of formula (Ixb) of the invention for the inhibition of SYK are:-

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methoxy-1H-indazole, (compound denoted as A9-B68), Example 235(b);

3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A55-B63), Example 235(j);

3-(5,6-diethyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A56-B63), Example 235(z);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid dimethylamide, Example 246(x);

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (Ixc) of the invention for the inhibition of SYK are:-

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-indazole;

5,6-dimethyl-2-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-1H-benzoimidazole;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,5,6,7,8-hexahydro-cycloheptapyrazole;

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Particularly preferred compounds of formula (Ixc), denoted as the product of the combination of group A1 in Table 1 and B1 in Table 2, of the invention for the inhibition of SYK are:-

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-indazole, (compound denoted as A9-B59), Example 241(a);

5,6-dimethyl-2-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-1H-benzoimidazole, (compound denoted as A9-B56), Example 241(d);

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (Ixd) of the invention for the inhibition of SYK are:-

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide;

cyclopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone;

isopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanonc;

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone;

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-mcthyl-propan-1-one;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester;

3-(5,6-dimcthyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid dimethylamide;

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-3-methyl-butan-1-one;

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-1-one;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;

[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyrrolidin-1-yl-methanone;

[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-piperidin-1-yl-methanone;

[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-morpholin-4-yl-methanone;

3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;

3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;

3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-1-one;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-(propane-2-sulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrano[4,3-c]pyrazole;

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Particularly preferred compounds of formula (Ixd), denoted as the product of the combination of group A1 in Table 1 and B1 in Table 2, of the invention for the inhibition of SYK are:-

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide, (compound denoted as A9-B121), Example 250(a);

cyclopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone, (compound denoted as A9-B122);

isopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone;

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-1-one;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide; 26(e)

prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;

[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyrrolidin-1-yl-methanone;

[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-piperidin-1-yl-methanone;

[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-morpholin-4-yl-methanone;

3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;

3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;

3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid dimethylamide, (compound denoted as A9-B119);

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-methyl-propan-1-one, (compound denoted as A9-B117);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester, (compound denoted as A9-B120);

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-3-methyl-butan-1-one, (compound denoted as A9-B118);

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-1-one, (compound denoted as A9-B123);

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Especially preferred compounds of formula (Ixd), denoted as the product of the combination of group A1 in Table 1 and B1 in Table 2, of the invention for the inhibition of SYK are:-

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide, (compound denoted as A9-B121), Example 250(a);

cyclopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone, (compound denoted as A9-B122); Example 250(b);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide, Example 255(e);

prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide, Example 258(i);

[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyrrolidin-1-yl-methanone, Example 258(j);

[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-piperidin-1-yl-methanone, Example 258(k);

3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide, Example 258(m);

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid dimethylamide, (compound denoted as A9-B119);

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Particular compounds of formula (Ix) of the invention for the inhibition of KDR are:-

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide;

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide;

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide;

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide;

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide;

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-morpholinoamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(N'-methylpiperazino)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-pyrrolidinoamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(isobutyl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide;
methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5- carboxylate;
5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole;
5-methoxy-2-(1H-indazol-3-yl)-1H-benzimidazole;
2-(1H-indazol-3-yl)-3H-benzimidazole-4-carboxylic acid;
5-bromo 2-(1H-indazol-3-yl)-3H-benzimidazole;
2-(5-ethoxy-2H-pyrazol-3-yl)-1H-benzimidazole-4-carboxylic acid;
5,6-dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-1H-benzimidazole;
5,6-dimethyl-2-(5-thiophen-2-yl-2H-pyrazol-3-yl)-1H-benzimidazole;
2-(4-bromo-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-4,5-ethylenedioxy-1H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-5-methoxy-1H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-4-hydroxy-1H-benzimidazole
2-(5-ethyl-2H-pyrazol-3-yl)-5-bromo-1H-benzimidazole;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-ethoxy-propyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methanesulfonyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (naphthalen-1-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-trifluoromethyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-dimethylamino-benzylamide;
4-({[2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonyl]-amino}-methyl)-piperidine-1-carboxylic acid tert-butyl ester;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-nitro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-bromo-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methoxy-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1,3-dimethyl-1H-pyrazol-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-trifluoromethoxy-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-methyl-thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-trifluoromethyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-phenoxy-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-trifluoromethoxy-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-isopropoxy-propyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1-methyl-1H-pyrazol-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-isopropyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,5-dimethyl-furan-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(3-acetylamino-phenoxy)-propyl]-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-chloro-pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid ([2,2']bithiophenyl-5-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzofuran-5-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-cyano-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (5-chloro-benzo[b]thiophen-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-trifluoromethyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methylsulfanyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (furan-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-nitro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (thiophen-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,5-dimethyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1-methyl-1H-benzoimidazol-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-chloro-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-sulfamoyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (3-ethoxy-propyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-bromo-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (naphthalen-1-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-dimethylamino-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-nitro-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-bromo-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-methoxy-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-phenoxy-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-trifluoromethoxy-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (6-chloro-pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (2,3-dihydro-benzofuran-5-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-trifluoromethyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-methylsulfanyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (furan-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-nitro-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3,5-dimethyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-chloro-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid phenylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid phenethyl-amide;
3-(6-phenyl-1H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(2,4-dichloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-(6-naphthalen-1-yl-1H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(4-fluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-chloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-methoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3-chloro-4-fluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3,5-dichloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-(6-thianthren-1-yl-1H-benzoimidazol-2-yl)-2H-indazole;
3-(6-biphenyl-4-yl-1H-benzoimidazol-2-yl)-2H-indazole;

3-(6-p-tolyl-1H-benzoimidazol-2-yl)-2H-indazole;

3-(6-m-tolyl-1H-benzoimidazol-2-yl)-2H-indazole;

3-(6-o-tolyl-1H-benzoimidazol-2-yl)-2H-indazole;

3-(6-thiophen-3-yl-1H-benzoimidazol-2-yl)-2H-indazole;

3-[6-(3-trifluoromethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-[6-(4-trifluoromethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-[6-(3-chloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-[6-(3-methoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-[6-(3,5-dimethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-[6-(3,4-dimethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-(6-benzo[1,3]dioxol-5-yl-1H-benzoimidazol-2-yl)-2H-indazole;

3-[6-(4-tert-butyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-(6-hex-1-enyl-1H-benzoimidazol-2-yl)-2H-indazole;

3-[6-(3,4-dimethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenol;

4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenol;

3-[6-(3,4-dichloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-[6-(4-trifluoromethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

1-{4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-ethanone;

3-(6-benzo[b]thiophen-2-yl-1H-benzoimidazol-2-yl)-2H-indazole;

3-[6-(3,4,5-trimethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

1-{5-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-thiophen-2-yl}-ethanone;

1-{3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-ethanone;

3-[6-(4-benzyloxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-[6-(2-fluoro-biphenyl-4-yl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-(6-benzo[b]thiophen-3-yl-1H-benzoimidazol-2-yl)-2H-indazole;

{3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-methanol;

3-[6-(4-ethylsulfanyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-[6-(2,4-difluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-[6-(3-trifluoromethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-[6-(4-fluoro-2-methyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-{6-[2-(4-fluoro-phenyl)-vinyl]-1H-benzoimidazol-2-yl}-2H-indazole;

3-{6-[2-(4-chloro-phenyl)-vinyl]-1H-benzoimidazol-2-yl}-2H-indazole;

3-{4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-propionic acid;

{4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-methanol;

3-(6-furan-2-yl-1H-benzoimidazol-2-yl)-2H-indazole;

3-[6-(3-benzyloxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-[6-(4-isopropyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

3-[6-(4-methanesulfonyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-acetylamino-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid isopropylamide;

[2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-morpholin-4-yl-methanone;

[2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-(4-methyl-piperazin-1-yl)-methanone;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzyl-methyl-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-nitro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-fluoro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-difluoro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,6-difluoro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-fluoro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,4-difluoro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,4,5-trifluoro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (4'-chloro-biphenyl-4-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3',5'-dichloro-biphenyl-4-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (4'-fluoro-biphenyl-4-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-fluoro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,6-difluoro-3-methyl-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-methyl-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-fluoro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2'-chloro-biphenyl-4-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-trifluoromethyl-pyridin-3-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (5-pyridin-2-yl-thiophen-2-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide;

4-[2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonyl]-piperazine-1-carboxylic acid tert-butyl ester;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,6-difluoro-4-chloro-benzyl)amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,4-dichloro-6-fluoro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-fluoro-4-chloro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-fluoro-4-chloro-6-methyl-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-methoxy-pyridin-3-ylmethyl)-amide;
2-[5-(benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3-phenyl-allyloxy)2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(2-methyl-allyloxy)2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3,7-dimethyl-octa-2,6-dienyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3-bromo-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
3-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxymethyl]-benzonitrile;
2-[5-(4-trifluoromethyl-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3,4-dichloro-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-pentafluorophenylmethoxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(4-*tert*-butyl-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(2-benzenesulfonylmethyl-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
4-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxymethyl]-benzonitrile;
2-[5-(biphenyl-4-ylmethoxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2,3-dichioro-benzenesulfonic acid 5-(1 H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
2-[5-(2-morpholin-4-yl-ethoxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(2-piperidin-1-yl-ethoxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3-methoxy-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1 -p-tolyl-ethanone;
1-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-3,3,4,4,4-pentafluoro-butan-2-one;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-biphenyl-4-yl-ethanone;
1-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-butan-2-one;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(4-dimethylamino-phenyl)-ethanone;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(3-phenyl-isoxazol-5-yl)-ethanone;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-N-phenyl-acetamide;
1-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-3,3-dimethyl-butan-2-one;
1-adamantan-1-yl-2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-ethanone;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-naphthalen-2-yl-ethanone;
4-{2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-acetyl}-benzonitrile;
6-{2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-acetyl}-3,4-dihydro-1H-quinolin-2-one;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(4-trifluoromethoxy-phenyl)-ethanone;
5-{2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-acetyl}-2-chloro-benzenesulfonamide;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(4-methoxy-phenyl)-ethanone;

2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1 -cyclopropyl-ethanone;
isonicotinic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
2,2-dimethyl-propionic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
benzyloxy-acetic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
4-methoxy-benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
phenyl-acetic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
2,3,4,5,6-Pentafluoro-benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
cyclopropanecarboxylic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
2,2,3,3,4,4,4-heptafluoro-butyric acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
cyclopentanecarboxylic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
3-phenyl-propionic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
biphenyl-4-carboxylic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
3,5-bis-trifluoromethyl-benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
4-trifluoromethyl-benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
thiophene-2-carboxylic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (Ixa), denoted as the product of the combination of group A1 in Table 1 and B1 in Table 2, of the invention for the inhibition of KDR are:-
2-(5-ethyl-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole, (compound denoted as A9-B3);
2-(5-methyl-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole (compound denoted as A9-B2);
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (Ixb), denoted as the product of the combination of group A1 in Table 1 and B1 in Table 2, of the invention for the inhibition of KDR are:-
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide, (compound denoted as A17-B63);
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide, (compound denoted as A15-B63);
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide, (compound denoted as A36-B63);
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide, (compound denoted as A37-B63);

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide, (compound denoted as A52-B63);

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide, (compound denoted as A51-B63);

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-morpholinoamide, (compound denoted as A92-B63);

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(N'-methylpiperazino)amide, (compound denoted as A93-B63);

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-pyrrolidinoamide, (compound denoted as A91-B63);

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(isobutyl)amide, (compound denoted as A82-B63);

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide, (compound denoted as A83-B63);

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide, (compound denoted as A84-B63);

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide, (compound denoted as A90-B63);

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-ethoxy-propyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methanesulfonyl-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (naphthalen-1-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-trifluoromethyl-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (thiophen-2-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-dimethylamino-benzylamide;

4-({[2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonyl]-amino}-methyl)-piperidine-1-carboxylic acid tert-butyl ester;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-nitro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-bromo-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methoxy-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1,3-dimethyl-1H-pyrazol-4-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-trifluoromethoxy-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-methyl-thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-trifluoromethyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-phenoxy-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-trifluoromethoxy-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-isopropoxy-propyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1-methyl-1H-pyrazol-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-isopropyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,5-dimethyl-furan-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(3-acetylamino-phenoxy)-propyl]-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-chloro-pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid ([2,2']bithiophenyl-5-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzofuran-5-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-cyano-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methylsulfanyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (furan-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-nitro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (thiophen-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,5-dimethyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1-methyl-1H-benzoimidazol-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-chloro-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-sulfamoyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-methoxy-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-methylsulfanyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (furan-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-nitro-benzylamide;

2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3,5-dimethyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid phenylamide;
3-[6-(4-fluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-methoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3-chloro-4-fluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-(6-m-tolyl-1H-benzoimidazol-2-yl)-2H-indazole;
3-(6-o-tolyl-1H-benzoimidazol-2-yl)-2H-indazole;
3-(6-thiophen-3-yl-1H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(3-chloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3-methoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3,5-dimethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-(6-benzo[1,3]dioxol-5-yl-1H-benzoimidazol-2-yl)-2H-indazole;
3-(6-hex-1-enyl-1H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(3,4-dimethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenol;
4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenol;
3-[6-(3,4,5-trimethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
1-{5-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-thiophen-2-yl}-ethanone;
{3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-methanol;
3-[6-(2,4-difluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-fluoro-2-methyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
{4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-methanol;
3-(6-furan-2-yl-1H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(4-isopropyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-acetylamino-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid isopropylamide;
[2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-morpholin-4-yl-methanone;
[2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-(4-methyl-piperazin-1-yl)-methanone;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzyl-methyl-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-nitro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-difluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,6-difluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,4-difluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,4,5-trifluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,6-difluoro-3-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2'-chloro-biphenyl-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-trifluoromethyl-pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (5-pyridin-2-yl-thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide;
4-[2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonyl]-piperazine-1-carboxylic acid tert-butyl ester;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,6-difluoro-4-chloro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,4-dichloro-6-fluoro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-fluoro-4-chloro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-fluoro-4-chloro-6-methyl-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-methoxy-pyridin-3-ylmethyl)-amide;
2-[5-(benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3-phenyl-allyloxy)2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3,7-dimethyl-octa-2,6-dienyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3-bromo-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3,4-dichloro-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(2-benzenesulfonylmethyl-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(biphenyl-4-ylmethoxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3-methoxy-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
isonicotinic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
3-phenyl-propionic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5- carboxylate;
5-methoxy-2-(1H-indazol-3-yl)-1H-benzimidazole;
5-bromo 2-(1H-indazol-3-yl)-3H-benzimidazole, (compound denoted as A32-B63);
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Particularly preferred compounds of formula (Ixb) of the invention for the inhibition of KDR are:-
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methanesulfonyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-nitro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-chloro-pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzofuran-5-ylmethyl)-amide;
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methylsulfanyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-chloro-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-methylsulfanyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,6-difluoro-4-chloro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,4-dichloro-6-fluoro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-fluoro-4-chloro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-fluoro-4-chloro-6-methyl-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-methoxy-pyridin-3-ylmethyl)-amide;
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Particular compounds of formula (Ix) of the invention for the inhibition of ITK are:-
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-piperidin-1-yl-ethyl)-amide, Example 246(ab);
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide, Example 246(ac);
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide, Example 246(ad);
N-[2-(1H-Indazol-3-yl)-1H-benzoimidazol-5-yl]-isobutyramide, Example 246(ae)

N-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-piperidin-1-yl-acetamide, Example 253(c)

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

The compounds of formula (Ix) of the invention exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. The present invention thus provides, according to a further aspect, compounds of formula (Ix) of the invention and compositions containing compounds of formula (Ix) of the invention for use in therapy.

Compounds of formula (Ix) within the scope of the present invention block kinase catalytic activity according to tests described in the literature and *in vitro* procedures described hereinafter, and which tests results are believed to correlate to pharmacological activity in humans and other mammals. Thus, in a further embodiment, the present invention provides compounds of formula (Ix) of the invention and compositions containing compounds of formula (Ix) of the invention for use in the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of protein kinase inhibitors (e.g. Syk, KDR, tie2 or ITK). For example, compounds of formula (Ix) of the present invention are useful in the treatment of inflammatory diseases, for example asthma: atopic dermatitis, inflammatory dermatoses (e.g. psoriasis, dematitis herpetiformis, eczema, necrotizing and cutaneous vasculitis, bullous disease, acute and chronic urticaria,); allergic rhinitis and allergic conjunctivitis; joint inflammation, including arthritis, rheumatoid arthritis and other arthritic conditions such as rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis and osteoarthritis. The compounds of formula (Ix) are also useful in the treatment of Chronic Obstructive Pulmonary Disease (COPD), adult respiratory distress syndrome, silicosis, pulmonary sarcoidosis, acute synovitis, autoimmune diabetes, autoimmune encephalomyelitis, collitis, atherosclerosis, peripheral vascular disease, cardiovascular disease, cutaneous and systemic anaphylaxis, endotoxemia, sepsis, septic shock, endotoxic shock, gram negative sepsis, diabetes, multiple sclerosis, restenosis, myocarditis, B cell lymphomas, systemic lupus erythematosus, viral infections, bacterial infections, parasitic infections, graft v host disease and other transplant associated rejection events, reperfusion injury, Crohn's disease and ulcerative colitis, cancers and tumours (such as colorectal, prostate, breast, thyroid, colon and lung cancers), atherosclerosis, degenerative muscle diseases, obesity, conjestive heart failure, Parkinson's, depression, schizophrenia, stroke, head trauma, spinal cord injury, Alzheimer's, neuropathic pain syndrome, amyotrophic lateral sclerosis, cachexia, osteoporosis, fibrotic diseases of the viscera, and inflammatory bowel disease.

The products of the present patent application as SYK inhibitors may be used for the treatment of diseases chosen from the following: asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, silicosis, pulmonary sarcoidosis, rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, acute and chronic urticaria, cutaneous and systemic anaphylaxis, endotoxemia, sepsis, septic shock, endotoxic shock, gram negative sepsis, diabetes, multiple sclerosis, systemic lupus erythromatosis, viral infections, bacterial infections, parasitic infections, graft vs. host disease, organ transplant rejection, reperfusion injury, Crohn's disease and ulcerative colitis.

The products of the present patent application as KDR inhibitors may be used especially for the treatment or prevention of diseases chosen from the following group: cancers, especially breast, colon, lung and prostate cancer, atherosclerosis, degenerative muscle diseases, obesity, conjestive heart failure, Parkinson's, depression, schizophrenia, stroke, head trauma, spinal cord injury, Alzheimer's, neuropathic pain syndrome, amyotrophic lateral sclerosis, cachexia, osteoporosis and fibrotic diseases of the viscera.

A special embodiment of the therapeutic methods of the present invention is the treating of asthma.

Another special embodiment of the therapeutic methods of the present invention is the treating of psoriasis.

Another special embodiment of the therapeutic methods of the present invention is the treating of joint inflammation.

Another special embodiment of the therapeutic methods of the present invention is the treating of inflammatory bowel disease.

Another special embodiment of the therapeutic methods of the present invention is the treating of cancers and tumours.

According to a further feature of the invention there is provided a method for the treatment of a human or animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of a protein kinase inhibitor (e.g. . Syk, KDR, tie2 or ITK) for example conditions as hereinbefore described, which comprises the administration to the patient of an effective amount of compound of the invention or a composition containing a compound of the invention. "Effective

amount" is meant to describe an amount of compound of the present invention effective in inhibiting the catalytic activity a protein kinase, such as. Syk, KDR, tie2 or ITK, and thus producing the desired therapeutic effect.

References herein to treatment should be understood to include prophylactic therapy as well as treatment of established conditions.

The present invention also includes within its scope pharmaceutical compositions comprising at least one of the compounds of formula (Ix) of the invention, as defined above, or a pharmaceutically acceptable salt or a prodrug, in association, where appropriate, with a pharmaceutically acceptable carrier or excipient.

Pharmaceutical compositions of the present invention for the treatment of KDR or tie2 associated disease states can also, where appropriate, contain active principles of other antimitotic medicinal products such as, in particular, those based on taxol, cis-platin, DNA-intercalating agents and the like.

Compounds of formula (Ix) of the invention may be administered by any suitable means. In practice compounds of formula (Ix) of the present invention may generally be administered parenterally, locally by topical application to the skin and mucous membranes, rectally, orally, by inhalation, or by intravenous or intramuscular injection, especially by the oral route.

Compositions according to the invention may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients. The adjuvants comprise, inter alia, diluents, sterile aqueous media and the various non-toxic organic solvents. The compositions may be presented in the form of tablets, pills, granules, powders, aqueous solutions or suspensions, injectable solutions, elixirs or syrups, and can contain one or more agents chosen from the group comprising sweeteners, flavourings, colourings, or stabilisers in order to obtain pharmaceutically acceptable preparations. The choice of vehicle and the content of active substance in the vehicle are generally determined in accordance with the solubility and chemical properties of the active compound, the particular mode of administration and the provisions to be observed in pharmaceutical practice. For example, excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for preparing tablets. To prepare a capsule, it is advantageous to use lactose and high molecular weight polyethylene glycols. When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate

suspension. Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used.

For parenteral administration, emulsions, suspensions or solutions of the products according to the invention in vegetable oil, for example sesame oil, groundnut oil or olive oil, or aqueous-organic solutions such as water and propylene glycol, injectable organic esters such as ethyl oleate, as well as sterile aqueous solutions of the pharmaceutically acceptable salts, are used. The solutions of the salts of the products according to the invention are especially useful for administration by intramuscular or subcutaneous injection. The aqueous solutions, also comprising solutions of the salts in pure distilled water, may be used for intravenous administration with the proviso that their pH is suitably adjusted, that they are judiciously buffered and rendered isotonic with a sufficient quantity of glucose or sodium chloride and that they are sterilised by heating, irradiation or microfiltration.

For topical administration, gels (water or alcohol based), creams or ointments containing compounds of formula (Ix) of the invention may be used. Compounds of formula (Ix) of the invention may also be incorporated in a gel or matrix base for application in a patch, which would allow a controlled release of compound through the transdermal barrier.

For administration by inhalation compounds of formula (Ix) of the invention may be dissolved or suspended in a suitable carrier for use in a nebuliser or a suspension or solution aerosol, or may be absorbed or adsorbed onto a suitable solid carrier for use in a dry powder inhaler.

Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of the invention.

The percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms may be administered at about the same time. The dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient. In the adult, the doses are generally from about 0.001 to about 50, preferably about 0.001 to about 5, mg/kg body weight per day by inhalation, from about 0.01 to about 100, preferably 0.1 to 70, more especially 0.5 to 10, mg/kg body weight per day by oral administration, and from about 0.001 to about 10, preferably 0.01 to 1, mg/kg body weight per day by intravenous administration. In each particular case, the doses will be determined in accordance with the factors distinctive to the subject to be treated, such as age,

weight, general state of health and other characteristics which can influence the efficacy of the medicinal product.

The compounds of formula (Ix) according to the invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the active product may be administered orally 1 to 4 times per day. Of course, for some patients, it will be necessary to prescribe not more than one or two doses per day.

Compounds of formula (Ix) of the invention may be prepared by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, for example those described by R.C.Larock in Comprehensive Organic Transformations, VCH publishers, 1989.

In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T.W. Greene and P.G.M.Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991.

Compounds of formula (Ix) wherein W, X, Y, Z and R^1 are as hereinbefore defined for compounds of formula (Ix) and A_5 is H, may be prepared by reaction of compounds of formula (IIx):-



(IIx)

in which W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix), with acids of formula (IIIx):-

$$R^1—CO_2H \qquad \text{(IIIx)}$$

in which R^1 is as hereinbefore defined for compounds of formula (Ix), at a temperature at about 160°C. Alternatively the reaction may (i) be carried in the presence of hydrochloric acid at about reflux

temperature, or polyphosphoric acid at a temperature at about 160°C or (ii) be carried out in a microwave oven.

Compounds of formula (Ix) wherein W, X, Y, Z and R^1 are as hereinbefore defined and A_5 is H, may be prepared by reaction of compounds of formula (IIx) in which W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix), with aldehydes of formula (IVx):-

$$R^1\text{—CHO} \qquad \text{(IVx)}$$

in which R^1 is as hereinbefore defined for compounds of formula (Ix), in the presence of in inert solvent, such as dimethylformamide or nitrobenzene, and at a temperature up to about 145°C. Alternatively the reaction may (i) be carried in the presence of sodium bisulfite at a temperature at about reflux temperature or (ii) be carried out in a microwave oven at a temperature up to about 200°C.

Compounds of formula (Ix) wherein W, X, Y, Z and R^1 are as hereinbefore defined for compounds of formula (Ix) and A_5 is H, may be prepared by cyclisation of compounds of formula (Vx):-



(Vx)

wherein W, X, Y, Z and R^1 are as hereinbefore defined for compounds of formula (Ix). The cyclisation may be carried out by heating in the presence of an acid catalyst, such as acetic acid, and at a temperature up to about 120°C.

Compounds of formula (Ixa) wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix) and R^1 is  , in which R^9 is as hereinbefore defined for compounds of formula (Ix), $R^7$is hydrogen and R^8 is SR^4, i.e. compounds of formula (Ixaa), may be prepared as shown in scheme 1.

Scheme 1



For example diamines of formula (IIx), wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix), may be treated, in Step 1, with formic acid in the presence of hydrochloric acid at a temperature at about 50°C. The imino group of the resulting compounds of formula (VIx) wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix), may then be protected, in Step 2, with a suitable protecting group, for example when this is a 2-(trimethylsilanyl)ethoxymethyl group the protection is conveniently carried out by (i) reaction with sodium hydride in dimethylformamide then (ii) reaction with 2-(trimethylsilanyl)ethoxymethyl chloride. The resulting compounds of formula (VIIx), wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix) and R^{11} is a suitable protecting group, such as a 2-(trimethylsilanyl)ethoxymethyl group, may then be treated, in Step 3, with (i) lithium diisopropylamide, in an inert solvent, such as tetrahydrofuran, and at a temperature at about -78°C, then (ii) acetamides of formula R^9-C(=O)-N(CH_3)$_2$ [in which R^9 is as hereinbefore defined for compounds of formula (Ix)]. The resulting compounds of formula (Xx), wherein W, X, Y, Z, R^9 and R^{11} are as hereinbefore defined for compounds of formula (Ix), [alternatively prepared by (i) reaction of diamines of formula (IIx) with β-hydroxy-acids of formula $R^9CH_2CH(OH)CO_2H$ [in which R^9 is as hereinbefore defined for compounds of formula (Ix)], in Step 1a, at a temperature at about 70°C, (ii) oxidation, in Step 2a, of the resulting compounds of formula (VIIIx) with manganese dioxide in an inert solvent, such as chloroform, and at a temperature at about 60°C and (iii) protection of the imino group, in Step 3a, as described in Step 2 above)] may then be treated, in Step 4, with (i) sodium tertiary butoxide, in an inert solvent, such as benzene or tetrahydrofuran, at -5°C, then (ii) carbon disulfide and then (iii) compounds of formula R^4-X^1 [in which R^4 is as hereinbefore defined for compounds of formula (Ix)] and X^1 is halo. The resulting compounds of formula (XIx), wherein W, X, Y, Z, R^4, R^9 and R^{11} are as hereinbefore defined for compounds of formula (Ix), may then be treated, in Step 5, with hydrazine, in an inert solvent, such as ethanol, and at a temperature from about room temperature to about reflux temperature. The resulting compounds of formula (XIIx), wherein W, X, Y, Z, R^4, R^9 and R^{11} are as hereinbefore defined for compounds of formula (Ix), may then be deprotected {for example when R^{11} is a 2-(trimethylsilanyl)ethoxymethyl group by treatment with hydrochloric acid in an inert solvent, such as ethanol, and at a temperature from about room temperature to about reflux temperature}, in Step 6, to liberate the pyrazoles of general formula (Ixaa), wherein W, X, Y, Z, R^4 and R^9 are as hereinbefore defined for compounds of formula (Ix). Compounds of formula (XIx) in which R^{11} is a tetrahydropyran-2-yl protecting group may be deprotected by treatment with an acid, such as p-toluenesulfonic acid, in water at reflux temperature and subsequently treated with hydrazine, in an inert solvent, such as ethanol, and at a temperature from about room temperature to about reflux

temperature to give pyrazoles of general formula (Ixaa), wherein W, X, Y, Z, R^4 and R^9 are as hereinbefore defined for compounds of formula (Ix).

Compounds of formula (Ix) wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix) and A_5 is H, and R^1 is  , in which R^9 is as hereinbefore defined for compounds of formula (Ix), $R^7$is hydrogen and R^8 is OR^4, i.e. compounds of formula (Ixab), may be prepared as shown in scheme 2.

Scheme 2



(XIx) (XIIIx) (Ixab)

For example compounds of formula (XIx), wherein W, X, Y, Z, R^9, R^{11} are as hereinbefore defined for compounds of formula (Ix), and R^4 is lower alkyl, may be treated, in Step 1, with the sodium salt of an alcohol of formula R^4-OH (in which R^4 is lower alkyl), such as sodium ethoxide, followed by treatment with hydrazine as described hereinabove for scheme 1. The resulting compounds of formula (XIIIx), wherein W, X, Y, Z, R^4, R^9 and R^{11} are as hereinbefore defined for compounds of formula (Ix), may then be deprotected [for example when R^{11} is a 2-(trimethylsilanyl)ethoxymethyl group by

treatment with trifluoroacetic acid at about 50°C], in Step 2, to liberate the pyrazoles of general formula (Ixab).

Compounds of formula (Ix) wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix) and A_5 is H, and R^1 is  , in which R^9 is as hereinbefore defined for compounds of formula (Ix), $R^7$is hydrogen and R^8 is $-NY^1Y^2$, i.e. compounds of formula (Ixac), may be prepared as shown in scheme 3.

Scheme 3



For example compounds of formula (XIx), wherein W, X, Y, Z, R^9 and R^{11} are as hereinbefore defined for compounds of formula (Ix), and R^4 is lower alkyl, may be treated, in Step 1, with an amine of formula HNY^1Y^2 [in which Y^1 and Y2 are as hereinbefore defined for compounds of formula (Ix)], e.g. morpholine. The resulting compounds of formula (XIVx), wherein W, X, Y, Z, R^9, R^{11}, Y^1 and Y^2 are as hereinbefore defined for compounds of formula (Ix), and R^4 is lower alkyl, may then be treated, in step 2, with hydrazine as described hereinabove for scheme 1. The resulting compounds of

formula (XVx), wherein W, X, Y, Z, R^9, R^{11}, Y^1 and Y^2 are as hereinbefore defined for compounds of formula (Ix), may then be deprotected as described hereinabove, in Step 3, to liberate the pyrazoles of general formula (Ixac).

Compounds of formula (Ix) wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix) and A_5 is H, and R^1 is  , i.e. compounds of formula (Ixad), may be prepared as shown in scheme 4.

Scheme 4



For example compounds of formula (XIx), wherein W, X, Y, Z, R^9 and R^{11} are as hereinbefore defined for compounds of formula (Ix), and R^4 is lower alkyl, may be treated, in Step 1, with hydroxylamine in the presence of sodium methoxide and in methanol at reflux temperature. The resulting compounds of formula (XVIx), wherein W, X, Y, Z, R^4, R^9 and R^{11} are as hereinbefore defined for compounds of formula (Ix), may then be deprotected as described hereinabove, in Step 2, to liberate the isoxazoles of general formula (Ixad).

Compounds of the invention of formula (Ix) may also be prepared by interconversion of other compounds of the invention.

Thus, for example, compounds of formula (Ix) containing a carboxy group may be prepared by hydrolysis of the corresponding esters. The hydrolysis may conveniently be carried out by alkaline hydrolysis using a base, such as an alkali metal hydroxide, e.g. lithium hydroxide, or an alkali metal carbonate, e.g. potassium carbonate, in the presence of an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol, at a temperature from about ambient to about reflux. The hydrolysis of the esters may also be carried out by acid hydrolysis using an inorganic acid, such as hydrochloric acid, in the presence of an aqueous/inert organic solvent mixture, using organic solvents such as dioxan or tetrahydrofuran, at a temperature from about 50°C to about 80°C.

As another example compounds of formula (Ix) containing a carboxy group may be prepared by acid catalysed removal of the *tert*-butyl group of the corresponding *tert*-butyl esters using standard reaction conditions, for example reaction with trifluoroacetic acid at a temperature at about room temperature.

As another example compounds of formula (Ix) containing a carboxy group may be prepared by hydrogenation of the corresponding benzyl esters. The reaction may be carried out in the presence of ammonium formate and a suitable metal catalyst, e.g. palladium, supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol and at a temperature at about reflux temperature. The reaction may alternatively be carried out in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol.

As another example compounds of formula (Ix) containing a carboxy group may be prepared by treatment of compounds of formula I(x) containing a cyano group with hydrochloric acid in acetic acid at a temperature at about 100°C.

As another example of the interconversion process, compounds of formula (Ix) containing a $-C(=O)-NY^1Y^2$ group may be prepared by reaction of compounds of formula (Ix) containing a carboxy group with an amine of formula HNY^1Y^2 to give an amide bond using standard peptide coupling procedures, for example coupling in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, hydroxybenzotriazole and di-isopropylethylamine in an inert solvent, such as dimethylformamide and a temperature up to about 80°C. The reaction may alternatively be carried out in the presence of O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate and triethylamine (or diisopropylethylamine) in tetrahydrofuran (or dimethylformamide) at room temperature.

As another example of the interconversion process, compounds of formula (Ix) containing a -NH-C(=O)-R^4 group may be prepared by: (i) coupling compounds of formula (Ix) containing an amino group with acids of formula R^4-CO_2H using standard coupling conditions as described above; or (ii) by reaction of compounds of formula (Ix) containing an amino group with acid chlorides of formula R^4-C(=)O-Cl in the presence of a tertiary base, such as di-isopropylethylamine, in an inert solvent, such a dichloromethane, and at a temperature at about room temperature. In some instances a bis-acylated derivative is obtained by reaction of compounds of formula (Ix) containing an amino group and in which A_5 is H, with acid chlorides of formula R^4-C(=)O-Cl. These bis-acylated derivatives may be converted to compounds of formula (Ix) containing a -NH-C(=O)-R^4 group and in which A_5 is H, by treatment with potassium hydroxide in aqueous methanol at a temperature at about 60°C.

As another example of the interconversion process, compounds of formula (Ix) wherein R^1 is a pyrazolyl moiety  in which R^8 and R^9 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing a NY^5 group (where Y^5 is -C(=O)R^4) may be prepared by reaction of compounds of formula (Ix) wherein R^1 is a pyrazolyl moiety  in which R^8 and R^9 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing a NY^5 group (where Y^5 is hydrogen) with acid chlorides of formula R^4-C(=O)-Cl in the presence of a tertiary base, such as di-isopropylethylamine, in an inert solvent, such a dichloromethane, and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (Ix) wherein R^1 is a pyrazolyl moiety  in which R^8 and R^9 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing a NY^5 group (where Y^5 is $-C(=O)NY^1Y^2$) may be prepared by reaction of compounds of formula (Ix) wherein R^1 is a pyrazolyl moiety  in which R^8 and R^9 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing a NY^5 group (where Y^5 is hydrogen) with carbamoyl chlorides of formula $Y^1Y^2N-C(=O)-Cl$ in the presence of a tertiary base, such as diisopropylethylamine, in an inert solvent, such a dichloromethane, and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (Ix) wherein R^1 is a pyrazolyl moiety  in which R^8 and R^9 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing a NY^5 group (where Y^5 is $-C(=O)OR^4$) may be prepared by reaction of compounds of formula (Ix) wherein R^1 is a pyrazolyl moiety  in which R^8 and R^9 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing a NY^5 group (where Y^5 is hydrogen) with chloroformates of formula $R^4O-C(=O)-Cl$ in the presence of a tertiary base, such as diisopropylethylamine, in an inert solvent, such a dichloromethane, and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (Ix) wherein R^1 is a pyrazolyl moiety  in which R^8 and R^9 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing a NY^5 group (where Y^5 is $-SO_2R^4$) may be prepared by reaction of compounds of formula (Ix) wherein R^1 is a pyrazolyl moiety  in which R^8 and R^9 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing a NY^5 group (where Y^5 is hydrogen) with sulfonyl chlorides of formula R^4SO_2-Cl in the presence of a tertiary base, such as diisopropylethylamine, in an inert solvent, such a dichloromethane, and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (Ix) containing a -NH-C(=O)-R^4 group, in which R^4 is alkyl substituted by NY^1Y^2, may be prepared by (i) coupling compounds of formula (Ix) containing an amino group with the appropriate chloroalkyl acid chloride, in the presence of a tertiary base, such as di-isopropylethylamine, in an inert solvent, such a dichloromethane, and at a temperature at about room temperature, followed by (ii) reaction with an amine of formula HNY^1Y^2.

As another example of the interconversion process, compounds of formula (Ix) containing a $-N(R^6)C(=O)NY^1Y^2$ group [in which R^6 is hydrogen, Y^1 is hydrogen and Y^2 is alkenyl, aryl, cycloalkyl, heteroaryl, or optionally substituted alkyl] may be prepared by reaction of compounds of formula (Ix) containing an amino group with isocyanates of formula $Y^2N{=}C{=}O$ [in which Y^2 is alkenyl, aryl, cycloalkyl, heteroaryl, or optionally substituted alkyl], in an inert solvent, such as tetrahydrofuran, and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (Ix) containing a $-N(R^6)C(=O)NY^1Y^2$ group [in which R^6 is hydrogen] may be prepared by reaction of compounds of formula (Ix) containing an amino group with 1,1-carbonyldiimidazole in an inert solvent such as

tetrahydrofuran and at a temperature at about 60°C followed by reaction with an amine of formula HNY^1Y^2.

As another example of the interconversion process, compounds of formula (Ix) containing an amino group may be prepared by reduction of the corresponding compounds of formula (Ix) containing a nitro group. For example, the reduction may conveniently be carried out by hydrogenation in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol. The reduction may also conveniently be carried out by means of reaction with tin chloride, in an inert solvent, such as methanol or ethanol, and at a temperature at about reflux temperature. Alternatively the reaction with tin chloride may be carried out in a microwave oven at a temperature at about 140°C.

As another example of the interconversion process, compounds of formula (Ix) containing a $-CH_2OH$ group may be prepared by the reduction of corresponding compounds of formula (Ix) containing a -CHO or $-CO_2$lower alkyl group. For example, the reduction may conveniently be carried out by means of reaction with lithium aluminium hydride, in an inert solvent, such as tetrahydrofuran, and at a temperature from about room temperature to about reflux temperature.

As another example of the interconversion process, compounds of formula (Ix) containing a $-CH(OH)R^4$ group may be prepared by treating compounds of formula (Ix) containing a $-C(=O)R^4$ group with diisobutylaluminium hydride, in an inert solvent, such as tetrahydrofuran, and at a temperature from about -78°C to about room temperature.

As another example of the interconversion process, compounds of formula (Ix) in which R^1 is aryl or heteroaryl substituted by hydroxy may be prepared by reaction of the corresponding compounds of formula (Ix) in which R^1 is aryl or heteroaryl substituted by methoxy with a Lewis acid, such as boron tribromide, in an inert solvent, such as dichloromethane, and at a temperature from about 0°C to about room temperature.

As another example of the interconversion process, compounds of formula (Ix) containing sulfoxide linkages may be prepared by the oxidation of corresponding compounds containing -S- linkages. For example, the oxidation may conveniently be carried out by means of reaction with a peroxyacid, e.g. 3-chloroperbenzoic acid, preferably in an inert solvent, e.g. dichloromethane, preferably at or near room temperature, or alternatively by means of potassium hydrogen peroxomonosulfate in a medium

such as aqueous methanol, buffered to about pH 5, at temperatures between about 0°C and room temperature. This latter method is preferred for compounds containing an acid-labile group.

As another example of the interconversion process, compounds of formula (Ix) containing sulfone linkages may be prepared by the oxidation of corresponding compounds containing -S- or sulfoxide linkages. For example, the oxidation may conveniently be carried out by means of reaction with a peroxyacid, e.g. 3-chloroperbenzoic acid, preferably in an inert solvent, e.g. dichloromethane, preferably at or near room temperature.

As another example of the interconversion process, compounds of formula (Ix) containing a cyano group may be prepared by reaction of the corresponding compounds of formula (Ix) containing a $-C(=O)-NH_2$ group with phosphorus pentachloride in the presence of triethylamine. The reaction may conveniently be carried out in an inert solvent, such as tetrahydrofuran, and at a temperature at about reflux temperature.

As another example of the interconversion process, compounds of formula (Ix) containing a $-C(=O)-NH_2$ group may be prepared by reaction of the corresponding compounds of formula (Ix) containing a cyano group with hydrogen peroxide in the presence of sodium hydroxide. The reaction may conveniently be carried out in methanol at a temperature at about room temperature. Alternatively compounds of formula (Ix) containing a $-C(=O)-NH_2$ group may be prepared by reaction of the corresponding compounds of formula (Ix) containing a cyano group with hydrochloric acid in acetic acid at a temperature from about 80°C to about 100°C.

As another example of the interconversion process, compounds of formula (Ix) containing a tetrazolyl group may be prepared by reaction of the corresponding compounds of formula (Ix) containing a cyano group with azidotributyltin. The reaction may conveniently be carried out in an inert solvent, such as toluene, and at a temperature at about reflux temperature.

According to a further feature of the invention, acid addition salts of the compounds of this invention may be prepared by reaction of the free base with the appropriate acid, by the application or adaptation of known methods. For example, the acid addition salts of the compounds of this invention may be prepared either by dissolving the free base in water or aqueous alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

Compounds of this invention can be regenerated from their acid addition salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their acid addition salts by treatment with an alkali, e.g. aqueous sodium bicarbonate solution or aqueous ammonia solution.

According to a further feature of the invention, base addition salts of the compounds of this invention may be prepared by reaction of the free acid with the appropriate base, by the application or adaptation of known methods. For example, the base addition salts of the compounds of this invention may be prepared either by dissolving the free acid in water or aqueous alcohol solution or other suitable solvents containing the appropriate base and isolating the salt by evaporating the solution, or by reacting the free acid and base in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

Compounds of this invention can be regenerated from their base addition salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their base addition salts by treatment with an acid, e.g. hydrochloric acid.

Compounds of the present invention may be conveniently prepared, or formed during the process of the invention, as solvates (e.g. hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallisation from an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol.

The starting materials and intermediates may be prepared by the application or adaptation of known methods, for example methods as described in the Reference Examples or their obvious chemical equivalents.

Intermediates of formula (IIx), wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix), may be prepared by reduction of the corresponding nitro compounds of formula (1):



(1)

wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix). For example, the reduction may conveniently be carried out by means of reaction with tin chloride, in an inert solvent,

such as methanol or ethanol, and at a temperature at about reflux tempcrature. Alternatively the reaction may be carried out in a microwave oven at a temperature at about 140°C.

Intermediates of formula (IIx), wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix), may also be prepared by reduction of the corresponding dinitro compounds of formula (2):



(2)

wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix), with tin chloride as above.

Nitro compounds of formula (1), wherein W is CH, X is C-R^2, Y is C-R^3 and Z is CH [in which R^3 is as hereinbefore defined for compounds of formula (Ix)], may be prepared from the corresponding anilines of formula (3)



(3)

wherein X is C-R^2 and Y is C-R^3 [in which R^3 is as hereinbefore defined for compounds of formula (Ix)], by (i) reaction with acetic anhydride in the presence of triethylamine, in an inert solvent, such as dichloromethane, and at a temperature from about 0°C to about room temperature, (ii) reaction with nitric acid in the presence of acetic acid and acetic anhydride at a temperature at about -5°C and (iii) reaction with an alkali metal alkoxide, such as sodium methoxide, in methanol and at room temperature.

Nitro compounds of formula (1), wherein W is CH, X is C-R^2 (in which R^2 is alkyl), Y is C-R^3 (in which R^3 is an aryl or heteroaryl group) and Z is CH may be prepared by reaction of compounds of formula (4):



(4)

wherein X is C-R^2 (in which R^2 is alkyl) and X^2 is bromo or iodo, with an aryl (or heteroaryl) boronic acid in the presence of a suitable catalyst, such as tetrakis(triphenylphosphine)palladium, in an inert solvent, such as tetrahydrofuran, and at a temperature at about 85°C.

Intermediates of formula (IIIx), wherein R^1 is  in which R^7 is hydrogen, R^8 is alkyl and R^9 is hydrogen or alkyl may be prepared by reaction of compounds of formula (5):



(5)

wherein R^8 is alkyl and R^9 is hydrogen, with hydrazine in the presence of acetic acid at reflux temperature, followed by hydrolysis.

Intermediates of formula (IIIx), wherein R^1 is  in which R^7 is hydrogen and R^8 and R^9 together with the carbon atoms to which they are attached form a 5, 6 or 7 membered carbocyclic ring may be similarly prepared by reaction of compounds of formula (5) wherein R^8 and R^9 together with the carbon atoms to which they are attached form a 5, 6 or 7 membered carbocyclic ring, with hydrazine, followed by hydrolysis.

Intermediates of formula (IIIx), wherein R^1 is  in which R^7 is hydrogen, R^{13} is alkyl and X^1 is O, S, SO_2, or NY^5 (where Y^5 is R^4, $-C(=O)R^4$, $-C(=O)NY^1Y^2$, $-C(=O)OR^4$ or $-SO_2R^4$) may be similarly prepared by reaction of compounds of formula (6):



(6)

wherein R^{13} is alkyl and X^1 is O, S, SO_2, or NY^5 (where Y^5 is R^4, $-C(=O)R^4$, $-C(=O)NY^1Y^2$, $-C(=O)OR^4$ or $-SO_2R^4$), with hydrazine, followed by hydrolysis.

Compounds of formula (5), wherein R^8 is alkyl and R^9 is hydrogen, may be prepared by reaction of compounds of formula (7):



(7)

wherein R^8 is alkyl, with diethyl oxalate, in the presence of an alkali metal alkoxide, such as sodium ethoxide, in an inert solvent, such as ethanol, and at a temperature at about 60°C.

Compounds of formula (5), wherein R^8 and R^9 together with the carbon atoms to which they are attached form a 5, 6 or 7 membered carbocyclic ring may be similarly prepared by reaction of cyclopentanone, or cyclohexanone, with diethyl oxalate.

Compounds of formula (6), wherein R^{13} is alkyl and X^1 is O, S, SO_2, or NY^5 (where Y^5 is R^4, $-C(=O)R^4$, $-C(=O)NY^1Y^2$, $-C(=O)OR^4$ or $-SO_2R^4$) may be similarly prepared by reaction of compounds of formula (8):



(8)

wherein R^{13} is alkyl and X^1 is O, S, SO_2, or NY^5 (where Y^5 is R^4, -C(=O)R^4, -C(=O)NY^1Y^2, -C(=O)OR^4 or -SO_2R^4), with diethyl oxalate.

Intermediates of formula (IVx), wherein R^1 is as hereinbefore defined for compounds of formula (Ix), may be prepared by oxidation of compounds of formula (9):

R^1-CH_2OH (9)

wherein R^1 is as hereinbefore defined for compounds of formula (Ix). The oxidation may conveniently be carried out with manganese dioxide, or pyridinium chlorochromate, in an inert solvent, such as chloroform, or dichloromethane, and at a temperature at about 60°C. This procedure is particularly suitable for intermediates of formula (IVx) wherein R^1 is  (in which R^{10} and p are as hereinbefore defined).

Compounds of formula (9), wherein R^1 is as hereinbefore defined for compounds of formula (Ix), may be prepared by reduction of acids of formula (10):

R^1-CO_2H (10)

wherein R^1 is as hereinbefore defined for compounds of formula (Ix). The reduction may conveniently be carried out with lithium aluminium hydride, in an inert solvent, such as tetrahydrofuran, and at a temperature at about room temperature.

Compounds of formula (9), wherein R^1 is as hereinbefore defined for compounds of formula (Ix), may be prepared by reduction of alkyl esters of formula (10a):

R^1-CO_2alkyl (10a)

wherein R^1 is as hereinbefore defined for compounds of formula (Ix). The reduction may conveniently be carried out with lithium aluminium hydride, in an inert solvent, such as tetrahydrofuran, and at a temperature at about room temperature.

Acids of formula (10), wherein R^1 is  (in which R^{10} and p are as hereinbefore defined), may be prepared by reaction of indole-diones of formula (11):



(11)

wherein R^{10} and p are as hereinbefore defined, with (i) sodium hydroxide at 50°C, (ii) sodium nitrite then sulfuric acid at 5°C and (iii) tin (II) chloride.

Indole-diones of formula (11), wherein R^{10} is as hereinbefore defined and p is one, may be prepared by reaction of compounds of formula (12):



(12)

wherein R^{10} is as hereinbefore defined, with polyphosphoric acid at a temperature at about 80°C.

Compounds of formula (12), wherein R^{10} is as hereinbefore defined, may be prepared by reaction of anilines of formula (13):



(13)

wherein R^{10} is as hereinbefore defined, with chloral hydrate and hydroxylamine in the presence of hydrochloric acid at a temperature at about 80°C.

Intermediates of formula (Vx), wherein W, X, Y, Z and R^1 are as hereinbefore defined for compounds of formula (Ix), may be prepared by reaction of compounds of formula (1) with acid chlorides of formula R^1-C(=O)-Cl, optionally in the presence of a tertiary base, such as pyridine, and in an inert solvent, such as dichloromethane, at a temperature at about room temperature.

The following references are also cited, which may be used for the preparation of benzimidazoles, pyrazoles or indazoles in the context of the present invention:

- G. R. Newkome, W.W. Paudler, Comtemporary Heterocyclic Chemistry, Syntheses, Reactions and Applications, J. Wiley, 1982
- Preston, Heterocyclic Compounds, Benzimidazoles and congeneric tricyclic compounds, J. Wiley, 1981
- Behr, Fusco, Jarboe, Heterocyclic Compounds, Pyrazoles, Pyrazolines, Pyrazolidines, indazoles and condensed rings, J. Wiley, 1967.

The following schemes, schemes 5 to 13, illustrate the synthesis of specific examples within the specification using the processes hereinbefore described with the use of appropriate protecting groups where necessary.

Scheme 5



Example 15

Scheme 6



Example 19

Scheme 7



Example 23

Scheme 8



Example 1

Scheme 9


OCH2CH3
CH2CH3
NO2
NH2
NH
O
O2N
N
H
H2N
HN
CH3CH2O
CH3CH2
N-NH
Example 256(a)

Scheme 10



Example 248(m)

Scheme 11



Example 256(c)

Scheme 12



Scheme 13



Scheme 14



Example 257(g)

The present invention is further exemplified but not limited by the following illustrative Examples and Reference Examples.

400M Hz ^{1}H nuclear magnetic resonance spectra (NMR) were recorded on a Varian Unity INOVA machine. In the nuclear magnetic resonance spectra (NMR) the chemical shifts (δ) are expressed in ppm relative to tetramethylsilane. Abbreviations have the following significances: s = singlet; d = doublet; t = triplet; m = multiplet; q = quartet; dd = doublet of doublets; ddd = doublet of double doublets.

The thin layer chromatography (TLC) R_F values were determined using Merck silica plates.

High Pressure Liquid Chromatography - Mass Spectrometry (LC-MS) conditions for determination of retention times (R_T) and associated mass ions were as follows:-

METHOD A:

Mass Spectrometer (MS) - LCT Time-of-Flight (Micromass UK Ltd) Serial No. KA014 [Ionization Mode: Electrospray (Positive Ion); Scan: Tof MS (Full Scan m/z 100 - 1200, sum for 0.4 s @ 50us/scan) Centroid Mode]. Liquid Chromatograph (LC): Hewlett Packard HP1100 Series Binary Pump (Serial # US80301343)& Degasser (serial # JP73008973). Hypersil BDS C-18, 3μ (4.6mm x 50mm), Reverse Phase Column operated under gradient elution conditions using (A) water containing 0.05% trifluoroacetic acid and (B) acetonitrile containing 0.05% trifluoroacetic acid as the mobile phase (gradient: 0.00 minutes, 100%A; linear gradient to 100% B at 2 minutes; then hold until 1.5 minutes); flow rate 1ml/minute to column & to UV detector, flow split after UV detector such that 0.75ml/minute to ELS detector and 0.25ml/minute to mass spectrometer; injection volume 10μl; Auxiliary Detectors: (i) Hewlett Packard Model HP1100 Series UV detector (serial # JP73704703) wavelength = 220nm; (ii) Sedere (France) Model SEDEX 75 Evaporative Light Scattering (ELS) detector (serial # 9970002A); temperature = 46°C, Nitrogen pressure = 4bar; Autosampler / Injector: Gilson Model 215 Liquid Handler with Model 819 injection valve (serial # 259E8280).

METHOD B:

Waters Symmetry C8 3.5μm HPLC column operated under gradient conditions with mixtures of (A) water containing 0.1% formic and (B) acetonitrile containing 0.1% formic acid as the mobile phase (gradient: 0.00 minutes, 95%A:5%B; 0.75minutes, 95%A:5%B; 3.00 minutes 100%B; 4.00 minutes 100%B; 4.25 minutes 95%A:5%B); flow rate 1.5ml/minute with approximately 200μl/minute split to the Mass Spectrometer; injection volume 20μl; in line

Diode Array (210-300nm), in line Evaporative light scattering (ELS) detection ELS – temperature 40°C, Gain 7 – 1.5ml/minute; Source temperature 150°C.

METHOD C:

Waters Symmetry C8 3.5µm HPLC column operated under gradient conditions with mixtures of (A) water containing 10mM ammonium acetate and (B) methanol containing 10mM ammonium acetate as the mobile phase (gradient : 0.00 minutes, 95%A:5%B; 0.75minutes, 95%A:5%B; 3.00 minutes 100%B; 4.00 minutes 100%B; 4.25 minutes 95%A:5%B); flow rate 1.5ml/minute with approximately 200µl/minute split to the Mass Spectrometer; injection volume 20µl; in line Diode Array (210-300nm), in line Evaporative light scattering (ELS) detection ELS – temperature 40°C, Gain 7 – 1.5ml/minute; Source temperature 150°C.

METHOD D:

C8 Phenomenex Luna 5µm (250 x 4.6mm) HPLC column operated under gradient conditions with mixtures of (A) methanol containing 10mM ammonium acetate and (B) water containing 10mM ammonium acetate as the mobile phase (gradient: 0 to 2 minutes 10%A:90%B; 2 to 23 minutes ramp up to 100%A; 23 to 30 minutes 100%A; 30 to 37 minutes 10%A:90%B); flow rate 1ml/minute.

METHOD E:

Mass Spectrometer (MS) - LCT Time-of-Flight (Micromass UK Ltd) Serial No. KA014 [Ionization Mode: Electrospray (Positive Ion); Scan: Tof MS (Full Scan m/z 100 - 1200, sum for 0.4 s @ 50us/scan) Centroid Mode]. Liquid Chromatograph (LC): Hewlett Packard HP1100 Series Binary Pump (Serial # US80301343)& Degasser (serial # JP73008973). Synergi 2U Hydro reverse phase 20X4 mm column. solvent A 0.1% trifluoroacetic acid in water; Solvent B 0.1% trifluoroacetic acid in acetonitrile. Gradient 5%B at time 0 to 90% B at time 2 minutes to 100% B at 5 minutes; flow rate lml/minute to column & to UV detector, flow split after UV detector such that 0.75ml/minute to ELS detector and 0.25ml/minute to mass spectrometer; injection volume 10µl; Auxiliary Detectors: (i) Hewlett Packard Model HP1100 Series UV detector (serial # JP73704703) wavelength = 220nm; (ii) Sedere (France) Model SEDEX 75 Evaporative Light Scattering (ELS) detector (serial # 9970002A); temperature = 46°C, Nitrogen pressure = 4bar; Autosampler / Injector: Gilson Model 215 Liquid Handler with Model 819 injection valve (serial # 259E8280).

METHOD F:

Agilent 1100 Series HPLC with a YMC CombiScreen Pro C18 5.5 µm 4.6 mm by 33 mm reverse phase column using gradient elution with a mixture of (A) acetonitrile/0.1% trifluoroacetic acid and (B) water/0.1% trifluoroacetic acid (5%A:95%B to 95%A:5%B over

5.1 minutes) with a 1.2 mL/minute flow rate; Agilent 1100 Series wellplate autosampler with 2 μL injection; Agilent 1100 Series diode array detector with 215, 254 and 300 nM wavelength detection; Hewlett Packard 1100 Series mass spectrometer with electrospray and positive ionisation.

METHOD G:

Rainin HPXL dual pump HPLC system with a Rainin Dynamax UV-D II detector for 254 nM wavelength, C18 Metachem Monochrom 10μM (100 x 4.6mm) column using gradient elution with a mixture of (A) water with 0.1% trifluoroacetic acid and (B) acetonitrile as the mobile phase (90%A:10%B to 0%A in 12 minutes) with a flow rate of 1.0 ml/minute
C18 Phenomenex Luna 5μM (150 x 4.6mm) column using gradient elution with a mixture of (A) methanol and (B) water with 10mM ammonium acetate as the mobile phase (0-2 minutes 10%A:90%B; 2-25 minutes ramp up to 100%A; 25-32 minutes 100%A; 32-33 minutes 10%A:90%B) with a flow rate of 1.0 ml/minute.

METHOD H:

Waters Symmetry C8 3.5μM Column (50 x 4.6mm) using gradient elution with a mixture of (A) water/0.1% formic acid and (B) acetonitrile/0.1% formic acid (5%B:95%A to 100%B in 3.5min, 100%Bfor 1 min, 100%B to 5%B:95%A in 0.1min, Equilibrate 5%B:95%A 0.49 minutes, Total run time 5 min)with a flow rate of 1.5mL/minute; Detection 210-300nM, 2nM range interval; Column Temp 30°C; Mass Spec Quadrupole, Electrospray, cone voltage25V, +/- ion switching, centroid data, 140 to 850 Da , 0.6 sec scan, 0.4 sec inter scan delay.

METHOD J:

Waters Symmetry C8 3.5μM Column (50 x 4.6mm) using gradient elution with a mixture of (A) 0.1% formic acid in water and (B) 0.1% formic acid in acetonitrile (5%B:95%A 0.75 minutes to 100%B in 4 minutes, 100%Bfor 0.5 minutes, 100%B to 5%B:95%A in 1 minute, Total run time 5 minutes with a flow rate of 1.5mL/minute; Detection 210-300nM, 2nM range interval; Column Temp 30°C; Mass Spec Quadrupole, Electrospray, cone voltage25V, +/- ion switching, centroid data, 140 to 850 Da , 0.6 sec scan, 0.4 sec inter scan delay.

METHOD K:

Waters Symmetry C8 3.5μ Column (50 x 4.6mm) using gradient elution with a mixture of (A) 10mM ammonium acetate in water and (B) 10mM ammonium acetate in methanol (5%B:95%A 0.75 minutes to 100%B in 4 minutes, 100%Bfor 0.5 minutes, 100%B to 5%B:95%A in 1 minute, Total run time 5 min)with a flow rate of 1.5mL/minute; Detection

210-300nM, 2nm range interval; Column Temp 30°C; Mass Spec Quadrupole, Electrospray, cone voltage25V, +/- ion switching, centroid data, 140 to 850 Da , 0.6 sec scan, 0.4 sec inter scan delay.

METHOD L:

Phenomenex Luna C18(2) 3μM Column (150 x 4.6mm) using gradient elution with a mixture of (A) 0.1% formic acid in water and (B) 0.1% formic acid in acetonitrile (20%B:80%A to 100%B in 10 minutes, 100%Bfor 2 minutes, 100%B to 20%B:80%A in 0.5 minutes, 20%B:80%A for 3.5 minutes, Total run time 16 minutes with a flow rate of 1.0mL/minute; 210-300nM, 220 and 254nM extracted and ELSD; Column Temp 30°C; Mass Spec Quadrupole, Electrospray, cone voltage25V, +/- ion switching, centroid data, 100 to 900 Da , 0.6 sec scan, 0.4 sec inter scan delay.

METHOD M:

Phenomenex Luna C18(2) 3μM Column (150 x 4.6mm) using gradient elution with a mixture of (A) 0.1% formic acid in water and (B) 0.1% formic acid in acetonitrile (5%B:95%A to 60%B:40%A in 10 minutes, 60%B:40%A for 2 minutes, 60%B:40%A to 5%B:95%A in 0.5 minutes, 5%B:95%A for 3.5 minutes, Total run time 16 minutes with a flow rate of 1.0mL/minute; 210-300nM, 220 and 254nM extracted and ELSD; Column Temp 30°C; Mass Spec Quadrupole, Electrospray, cone voltage25V, +/- ion switching, centroid data, 100 to 900 Da , 0.6 sec scan, 0.4 sec inter scan delay.

METHOD N:

Waters Symmetry C8 3.5μM Column (50 x 4.6mm) using gradient elution with a mixture of (A) 10mM ammonium acetate in water and (B) 10mM ammonium acetate in methanol (5%B:95%A to 100%B in 3.5minutes, 100%Bfor 1 minute, 100%B to 5%B:95%A in 0.1minute, Equilibrate 5%B:95%A 0.49 minutes, Total run time 5 minutes)with a flow rate of 1.5mL/minute; Detection 210-300nM, 2nM range interval; Column Temp 30°C; Mass Spec Quadrupole, Electrospray, cone voltage25V, +/- ion switching, centroid data, 140 to 850 Da , 0.6 sec scan, 0.4 sec inter scan delay.

METHOD P:

Phenomenex Luna C18(2) 3μM Column (150 x 4.6mm) using gradient elution with a mixture of (A) 10mm ammonium acetate in water and (B) 10mm ammonium acetate in methanol (5%B:95%A to 60%B:40%A in 10 minutes, 60%B:40%A for 2 minutes, 60%B:40%A to 5%B:95%A in 0.5 minutes, 5%B:95%A for 3.5 minutes, Total run time 16 minutes with a flow

rate of 1.0mL/minute; 210-300nM, 220 and 254nM extracted and ELSD; Column Temp 30°C; Mass Spec Quadrupole, Electrospray, cone voltage25V, +/- ion switching, centroid data, 100 to 900 Da , 0.6 sec scan, 0.4 sec inter scan delay.

METHOD Q:

Phenomenex Luna C18(2) 3µM Column (150 x 4.6mm) using gradient elution with a mixture of (A) 10mm ammonium acetate in water and (B) 10mm ammonium acetate in methanol (20%B:80%A to 100%B in 10 minutes, 100%Bfor 2 minutes, 100%B to 20%B:80%A in 0.5 minutes, 20%B:80%A for 3.5 minutes, Total run time 16 minutes with a flow rate of 1.0mL/minute; 210-300nM, 220 and 254nM extracted and ELSD; Column Temp 30°C; Mass Spec Quadrupole, Electrospray, cone voltage25V, +/- ion switching, centroid data, 100 to 900 Da , 0.6 sec scan, 0.4 sec inter scan delay.

METHOD R:

Phenomenex Luna C18(2) 5µM Column (150 x 4.6mm) using gradient elution with a mixture of (A) 10mm ammonium acetate in water and (B) 10mm ammonium acetate in methanol (40%B:60%A to 100%B in 10 minutes, 100%Bfor 2 minutes, 100%B to 40%B:60%A in 0.5 minutes, 40%B:60%A for 3.5 minutes, Total run time 16 minutes with a flow rate of 1.0mL/minute; 210-300nM, 220 and 254nM extracted and ELSD; Column Temp 30°C; Mass Spec Quadrupole, Electrospray, cone voltage25V, +/- ion switching, centroid data, 100 to 900 Da , 0.6 sec scan, 0.4 sec inter scan delay.

High Pressure Liquid Chromatography conditions for determination of retention times (R_T) were as follows:-

METHOD A1:

YMC ODS-AQ (2 x 50mm) column using gradient elution conditions with mixtures of acetonitrile, water and formic acid as the mobile phase [95/5/0.1% to 5/95/0.1%] and a flow rate of 0.4mL/minute.

METHOD B1:

C18 Phenomenex Luna 5µM (150 x 4.6mm) column using gradient elution with a mixtures of (A) acetonitrile containing 0.1% formic acid and (B) water containing 0.1% formic acid as the mobile phase (gradient: 0-2 minutes 10%A:90%B; 2-25 minutes ramp up to 100%A; 25-32 minutes 100%A; 32-33 minutes 10%A:90%B) with a flow rate of 1.0 ml/minute.

METHOD C1:

C18 Phenomenex Luna 5μM (150 x 4.6mm) column using gradient elution with a mixture of (A) methanol and (B) water with 10mM ammonium acetate as the mobile phase (0-2 minutes 10%A:90%B; 2-25 minutes ramp up to 100%A; 25-32 minutes 100%A; 32-33 minutes 10%A:90%B) with a flow rate of 1.0 ml/minute.

METHOD D1:

C18 Phenomenex Luna 3μM (150 x 4.6mm) column using gradient elution with a mixture of (A) acetonitrile containing 0.1% formic acid and (B) water containing 0.1% formic acid with a flow rate of 1.0 ml/minute

METHOD E1:

C18 Phenomenex Luna 3μM (150 x 4.6mm) column using gradient elution with a mixture of (A) methanol and (B) water with 10mM ammonium acetate as the mobile phase (20%A:80%B to 100%A in 10 minutes; 100%A for 2 minutes; 100%Ato 20%A:80%B in 0.5 minutes; 20%A:80%B for 3.5 minutes) with a flow rate of 1.0 ml/minute.

METHOD F1:

C18 Phenomenex Luna 3μM (150 x 4.6mm) column using gradient elution with a mixture of acetonitrile and water with 0.1% formic acid.

METHOD G1:

C18 Phenomenex Luna 3μM (150 x 4.6mm) column using gradient elution with a mixture of (A) methanol and (B) water with 10mM ammonium acetate as the mobile phase (5%A;95%B to 60%A:40%B in 10 minutes; 60%A:40%B for 2 minutes; 60%A:40%B to 5%A:95%B in 0.5 minutes; 5%A:95%B for 3.5 minutes) with a flow rate of 1.5 ml/minute.

Gas Chromatography - Mass Spectrometry (GC-MS) conditions for determination of retention times (R_T) and associated mass ions were as follows:

Varian 3800 Gas Chromatograph with Chrompack 0.25 mm diameter fused silica 30 m column using a 20 minute elution with 25°C /minute gradient from 50 to 300°C from time 1 to 11 minute; helium mobile phase with 1.2 mL/minute flow rate; 3-8 μL injection volume with 50:50 injection split ratio; Varian 2000R mass spectrometer with electron impact detection for ions 40 to 650 m/z.

General method of LC-MS purification of examples 1 to 229: a Waters Fraction Lynx system is used, and the separations were carried out on a Waters Symmetry column (C18, 5 μM, 19x50 mm, catalogue number 186000210), eluting with a linear gradient of acetonitrile containing 0.07% trifluoroacetic acid

(v/v) in water containing 0.07% trifluoroacetic acid (v/v), gradient rising from 5% to 95% (v/v) of acetonitrile/ trifluoroacetic acid over 8 minutes, and then 2 minutes at 95% acetonitrile/ trifluoroacetic acid at a flow rate of 10 ml/minute. The products are injected in solution in dimethylsulfoxide, and collected according to the detection of their molecular weight.

Compound names were generated using an auto-nom plug in for ISIS2.3 or ISIS2.4.

EXAMPLE 1

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide



2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide may be prepared in the following manner.

A solution of 27.3 mg of HBTU in 0.2 ml of dimethylformamide is added, at a temperature in the region of 20°C, to a solution of 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid in 0.42 ml of anhydrous dimethylformamide. After stirring at a temperature in the region of 20°C for one hour, 15.7 ml of benzylamine are added, followed by addition of 12.4 ml of N,N-diisopropylethylamine dissolved in 0.32 ml of dimethylformamide. After 20 hours, at a temperature in the region of 20°C, the reaction medium is concentrated under reduced pressure, at a temperature in the region of 40°C. The crude residue obtained is dissolved in DMSO and purified by preparative LC-MS. The fractions containing the desired product are combined and concentrated under reduced pressure at a temperature in the region of 40°C. 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide are thus obtained in the form of a cream-coloured powder, the characteristics of which are as follows:

LC-MS retention time = 2.86 minutes

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid may be prepared in the following manner:

1.3 g of sodium metabisulphite and 1.04 g of 3,4-diaminobenzoic acid are added, at a temperature in the region of 20°C, to a solution of 1 g of 1H-indazole-3-carboxaldehyde in 10 ml of dimethylformamide. The reaction mixture is refluxed for one hour and then cooled to a temperature in the region of 20°C and diluted with dichloromethane, and the mixture is filtered. The collected filtrate is concentrated under reduced pressure. The brown lacquer obtained (340 mg) is purified by

preparative LC-MS. 138.8 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid are thus obtained in the form of a beige-coloured powder.

1H-Indazole-3-carboxaldehyde may be prepared in the following manner:

A solution of 2.27 g of (1H-indazol-3-yl)methanol in 220 ml of 1,2-dimethoxyethane is added to 13.32 g of manganese dioxide. After one hour at a temperature in the region of 20°C, the reaction mixture is refluxed for 15 minutes. After cooling to a temperature in the region of 20°C, the reaction medium is filtered through a sinter funnel packed with Celite. The collected filtrate is concentrated under reduced pressure at a temperature in the region of 40°C. 2.02 g of 1H-indazole-3-carboxaldehyde are thus obtained in the form of a yellow powder, the characteristics of which are as follows:

^1H NMR (DMSO d6, 400 MHz): 7.40 ppm (triplet, 1H); 7.55 ppm (triplet, 1H); 7.75 ppm (doublet, 1H); 8.18 ppm (doublet, 1H); 10.23 ppm (singlet, 1H); 14.2 ppm (multiplet, 1H).

(1H-Indazol-3-yl)methanol may be prepared in the following manner:

3.2 g of lithium aluminium hydride are added portionwise to a solution of 7.08 g of methyl 3-indazolecarboxylate in 80 ml of tetrahydrofuran, cooled to a temperature in the region of 0°C by an ice bath. After 4 hours at a temperature in the region of 0°C, 1.6 g of lithium aluminium hydride are added. After 2 hours at a temperature in the region of 0°C, the reaction medium is treated successively with 6 ml of water and then 6 ml of aqueous 1N sodium hydroxide solution and finally 18 ml of water. The reaction mixture is filtered through paper and the aqueous filtrate is then extracted with dichloromethane. The collected organic fractions are combined, dried over magnesium sulphate and concentrated under reduced pressure at a temperature in the region of 40°C. 3.15 g of (1H-indazol-3-yl)methanol are obtained in the form of an off-white powder, the characteristics of which are as follows:

^1H NMR (DMSO d6, 400 MHz): 4.80 ppm (doublet, 2H); 5.25 ppm (triplet, 1H); 7.15 ppm (triplet, 1H); 7.35 ppm (triplet, 1H); 7.51 ppm (doublet, 1H); 7.87 ppm (doublet, 1H); 12.81 ppm (multiplet, 1H).

Methyl 3-indazolecarboxylate may be prepared in the following manner:

0.5 ml of concentrated sulphuric acid (95%) is added dropwise, at a temperature in the region of 20°C, to a solution of 9.13 g of 3-indazolecarboxylic acid in 100 ml of methanol. After refluxing for 20

hours, the reaction medium is concentrated under reduced pressure at a temperature in the region of 40°C. The aqueous residue obtained is extracted with dichloromethane. The organic phases are combined, washed with water until neutral, dried over magnesium sulphate and then concentrated under reduced pressure at a temperature in the region of 40°C. The yellow powder obtained is washed with ethyl ether. A white powder is obtained. The filtrate is concentrated under reduced pressure until a yellow powder is obtained. This yellow powder is washed again with ethyl ether until a white powder is obtained. The yellow filtrate is concentrated a third time under reduced pressure and the yellow powder collected is itself also washed with ethyl ether. All the fractions of white powder are combined. 7.08 g of methyl 3-indazolecarboxylate are thus obtained in the form of a white powder.

EXAMPLE 2

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide



2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 71.8 µl of a methylamine solution (2M in tetrahydrofuran), 14.8 mg of expected product are obtained.

EXAMPLE 3

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide



2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 19.4 ml of an ethylamine solution (33% in water) 14.8 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide are obtained.

EXAMPLE 4

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide



2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 12.3 ml of isopropylamine, 16.5 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide are obtained.

EXAMPLE 5

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide



2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 13.1 ml of aniline, 14.1 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide are obtained in the form of a white powder.

EXAMPLE 6

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide



2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 18 ml of phenethylamine, 17.7 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide are obtained in the form of a white powder.

EXAMPLE 7

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-morpholinoamide



2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-morpholinoamide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 12.5 ml of morpholine, 18.6 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-morpholinoamide are obtained in the form of a pale yellow powder.

EXAMPLE 8

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(N'-methyl-piperazino)amide



2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(N'-methyl-piperazino)amide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 15.9 ml of N-methylpiperazine, 16.1 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(N'-methyl-piperazino)amide are obtained in the form of a yellow oil.

EXAMPLE 9

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-pyrrolidinoamide



2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-pyrrolidinoamide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 12 ml of pyrrolidine, 17.7 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-pyrrolidinoamide are obtained in the form of a pale yellow powder.

EXAMPLE 10

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(isobutyl)amide



2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(isobutyl)amide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 14.6 ml of isobutylamine, 7.6 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(isobutyl)amide are obtained in the form of a pale yellow powder.

EXAMPLE 11

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide



2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 18.7 ml of cyclohexylmethylamine, 16.1 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide are obtained in the form of a white powder.

EXAMPLE 12

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide



2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 13.3 ml of 2-furfurylamine, 14.8 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide are obtained in the form of a white powder.

EXAMPLE 13

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide



2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 18.6 ml of N-methylbenzylamine, 7.3 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide are obtained in the form of a pale yellow powder.

EXAMPLE 14

Methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5-carboxylate



Methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5-carboxylate may be prepared in the following manner:

A mixture of 0.1 g of 1H-indazole-3-carboxaldehyde and 113.7 mg of methyl 3,4-diaminobenzoate in 10 ml of nitrobenzene is maintained at a temperature in the region of 145°C for 3 hours and 45 minutes. After cooling to a temperature in the region of 20°C, the reaction mixture is purified on SPE (5 g of SCX phase, processing and washing with methanol, extraction with a 2N ammoniacal methanol solution). The ammoniacal solution collected during the detachment is then concentrated under reduced pressure at a temperature in the region of 40°C. 198.3 mg of an orange lacquer are obtained and are purified by preparative LC-MS. 42.7 mg of methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5-carboxylate are thus obtained in the form of a beige-coloured powder, the characteristics of which are as follows:

^1H NMR (DMSO d6, 400 MHz): 3.95 ppm (singlet, 3H); 7.40 ppm (triplet, 1H); 7.55 ppm (triplet, 1H); 7.75 ppm (doublet, 1H); 7.77 ppm (doublet, 1H); 7.95 ppm (doublet, 1H); 8.57 ppm (doublet, 1H); 13.85 ppm (multiplet, 1H).

EXAMPLE 15

5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole



5,6-Dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole may be prepared by following the procedure for the preparation of methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5-carboxylate (Example 14):

Starting with 200 mg of 1H-indazole-3-carboxaldehyde and 177 mg of 4,5-dimethyl-1,2-phenylenediamine in 10 ml of nitrobenzene, 15.9 mg of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole are obtained in the form of a dark red powder, the characteristics of which are as follows:

^{1}H NMR (DMSO d6, 400 MHz): 2.60 ppm (singlet, 6H); 7.42 ppm (triplet, 1H); 7.53 ppm (singlet, 2H); 7.58 ppm (triplet, 1H); 7.78 ppm (doublet, 1H); 8.52 ppm (doublet, 1H); 14.05 ppm (multiplet, 1H).

5,6-Dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole may also be prepared according to the following procedure:

389 mg of sodium metabisulphite are added, at a temperature in the region of 20°C, to a solution of 300 mg of 1H-indazole-3-carboxaldehyde and 279 mg of 4,5-dimethyl-1,2-phenylenediamine in 3 ml of dimethylformamide. The reaction mixture is refluxed for 4 hours and then cooled to a temperature in the region of 20°C and filtered through paper. The collected filtrate is concentrated under reduced pressure. The brown lacquer obtained (340 mg) is purified by preparative LC-MS. 138.8 mg of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole are thus obtained in the form of a beige-coloured powder.

EXAMPLE 16

5-methoxy-2-(1H-indazol-3-yl)-1H-benzimidazole



5-Methoxy-2-(1H-indazol-3-yl)-1H-benzimidazole may be prepared by following the procedure for the preparation of methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5-carboxylate (Example 14):

Starting with 200 mg of 1H-indazole-3-carboxaldehyde and 274.4 mg of 4-methoxy-1,2-phenylenediamine dihydrochloride in 10 ml of nitrobenzene, 45.6 mg of 5-methoxy-2-(1H-indazol-3-yl)-1H-benzimidazole are obtained in the form of a light brown powder, the characteristics of which are as follows:

^{1}H NMR (DMSO d6, 400 MHz): 3.90 ppm (singlet, 3H); 7.00 ppm (doublet, 1H); 7.18 ppm (doublet, 1H); 7.40 ppm (triplet, 1H); 7.55 ppm (triplet, 1H); 7.64 ppm (doublet, 1H); 7.73 ppm (doublet, 1H); 8.52 ppm (doublet, 1H); 13.91 ppm (multiplet, 1H).

EXAMPLE 17

2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid



2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid may be prepared by following the procedure for the preparation of methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5-carboxylate (Example 14):

Starting with 237 mg of 1H-indazole-3-carboxaldehyde and 305.5 mg of 2,3-diaminobenzoic acid hydrochloride in 10 ml of nitrobenzene, 20.5 mg of 2-(1H-indazol-3-yl)-3H-benzimidazole-4-carboxylic acid are obtained in the form of a beige-coloured powder, the characteristics of which are as follows:

1H NMR, DMSO d6, 400 MHz: 7.40 ppm (triplet, 1H); 7.42 ppm (triplet, 1H); 7.55 ppm (triplet, 1H); 7.72 ppm (doublet, 1H); 7.90 ppm (doublet, 1H); 8.02 ppm (doublet, 1H); 8.52 ppm (doublet, 1H); 13.68 ppm (multiplet, 1H).

EXAMPLE 18

5-bromo-2-(1H-indazol-3-yl)-3H-benzimidazole



5-Bromo-2-(1H-indazol-3-yl)-3H-benzimidazole may be prepared by following the procedure for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 643 mg of 1H-indazole-3-carboxaldehyde, 816 mg of 4-bromo-1,2-phenylenediamine, and 836.5 mg of sodium metabisulphite in 15 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a chromatography under pressure on silica, 939 mg of 5-bromo-2-(1H-indazol-3-yl)-3H-benzimidazole are obtained in the form of a brick-red powder.

EXAMPLE 19

2-(5-Ethoxy-2H-pyrazol-3-yl)-1H-benzimidazole-4-carboxylic acid



2-(5-Ethoxy-2H-pyrazol-3-yl)-1H-benzimidazole-4-carboxylic acid may be obtained from 2-(2-benzyl-5-ethoxy-2H-pyrazol-3-yl)-1H-benzimidazole-4-carboxylic acid by deprotection of the benzyl group in the presence of hydrogen and a catalyst such as palladium.

2-(2-Benzyl-5-ethoxy-2H-pyrazol-3-yl)-1H-benzimidazole-4-carboxylic acid may be prepared by following the procedure for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 21.6 mg of 2-benzyl-5-ethoxy-2H-pyrazole-3-carboxaldehyde, and 17.7 mg of 3,4-diaminobenzoic acid hydrochloride in 1 ml of nitrobenzene, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol), 50.9 mg of 2-(2-benzyl-5-ethoxy-2H-pyrazol-3-yl)-1H-benzimidazole-4-carboxylic acid are obtained in the form of a yellow lacquer.

2-Benzyl-5-ethoxy-2H-pyrazole-3-carboxaldehyde may be prepared in the following manner:

4 Å molecular sieves are added to a solution of 45.7 mg of (2-benzyl-5-ethoxy-2H-pyrazol-3-yl)methanol in 0.5 ml of dichloromethane, followed by addition of 43.1 mg of pyridinium chlorochromate. After 20 hours at a temperature in the region of 20°C, the reaction mixture is filtered through Celite. The insoluble material formed is rinsed with ethyl acetate and then with dichloromethane. The filtrate is washed with water. After separation of the phases by settling, the aqueous phase is re-extracted with dichloromethane. The organic phases are combined, dried over magnesium sulphate, filtered and then concentrated under reduced pressure. 21.6 mg of 2-benzyl-5-ethoxy-2H-pyrazole-3-carboxaldehyde are thus obtained in the form of a brown lacquer, the characteristics of which are as follows:

^{1}H NMR (DMSO d6, 400 MHz): 1.35 ppm (triplet, 3H); 4.25 ppm (quartet, 2H); 5.30 ppm (singlet, 2H); 6.30 ppm (singlet, 1H); 7.25-7.40 ppm (multiplet, 5H); 9.72 ppm (singlet, 1H).

(2-Benzyl-5-ethoxy-2H-pyrazol-3-yl)methanol may be prepared in the following manner:

11.1 mg of lithium aluminium hydride are added to a solution of 76 mg of methyl 2-benzyl-5-ethoxy-2H-pyrazole-3-carboxylate in 0.75 ml of tetrahydrofuran, cooled to a temperature in the region of 0°C by an ice bath. After 3 hours at a temperature in the region of 0°C, 22.2 mg of lithium aluminium hydride are added and the reaction medium is allowed to warm to a temperature in the region of 20°C. After 30 minutes at a temperature in the region of 20°C, 10 ml of ice-cold water are added and the reaction mixture is then filtered through Celite. After separation of the phases by settling, the aqueous phase is extracted with ethyl acetate. The organic phases are combined, dried over magnesium sulphate and concentrated under reduced pressure. 45.7 mg of (2-benzyl-5-ethoxy-2H-pyrazol-3-yl)methanol are thus obtained in the form of a brown lacquer, the characteristics of which are as follows:

^{1}H NMR (DMSO d6, 400 MHz): 1.35 ppm (triplet, 3H); 4.15 ppm (quartet, 2H); 4.30 ppm (doublet, 2H); 5.00 ppm (triplet, 1H); 5.08 ppm (singlet, 2H); 5.70 ppm (singlet, 1H); 7.20-7.40 ppm (multiplet, 5H).

Methyl 2-benzyl-5-ethoxy-2H-pyrazole-3-carboxylate may be prepared in the following manner:

5 mg of sodium iodide, 36 µl of bromoethane and 70 mg of potassium carbonate are added, at a temperature in the region of 20°C, to a solution of 100 mg of methyl 2-benzyl-5-hydroxy-2H-pyrazole-3-carboxylate in 1 ml of acetone. The reaction mixture is refluxed for 9 hours, cooled to a temperature

in the region of 20°C and filtered. The filtrate is concentrated under reduced pressure. 76 mg of methyl 2-benzyl-5-ethoxy-2H-pyrazole-3-carboxylate are thus obtained in the form of a solid, the characteristics of which are as follows:

^{1}H NMR (DMSO d6, 400 MHz): 1.35 ppm (triplet, 3H); 3.50 ppm (singlet, 3H); 4.22 ppm (quartet, 2H); 5.22 ppm (singlet, 2H); 6.28 ppm (singlet, 1H); 7.20-7.40 ppm (multiplet, 5H).

Methyl 2-benzyl-5-hydroxy-2H-pyrazole-3-carboxylate may be prepared in the following manner:

1.72 ml of dimethylacetylene dicarboxylate are added, at a temperature in the region of 20°C, to a solution of 2.73 g of benzylhydrazine dihydrochloride in 45 ml of glacial acetic acid. The reaction mixture is refluxed for 3 hours, cooled to a temperature in the region of 20°C and then concentrated under reduced pressure. After filtering off the insoluble material formed, 252 mg of methyl 2-benzyl-5-hydroxy-2H-pyrazole-3-carboxylate are collected in the form of a white powder, the characteristics of which are as follows:

^{1}H NMR (DMSO d6, 400 MHz): 3.76 ppm (singlet, 3H); 5.19 ppm (singlet, 2H); 5.85 ppm (singlet, 1H); 7.25-7.45 ppm (multiplet, 5H); 11.69 ppm (multiplet, 1H).

The filtrate may be purified by flash chromatography on 400 g of 20-45 µm silica (applied in a 25/75 ethyl acetate/cyclohexane mixture; eluant: 25/75 and then 40/60 ethyl acetate/cyclohexane) to give an additional batch of methyl 2-benzyl-5-hydroxy-2H-pyrazole-3-carboxylate in the form of a white powder.

EXAMPLE 20

5,6-dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-1H-benzimidazole



5,6-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-1H-benzimidazole may be prepared by following the procedure described for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 53.3 mg of 5-methyl-2H-pyrazole-3-carboxaldehyde, 65.9 mg of 4,5-dimethyl-1,2-phenylenediamine, and 92 mg of sodium metabisulphite, in 0.5 ml of ethanol and 1.5 ml of

dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a chromatography under pressure on silica, 20.8 mg of 5,6-dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-1H-benzimidazole are obtained in the form of a white powder.

5-Methyl-2H-pyrazole-3-carboxaldehyde may be prepared from commercial ethyl 5-methyl-2H-pyrazole-3-carboxylate by following the procedure described for the preparation of 1H-indazole-3-carboxaldehyde, starting with methyl 3-indazolecarboxylate.

EXAMPLE 21

5,6-dimethyl-2-(5-thiophen-2-yl-2H-pyrazol-3-yl)-1H-benzimidazole



5,6-Dimethyl-2-(5-thiophen-2-yl-2H-pyrazol-3-yl)-1H-benzimidazole may be prepared by following the procedure described for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 16.2 mg of 5-thiophen-2-yl-2H-pyrazole-3-carboxaldehyde, 12.4 mg of 4,5-dimethyl-1,2-phenylenediamine, and 17.3 mg of sodium metabisulphite, in 0.2 ml of ethanol and 0.6 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a chromatography under pressure on silica and a purification by LC-MS, 5,6-dimethyl-2-(5-thiophen-2-yl-2H-pyrazol-3-yl)-1H-benzimidazole is obtained in the form of a white powder.

5-Thiophen-2-yl-2H-pyrazole-3-carboxaldehyde may be prepared from commercial ethyl 5-thiophen-2-yl-2H-pyrazole-3-carboxylate by following the procedure described for the preparation of 1H-indazole-3-carboxaldehyde starting with methyl 3-indazolecarboxylate.

EXAMPLE 22

2-(4-bromo-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole



2-(4-Bromo-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole may be prepared by following the procedure described for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 100 mg of commercial 4-bromo-2H-pyrazole-3-carboxaldehyde, 77.8 mg of 4,5-dimethyl-1,2-phenylenediamine, and 108.6 mg of sodium metabisulphite, in 1 ml of ethanol and 2 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a chromatography under pressure on silica, 143.2 mg of 2-(4-bromo-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole are obtained in the form of a yellow foam.

EXAMPLE 23

2-(5-ethyl-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole



2-(5-Ethyl-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole may be prepared by following the procedure described for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 100 mg of 5-ethyl-2H-pyrazole-3-carboxaldehyde, 110 mg of 4,5-dimethyl-1,2-phenylenediamine, and 153 mg of sodium metabisulphite, in 1 ml of ethanol and 3 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a reverse-phase HPLC (5 mm C18 phase, dimensions 100x25 mm, flow rate 20 ml/min, elution gradient acetonitrile/0.07% TFA – water/0.07% TFA from 5-95 to 95-5 (v/v)), and desalification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol), 82 mg of 2-(5-ethyl-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole are obtained in the form of a beige-coloured powder, the characteristics of which are as follows:

^{1}H NMR (DMSO d6, 300 MHz): 1.26 (t, J = 7 Hz: 3H); 2.31 (s: 6H); 2.70 (broad q, J = 7 Hz: 2H); 6.60 (broad s: 1H); 7.22 (mult: 1H); 7.36 (mult: 1H); 12.37 (mult: 1H); 12.92 (mult: 1H).

5-Ethyl-2H-pyrazole-3-carboxaldehyde may be prepared from ethyl 5-ethyl-2H-pyrazole-3-carboxylate by following the procedure described for the preparation of 1H-indazole-3-carboxaldehyde starting with methyl 3-indazolecarboxylate.

Ethyl 5-ethyl-2H-pyrazole-3-carboxylate may be prepared according to the general procedure in the following reference: Kunio Seki et al., Chem. Pharm. Bull., 32(4), 1568-1577 (1984).

EXAMPLE 24

2-(5-ethyl-2H-pyrazol-3-yl)-4,5-ethylenedioxy-1H-benzimidazole



2-(5-Ethyl-2H-pyrazol-3-yl)-4,5-ethylenedioxy-1H-benzimidazole may be prepared by following the procedure described for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 100 mg of 5-ethyl-2H-pyrazole-3-carboxaldehyde, 134 mg of 3,4-ethylenedioxy-1,2-phenylenediamine, and 153 mg of sodium metabisulphite, in 1 ml of ethanol and 3 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a reverse-phase HPLC (5 mm, C18 phase, dimensions 100x25 mm, flow rate 20 ml/min, elution gradient acetonitrile/0.07% TFA – water/0.07% TFA from 5-95 to 95-5 (v/v)), and desalification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol), 60 mg of 2-(5-ethyl-2H-pyrazol-3-yl)-4,5-ethylenedioxy-1H-benzimidazole are obtained in the form of a brown lacquer, the characteristics of which are as follows:

^{1}H NMR (DMSO d6, 300 MHz): 1.27 (t, J = 7 Hz: 3H); 2.70 (broad q, J = 7 Hz: 2H); from 4.20 to 4.45 (mt: 4H); 6.61 (broad s: 1H); 6.72 (d, J = 8 Hz: 1H); 6.88 (broad d, J = 8 Hz: 1H); 12.50 (mult: 1H); 12.94 (mult: 1H).

EXAMPLE 25

2-(5-ethyl-2H-pyrazol-3-yl)-5-methoxy-1H-benzimidazole



2-(5-Ethyl-2H-pyrazol-3-yl)-5-methoxy-1H-benzimidazole may be prepared by following the procedure described for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 100 mg of 5-ethyl-2H-pyrazole-3-carboxaldehyde, 138 mg of 4-methoxy-1,2-phenylenediamine, and 153 mg of sodium metabisulphite, in 1 ml of ethanol and 3 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a reverse-phase HPLC (5 mm C18 phase, dimensions 100x25 mm, flow rate 20 ml/min, elution gradient: acetonitrile/0.07% TFA – water/0.07% TFA from 5-95 to 95-5 (v/v)), and desalification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol), 61 mg of 2-(5-ethyl-2H-pyrazol-3-yl)-5-methoxy-1H-benzimidazole are obtained in the form of a brown lacquer, the characteristics of which are as follows:

^1H NMR (DMSO d6 with addition of a few drops of CD_3COOD, 300 MHz): 1.26 (t, J = 7 Hz: 3H); 2.70 (q, J = 7 Hz: 2H); 3.79 (s: 3H); 6.61 (s: 1H); 6.81 (dd, J = 8.5 and 2.5 Hz: 1H); 7.03 (broad s: 1H); 7.42 (d, J = 8.5 Hz: 1H).

EXAMPLE 26

2-(5-ethyl-2H-pyrazol-3-yl)-4-hydroxy-1H-benzimidazole



2-(5-Ethyl-2H-pyrazol-3-yl)-4-hydroxy-1H-benzimidazole may be prepared by following the procedure described for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15): Starting with 100 mg of 5-ethyl-2H-pyrazole-3-carboxaldehyde, 100 mg of 2,3-diaminophenol, and 153 mg of sodium metabisulphite, in 1 ml of ethanol and 3 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a reverse-phase HPLC (5 mm, C18 phase, dimensions: 100x25 mm, flow rate 20 ml/min, elution gradient: acetonitrile/0.07% TFA – water/0.07% TFA from 5-95 to 95-5 (v/v)), and desalification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol), 16 mg of

2-(5-ethyl-2H-pyrazol-3-yl)-4-hydroxy-1H-benzimidazole are obtained in the form of a brown lacquer, the characteristics of which are as follows:

^{1}H NMR (DMSO d6 with addition of a few drops of CD_3COOD, 300 MHz): 1.26 (t, J = 7 Hz: 3H); 2.70 (q, J = 7 Hz: 2H); 6.55 (t, J = 4.5 Hz: 1H); 6.66 (s: 1H); 6.96 (broad d, J = 4.5 Hz: 2H).

EXAMPLE 27

2-(5-ethyl-2H-pyrazol-3-yl)-5-bromo-1H-benzimidazole



2-(5-Ethyl-2H-pyrazol-3-yl)-5-bromo-1H-benzimidazole may be prepared by following the procedure described for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 20 mg of 5-ethyl-2H-pyrazole-3-carboxaldehyde, 30 mg of 4-bromo-1,2-phenylenediamine and 30 mg of sodium metabisulphite, in 1 ml of ethanol and 2 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a reverse-phase HPLC (5 mm C18 phase, dimensions: 100x25 mm, flow rate 20 ml/min, elution gradient: acetonitrile/0.07% TFA – water/0.07% TFA from 5-95 to 95-5 (v/v)), and desalification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol), 21 mg of 2-(5-ethyl-2H-pyrazol-3-yl)-5-bromo-1H-benzimidazole are obtained in the form of a yellow powder, the characteristics of which are as follows:

^{1}H NMR (DMSO d6, 300 MHz): 1.28 (t, J = 7 Hz: 3H); 2.71 (q, J = 7 Hz: 2H); 6.67 (s: 1H); 7.30 (dd, J = 8.5 and 2.5 Hz: 1H); 7.49 (mt: 1H); 7.712 (broad s: 1H); from 12.5 to 13.5 (broad mult: 2H).

The products of formula (I) of the present application can also be prepared according to the following process:



The products of Examples 97 to 145 of the present application represented in the TABLE 3 below can be prepared according to the schemes indicated above and in particular according to the procedures indicated below.

EXAMPLE 97

3-(6-phenyl-1H-benzimidazol-2-yl)-2H-indazole

Step 1 : Synthesis of 3-(6-bromo-1H-benzimidazol-2-yl)-2H-indazole (other preparation of example 18) 4.25 g of 1-hydroxybenzotriazole and 4.3 g of calcium sulphate are added at ambient temperature to a solution of 4.6 g of indazole-3-carboxylic acid in 50 ml of dimethylformamide. The reaction mixture is cooled to approximately 0°C and then 4.9 ml of N,N-diisopropylcarbodiimide are slowly added. After stirring for 2 hours at ambient temperature, 5.9 g of 4-bromo-o-phenylenediamine are added. After stirring for 60 hours at ambient temperature, the reaction mixture is concentrated to dryness under reduced pressure. The brown oil obtained is taken up in 50 ml of water and extracted 3 times with 50 ml of ethyl acetate. The organic phases are combined, dried over magnesium sulphate and then concentrated to dryness under reduced pressure. 18 g of a brown oil are thus obtained, which oil is taken up in 100 ml of a 20% solution of hydrochloric acid in ethanol. The mixture is brought to reflux for 4 hours and then concentrated to dryness, the brown oil obtained is taken up in 20 ml of water, and an aqueous ammonia solution is run in until a pH of the mixture of about 8-9 is obtained. The aqueous phase is then extracted 3 times with 30 ml of ethyl acetate and the organic phases are combined, dried over magnesium sulphate and concentrated to dryness under reduced pressure. After purification by chromatography under pressure on silica (eluent water/acetonitrile), 5 g of 3-(6-bromo-1H-benzimidazol-2-yl)-2H-indazole are thus obtained.

IR spectrum (KBr): characteristic bands at 1621, 1570, 1441, 1344, 1324, 1273, 1239, 1135, 1042, 914, 804, 774 and 746 cm^{-1}

Step 2 : Synthesis of 1-[2-(1-acetyl-1H-indazol-3-yl)-5-bromobenzimidazol-1-yl]ethanone

5 g of 3-(6-bromo-1H-benzimidazol-2-yl)-2H-indazole are charged to a solution of 40 ml of acetic anhydride and 40 ml of pyridine. The mixture is brought to reflux for 4 hours and then concentrated to dryness after returning to ambient temperature. The brown solid obtained is taken up in 50 ml of ethyl acetate and washed with 50 ml of a saturated sodium hydrogencarbonate solution until a pH of 7-8 is obtained. The organic phase is dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure. The light brown solid obtained is triturated in 20 ml of ethyl acetate and then filtered off on a sintered glass funnel. 1.5 g of the compound 1-[2-(1-acetyl-1H-indazol-3-yl)-5-bromobenzimidazol-1-yl]ethanone are thus obtained. A second crop is obtained by chromatographing the filtrate obtained above under pressure on silica (eluent cyclohexane/ethyl acetate), i.e. 1.3 g of the same compound.

Characteristics of the compound:

^1H NMR spectrum (300 MHz, $(CD_3)_2SO$ d6, δ in ppm).

The mixture of the two positional isomers in the proportions 50/50 is observed.

2.61 and 2.62 (2 s, 3H in all); 2.80 (s, 3H); 7.62 (broad t, J = 7.5 Hz, 1H); 7.68 and 7.71 (2 dd, J = 9 and 2 Hz, 1H in all); 7.80 (ddd, J = 8.5, 7.5 and 0.5 Hz, 1H); 7.91 and 8.01 (2 d, J = 9 Hz, 1H); 8.18 and 8.20 (2 d, J = 2 Hz, 1H in all); 8.27 and 8.30 (2 d, J = 7.5 Hz, 1H in all); 8.46 (d, J = 8.5 Hz, 1H)

IR spectrum (KBr): characteristic bands at 1727, 1610, 1450, 1405, 1374, 1326, 1290, 1198, 1176, 964 and 760 cm^{-1}

Step 3 : Synthesis of 3-(6-phenyl-1H-benzimidazol-2-yl)-2H-indazole

40 mg of sodium carbonate, 7 mg of dihydrogendichlorobis(di-tert-butylphosphonite-κP)palladate(2-) (POPd[0]) and 46 mg of phenylboronic acid are added under an argon atmosphere to a solution of 50 mg of 1-[2-(1-acetyl-1H-indazol-3-yl)-5-bromobenzimidazol-1-yl]ethanone in 800 μl of anhydrous tetrahydrofuran. The reaction mixture is brought to reflux for 3 hours and then cooled to ambient temperature. The mixture is then diluted with 3 ml of ethyl acetate and then washed with 2 times 2 ml of water. The organic phase is dried over magnesium sulphate and then concentrated to dryness under reduced pressure. 48 mg of a brown solid are obtained, which solid is dissolved in 500 μl of tetrahydrofuran, to which 500 μl of diethylamine are added. The reaction mixture is heated at 60°C for 4 hours and then allowed to return to ambient temperature. The mixture is then concentrated to dryness and then the brown solid obtained is purified by LC-MS to produce 12.5 mg of 3-(6-phenyl-1H-benzimidazol-2-yl)-2H-indazole (6); analytical retention time 3.10, MS 311 $[M+H]^+$.

The products of formula (I) of the present application and in particular examples 98 to 145 can be prepared according to the following process :



The synthesis of examples 98 to 145 is carried out in a similar way to the synthesis of 3-(6-phenyl-1H-benzimidazol-2-yl)-2H- indazole (example 97) but replacing phenylboronic acid with boronic acids of formula $RB(OH)_2$.

Products of formula (I) of the present application which constitute Examples 28 to 96 and 146 to 180 of the present application are represented in Table 3: these products can be prepared according to the schemes indicated above and in particular as indicated above for the product of Example 1.

TABLE 3

Example number	STRUCTURE	RNH_2 or $RB(OH)_2$	Molecular Formula	MW	MS Characteristic Method		retention time (minutes)	Nomenclature
28			C22H18N6O3S	446.49	447	$[M+H]^+$	2.77	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide
29			C20H21N5O2	363.42	364	$[M+H]^+$	2.8	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-ethoxy-propyl)-amide

30			C22H16BrN5O	446.31	447	$[M+H]^+$	3.35	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-benzylamide
31			C23H19N5O3S	445.50	446	$[M+H]^+$	2.81	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methanesulfonyl-benzylamide

32			C26H19N5O	417.47	418	$[M+H]^+$	3.38	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (naphthalen-1-ylmethyl)-amide
33			C23H16F3N5O	435.41	436	$[M+H]^+$	3.41	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-trifluoromethyl-benzylamide
34			C20H15N5OS	373.44	374	$[M+H]^+$	3.01	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (thiophen-2-ylmethyl)-amide

35			C24H22N6O	410.48	411	$[M+H]^+$	2.49	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-dimethylamino-benzylamide
36			C26H30N6O3	474.56	475	$[M+H]^+$	3.31	4-({[2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carbonyl]-amino}-methyl)-piperidine-1-carboxylic acid tert-butyl ester

37			C22H16N6O3	412.41	413	[M+H]$^+$	3.14	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-nitro-benzylamide
38			C21H16N6O	368.40	369	[M+H]$^+$	2.39	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide

39			C22H16BrN5O	446.31	447	$[M+H]^+$	3.36	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-bromo-benzylamide
40			C23H19N5O2	397.44	398	$[M+H]^+$	3.1	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methoxy-benzylamide

41			C23H17N5O3	411.42	412	$[M+H]^+$	3.07	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide
42			C24H17N5OS	423.50	424	$[M+H]^+$	3.42	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide

43			C21H19N7O	385.43	386	[M+H]+	2.59	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1,3-dimethyl-1H-pyrazol-4-ylmethyl)-amide
44			C23H16F3N5O2	451.41	452	[M+H]+	3.44	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-trifluoromethoxy-benzylamide
45			C23H19N5O	381.44	382	[M+H]+	3.21	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methyl-benzylamide

46			C21H17N5OS	387.46	388	[M+H]+	3.16	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-methyl-thiophen-2-ylmethyl)-amide
47			C23H16F3N5O	435.41	436	[M+H]+	3.38	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-trifluoromethyl-benzylamide

48			C28H21N5O2	459.51	460	$[M+H]^+$	3.56	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-phenoxy-benzylamide
49			C23H16F3N5O2	451.41	452	$[M+H]^+$	3.46	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-trifluoromethoxy-benzylamide

50			C21H23N5O2	377.45	378	[M+H]$^+$	2.94	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-isopropoxy-propyl)-amide
51			C20H17N7O	371.40	372	[M+H]$^+$	2.56	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1-methyl-1H-pyrazol-4-ylmethyl)-amide

52			C25H23N5O	409.49	410	$[M+H]^+$	3.51	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-isopropyl-benzylamide
53			C22H19N5O2	385.43	386	$[M+H]^+$	3.19	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,5-dimethyl-furan-3-ylmethyl)-amide

54			C24H17N5OS	423.50	424	$[M+H]^+$	3.38	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-2-ylmethyl)-amide
55			C26H24N6O3	468.52	469	$[M+H]^+$	2.92	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(3-acetylamino-phenoxy)-propyl]-amide

56			C21H15ClN6O	402.84	403	$[M+H]^+$	2.92	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-chloro-pyridin-3-ylmethyl)-amide
57			C24H17N5OS2	455.56	456	$[M+H]^+$	3.47	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid ([2,2']bithiophenyl-5-ylmethyl)-amide

58			C24H19N5O2	409.45	410	$[M+H]^+$	3.07	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzofuran-5-ylmethyl)-amide
59			C23H16N6O	392.42	393	$[M+H]^+$	3.03	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-cyano-benzylamide

60			C24H16ClN5OS	457.94	458	$[M+H]^+$	3.55	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (5-chloro-benzo[b]thiophen-3-ylmethyl)-amide
61			C23H16F3N5O	435.41	436	$[M+H]^+$	3.41	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-trifluoromethyl-benzylamide

62			C23H19N5OS	413.50	414	$[M+H]^+$	3.26	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methylsulfanyl-benzylamide
63			C24H17N5OS	423.50	424	$[M+H]^+$	3.38	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide

64			C21H21N5O2	375.43	376	$[M+H]^+$	2.65	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide
65			C24H19N5O3	425.45	426	$[M+H]^+$	3.28	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-amide

66			C20H15N5O2	357.37	358	$[M+H]^+$	2.92	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (furan-3-ylmethyl)-amide
67			C22H16N6O3	412.41	413	$[M+H]^+$	3.14	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-nitro-benzylamide

68			C20H15N5OS	373.44	374	$[M+H]^+$	3.03	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (thiophen-3-ylmethyl)-amide
69			C24H21N5O	395.47	396	$[M+H]^+$	3.37	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,5-dimethyl-benzylamide

70			C24H19N7O	421.46	422	$[M+H]^+$	2.61	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1-methyl-1H-benzoimidazol-2-ylmethyl)-amide
71			C23H19N5O	381.44	382	$[M+H]^+$	3.24	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide

72			C22H16ClN5O	401.86	402	[M+H]+	3.29	2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-chloro-benzylamide
73			C22H18N6O3S	446.49	447	[M+H]+	3.07	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-sulfamoyl-benzylamide
74			C20H21N5O2	363.42	364	[M+H]+	3.45	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (3-ethoxy-propyl)-amide

75			C22H16BrN5O	446.31	447	$[M+H]^+$	4.38	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-bromo-benzylamide
76			C26H19N5O	417.47	418	$[M+H]^+$	4.4	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (naphthalen-1-ylmethyl)-amide
77			C20H15N5OS	373.44	374	$[M+H]^+$	3.93	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (thiophen-2-ylmethyl)-amide

78		HCl HCl 	C24H22N6O	410.48	411	[M+H]+	2.93	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-dimethylamino-benzylamide
79		HCl 	C22H16N6O3	412.41	413	[M+H]+	3.87	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-nitro-benzylamide
80			C21H16N6O	368.40	369	[M+H]+	2.4	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide

81			C22H16BrN5O	446.31	447	[M+H]+	4.18	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-bromo-benzylamide
82			C23H19N5O2	397.44	398	[M+H]+	3.95	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-methoxy-benzylamide
83			C24H17N5OS	423.50	424	[M+H]+	4.68	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide

84			C28H21N5O2	459.51	460	$[M+H]^+$	4.55	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-phenoxy-benzylamide
85			C23H16F3N5O2	451.41	452	$[M+H]^+$	4.43	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-trifluoromethoxy-benzylamide
86			C21H15ClN6O	402.84	403	$[M+H]^+$	3.9	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (6-chloro-pyridin-3-ylmethyl)-amide

87			C24H19N5O2	409.45	410	$[M+H]^+$	3.9	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (2,3-dihydro-benzofuran-5-ylmethyl)-amide
88			C23H16F3N5O	435.41	436	$[M+H]^+$	4.3	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-trifluoromethyl-benzylamide
89			C23H19N5OS	413.50	414	$[M+H]^+$	3.98	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-methylsulfanyl-benzylamide

90			C20H15N5O2	357.37	358	$[M+H]^+$	3.68	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (furan-3-ylmethyl)-amide
91			C22H16N6O3	412.41	413	$[M+H]^+$	3.95	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-nitro-benzylamide
92			C24H21N5O	395.47	396	$[M+H]^+$	4.45	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3,5-dimethyl-benzylamide

93			C22H16ClN5O	401.86	402	$[M+H]^+$	5.03	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-chloro-benzylamide
94			C21H15N5O	353.38	354	$[M+H]^+$	4.27	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid phenylamide
95			C22H17N5O	367.41	368	$[M+H]^+$	3.94	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid benzylamide

96			C23H19N5O	381.44	382	$[M+H]^+$	4.01	2-(1H-Indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid phenethyl-amide
97			C20H14N4	310.36	311	[M+H]+	3.14	3-(6-Phenyl-1H-benzoimidazol-2-yl)-2H-indazole
98			C20H12Cl2N4	379.25	379	[M+H]+	3.63	3-[6-(2,4-Dichloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole

99			C24H16N4	360.42	361	[M+H]+	3.51	3-(6-Naphthalen-1-yl-1H-benzoimidazol-2-yl)-2H-indazole
100			C20H13FN4	328.35	329	[M+H]+	3.21	3-[6-(4-Fluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole
101			C20H13ClN4	344.805	345	[M+H]+	3.44	3-[6-(4-Chloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole

102			C21H16N4O	340.386	341	[M+H]+	3.14	3-[6-(4-Methoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole
103			C20H12ClFN4	362.795	362	[M+H]+	3.51	3-[6-(3-Chloro-4-fluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole
104			C20H12Cl2N4	379.25	[378-380]	[M+H]+	3.81	3-[6-(3,5-Dichloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole

105			C26H16N4S2	448.57	449	[M+H]+	3.91	3-(6-Thianthren-1-yl-1H-benzoimidazol-2-yl)-2H-indazole
106			C26H18N4	386.458	387	[M+H]+	3.78	3-(6-Biphenyl-4-yl-1H-benzoimidazol-2-yl)-2H-indazole

107			C21H16N4	324.387	324	[M]	3.38	3-(6-p-Tolyl-1H-benzoimidazol-2-yl)-2H-indazole
108			C21H16N4	324.387	325	[M+H]+	3.41	3-(6-m-Tolyl-1H-benzoimidazol-2-yl)-2H-indazole
109			C21H16N4	324.387	325	[M+H]+	3.41	3-(6-o-Tolyl-1H-benzoimidazol-2-yl)-2H-indazole

110			C18H12N4S	316.386	317	[M+H]+	3.13	3-(6-Thiophen-3-yl-1H-benzoimidazol-2-yl)-2H-indazole
111			C21H13F3N4	378.357	379	[M+H]+	3.65	3-[6-(3-Trifluoromethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole
112			C21H13F3N4	378.357	379	[M+H]+	3.68	3-[6-(4-Trifluoromethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole

113			C20H13ClN4	344.805	345	[M+H]+	3.55	3-[6-(3-Chloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole
114			C21H16N4O	340.386	341	[M+H]+	3.41	3-[6-(3-Methoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole

115			C22H18N4	338.414	339	[M+H]+	3.39	3-[6-(3,5-Dimethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole
116			C22H18N4	338.414	339	[M+H]+	3.55	3-[6-(3,4-Dimethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole
117			C21H14N4O2	354.369	354	[M]	3.18	3-(6-Benzo[1,3]dioxol-5-yl-1H-benzoimidazol-2-yl)-2H-indazole

118			C24H22N4	366.468	367	[M+H]+	3.95	3-[6-(4-tert-Butyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole
119			C20H20N4	316.408	317	[M+H]+	3.72	3-(6-Hex-1-enyl-1H-benzoimidazol-2-yl)-2H-indazole
120			C22H18N4O2	370.412	371	[M+H]+	3.00	3-[6-(3,4-Dimethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole

121			C20H14N4O	326.359	327	[M+H]+	2.92	3-[2-(2H-Indazol-3-yl)-3H-benzoimidazol-5-yl]-phenol
122			C20H14N4O	326.359	327	[M+H]+	2.84	4-[2-(2H-Indazol-3-yl)-3H-benzoimidazol-5-yl]-phenol

123			C20H12Cl2N4	379.25	378	[M+H]+	3.82	3-[6-(3,4-Dichloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole
124			C21H13F3N4O	394.356	395	[M+H]+	3.72	3-[6-(4-Trifluoromethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole

125			C22H16N4O	352.397	353	[M+H]+	3.08	1-{4-[2-(2H-Indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-ethanone
126			C22H14N4S	366.446	367	[M+H]+	3.82	3-(6-Benzo[b]thiophen-2-yl-1H-benzoimidazol-2-yl)-2H-indazole

127			C23H20N4O3	400.438	401	[M+H]+	3.02	3-[6-(3,4,5-Trimethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole
128			C20H14N4OS	358.423	359	[M+H]+	3.09	1-{5-[2-(2H-Indazol-3-yl)-3H-benzoimidazol-5-yl]-thiophen-2-yl}-ethanone

129			C22H16N4O	352.397	353	[M+H]+	3.05	1-{3-[2-(2H-Indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-ethanone
130			C27H20N4O	416.484	417	[M+H]+	3.75	3-[6-(4-Benzyloxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole

131			C26H17FN4	404.448	405	[M+H]+	4.02	3-[6-(2-Fluoro-biphenyl-4-yl)-1H-benzoimidazol-2-yl]-2H-indazole
132			C22H14N4S	366.446	367	[M+H]+	3.55	3-(6-Benzo[b]thiophen-3-yl-1H-benzoimidazol-2-yl)-2H-indazole

133			C21H16N4O	340.386	341	[M+H]+	2.79	{3-[2-(2H-Indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-methanol
134			C22H18N4S	370.478	371	[M+H]+	3.62	3-[6-(4-Ethylsulfanyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole

135			C20H12F2N4	346.34	347	[M+H]+	3.29	3-[6-(2,4-Difluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole
136			C21H13F3N4O	394.356	395	[M+H]+	3.66	3-[6-(3-Trifluoromethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole
137			C21H15FN4	342.377	343	[M+H]+	3.36	3-[6-(4-Fluoro-2-methyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole

138			C22H15FN4	354.388	355	[M+H]+	3.49	3-{6-[2-(4-Fluoro-phenyl)-vinyl]-1H-benzoimidazol-2-yl}-2H-indazole
139			C22H15ClN4	370.843	371	[M+H]+	3.76	3-{6-[2-(4-Chloro-phenyl)-vinyl]-1H-benzoimidazol-2-yl}-2H-indazole

140			C23H18N4O2	382.423	383	[M+H]+	3.03	3-{4-[2-(2H-Indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-propionic acid
141			C21H16N4O	340.386	341	[M+H]+	2.72	{4-[2-(2H-Indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-methanol
142			C18H12N4O	300.321	301	[M+H]+	3.02	3-(6-Furan-2-yl-1H-benzoimidazol-2-yl)-2H-indazole